{\rtf1\ansi\ansicpg1252\uc1 \deff28\deflang1033\deflangfe1033\deftab360{\fonttbl{\f0\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\f2\fmodern\fcharset0\fprq1{\*\panose 02070309020205020404}Courier New;}{\f3\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}{\f4\froman\fcharset0\fprq2{\*\panose 00000000000000000000}Times;}{\f14\fnil\fcharset2\fprq2{\*\panose 05000000000000000000}Wingdings;}{\f28\fswiss\fcharset128\fprq2{\*\panose 020b0604020202020204}Arial Unicode MS;}{\f29\fswiss\fcharset128\fprq2{\*\panose 00000000000000000000}@Arial Unicode MS;}{\f128\froman\fcharset238\fprq2 Times New Roman CE;}{\f129\froman\fcharset204\fprq2 Times New Roman Cyr;}{\f131\froman\fcharset161\fprq2 Times New Roman Greek;}{\f132\froman\fcharset162\fprq2 Times New Roman Tur;}{\f133\froman\fcharset177\fprq2 Times New Roman (Hebrew);}{\f134\froman\fcharset178\fprq2 Times New Roman (Arabic);}{\f135\froman\fcharset186\fprq2 Times New Roman Baltic;}{\f144\fmodern\fcharset238\fprq1 Courier New CE;}{\f145\fmodern\fcharset204\fprq1 Courier New Cyr;}{\f147\fmodern\fcharset161\fprq1 Courier New Greek;}{\f148\fmodern\fcharset162\fprq1 Courier New Tur;}{\f149\fmodern\fcharset177\fprq1 Courier New (Hebrew);}{\f150\fmodern\fcharset178\fprq1 Courier New (Arabic);}{\f151\fmodern\fcharset186\fprq1 Courier New Baltic;}{\f354\fswiss\fcharset0\fprq2 Arial Unicode MS Western;}{\f352\fswiss\fcharset238\fprq2 Arial Unicode MS CE;}{\f353\fswiss\fcharset204\fprq2 Arial Unicode MS Cyr;}{\f355\fswiss\fcharset161\fprq2 Arial Unicode MS Greek;}{\f356\fswiss\fcharset162\fprq2 Arial Unicode MS Tur;}{\f357\fswiss\fcharset177\fprq2 Arial Unicode MS (Hebrew);}{\f358\fswiss\fcharset178\fprq2 Arial Unicode MS (Arabic);}{\f359\fswiss\fcharset186\fprq2 Arial Unicode MS Baltic;}}{\colortbl;\red0\green0\blue0;\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;\red128\green0\blue128;\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\red221\green221\blue221;\red153\green153\blue153;\red222\green222\blue233;\red102\green51\blue204;\red150\green150\blue150;\red254\green248\blue217;}{\info{\title Factiva RTF Display Format}{\author Factiva, from Dow Jones.}{\operator Factiva, from Dow Jones.}{\creatim\yr2005\mo2\dy5\hr12\min00}{\revtim\yr2005\mo2\dy5\hr12\min00}{\version2}{\edmins4}{\nofpages1}{\nofwords16}{\nofchars93}{\*\company Factiva, from Dow Jones.}{\nofcharsws114}{\vern8279}} \paperh15840\paperw12240\widowctrl\ftnbj\aenddoc\noxlattoyen\expshrtn\noultrlspc\dntblnsbdb\nospaceforul\hyphcaps0\formshade\horzdoc\dgmargin\dghspace180\dgvspace180\dghorigin1800\dgvorigin1440\dghshow1\dgvshow1\jexpand\viewkind1\viewscale100\pgbrdrhead\pgbrdrfoot\splytwnine\ftnlytwnine\htmautsp\nolnhtadjtbl\useltbaln\alntblind\lytcalctblwd\lyttblrtgr\lnbrkrule \fet0\sectd \titlepg \linex0\endnhere\pgbrdropt32\sectlinegrid360\sectdefaultcl\margr1440\margl1440 {\headerf\pard\plain \s21\qc \li-1008\ri-1008\widctlpar\tqc\tx4320\tqr\tx8640\aspalpha\aspnum\faauto\adjustright\rin-1008\lin-1008\itap0 \fs20\lang1033\langfe1033\loch\af28\hich\af28\dbch\af28\cgrid\langnp1033\langfenp1033 {\f0\fs16\qr\ri0{\*\shppict{\pict\jpegblip\picw117\pich70\picscaley100\picscalex100\picwgoal1755\pichgoal1050
FF
D8FFE1001845786966000049492A00080000000000000000000000FFEC00114475636B79000100040000003C0000FFE1031F687474703A2F2F6E732E61646F62
652E636F6D2F7861702F312E302F003C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A7265537A4E54637A6B6339
64223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F626520584D5020436F7265
20352E362D633036372037392E3135373734372C20323031352F30332F33302D32333A34303A34322020202020202020223E203C7264663A52444620786D6C6E
733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E203C7264663A446573637269
7074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F22
20786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D
6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A446F63756D656E7449443D22786D702E646964
3A41323833444137413541454331314535423730414642454331423332443443442220786D704D4D3A496E7374616E636549443D22786D702E6969643A413238
33444137393541454331314535423730414642454331423332443443442220786D703A43726561746F72546F6F6C3D2241646F62652050686F746F73686F7020
43432032303135204D6163696E746F7368223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E636549443D2243353942433442
41323033324339414238413541444443363033343137334630222073745265663A646F63756D656E7449443D2243353942433442413230333243394142384135
41444443363033343137334630222F3E203C2F7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F7870
61636B657420656E643D2272223F3EFFEE000E41646F62650064C000000001FFDB0084000604040405040605050609060506090B080606080B0C0A0A0B0A0A0C
100C0C0C0C0C0C100C0E0F100F0E0C1313141413131C1B1B1B1C1F1F1F1F1F1F1F1F1F1F010707070D0C0D181010181A1511151A1F1F1F1F1F1F1F1F1F1F1F1F
1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1FFFC00011080046007503011100021101031101FFC4007C00010003
01010100000000000000000000000306070405080101010101000000000000000000000000000102031000010303030203070403010000000000020001030405
061112072113314122513223141516086142331752433618110101010101000203010101000000000000010211213112415103226113FFDA000C030100021103
11003F00FAA501010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101
01061F985B723C9F9CA6C669328BAD86DF15942B986DF532C62F20CCC0FF000C4C47AB1F57FD1749E471D4B75CEBB78BAEF9759793EFBC757CBCCB7FA4A3A20B
8505C2AB579C59DE26702277227D5A7F327F77A69AA9AE73A62D9AE556305B4E7DCA768BBE5D2E6B73B219554D05B2DB412C915344D10898EF0030DCDEB61F6F
4D5DDF556F278CE65D7BD1F36CCB26FC6BACBF0DCAA69AFD67A91092BE9253A79658E290189CCA270FF54DEAF6EDD539268FB5B8EA3CBF9AEE1167D814D49592
C7678E8E8EAEFD1C6643097D4C4589A7067DA5DA8DD8877783BF45667CA6BFA7B176E31BCDE6FBCABC8359357D4CB67B64F15B68684A590A980E377090A389DF
6096B4FABBB37EEFD56753C8DE2DBAAD6161D593E417ABCC5F9218CDA22AFA88ED551679659EDE329B539C8DF37A19C4CFB08BD03D5DBC996E4FF2E56DFBC576
829B32E4CE42CC69DF2BB8E3D69C66ABE9F47496B90A1DE4C7206F37021DDD61727D757EBA368CCAF92333BAB7DF8498565D969F1EF26D96EB7396B6E787C771
A5A3BCB11054176E19C44F7B3EFDC2706E12D7775F1E8964EC33ABCB3F4AD71BF2C647271E64B8FE415D54D7BFA3575D31CBACD29BD44D13432396C99DF7B944
60E40FAEBD1DBA6D5759F59C6EF2CAECCBB2ACA20FC68C6EF105E2BA2BB4F5318CF710A9986A4C5CAA3563998B7937A5BC5FC924FF004BAD5FA45838ABEDAAAC
C602B57275E3279E9A29653B4561D53C060E1DB723697417D8523137EAA6BE3E1AC73BF3D52EFD94DCABF9072AB76599D5D70CA8A4A93871FA6A6EFC74650B11
768E4ECBB7420602DCFA6BAF8F92B279E462EBDBDBC6C5BF28FEA1DDF75DBFEADF2FFF005BAB7CAF67B9FCDBBDDDDD9F4EEFF2EAB1F975F7EBF2AE66566E51B6
72F4997E298EC77AA596D216F779AAA9E0162797B85D0E58CF56DADE5A755659CE56753535D91DDC6584E71F7D5E7903348E9E86E972A61A1A6B5D29B4831422
F1BBB910918EBF0474D09FCFC13567391719BDED5631CC6F9C38EA8EEB8D63362A3BE59EA2A25A8B6DCCEA6288A2EE8B036F8E492322D0405DC74F1D7ABB2B6C
ACC9ACF916EC1F8A6AEC5C395F8757184D71BA53D5BD4F6DF58C26A98DC00449F4D76330F5F6A975EF5BCE399E33DC33813286E33CBE8F20A3ED649730863B54
273432930D00B490334A06602D21FC3EA5D19BD8B577EB9E7F95FADEFCB45E00C1EFF89E1F57164503C17BB857CB5754252473168E2003B8E32317D76B978F9A
C6EF6BA7F2CD93D5AB3F87349318A9FB3278A0BFC6E274CD30810482CFEB8FE23388B90F83BF9FB149CFCB5AEF3C6738962DCA17CE57B7E6D995A69EC91DA2DC
5451C314F14EF399B48CE4CD11CBB7ACE4EFABB79375F15AB67391CF39D5D76A27C6796706CEB26BAE2166A5C8AD193CFF003A612D4474F24136E33767EE1C7D
374A5E1AEADA783A7659E9CD66DE7E5D387F19E6141C7F9EC978088F2BCCE2AE98A82031ED84D3C32B471EF72EDB3949317EEDACDA754BA9D8671797F75E25EB
83EFD75E16B0DBDA95A9736B0C530C50B4B133C91CF29F7698A51378F4303D5BD5A6BD3A6AEACD7A97F9DB9FFA9728E31CE6B7F1FAC189D2DB7B990515404955
45DFA71D82253BBBF70A4689FF00907C0926A77A6B17E922CD811F22864D4ED75E3BB5E3D6E90241A9BA51CD4852836C72116184C8DD88C459FA2979FB6B3DEF
C3C3CC31FE622BBDE2927C76D99E586B1CCAD12D6BD2412D101B938C7EA780DDC7769AB78E8CEC4CACB13535FAEA4FEA1CB7FF003CFD91BE2FAFEEF98EC773E1
6BF35F31D9EE7BBAEDF3F77779E9D54FB4FB74FF00CEFD38DB161D84040404040404040404040404040404040404040404040404040404040404040404040404
040404040404041FFFD9}}
\par }{\fs20\lang1024\langfe1024\noproof {\shp{\*\shpinst\shpleft1440\shptop2070\shpright10800\shpbottom2070\shpfhdr1\shpbxpage\shpbxignore\shpbypage\shpbyignore\shpwr3\shpwrk0\shpfblwtxt0\shpz2\shplockanchor\shplid2049{\sp{\sn shapeType}{\sv 20}}{\sp{\sn fFlipH}{\sv 0}}{\sp{\sn fFlipV}{\sv 0}}{\sp{\sn shapePath}{\sv 4}}{\sp{\sn fFillOK}{\sv 0}}{\sp{\sn fFilled}{\sv 0}}{\sp{\sn fArrowheadsOK}{\sv 1}}{\sp{\sn posrelh}{\sv 1}}{\sp{\sn posrelv}{\sv 1}}{\sp{\sn fLayoutInCell}{\sv 1}}{\sp{\sn fLayoutInCell}{\sv 1}}}{\shprslt{\*\do\dobxpage\dobypage\dodhgt8194\dpline\dpptx0\dppty0\dpptx9920\dppty0\dpx1190\dpy2070\dpxsize9920\dpysize0\dplinew15\dplinecor0\dplinecog0\dplinecob0}}}}{\f0\fs16  \par }}{\footerf \pard\plain \s22\ql \b\f354\fs18  Page {\field{\*\fldinst PAGE}{\fldrslt 1}}{     }\'a9 2019 \uc2 Factiva, Inc.  All rights reserved.\par }{\footer \pard\plain \s22\ql \b\f354\fs18  Page {\field{\*\fldinst PAGE}{\fldrslt 1}} of {\field{\*\fldinst NUMPAGES}{\fldrslt 1}}{     }\'a9 2019 \uc2 Factiva, Inc.  All rights reserved.\par }\pard\plain \ql \li0\ri0\nowidctlpar\faauto\rin0\lin0\itap0 {\fs20 {\par\fs20{\*\shppict{\pict\pngblip\picw166\pich40\picscaley100\picscalex100\picwgoal2490\pichgoal600
47
4946383961A6002800F700002A4A9CD1D8EA95A4CE4964AAF0F2F85871B18598C6768BBF3957A3E1E5F1677EB8B3BEDCA4B1D5C2CBE3F2F4F9FBFBFDF4F6FAEC
EFF6F8F9FCC6CFE5C5CDE4E0E4F0F1F3F8F5F7FBE1E6F1D5DBEBF7F8FBD9DEEDEEF0F7DFE3F0D4DAEBE3E7F2D7DDECBFC8E1BBC5DFFDFEFEEBEEF6FBFCFDCED5
E8DBE0EEFAFAFC9DABD1AEBAD99EACD2E4E8F2F6F7FBF3F5FAE7EAF4E7EBF4D2D9EAE8EBF4C2CBE2E6E9F3AFBAD9C9D1E6AFBADAA8B5D74F69AE90A0CBCCD4E8
DADFED9FADD3E6EAF3DADFEEAFBBDAD5DBECD9DFEEA1AFD3DDE2EFEEF1F7D2D8E9EFF1F8E9ECF5F5F6FA798DC0798CC0DEE3F0BAC4DFE4E8F3DCE0EEA6B3D5D0
D6E9CBD2E791A1CC7388BFEDEFF7ABB7D73A56A3BEC7E1566EB1C2CAE3F3F5F9B7C1DED3DAEB6C81BBCCD3E7ECEEF6C1CAE2EDEFF6D3DAEA9DABD2D6DCECEFF1
F7C9D1E5C7CFE5C0C9E1FDFDFE94A3CDF5F7FAD0D7E9B7C2DE899AC8E2E6F2D1D7E9FEFFFFA5B2D5D1D7EAB0BBDAFCFDFEA7B4D6E9EDF5FAFAFDD8DEECAEBADA
ADB9D9DCE1EFCBD3E793A2CC8597C6CFD6E9FEFEFEE5E9F37D8FC298A7D0B9C3DFB6C0DDD9DFEDF9FAFCE2E7F2FEFEFFDDE2F06E83BC4E68AD8395C599A8D099
A8CF1B3D95FFFFFF0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000021F90400000000002C00000000A60028000008FF0027091C48B0A0C18308132A5CC8B0A1C38710234A1428491280041019549434
B1A3C78F204336DC38E06102001B45AA5CC9B2E5C18D920C381C00D3A5CD9B3821564429690143033B2BE61C4AB468C502052C624C18A0E2019E071148125010
C080A50207001048C022C105310502855931C04001921010207892ACA40393D0BAED3989A659AE924A0AE409536F5399939A1620D8558140B06ED53A3CDAA0A2
DE8304A4AA4D595000800200D60E4409C067D6AD93BA823E1C761250AA901128282D102DEAD079AB8ECE2AE92EECC756091EA81DB874D3BC4B0B0B5C6D3BAE01
AC0B8F9A768A70355DCA034F1A2000C0F0E60152016BC53B1B2CE0D3089F12FF006ADB3541060601CCAECB1B2FEEC793769BFD2B50B045F4C22711F7A89CFD54
831A9506DD7008B446D75E0A10905401046C075B77A58D55D16BBD5115D963E60D749C6C05D9355057B8B9E5976F530520D501F9ED8758459E31D45F5BED09D4
9662930CB8E246052228D06E0820009A685F45F89F413491855A86B771489087EE5D17180008D8465F85A125459375FB6978A08B920C465A5A9AF967DB80AA05
895A750331C0D966737D372441681587DD5A729105DF24EA159494884E3ED9597D24BE361696736D995C97040D2A5645805124D4A20D740880596846E7607C73
45BA1C859324808097038165188C30A147509EE7CDF55A6EF5A144D5944D51FFB840A50192452397A0D2566245390E34E0446A8C20D01C1A4CE2011245253B54
7FD1F124558C8E72F411059AA6D0C22487F4A1ECB636311B2A4C9CD6F8A847265030C90A124C32C5059370400106DCC61B92B703ED169B41BF3E94C20B45B831
09185D48004915246801850376C8AB7047F472251572BE8E1BD10A11B8A0C2246BB0D0E92417C06B43064414B7F0C80A355C5F8B05E5EBD00E1784F145428A10
E0800B24D75C32A211A9ACD0106F4C42080B1F20B2D00651741081CD481364F2A1D23EF444069380E083430F38F040D258C7DB861891185210014F6D7480591A
5470421E59A73DD42293340275410D58656A00AB51F580CC6AE7ED92145724FF314919570F142B800310C086057A27BE9205224CF2400E4E1054C09D8A577E93
17637C2D89A909BD55D0B3380E4716467B6EA4A9AF705104579DCC597ED31233C00DED4BA9CBF8265A0221903AD86615D0AB407BA2E7B9EA7149B2D401B9BAAE
D2237F4C62441604352632BEB5777ABBB4A5571469E99C2B5DBBE7AC0FAFFC4A85DC31090C67106628ED6C5D1FDA014B25B0F924BE97FCFDEAC68F9F93155418
8414D3CA011DAF724796ED15B04364410F5A20A63F96FC40041598004106571006146E1212085C033778101EEC61127A2083EC06A0A90024852A1DA8000438C8
C2826001102388C14112602FA7DCC5021C58610B7728101438C20C359020437F98D0010E2482873C14C4B542F0818540C0015044221241A0043900210411E8C1
41503089137840088390220F4BB085496C000E1AA043095E80864EADA50E7138820EC528451AF061123A500104FC10810098400651C3C006E828C60FDC601224
F0800402C185493062026920A424078283209CAF0902C1C32437C949960404003B}}
\par\par \b \uc2 Circadiance\uc2  Debuts SleepWeaver Anew Soft Cloth Full Face PAP Mask for Sleep Apnea Sufferers\b0\par\par\uc2 326 \uc2 words\par \uc2 20 September 2013\par \uc2 Manufacturing Close-Up\par \uc2 MFGCLU\par \uc2 English\par \uc2 (c) 2013. Close-Up Media, Inc. All rights reserved.   \par \par \uc2 Circadiance\b \highlight22\uc2 announced the launch\b0 \highlight\uc2  of SleepWeaver Anew Soft Cloth Full Face PAP mask, a \b \highlight22\uc2 new product\b0 \highlight\uc2  specifically designed for CPAP users who breathe through their mouth while sleeping.\par \par \uc2 With the \b \highlight22\uc2 launch\b0 \highlight\uc2  of the SleepWeaver Anew, \uc2 Circadiance\uc2  is able to offer its technology to a larger audience of people who use CPAP masks.\par \par \uc2 According to a release, SleepWeaver Anew features a dual interface design that seals around both the nose and the mouth, with only soft cloth touching the skin. Unlike the hard plastic masks made by other manufacturers, \uc2 Circadiance\uc2  soft cloth technology allows the skin to breathe, without moisture accumulating between the mask and the user's skin. The loose fit provides added comfort and eliminates strap marks, and the open-face headgear design accommodates eyeglasses and allows virtually unrestricted vision. All \uc2 Circadiance\uc2  masks allow for a greater variety of sleep positions. The mask is available in three sizes.\par \par \uc2 "We're excited to offer our soft cloth technology to even more people who use CPAP to treat obstructive sleep apnea or to provide non-invasive ventilation," said \uc2 David Groll\uc2 , founder and CEO of Circadiance. "With the SleepWeaver Anew, even mouth breathers can sleep in comfort. We're always working to develop products that make PAP therapy more comfortable."\par \par \uc2 Circadiance\uc2  introduced the first all-cloth respiratory interface, SleepWeaver, in 2007. Before SleepWeaver, people who used non-invasive ventilation or CPAP systems were limited in their choice of mask-only hard plastic masks were available. \uc2 Circadiance\uc2  changed the future of patient interface by developing a line of high-performance soft cloth masks that deliver comfort and ease of use and increase patient compliance.\par \par \uc2 Circadiance\uc2  develops, manufactures, and markets respiratory products under the SleepWeaver brand for people with sleep-disordered breathing or who need non-invasive ventilation.\par \par \uc2 More Information:\par \par {\field{\*\fldinst{HYPERLINK "http://www.circadiance.com"}}{\fldrslt{\cf2 \uc2 http://www.circadiance.com}}}\par \par \uc2 ((Comments on this story may be sent to newsdesk@closeupmedia.com))\par \par \uc2 Document MFGCLU0020130920e99k0000b\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw35\pich40\picscaley100\picscalex100\picwgoal525\pichgoal600
47
494638396123002800F70000FFFFFFFFF9F9FF322EFF2B27FF2924FF3C39FFF6F6FFDDDC3333331010108383833636360E0E0E0000000D0D0D32323282828213
13133434343030300B0B0B3B3B3B2D2D2D2A2A2A1F1F1F2222222121211D1D1DF5F5F59090903131317272723838383939391111112F2F2F050505F4F4F40C0C
0C1919191414147575752C2C2CF7F7F7949494C8C8C89696964F4F4F6E6E6EDCDCDC0F0F0F4545452323231B1B1B1212121A1A1A1C1C1C999999060606181818
7D7D7DFCFCFCBEBEBEC2C2C2979797F2F2F2F3F3F33535352E2E2E919191151515BFBFBFB4B4B42424242B2B2B4E4E4E3A3A3A7878781E1E1EBABABA8F8F8FFF
DAD9959595B7B7B7B8B8B8FF3632FF342F090909202020262626A9A9A9FFE0DFFFFCFC505050B5B5B59C9C9C6464648B8B8BAEAEAEEEEEEEFF39340A0A0A3D3D
3D484848E8E8E8929292535353A0A0A07B7B7B9D9D9D8C8C8C8E8E8E080808FFFAFAFF4A47C4C4C4D4D4D48888889B9B9BD8D8D89F9F9FFF4743B6B6B6C7C7C7
B1B1B10303038585855C5C5CFFF8F8070707656565767676666666BBBBBB616161777777FCFFFF404040D3D3D3FFFBFBFF39357F7F7FFFF8F7FFE2E1FFF1F1E2
E2E26D6D6DFFF4F4989898282828676767292929B2B2B2737373707070F1F1F1FFD7D6464646EFEFEFFF403C7979798686868787873E3E3EA4A4A41616167C7C
7C000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000021FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A31384139344338393530463031314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3138
413934433841353046303131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3138413934433837353046303131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3138413934433838353046303131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000002300280040
08FF0027710940B0A0C18308131604002900808710234A9C4851A2018710F54440508A108033181E44980251410204092044848142820C180000391CB320C908
1C8A001C69D122128B1A0892800020E564CA8A0F2F225DCA14A2D2A650293E8558A282060458B1985911D12482092166CCB810C143880817840098FAC1C1020A
4000FC8861E98404071F1E7A4D500480920614188CFAE11463D4C349AB0C58CCB8B1E3C7901D33328C38EAD4CA502F3FF4D14087031D0D8E4894D4808169D326
1860F873A7B0C4146E1F4C98B0C0C1A0AE46554234B4430283BC8E0C070991C142063A009E187990A14209BD46DD0068C2C4C805263534A0598B918F080437BA
00FF38144885050F121088F00260AFEE8A061601F063E1C588B81321207841648D98074B4C90C6529A6146206506125880000C36E8E0831046F8E0270826085F
85164E5460861661C8A16B12714009142E409103071215C243072C76F0060B5AC4D0E1444D38909E0426802291570BA8808106974860011C11CC9114825444F0
80071720F0000A4FE0A65E230F05C1C30D0F2C40821DDC455455064A7492C3041E6850018AD0A1F41E00A2C880000A82004050446DBDE502006C98505B0A25E5
06111E4E8CA0250B5D3E84840D08ECA006444B6CF0800D48A4C917002A5C81C010119080C9910F6D02020D4460C0410B0D9C401B023480A0D65E6100600A1875
F86FD043444F69C2C05B5F00904519389CE0C4A50C640240287E22A514290D6CD0472213795209051B34B0471BC936C0A7B17120C255542BCC9A99871F161AAE
86E07E6840145B1CA0EEBAECB6EBEEBBEB3EC2891504D46BEFBDF8E6AB2FBE64E421400100072CF0C004171CB000720404003B}}
\par\par \b \uc2 Researchers at Washington University  \highlight22\uc2 launch \highlight\uc2  clinical trial for Alzheimer's treatment\b0\par\par\uc2 119 \uc2 words\par \uc2 19 September 2013\par 06:45\par \uc2 Associated Press Newswires\par \uc2 APRS\par \uc2 English\par \uc2 (c) 2013.  The Associated Press.  All Rights Reserved.   \par \par \uc2 ST. LOUIS (AP) - Researchers at Washington University in St. Louis are launching a clinical trial to see if \b \highlight22\uc2 new drug\b0 \highlight\uc2  treatments given before dementia can prevent Alzheimer's disease.\par \par \uc2 The trial will test two \b \highlight22\uc2 new drug\b0 \highlight\uc2  treatments. It is led by Dr. Randall Bateman, a neurology professor at the Washington University School of Medicine.\par \par \uc2 Funding is a mix of private and public money, including a $1.5 million grant from the \uc2 National Institutes of Health\uc2  and a $4.2 million grant from the \uc2 Alzheimer's Association\uc2 .\par \par \uc2 University officials say research in recent years has indicated that prevention is more likely to succeed than treatment after cognitive impairment.\par \par \uc2 7\par \par \uc2 Document APRS000020130919e99j0018r\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw189\pich40\picscaley100\picscalex100\picwgoal2835\pichgoal600
47
4946383961BD002800F7FF00FF6767FF0000FF5252FF0606FF0101FF0E0EFF0202FF1010FF1717FFFEFEFF0B0BFF1C1CFFF7F7FFB4B4FF5454FF4545FFC6C6FF
7D7DFFFFFFFF9393FF3838FF7272FF2626FFC9C9FF8888FFDEDEFFF2F2FFF4F4FF1616FF6B6BFF0A0AFF0505FF4D4DFF2C2CFF4F4FFFF3F3FF1818FF8080FFDF
DFFFFDFDFF2222FFC4C4FF4242FF2929FFF0F0FFEBEBFF0303FF0404FF3434FFADADFF0F0FFFF5F5FFE0E0FF2A2AFF4B4BFF1A1AFF3D3DFF1919FF1212FF9292
FF8D8DFF6565FFEAEAFFE1E1FF7B7BFFF6F6FFFCFCFF2D2DFFF1F1FF5959FF3E3EFFF8F8FFE2E2FF0808FF0909FF0D0DFF1515FF0707FF2727FFA2A2FF5A5AFF
F9F9FF7E7EFF3A3AFF1111FFD2D2FF2020FF1F1FFFE4E4FF7676FFBDBDFF1313FFFBFBFFC7C7FF1B1BFFA1A1FFEEEEFFA6A6FFDCDCFF6060FF0C0CFF2424FF7C
7CFFB6B6FF2B2BFFB0B0FFE3E3FF6161FFD1D1FF2121FF2323FF5353FF6C6CFFC2C2FF6262FFEFEFFF5757FFFAFAFFE6E6FFC5C5FFA0A0FF3535FFA7A7FF1414
FF1D1DFFACACFFECECFFB9B9FF5050FF5E5EFF9797FF3737FF8383FFE5E5FFDBDBFFCCCCFFEDEDFF5151FF6969FF5D5DFFE7E7FFD0D0FFD4D4FF4040FF8686FF
5B5BFF8E8EFFB7B7FF5555FFB5B5FF4141FFCDCDFF4949FFD5D5FFA5A5FF4E4EFF7F7FFFE9E9FF6D6DFF9090FFAAAAFF5F5FFFC0C0FF4848FF2525FF9D9DFF2F
2FFF7373FFAEAEFF3030FF3131FF7474FF3333FF6F6FFFBBBBFF7171FFCFCFFF7777FFD9D9FFDDDDFFD7D7FFDADAFFE8E8FF7A7AFFD6D6FF4A4AFF6868FF5656
FF3636FF1E1EFF9A9AFF9191FF8A8AFF6363FF8989FF7979FFA9A9FF6A6AFFABABFFB8B8FF4C4CFFA3A3FFCECEFF9C9CFFBFBFFFBEBEFF3C3CFF5C5CFF3B3BFF
7070FF6E6EFF9999FF9494FF3939FF2E2EFF3232FF3F3FFF9F9FFF8484FF9595FF8181FFD8D8FF4343FFD3D3FFA4A4FFCBCBFFBABAFF5858FFCACAFF2828FF9E
9EFFB2B2FF4646FF4747FF8B8BFFAFAFFFC3C3FF8787FFBCBCFF8C8CFF4444FF6464FF9696FF7575FF8282FF9B9BFF9898FFB3B3FF7878F8F7F7FFB1B1FA4747
FC7C7CFED9D9FFC8C8FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A45374239373346443531423531314536383342314337334644453946314437322220786D704D4D3A446F63756D656E7449443D22786D702E6469643A4537
423937334645353142353131453638334231433733464445394631443732223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A4537423937334642353142353131453638334231433733464445394631443732222073745265663A646F63756D656E744944
3D22786D702E6469643A4537423937334643353142353131453638334231433733464445394631443732222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000BD00280040
08FF00FFFD93606BDBA21C0512A6F2C548A0C38710234A9C48B1A2C58B181F76D383E7C9932FE782083CE1AE6336654204DA42D5F149291A09324A4C60A894C7
52B862420CD2A0E3173D8E3016084094A803812C96147D41C961A558020450FA54CBA1B8183140B99220449A003A9A540A8BCAA9DBBF23A8FAC43016450890A8
4094FD4B104713D6187EFE352216A3CFBA14C71AD0291A408E26665C044E1A165500355902B934001583582321B33A08D0B580B0B57F3FA6100E90E51F2C0E45
A9101A782650D43569A240CC14E64D5439E136FC9BD183309411FF3401E114E15DA61A450DC0A9A4161C8413732B19EB2B6A28E1A3127D38284A42CB3F108479
C0FF208C814104C20F3464E84CD4C0840345115C3041817009118421FCEB50744005812A10B643022DD8505401D4FCF3CA00458D71435104A4F110230F16F508
2045C94094077010509437AE10C6811A239052940559C047D414FF54D14651140840980846148543503F84405825128047541E970C5154182758575424913141
D8384570D7CC77E18D575479E71595DE7AC9BD17DF7CF515755F7EFFC0D1DF7FFF0458D4800516758030FFD843D82E5E40D8004473C8315A0079FC93012F7702
F04F0A84B971C93F83A4760A1545B1188E91A424425812DA204714141A8CB042510A9C2210381E8C06433F12C972061EC93C014B0613D901C11D9930201345AE
28FF50540E2944F10D04833ED4421C5D1CF12A442D5C90822C22FD6AEC43B5A490C20F1375F2431C10D471AC445C0053D407403C34C19D013048980B294C2BAE
B80C1CB2CC2E35E89198B851BC419801A0086446A7442D91C93F412842182F4189BB416F45FD16518E984A21D468D8097141175D40D0851A92108602254AA486
C4188F52E021615EC84AD82F8816758529A309E32351FAF147D400A338C16D00BC2C4218029128459412D958F0B23C4010464217B06C3CEB1CAF103685814519
6126519B88A1735198B04258075512F586049E100606184F13D54718457930271CDE060086914609B401268F3C828D25520C4654775016251E79E6A1A71E7B01
B8FFA76200F2D1671F7E45A53C268002128834513A5870451B28A0E0862724C8F9900476BCFC0535DC2EB10D3384114002299147FEC02D460E60050A90476EDB
CB016823C13F26E8489402FF616145514EE8409427AE32821AEC44A912451C84955DBC184D4E99B7957B67F937B72F80B238B703BC2290080614E5C006098872
A70B45A131492F9643D4051AA3F92090F8845DD1C83F5CF47CED68D3D451236115B7574A058479C606D84186A28CC20FECBB9DC1FE51070016C5143418970425
F2870F1445071798A00637C8416395E04ED94889434E6088DDC18E04E4804E0757C8428784A30C8479010B04D28038FDC810024903FF6031AE7FF90638102198
02FF3162C3A2C80109FFD0829288F28240B4B0858A7841517E21AD7141A209C981C33F4E6086D1848B06FB238A1966272EDEFC3022B52B0A198671B0EB20C566
62FC07289457943DC88201422A0A344633087ADC691E0D205E006E11854B15EE1F00208C25AEF0322B24A082DC6AC32CC4E0B100A0A16B3BB05DF1C0E00A3E8C
C61B2738046142A00628BC0C103364811BB845804F1C21188409C41CE28045A23C8008920AC00782211AA22CE00CFF4843F788120CB405003B11E984A388C281
3BFC631C51228C24EA60ADA280600319405F7BB444941C54C107610CC0970EA9B26EC54220B9204C32FEB101C205A0005FF8C72DCA16881C106601F870841888
80FF8BD061A08BA329C0249C5194052CC28244E1031634608DA294211A1A228A25FEA10613066010182A8A22F49084A27C820B603064003C308D146833007010
42D68862032C18139910410425B8E39D9305E06ECEAB5A00AEC437BF6D49705E7267000CB732322D2D00685A9C126A20002B94CD41E913C8088AF12D6F8D22A3
A37941114057140E5C0307F6240A8AFEA603011821A20188D1CB0A800A810831004B68C53F9641AF02B4829101288328FEF1D23712A608CD0B00DD6C8A53A250
496F58DAE6DF02D725A28C1365FB395C99129726A224E1090319C11C5840844B6C21AA0269442AEEE4813A30825B24F8C71D08638543E08B052C980303BE30CC
00FF5443AA9B25C206ECF43219408606B9544069FE1188DA5A5642841A4D13CC51889916C5053D9011519810867F7CB028BE20684E11DB536E06E00629288476
89C209A186EB19923D2A064ED0094C10E65E66A8A42E3C491402CC0922EE306E00F0F18F3984E24ECE24C71E8A5283E7ACA128BD68C5DF72F18F42AC9228D088
0461D630832C084D0CB670D9ED38219004E095282EE007445250003AFA9210B249002E78D151C2C8E014B32B60518611049DDEB216DDFD9B0B069C2171FCE31E
15224A192A20C56E254220C9F05D51683117134C815E45D90227122086BF11C01811D9C02608638A2A08440F7C0B802EC0E09030944168BEC432BE08415FC2E4
41FF0D12F86FC066F00F0D074009B7C8630014200D87B060944F14D724101A001D9023D0884EB4B18E400454746D0BBE52F4ABCE40681DE847D298CE3444AE1B
002B7C818C1091001B9679A772E843D3A8BE88202A491487C421AC01C0841D0422885A12A51EA036D606E46C350D44840630ACEF3C30B281420972103A49F5B8
7C90EB63D9A1A1C9898340EC11B2BC064502DB2A8A158ED143804D0A880F79AB021668114B8C860CD578460E6A3B805B28FB5840D04112180409D98C6B17E4DB
A64062D1BE7FD842BA4401445EFCE5ED00082C889A5400872F62CC553864780178413CDE6D2C3310DA17132406C409F0807F44C1A60190C73F68D1B501984382
66FF0C18B81DC2800406A0091868A3F7FCCA44100C84104CE81F0164700D3D080405084000076ED0820A6091004C98C408E8601D0560A31387580007820E8937
D0CB0316A081102CC184A023C09959E83A0716308E2990C0D611DFC2147423080E40F900A688C13F665183A93321161718028322D0E6B4FE23EFA341522184B6
075CF8A10308C8F70B1030062CE8C40E165862C47B110D211CA1E00E38410250E0010528E00A8570B90736C18AA0EFC1086C18390AA6CE8144F4F51F445881EC
57E0842FF880D5A3294617D221486EF1A114C61C8D0CCE7054A276AB652FC3C11F247FA745B00101F72BCA3602411834FCA1129F250C05C0A00EC220A39A2FEB
83FF04A8DA5B36E862C21A9004A1EB6108918A3391CC14C43F7CD1E200F4E1F51109C27688F28127F8001E84D10036B50662004B4531047FA00E68E553F59206
87602245610658355491B5323D70157A561831E00B5B0662920006BC4514ABF022A3B1076E80077810435DB00E77720341C06B1F60092870416C60076D660140
805621600777D03F016004FA722476008178C20023904B4A9006970065198403F9E60588807F10A11DB3F22484252544210C4760631B800439B62519D058E224
54C6E71F88732609E007E9441407F009FF200DF5170A411600522042B087661D5070B7F30B1F5603F643143720067E20526395287AF16017456A015001E7C744
A9FF8705E5901CC460087A960E09706044D10A4420850F4185735353D1B45DD093587DE35D8C353860524E66385968585980237FAB2063010055F5054C0E8108
A3C03152D369A3A54BD5B03104100A6AC06555F00361548844F108B4E3726A5514372079DC901234A0491F0009FF9082448102E6F0341E800B7C85300E3103E2
288E48B00B345537445158017058A3F88544718A41958AE94559D7C32D505044F6F51051C003AC0404A7C02D4AA00DF0033B39B00AD5C62D43A088C933090231
8D98922D7A007D01C0713664044CF67A2C807674105883158A86F53CB6143D8AF55362F85814A88A46458F84410D88600258800448800529907D13795F0E8105
3EFF981C62204A77220355803CA971068C400330F90388B00CF98627B340038500936AE00318937C4141037AA6001D301038D01FC3F424DFE846FF3002701400
80758E578837362692A5B8585C828AE4348FADB838AAF10FFE300A388003D8300C12599310410300381A6DF00FCA504445910A7F421865C00EFFE0007589038B
2005B29827B54007750984EEE233B248248860670A1001FB4647A4608BC60402D0C1025016001BE98C7B457D45010CBBF89167498A0C0838B0A006D5C0964411
41D1E09644210809E0036B180064300DFF10067FA36EA0351011331A6BF00F8CE05EA3F10EAA25346E90410F7022ABF037CAC8068898071D4814DEC0008F1065
5CFFB0019A49269D109601B00FF92010EDD07BDD72064118002E6003BF908185B052AEC95DD2A346E81009104787DD190030B0067939009AC28A443106273003
F04714C5D0002120349FD035F908115F709001700F5BC40DCAD502FF70092EB705592009249856C4D9550D10019544077F18008AF00318507F705005C1B54033
800E2EC6990EF10DA5C92D95007BC8003B29C000BD989FEDB89FB0630144E047A3919403A0456F686B21A01B473081A3D1087E606536E910DDD04BCC64023484
36988005026102B0E697EE13066846188B900051491445C00041106465800409B74027000A84710D12710EADA00A57B0057BB007D65003E7106902410B664001
2BE9500EAA900BCBB02E9ED01802800A75A00794CA0D41D009D1D518BFA06401B0003B900EBC207B6121105F000D16B002E8D00C201815BBE086FF8008F140A9
CCE010B30009CE50034EC00AC8000E31610863D0186FE05A11710C948A0173201086100D949A0C552410C7B00830E0044E4001EDE00A0F31030D000D14B0AA0F
50011E7A048240A992E02BD3D018944008AFD01845E07303A10CC9810C14371177909407907AF5BAAF2B5434C7C5AF1001498C9341005BB0D3020C0580762290
6C052BB08546B0061BB1324108A3618D12FB95DF50051A9B09C572B11E4B1155A009A5D005B5A042101110003B}}
\par\par \b \uc2 DiCentral Inc\uc2 . Skin Sake Selects \uc2 DiCentral\uc2  - Streamlines Processes, Enjoys Immediate Benefits\b0\par\par\uc2 546 \uc2 words\par \uc2 19 September 2013\par \uc2 Computer Weekly News\par \uc2 COMWKN\par 357\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2013 Computer Weekly News via via VerticalNews.com   \par \par \uc2 2013 SEP 19 (VerticalNews) -- By a News Reporter-Staff News Editor at Computer Weekly News -- \uc2 DiCentral Inc\uc2 ., the leading innovator in supply chain management solutions and B2B integration, and Skin Sake, a leading over-the-counter drug company, announced that Skin Sake has selected \uc2 DiCentral\uc2 's leading B2B integration management solutions and that the company has realized immediate benefits.\par \par \uc2 Prior to tapping \uc2 DiCentral\uc2 's expertise, Skin Sake had been using traditional, time consuming and cumbersome methods. In addition to the many distributors and health care customers Skin Sake touts, the company's customer base has grown tremendously over the last few years. The company also recently \b \highlight22\uc2 launched\b0 \highlight\uc2  a \b \highlight22\uc2 new product\b0 \highlight\uc2 , Booty Goo Diaper Change Ointment, in more than 7,000 \uc2 Walgreen's\uc2  stores nationally. With all the expansion, increased transactions and customer interactions, the company saw the immediate need for a better way to manage its operations.\par \par \uc2 "Luckily, we found \uc2 DiCentral\uc2  fairly quickly through a customer referral," said \uc2 Matt Burns\uc2 , sales manager for Skin Sake. "Working with \uc2 DiCentral\uc2  has improved our entire business because the EDI-based solution completely streamlined our daily operations."\par \par \uc2 "Skin Sake is a savvy company that recognizes the importance of excellent supply chain management operations," says \uc2 Thuy Mai\uc2 , Founder and CEO of DiCentral. "We are excited to continue working with Skin Sake to further this strategic initiative as their business grows and to accelerate the sustainable savings across their service organization."\par \par \uc2 Being able to receive purchase orders, tracking reports, and sending ASNs and other communications from a central point has had an immediate impact that has led to savings across the Skin Sake organization, which they have, in turn, been able to pay forward in different ways to their customers.\par \par \uc2 Burns continues, "We look forward to growing Skin Sake with \uc2 DiCentral\uc2 . Our company is rapidly expanding and we want to add as many customers as possible onto the \uc2 DiCentral\uc2  platform!" About \uc2 DiCentral\uc2  Founded in 2000, today \uc2 DiCentral\uc2  is a leading global innovator in EDI (Electronic Data Interchange) software and service solutions. Our broad range of solutions enables a seamless exchange of data throughout the entire supply chain, creating a seamless communication stream from source to last mile. \uc2 DiCentral\uc2 's integration solutions are scalable to the size, growth, and unique requirements of each business. In addition, \uc2 DiCentral\uc2  develops and markets a complementary suite of supply chain applications for retailers and suppliers, including MFT software, WMS software, POS analytic software, outlier management software, managed EDI services, and more. About Skin Sake Jeff Foote from Hamburg, AR created Skin Sake. A pharmacist for over 37 years, he began compounding ointments for his pharmacy customers in the 1970's. Today, Skin Sake distributes nationally and manufactures 4 products: Skin Sake Ointment, Booty Goo Diaper Rash Ointment, Surface Protectant, and Skin Sake Athletic Ointment. Skin Sake strives to make the best over-the-counter skin care available, with products known for their high quality, fast acting formulas at affordable prices. For more information, please visit {\field{\*\fldinst{HYPERLINK "http://www.skinsake.com"}}{\fldrslt{\cf2 \uc2 www.skinsake.com}}}\uc2 , e-mail info@skinsake.com or call 870-734-6778.\par \par \uc2 Keywords for this news article include: Software, \uc2 DiCentral Inc\uc2 ..\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC\par \par \uc2 Document COMWKN0020130913e99j0008e\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Circadiance\uc2 (R) Dreams up SleepWeaver(R) Anew(TM) Soft Cloth Full Face PAP Mask for Sleep Apnea Sufferers\b0\par\par\uc2 452 \uc2 words\par \uc2 17 September 2013\par 08:30\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2013  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 \f2 \par All-cloth interface is designed for mouth breathing \par  \f28 \par \par \uc2 \f2 EXPORT, Penn., Sept. 17, 2013 /PRNewswire/ -- \f28 \uc2 \f2 Circadiance\f28 \uc2 \f2 \f28 \b \highlight22\uc2 \f2 announces the launch\f28 \b0 \highlight\uc2 \f2  of SleepWeaver(R) Anew(TM) Soft Cloth Full Face PAP mask, a \f28 \b \highlight22\uc2 \f2 new product\f28 \b0 \highlight\uc2 \f2  specifically designed for CPAP users who breathe through their mouth while sleeping. With the \f28 \b \highlight22\uc2 \f2 launch\f28 \b0 \highlight\uc2 \f2  of the SleepWeaver Anew, \f28 \uc2 \f2 Circadiance\f28 \uc2 \f2  is able to offer its groundbreaking technology to a larger audience of people who use CPAP masks.\f28 \par \par \uc2 (Photo: {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20130917/PH80937-a"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20130917/PH80937-a}}}\uc2  )\par \par \uc2 (Photo: {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20130917/PH80937-b"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20130917/PH80937-b}}}\uc2  )\par \par \uc2 SleepWeaver Anew features a dual interface design that seals around both the nose and the mouth, with only soft cloth touching the skin. Unlike the hard plastic masks made by other manufacturers, \uc2 Circadiance\uc2  soft cloth technology allows the skin to breathe, without moisture accumulating between the mask and the user's skin. The unique loose fit provides added comfort and eliminates strap marks, and the open-face headgear design accommodates eyeglasses and allows virtually unrestricted vision. All \uc2 Circadiance\uc2  masks allow for a greater variety of sleep positions. The mask is available in three sizes.\par \par \uc2 "We're excited to offer our soft cloth technology to even more people who use CPAP to treat obstructive sleep apnea or to provide non-invasive ventilation," said \uc2 David Groll\uc2 , founder and CEO of Circadiance. "With the SleepWeaver(R) Anew(TM), even mouth breathers can sleep in comfort. We're always working to develop products that make PAP therapy more comfortable."\par \par \uc2 Circadiance\uc2  introduced the world's first all-cloth respiratory interface, SleepWeaver, in 2007. Before SleepWeaver, people who used non-invasive ventilation or CPAP systems were limited in their choice of mask--only hard plastic masks were available. \uc2 Circadiance\uc2  changed the future of patient interface by developing a line of high-performance soft cloth masks that deliver comfort and ease of use and increase patient compliance.\par \par \uc2 For more information, call \uc2 Sean Johnson\uc2 , Marketing Communications Manager, at 724-858-2837 or visit {\field{\*\fldinst{HYPERLINK "http://www.circadiance.com"}}{\fldrslt{\cf2 \uc2 www.circadiance.com}}}\uc2 .\par \par \uc2 About \uc2 Circadiance\uc2 (R)\par \par \uc2 Circadiance\uc2 (R) develops, manufactures, and markets respiratory products under the SleepWeaver(R) brand for people with sleep-disordered breathing or who need non-invasive ventilation. Our innovative solutions increase patient compliance and have revolutionized the sleep therapy market. Sleep apnea patients and sleep specialists have lauded SleepWeaver soft cloth nasal positive airway pressure CPAP masks as a key to comfort and better sleep. With our cutting-edge technology and global distribution network, \uc2 Circadiance\uc2  will continue to deliver superior patient outcomes through the development of respiratory therapy products.\par \par \uc2 Read more news from \uc2 Circadiance\uc2 .\par \par \uc2 SOURCE \uc2 Circadiance\par \par \uc2 /Web site: {\field{\*\fldinst{HYPERLINK "http://www.sleepweaver.com"}}{\fldrslt{\cf2 \uc2 http://www.sleepweaver.com}}}\par \par \uc2 Web site: {\field{\*\fldinst{HYPERLINK "http://www.circadiance.com"}}{\fldrslt{\cf2 \uc2 http://www.circadiance.com}}}\par \par \uc2 Document PRN0000020130917e99h00089\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ NovaBay Files 8K - Other Events >NBY\b0\par\par\uc2 448 \uc2 words\par \uc2 17 September 2013\par 09:31\par \uc2 Dow Jones Newswires\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright (c) 2013, Dow Jones & Company, Inc.   \par \par \uc2 NovaBay Pharmaceuticals Inc\uc2 . (NBY) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on September 16, 2013.\par \par \uc2 On September 16, 2013, \uc2 NovaBay Pharmaceuticals, Inc\uc2 . announced positive top-line results from its recently completed Phase 2 clinical study CL1001 for auriclosene (NVC-422) to prevent urinary catheter blockage and encrustation (UCBE) of indwelling urinary catheters.\par \par \uc2 Study Results\par \par \uc2 This three part study utilized randomized double-blinded, placebo-controlled crossover design, where patients served as their own control and received both placebo and auriclosene. The study enrolled 67 subjects with chronic indwelling transurethral or suprapubic urinary catheters. There were a total of 125 treated catheters: 62 in the auriclosene arm and 63 in saline arm. In Part 3 of the study, which represents the clinical paradigm of four weeks of catheter duration use, subjects' catheters were irrigated twice weekly with a solution of either 0.2% auriclosene or saline for a total of eight treatments over four weeks, followed by a washout period and a similar cross-over treatment.\par \par \uc2 The top-line results show auriclosene was effective at reducing the degree of catheter encrustation and maintaining the catheter patency over the course of the study. Overall, the auriclosene irrigation solution reduced the average encrustation at the time of catheter removal from 77% encrusted (saline arm) to 22% encrusted (auriclosene arm). Importantly, a within-subject comparison for the degree of encrustation showed that the auriclosene arm demonstrated a statistically significant reduction (p = 0.005) in the degree of encrustation. Complete catheter blockage was not observed in any of the auriclosene-treated catheters, but was observed in 64% of the catheters treated with saline (p = 0.0004). Fifty percent of the saline-treated catheters had to be removed early because of laboratory-confirmed blockage, compared to none of the auriclosene-treated catheters. The drug was well tolerated; there were no treatment-related serious adverse events and only transient manageable adverse events in both treatment arms.\par \par \uc2 Based on these study results, NovaBay plans to continue discussions with the FDA and move toward registration.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1389545/000143774913012051/nby20130916_8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1389545/000143774913012051/nby20130916_8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1389545/000143774913012051/0001437749-13-012051-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1389545/000143774913012051/0001437749-13-012051-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 September 17, 2013 09:31 ET (13:31 GMT)\par \par \uc2 Document DJDN000020130917e99h002ju\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ NovaBay Files 8K - Regulation FD >NBY\b0\par\par\uc2 249 \uc2 words\par \uc2 17 September 2013\par 09:31\par \uc2 Dow Jones Newswires\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright (c) 2013, Dow Jones & Company, Inc.   \par \par \uc2 NovaBay Pharmaceuticals Inc\uc2 . (NBY) filed a Form 8K - Regulation FD Disclosure - with the U.S Securities and Exchange Commission on September 16, 2013.\par \par \uc2 On September 16, 2013, \uc2 NovaBay Pharmaceuticals, Inc\uc2 . issued a press release announcing results from its recently completed Phase 2 clinical study CL1001 for auriclosene (NVC-422) to prevent urinary catheter blockage and encrustation (UCBE) of indwelling urinary catheters. The press release is furnished as Exhibit 99.1 to this current report. NovaBay is also furnishing as Exhibit 99.2 to this current report its presentation that it will be presenting at an investor conference on September 17, 2013. NovaBay expressly disclaims any obligation to update this information and cautions that it is only accurate on the date it was presented. The inclusion of any data or statements in these documents does not signify that the information is necessarily considered material.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1389545/000143774913012051/nby20130916_8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1389545/000143774913012051/nby20130916_8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1389545/000143774913012051/0001437749-13-012051-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1389545/000143774913012051/0001437749-13-012051-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 September 17, 2013 09:31 ET (13:31 GMT)\par \par \uc2 Document DJDN000020130917e99h002jm\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 *DJ \uc2 NewLink Genetics\uc2  Completes Patient Enrollment in Phase 3 Algenpantucel-L Clinical Study\b0\par\par\uc2 51 \uc2 words\par \uc2 17 September 2013\par 08:57\par \uc2 Dow Jones Newswires\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright (c) 2013, Dow Jones & Company, Inc.   \par \par \uc2 17 Sep 2013 08:58 EDT *DJ  NewLink: Algenpantucel-L Designed to Stimulate Immune System to Recognize, Attack Cancer Cells\par \par \uc2 (MORE TO FOLLOW) Dow Jones Newswires (212-416-2800)\par \par \uc2 September 17, 2013 08:58 ET (12:58 GMT)\par \par \uc2 Document DJDN000020130917e99h0028y\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ \uc2 NewLink Genetics\uc2  Files 8K - Other Events >NLNK\b0\par\par\uc2 191 \uc2 words\par \uc2 17 September 2013\par 08:56\par \uc2 Dow Jones Newswires\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright (c) 2013, Dow Jones & Company, Inc.   \par \par \uc2 NewLink Genetics Corp\uc2 . (NLNK) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on September 17, 2013.\par \par \uc2 On September 17, 2013, \uc2 NewLink Genetics\uc2  (NASDAQ:NLNK) announced that a major milestone has been reached in the IMPRESS (Immunotherapy for Pancreatic Resectable cancer Survival Study) Phase 3 clinical trial of algenpantucel-L. The accrual goal of 722 subjects with surgically resected pancreatic cancer has been met.\par \par \uc2 The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1126234/000112623413000126/nlnk-20130917x8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1126234/000112623413000126/nlnk-20130917x8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1126234/000112623413000126/0001126234-13-000126-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1126234/000112623413000126/0001126234-13-000126-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 September 17, 2013 08:56 ET (12:56 GMT)\par \par \uc2 Document DJDN000020130917e99h0028w\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ Kythera Biopharma Files 8K - Regulation FD >KYTH\b0\par\par\uc2 458 \uc2 words\par \uc2 17 September 2013\par 06:04\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2013, Dow Jones & Company, Inc.   \par \par \uc2 Kythera Biopharmaceuticals Inc\uc2 . (KYTH) filed a Form 8K - Regulation FD Disclosure - with the U.S Securities and Exchange Commission on September 16, 2013.\par \par \uc2 On September 16, 2013, \uc2 KYTHERA Biopharmaceuticals, Inc\uc2 . (the "Company") issued a press release announcing its ATX-101 REFINE-1 and REFINE-2 Phase III trials met all primary and secondary endpoints. The Company will host an investor conference call at 8:00 a.m. Eastern Time on Tuesday, September 17, 2013 to discuss the Phase III clinical trial results. Conference call information is as follows:\par \par \uc2 Conference Call Numbers - (877) 344-3890 (U.S. and Canada) or (760) 666-3770 (international) Conference ID Number - 65266554\par \par \uc2 Representatives of the Company intend to present the information in the slides attached hereto as Exhibit 99.1, which is being furnished herewith under this Item 7.01.\par \par \uc2 The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.\par \par \uc2 The furnishing of the attached presentation is not an admission as to the materiality of any information therein. The information contained in the slide is summary information that is intended to be considered in the context of more complete information included in the Company's filings with the Securities and Exchange Commission (the "SEC") and other public announcements that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1436304/000110465913070289/a13-20822_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1436304/000110465913070289/a13-20822_18k.htm  }}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1436304/000110465913070289/0001104659-13-070289-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1436304/000110465913070289/0001104659-13-070289-index.htm  }}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 September 17, 2013 06:04 ET (10:04 GMT)\par \par \uc2 Document DJDN000020130917e99h001ju\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ Kythera Biopharma Files 8K - Other Events >KYTH\b0\par\par\uc2 974 \uc2 words\par \uc2 17 September 2013\par 06:04\par \uc2 Dow Jones Newswires\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright (c) 2013, Dow Jones & Company, Inc.   \par \par \uc2 Kythera Biopharmaceuticals Inc\uc2 . (KYTH) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on September 16, 2013.\par \par \uc2 On September 16, 2013, the Company announced that its ATX-101 REFINE-1 and REFINE-2 Phase III trials met all primary and secondary endpoints. These two pivotal Phase III trials were conducted in the U.S. and Canada to compare the efficacy and safety of a 2 mg/cm2 dose of ATX-101 versus placebo for the reduction of submental fat, which commonly presents as a double chin. ATX-101 is a proprietary formulation of a purified synthetic version of deoxycholic acid, a naturally occurring molecule in the body that aids in the breakdown of dietary fat.\par \par \uc2 REFINE-1 and REFINE-2 are two identical multicenter, double-blind, randomized, placebo-controlled trials that enrolled more than 1,000 subjects with moderate to severe submental fat in 70 centers in the U.S. and Canada. Validated clinician- and patient-rating scales were used to evaluate primary efficacy endpoints, assessed 12 weeks after the last treatment.\par \par \uc2 Primary Efficacy Endpoints\par \par \uc2 REFINE-1 (Study ATX-101-11-22)\par \par \uc2 70.3 percent of ATX-101 (2mg/cm2) REFINE-1 subjects demonstrated a simultaneous improvement of at least one grade from baseline on the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and Patient-Reported Submental Fat Rating Scale (PR-SMFRS) vs. 18.7 percent in placebo (p<0.001).\par \par \uc2 13.4 percent of ATX-101 (2mg/cm2) REFINE-1 subjects demonstrated a simultaneous improvement of at least two grades from baseline on the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and Patient-Reported Submental Fat Rating Scale (PR-SMFRS) vs. 0 percent in placebo (p<0.001).\par \par \uc2 REFINE-2 (Study ATX-101-11-23)\par \par \uc2 66.9 percent of ATX-101 (2mg/cm2) REFINE-2 subjects demonstrated a simultaneous improvement of at least one grade from baseline on the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and Patient-Reported Submental Fat Rating Scale (PR-SMFRS) vs. 22.4 percent in placebo (p<0.001).\par \par \uc2 18.7 percent of ATX-101 (2mg/cm2) REFINE-2 subjects demonstrated a simultaneous improvement of at least two grades from baseline on the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and Patient-Reported Submental Fat Rating Scale (PR-SMFRS) vs. 3.2 percent in placebo (p<0.001).\par \par \uc2 Secondary Efficacy Endpoints\par \par \uc2 Additionally, an assessment of the trials' first secondary endpoint showed 46.6 percent of REFINE-1 and 40.0 percent of REFINE-2 patients achieved a predefined, statistically significant reduction in the volume of their submental region vs. 5.4 and 5.1 percent for placebo, respectively (both p<0.001), as measured through magnetic resonance imaging (MRI).\par \par \uc2 Subjects also rated the visual and psychological impacts of submental fat using the Patient-Reported Submental Fat Impact Scale (PR-SMFIS), which assessed whether they perceived themselves to be happier, less bothered, less self-conscious, less embarrassed, younger or less overweight after treatment with ATX-101. Statistical significance was achieved for the change from baseline in PR-SMFIS with 3.63 vs. 1.14, and 3.47 vs. 1.48, for ATX-101 (2mg/cm2) and placebo for REFINE-1 and REFINE-2, respectively (p<0.001 for both). Each individual component within the PR-SMFIS also demonstrated statistical significance vs. placebo in both trials (p<0.001 for all PR-SMFIS measures).\par \par \uc2 Safety\par \par \uc2 There were no treatment-related serious adverse events. The most common adverse events, which were predominantly mild to moderate, were swelling, pain, bruising, numbness and redness. Consistent with previous studies, these adverse events were predominately transient and local to the treatment area. Less than 4 percent of subjects discontinued the study due to adverse events.\par \par \uc2 Forward-Looking Statements\par \par \uc2 To the extent that statements contained herein are not descriptions of historical facts regarding \uc2 KYTHERA Biopharmaceuticals\uc2 , they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including that the topline results of the REFINE-1 and REFINE-2 trials for ATX-101 are indicative of the final results of the respective studies. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, the regulatory approval process, the development progress of our collaborative partners, our substantial dependence on ATX-101 and other matters that could affect the availability or commercial potential of our drug candidate. KYTHERA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see KYTHERA's reports filed with the SEC, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2013 and our Annual Report on Form 10-K for the year ended December 31, 2012.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1436304/000110465913070289/a13-20822_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1436304/000110465913070289/a13-20822_18k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1436304/000110465913070289/0001104659-13-070289-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1436304/000110465913070289/0001104659-13-070289-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 September 17, 2013 06:04 ET (10:04 GMT)\par \par \uc2 Document DJDN000020130917e99h001h0\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw166\pich40\picscaley100\picscalex100\picwgoal2490\pichgoal600
47
4946383961A6002800F7000095A4CEF0F2F8768BBFD1D8EA4964AA677EB85871B12A4A9CA4B1D5E1E5F18598C63957A3C2CBE3B3BEDCF2F4F9FBFBFDF4F6FAEC
EFF6F8F9FCC6CFE5E0E4F0F1F3F8DFE3F0F5F7FBC5CDE4E1E6F1D5DBEBD9DEEDEEF0F7D4DAEBE3E7F2D7DDECF7F8FB9DABD1F6F7FBCED5E8FAFAFCEBEEF6FDFE
FEFBFCFDF3F5FADBE0EEE4E8F2AEBAD99EACD2BFC8E1BBC5DFE7EBF4E7EAF4CFD6E9B0BBDA90A0CB9DABD2D3DAEBD9DFEDEEF1F7ADB9D94F69AEF9FAFCC9D1E6
C1CAE2AFBBDAE6EAF3A1AFD3D9DFEE94A3CDFEFEFFE4E8F3AFBADA7D8FC2E5E9F3F3F5F9F5F7FAF5F6FA798CC04E68ADBAC4DFCBD2E7FCFDFE93A2CCDCE0EED0
D6E991A1CC6C81BBEDEFF6A8B5D7ABB7D7D6DCECB7C1DEC0C9E1DDE2F0B6C0DD6E83BCCCD4E8D8DEECFAFAFDE2E7F2AEBADAEDEFF7D2D9EAA7B4D6D3DAEACBD3
E798A7D0566EB1D5DBECC2CBE2FEFEFE8597C6AFBAD98395C5DADFEDA6B3D5DEE3F0EFF1F8BEC7E17388BFDDE2EFCCD3E7E8EBF4D1D7EAD0D7E9A5B2D599A8D0
DCE1EFC9D1E5DADFEEE9EDF5FEFFFFE2E6F2798DC0D1D7E9FDFDFED2D8E93A56A3ECEEF6C7CFE59FADD3E6E9F3E9ECF5B7C2DE99A8CF899AC8C2CAE3B9C3DFEF
F1F71B3D95FFFFFF0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000021F90400000000002C00000000A60028000008FF0027091C48B0A0C18308132A5CC8B0A1C38710234A9C244092A4020A0B5C5448
C062828920438A1C49D220038B0702200C605192CA83032C622C49B3A6CD9B931658448010404B000815586C80B3A8D1A30B7D6E3CD8D1A201843A0F209D4AF5
6882962F099E94A453D2C7825B1514D4F852634B941F599E9529B0E3008342D74A7A3BC9805C0103EDAEC5DB5312D0810DFC0A8CBB7640E099930E203EF0B4EE
5D887AFF12AC7820A6E08215E78E752990EC400482594A65AAB9A050C904598A1D08E0AF6A82AD132A6D3C29F0DFD34C534E52FA11348349AF59A366085A126D
81010E4812DB718141E5040C7A9E347D1268A0A211BA857BB9A0DABDC8E54AFFE27BD0A75D026F6D0FEE0E5B3001BB620D38072E9E7CC3E41E09167FABF43760
8BC351C799806B1D90D65A440DB49D69674547905E678DE65881B2CD551C02EA4D4298240E2277007A7315B0C0559241D892840E6586DA79E18D4790595FBD38
20590174C453782812B42041B8193440017475C6D98F410A9855413EBD35804E1DDDC6DE64C645171801BA4D42A48C4732B455875775A75195F81D37D0749ED5
785976A415B95E80D689375A7114F645570091AD89906537EA441E9C114AD4155D4A65159824375E781099039A594000DF35D8965C186DD812516682075C5367
D987646902F9E4A45C094E42C07CBB49E2DFA58F4514D76A3A21069C728DD9FF55E544849820901E204CD2C12255F5DAAB65CE6D15AA409925A096A61161E05F
08224CB2051FBE463B55530C50661280FD8934020693B020C124525C300907186420EDB9362995D96A0531D91C4821C0700323931C5283047B8851C2237038E0
04BA0093D4A857E59DC566432C4480C20A9304A1C2241F5D60EE0E1AD4A166C0183B649671087599DF445D5CC0831D09811180032864ACF24383129A905E6236
F483239314A18207362CB441141644B0F2CF0A2937AB418646048506937CE083430F38F000D0509F9B07158D40E29D00CA5924C05B205090C21751873D951093
708134581FDEF8A3600F9C2CF6DB3835614812935CF1F44031058800010120FF5101DC80D754810B933C90C3100F7618F8E2484D5186772E2BE422415DB534DF
C6F999686A41934FE2A2522D21CB784D4AA80116A708750E71773E09B4005F016C5D17A902E9C553E79F134C51CCA393E4C6139314828656A81FA43A89AC4952
FB5ABF417823E7E4E59E69EF379D41C6242FF4919A24C31A6F1FF29D2A1FFB5757F1249FE4D1E3E5538CD41765051D0619C03B416B3D55B945F3DDBFB9E6A73E
7A164FEB6BDF51FCE0020A4C802079231ADF262181BB09F0810779431826E1051A9C8E00FE19805D8062010A400082202CC81CD86082311C240199D11A5D2AC0
810F86F0850221C11222D1860332240E16E0800E6008C33534AB051E5808046F1C40441EF2F0038200440F5A1081441C84049348410780600423C2F0044798C4
060201023C9C00068880984A64300839B8D08A4654040E2631831540C00C1118C008EE90B40C6C008D56F400112651820E482006589884162690053C1A722055
4803F69820903F1CF29190B4494000003B}}
\par\par \b \uc2 Cook Medical \highlight22\uc2 Introduces \highlight\uc2  LithAssist to Streamline Stone Management and Treatment\b0\par\par\uc2 271 \uc2 words\par \uc2 14 September 2013\par \uc2 Wireless News\par \uc2 WLNW\par \uc2 English\par \uc2 (c) 2013. Close-Up Media, Inc. All rights reserved.   \par \par \uc2 Cook Medical\uc2  said that it has a \b \highlight22\uc2 new device\b0 \highlight\uc2  to simplify percutaneous nephrolithotomy (PCNL) procedures, during which physicians break up and remove large kidney stones, or can use it in the bladder to break up large bladder stones.\par \par \uc2 In a release, Cook noted:\par \par \uc2 LithAssist combines suction control and provides access for a laser fiber. It is the first device globally to provide suction control and laser fiber access. Approximately 67,000 PCNL procedures are performed each year in the United States, and 466,000 are performed globally.\par \par \uc2 Prior to the availability of LithAssist, an assistant controlled suction by kinking a tube, similar to how one would stop water flow from a garden hose. LithAssist allows physicians to control suction more easily during the procedure. The ergonomic handle allows the physician to position the laser fiber and suction with one hand. Not only does this synchronize the procedure by giving the physician more control, but it also can free an assistant to help with other aspects of the procedure.\par \par \uc2 LithAssist works with any holmium laser, so hospitals can use their current equipment and don't have to purchase any additional capital equipment.\par \par \uc2 "Our goal for this product is to help physicians use their lasers for PCNL procedures in a simple way," said Jean-Marc Creissel, global leader of \uc2 Cook Medical\uc2 's Urology division. "Streamlined procedures are beneficial for the physician, the hospital and ultimately the patient. This is just one more example of our commitment to solving problems for physicians."\par \par \uc2 ((Comments on this story may be sent to health@closeupmedia.com))\par \par \uc2 Document WLNW000020130914e99e000b9\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ Delcath Systems Files 8K - Other Events >DCTH\b0\par\par\uc2 217 \uc2 words\par \uc2 13 September 2013\par 17:01\par \uc2 Dow Jones Newswires\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright (c) 2013, Dow Jones & Company, Inc.   \par \par \uc2 Delcath Systems Inc\uc2 . (DCTH) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on September 13, 2013.\par \par \uc2 On September 13, 2013, \uc2 Delcath Systems, Inc\uc2 . ("Delcath") issued a press release announcing that it has received a "Complete Response" letter from the \uc2 U.S. Food & Drug Administration\uc2  for the New Drug Application for Delcath's MelblezTM Kit (Melblez (melphalan) for Injection for use with the Delcath Hepatic Delivery System) for the treatment of patients with unresectable ocular melanoma metastatic to the liver. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/872912/000134100413000920/form8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/872912/000134100413000920/form8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/872912/000134100413000920/0001341004-13-000920-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/872912/000134100413000920/0001341004-13-000920-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 September 13, 2013 17:01 ET (21:01 GMT)\par \par \uc2 Document DJDN000020130913e99d005a7\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ Chimerix Files 8K - Other Events >CMRX\b0\par\par\uc2 298 \uc2 words\par \uc2 12 September 2013\par 09:20\par \uc2 Dow Jones Newswires\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright (c) 2013, Dow Jones & Company, Inc.   \par \par \uc2 Chimerix Inc\uc2 . (CMRX) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on September 11, 2013.\par \par \uc2 On September 11, 2013, in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference, we announced results from Study 202, our exploratory Phase 2 study evaluating brincidofovir (CMX001) in hematopoietic cell transplant (HCT) recipients with early adenovirus (AdV) infection. Study 202 is the first trial of an antiviral agent in AdV infection. Brincidofovir is an investigational oral nucleotide analog lipid-conjugate that has demonstrated broad-spectrum activity in vitro against all pathogenic families of double-stranded DNA (dsDNA) viruses, including herpesviruses, adenoviruses, and polyomaviruses.\par \par \uc2 The information in this Item 8.01 and the attached Exhibit 99.1 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 8.01 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1117480/000114420413050365/v354859_8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1117480/000114420413050365/v354859_8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1117480/000114420413050365/0001144204-13-050365-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1117480/000114420413050365/0001144204-13-050365-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 September 12, 2013 09:20 ET (13:20 GMT)\par \par \uc2 Document DJDN000020130912e99c002yj\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ Synta Pharmaceuticals Files 8K - Other Events >SNTA\b0\par\par\uc2 178 \uc2 words\par \uc2 11 September 2013\par 16:17\par \uc2 Dow Jones Newswires\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright (c) 2013, Dow Jones & Company, Inc.   \par \par \uc2 Synta Pharmaceuticals Corp\uc2 . (SNTA) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on September 10, 2013.\par \par \uc2 On September 10, 2013, \uc2 Synta Pharmaceuticals Corp\uc2 . issued a press release announcing the launch of its Hsp90-inhibitor Drug Conjugate (HDC) platform. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1157601/000110465913069265/a13-20541_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1157601/000110465913069265/a13-20541_18k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1157601/000110465913069265/0001104659-13-069265-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1157601/000110465913069265/0001104659-13-069265-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 September 11, 2013 16:17 ET (20:17 GMT)\par \par \uc2 Document DJDN000020130911e99b00535\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 PRESS RELEASE: \uc2 Raven Industries \highlight22\uc2 Announces  \highlight \highlight22\uc2 New \highlight \highlight22\uc2  Product \highlight\uc2  Line: NEMESIS(TM) Garments, Personal Hides & Equipment Covers, Multispectral Signature Concealment\b0\par\par\uc2 902 \uc2 words\par \uc2 10 September 2013\par 14:26\par \uc2 Dow Jones Newswires\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright (c) 2013, Dow Jones & Company, Inc.   \par \par \uc2 Raven Industries\b \highlight22\uc2 Announces \b0 \highlight\b \highlight22\uc2 New\b0 \highlight\b \highlight22\uc2  Product\b0 \highlight\uc2  Line: NEMESIS(TM) Garments, Personal Hides & Equipment Covers, Multispectral Signature Concealment\par \par \uc2 SIOUX FALLS, S.D., Sept. 10, 2013 (GLOBE NEWSWIRE) -- Raven Aerostar (Nasdaq:RAVN), leader in the design and manufacture of specialty sewn and sealed products and surveillance technology, announced today its groundbreaking signature management product line: NEMESIS(TM) Garments, Personal Hides and Equipment Covers. Raven Aerostar and \uc2 W.L. Gore & Associates\uc2  (Gore(R)) have partnered together to develop multispectral camouflage and signature concealment garments, hides and covers. NEMESIS represents a breakthrough in signature concealment for warfighters and security personnel. Using GORE(R) Multispectral Concealment materials, NEMESIS Garments, Personal Hides and Equipment Covers are the first material technology that greatly reduces the range of detection from sophisticated radar technology and multi-spectral electro-optical/infrared (EO/IR) sensors.\par \par \uc2 The modern warfighter and security personnel have an amplified need for detection protection against rapidly advancing persistent sensor technology. NEMESIS conceals personnel and high value equipment against advanced infrared surveillance sensors and radio frequency (RF). NEMESIS Garments, Personal Hides and Equipment Covers present a significant tactical advantage for daytime and nighttime operations, specifically minimizing detection during infiltration and exfiltration.\par \par \uc2 "Much like consumer electronics, sensor systems have improved in quality, and decreased in cost. Thus, military sensors (image intensifiers, thermal imagers, and radar systems) are beginning to proliferate into unfriendly hands. Gore's unique material sets and technologies enable the creation of true multispectral protection against these threats. Through Gore's partnership with Raven Aerostar, a world class manufacturer, the NEMESIS Turkey Suits with GORE(R) Multispectral Concealment Technologies offer a truly revolutionary protection capability for those going into harm's way," stated John Holcombe, \uc2 W. L. Gore & Associates\uc2  co-inventor and business leader.\par \par \uc2 Raven Aerostar and Gore(R) have optimized the NEMESIS product line through years of development, prototyping and field testing. NEMESIS Garments, Personal Hides and Equipment Covers have proven results alleviating current and emerging signature threats to ultimately protect lives and strategic assets. Raven Aerostar's NEMESIS Turkey Suit, an over garment, is available for purchase directly through Raven Aerostar and through GSA Advantage. The camouflage, concealment and deception NEMESIS Turkey Suit system allows full-body coverage and is available in a broad range of military camouflage textile patterns.\par \par \uc2 "Lead users have validated the superior performance of the NEMESIS Turkey Suits with GORE(R) Multispectral Concealment Technologies through extensive field trials. Making this product available for purchase through Raven Aerostar's commercial channels now enables the U.S. warfighter to achieve unparalleled comprehensive personal signature reduction, thus enabling greater likelihood for mission success," stated Sean McDearmon, \uc2 W.L. Gore & Associates\uc2  Branch Specialist.\par \par \uc2 "Raven Aerostar is committed to the design, development and manufacture of life-saving solutions," stated Raven Aerostar Vice President and General Manager \uc2 Lon Stroschein\uc2 . "The applications of the NEMESIS garments are endless, and through our partnership with Gore(R), we continue to develop new, innovative solutions to provide multispectral signature management to the individual soldier and his equipment."\par \par \uc2 About Aerostar International, Inc: Aerostar International (Raven Aerostar), a wholly owned subsidiary of \uc2 Raven Industries\uc2 , is a world leader in the design and manufacture of highly technical aerospace, surveillance technology, electronics and specialty sewn products. Aerostar and Raven are based in Sioux Falls, S.D. The company has a rich history, helping save lives through its unique product lines. Raven Aerostar's engineers design and manufacture protective wear, persistent surveillance technologies, high altitude scientific balloons, inflatable military decoys, marine navigation equipment and specialty electronics. Raven Aerostar is committed to providing its customers with the innovative solutions that they require and the answers that they can trust.\par \par \uc2 About \uc2 Raven Industries, Inc\uc2 : Since 1956, \uc2 Raven Industries\uc2  has designed and manufactured high quality, high-value technical products. Raven is publicly traded on NASDAQ (RAVN) and has earned an international reputation for innovation, product quality, high performance, and unmatched service. Raven's purpose is to solve great challenges in areas of study, feeding the world, energy independence and resource preservation. To realize this purpose, we utilize our strengths in engineering, manufacturing and technological innovation to serve the precision agriculture, high performance specialty films, aerospace, and electronic manufacturing services markets.\par \par \uc2 About \uc2 W. L. Gore & Associates\par \par \uc2 Gore is a technology-driven company focused on discovery and product innovation. Well known for waterproof, breathable GORE-TEX(R) fabric, the company's portfolio includes everything from high-performance fabrics and implantable medical devices to industrial manufacturing components and aerospace electronics. Founded in 1958 and headquartered in Newark, Del., Gore posts annual sales of more than $3.2 billion and employs approximately 10,000 associates with manufacturing facilities in the United States, Germany, the United Kingdom, Japan and China, and sales offices around the world. Gore is one of a select few companies to appear on all of the U.S. "100 Best Companies to Work For" lists since the rankings debuted in 1984. The company also appears regularly on similar lists around the world. Learn more at gore.com.\par \par \uc2 On the Internet, information is available at:\par \par {\field{\*\fldinst{HYPERLINK "http://www.ravenaerostar.com"}}{\fldrslt{\cf2 \uc2 www.ravenaerostar.com}}}\par \par {\field{\*\fldinst{HYPERLINK "http://www.ravenind.com"}}{\fldrslt{\cf2 \uc2 www.ravenind.com}}}\par \par {\field{\*\fldinst{HYPERLINK "http://www.gsaadvantage.gov"}}{\fldrslt{\cf2 \uc2 www.gsaadvantage.gov}}}\uc2  (search "Turkey Suit") \par \par \uc2 \f2 \par CONTACT: Aerostar International, Inc. \par          Abby O'Hara \par          Ph: 605-331-3500, Fax: 605-331-3520 \par          Email:  AEROsales@ravenind.com \f28 \par \par \uc2 \f2 (END) Dow Jones Newswires\f28 \par \par \uc2 \f2 September 10, 2013 14:26 ET (18:26 GMT)\f28 \par \par \uc2 Document DJDN000020130910e99a004qi\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ Theravance Files 8K - Other Events >THRX\b0\par\par\uc2 455 \uc2 words\par \uc2 9 September 2013\par 08:01\par \uc2 Dow Jones Newswires\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright (c) 2013, Dow Jones & Company, Inc.   \par \par \uc2 Theravance Inc\uc2 . (THRX) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on September 08, 2013.\par \par \uc2 On September 8, 2013 at the \uc2 European Respiratory Society\uc2  (ERS) Annual Congress 2013 in Barcelona, Spain, \uc2 GlaxoSmithKline\uc2  (GSK) presented posters containing information from Phase 3 studies of umeclidinium/vilanterol (UMEC/VI) in chronic obstructive pulmonary disease (COPD). UMEC/VI is a combination of two investigational bronchodilator molecules - GSK573719 or umeclidinium, a long-acting muscarinic antagonist (LAMA) and vilanterol (VI), a long-acting beta2 agonist (LABA), administered using the ELLIPTA inhaler. UMEC/VI is under regulatory review by the \uc2 U.S. Food and Drug Administration\uc2  (FDA), \uc2 European Medicines Agency\uc2  and the \uc2 Japanese Ministry of Health, Labor and Welfare\uc2 . Marketing applications for UMEC/VI have been submitted to regulatory authorities in a number of other countries worldwide.\par \par \uc2 In addition, GSK presented data on ELLIPTA from Phase 3 asthma studies of FF/VI, the treatment combination of fluticasone furoate (FF), an inhaled corticosteroid, and VI, and FF monotherapy. FF/VI, known in the United States as BREO ELLIPTA (100/25mcg), is approved by the FDA as an inhaled long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. It is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations. It is not indicated for the relief of acute bronchospasm or the treatment of asthma. FF/VI is not currently approved or licensed in the \uc2 European Union\uc2  or anywhere outside of the U.S. and Canada.\par \par \uc2 GSK also presented a poster containing information from a Phase 2 study of GSK961081 in patients with COPD. GSK961081 ('081) is an investigational, single molecule bifunctional bronchodilator with both muscarinic antagonist and beta2 receptor agonist activities.\par \par \uc2 UMEC/VI and FF/VI are in development under the LABA collaboration agreement between \uc2 Glaxo Group Limited\uc2  and \uc2 Theravance, Inc\uc2 . '081 is in development under the strategic alliance between \uc2 Glaxo Group Limited\uc2  and \uc2 Theravance, Inc\uc2 .\par \par \uc2 The posters are filed as Exhibits 99.1 to 99.4 to this report and are incorporated herein by reference.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1080014/000110465913068581/a13-20084_28k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1080014/000110465913068581/a13-20084_28k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1080014/000110465913068581/0001104659-13-068581-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1080014/000110465913068581/0001104659-13-068581-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 September 09, 2013 08:01 ET (12:01 GMT)\par \par \uc2 Document DJDN000020130909e99900230\par }\page {\par\fs20\b \uc2 Orexigen Therapeutics, Inc\uc2 . \uc2 Orexigen Therapeutics\uc2  Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee\b0\par\par\uc2 393 \uc2 words\par \uc2 9 September 2013\par \uc2 Pharma Business Week\par \uc2 PHBW\par 21\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2013 Pharma Business Week via NewsRx.com    \par \par \uc2 2013 SEP 9 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- Orexigen(R) \uc2 Therapeutics, Inc\uc2 . (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, announced that the Light Study independent Data Monitoring Committee has recently confirmed that sufficient major adverse cardiovascular events (MACE) are expected to occur within the next two months, enabling the interim analysis to be conducted by early December and the potential resubmission of the Contrave(R) \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (NDA) by year end. The DMC also recommended that the Light Study continue as planned with no changes to the protocol.\par \par \uc2 "I'm proud of the progress made by our Light Study team," said \uc2 Michael Narachi\uc2 , Chief Executive Officer of Orexigen. "We remain focused on trial execution and \b \highlight22\uc2 launch\b0 \highlight\uc2  preparation and look forward to the interim analysis and upcoming regulatory submissions."\par \par \uc2 Orexigen also today reiterated its plan to submit a Marketing Authorization Application (MAA) for Contrave(R) to the \uc2 European Medicines Agency\uc2  (EMA) in advance of the Light Study interim analysis and to have cardiovascular outcomes data from the Light Study available for the Committee for Medicinal Products for Human Use (CHMP) Day 120 List of Questions.\par \par \uc2 About Contrave (32 mg naltrexone sustained?release (SR)/360 mg bupropion SR) for the treatment of obesity: In 2012, Orexigen screened more than 13,000 patients, enrolled more than 10,400 and ultimately completed recruitment of the Light Study with approximately 8,900 randomized patients. The primary objective of the double?blind, randomized, placebo?controlled Light Study, which Orexigen is conducting under a Special Protocol Assessment with the \uc2 U.S. Food and Drug Administration\uc2  (FDA), is to rule out excess cardiovascular risk in overweight and obese patients receiving Contrave. An interim analysis and NDA resubmission is planned once the DMC has determined that sufficient information has been gathered for the analysis that would include at least 87 adjudicated MACE.\par \par \uc2 Orexigen has licensed North American commercial rights to \uc2 Takeda Pharmaceuticals\uc2 . Orexigen owns Contrave rights throughout the rest of the world and intends to license commercial rights outside North America.\par \par \uc2 Keywords for this news article include: Treatment, Cardiology, Cardiovascular, \uc2 Orexigen Therapeutics Inc\uc2 ..\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC\par \par \uc2 Document PHBW000020130906e99900005\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw108\pich40\picscaley100\picscalex100\picwgoal1620\pichgoal600
47
49463839616C002800F70000F2899AEA3856F7B5C0F38D9EF18294EB4561E93F53E82446F07086E71F41F59EADF1798DE40429E6203AED556EFEFAFBF8BDC6FB
DDE2F391A2E20015FCE2E6DE0000F6A6B4F5A0AFFBD8DEFAD2D9F5A5B3FBD6DCFFFDFDFDECEFE93755E71D40E93151E8294AE92E4DF9CAD2F28698FEF9FAEF6C
82F6AEBAFEF5F6F7B8C3FDF0F3F38A9DFEF2F4EA3D5AFCE5EAFCE4E8F6ACB8E00006F496A4EE677AEC4A65F8C3CCEA4159E2001CE2001AF28496F6AAB7FBDBE1
FEF7F8EC4F6AE93C4FF9C6CFFEF8F9F17C90E7193CE20017FCE8ECE30124F8BFC9E61438FEFBFBFBE0E5E1000EE50A2FED5A73FEF0F3E92F50FDEBEEF49BAAEF
697FE61237F5A3B2E40826E6183BFFFCFFFDEDF0E40227E72844EA3B58EF6F84E71B3EEF6A81F18093E3001EEE667CEE637BE4112DE30022E0000BE30020F9C5
CEF8C0C9E82648E4082DE10012E82D4AE9324DF6B0BCFAD2DAF07586E71C40FFFAFEED5972EB4864F38EA0FDEEF1FDEAEDFCE4EAE82746E50E32E51131E6173A
E4022AFAD4DAFAD0D7FACED6EB405CE71A3CF9C7D0E71C3EF8C1CBFFFFFFF8BBC5E51631E40127EE647BF7B4BFE40A29ED5870F07489F49AA9E50F34E40426E5
082EEB425FE50D32DF0003EC596EFBDEE3E82B4CED536DED5269F0778BF9CED5E61338EE6179EE5D75E30024F499A9DA0000E61539E61536EB415EEA3F5CE50C
31E4062AEF6F7FE6143AE30621EC4D67EA425CE71E41E6173BE50C2FFFFEFEF8C2CBE50B30FACED5F498A7ED5771FBDADFFAD1D8FCE1E6E61035F6ABB8F396A6
FFFEFFE7193EF49CABFCE1E5F6A8B5F17F92E51034EF677EE30223F5A2B5E60E33F7B3BEE93554F7B6C1E50D2BE61137E72142E72641F6AFBBEA4157F497ACF5
A9B0EC5468F6ADB9FCDDE3FDE9EFFCDFE4ED5B73EB4A63EB4C67F07287F1728EEE6A79F8BAC8FCE3E7E51438E83747FCE7EBEB5061F5A8B5F6AAB5FDEBF0E61E
3AFEFEFEE5092DF8C4CDF9BECAE51E37E51036F491A6F4A1A6F4A8ABE40326FDF1F3FEF3F5FDF3F6F9CFD6FACDD5EF7388FEEFF1F17D91FBD4DEF17B8FF6B2BD
F0758BF07688FDF4F5FEF5F721FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A32343236453736353530464231314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3234
323645373636353046423131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3234323645373633353046423131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3234323645373634353046423131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000006C00280040
08FF000B091C48B0A0C18308132A5CC8B0A1C387100FA6F8D2EB40883D656A113C76830B336655700C23E86B88476642706823B862C8A30FF222CA9CA9B00F16
575F0C152C058F4B152E45461414814EC89E2A692210F4D7EA91902AA2F278A349B5AAD5AB58155EA830A51013250F0ADD20500888197C4A5E68A840AB900E74
9EB0A82BE4E1D50F4215F0C1FA92A41002598530A98A57084F17084AEA1482A18687843C851891B95008C70E07766351DA0246CF8F58154808D0E38941BE8119
C8C810880402A53602D9680977234CA1AD290A850094B521A99E9F041D04718ACB277A0691A0597244162E83F25A19C3D1B6B7F5840ECA7C6122304599234B5E
14FF9A03EF461481306E707A4438C0A9218D043AC2F1080E87422296E0C871BDBFC13915C4E00142165052410F0841514105DC1D04C0825BF8675D3292DC9310
10149450083E8184256121A0D0008B84B6E812560D3A71A0CB2FB76912813A2A60005B2196E8024421354051082F00BC718687EE8C9084338518618440861C59
08072C08A0C42D85B8F0CE1585D812CD8D8558B1C21B466868458F67C0D20791852892C22CC008E4463F048857C8086F00104721769063472118C0709F21B17C
68D015C8A832A34144384105040859C28C323F2004C129522C01A59FFE79814302AD4CF2813F052170692B698460D0355F249000162D18544B191951EA1F0B5C
3CFF82036C1F4C575D38B9703204A28F708283050259128928376050C8129C94918C40B330204A11C2B97A1D2D43E4C10C0A033582C3120E1080882C97203150
173830104610639C32E040727C010902FA8C014901D2F6E7043A4378619037931CC1CC102418940122422430848E058D504420ADDC4066BD598D08F1C414577C
1521D0B831C70285586000B04D10600323D514328E06190C40CB12D8BE314D217F0002882585447143261B84F3B22FDD08600009E296C34836E328408F17C865
E0C58D1604EC062B2DB821503DAC949241218D00560837CB0E34850DAB74ED880D98D85288377460D08503BC60F08C17F70D440722F314428313652DA100086B
14FFE24C0C140020857C4B8C674E606208A4020723504259239114A2056F853811052E319080CB3543EC801F15F6E0F7850992275E0861341C2210610B045248
020114D24104494C308340464040067F251C82891D889C5108007C6828C21C161FE4C81A59F097FCF3053DB150070A3DD084422EB8608BF4D0D344470C38A081
D002314C80F741DAC4A006290875A2C6105A744F530658148C03E9051931061709E0C0714127B8C1070C06008368000752E00495E417110E5C4216A21006336E
F0B281A080198F108514123006440DE409AEE0842838F10178CC8220149804276E700206CAC466F0D88222C69040EA09C4135F28823E7451864930E31F03E901
31FFBE40820BDCC01468885B214AC180FBB93022BAB88114D841844284E10645405E217631845C5481058119C3181054083AE0008961C9C6186ED00981E06308
6900C11321620729480107692AC439D0208B214C0116CEFA8207817000530C21194D18832BC6900E81D44114CB18C226E2F10557306003737C08202071033010
E4160C1082103861B0FF0924169FE082105CD10A1C0C80206D10A0288E9080094820930EB1143AE45890155C2A01F048554182F1CB22ACC2205BC0013312B01D
5C36A4064510C529FC70101A8C2115E8B0C6415A80855C7CE34E060101034C0187983853214800030D58A1038470801FE2D0E641608100695000213C4844256C
78FFCE7EFAF39F000D687FBE774F8450630CD4DB470EC4F521F749AC3F248881134280081FB4A0194AC0C02FD0B0854B348003C318C2111CA0005114420215F8
430DA8C0995164400EE8380404824106C9A9410B22A0848E1A700A1A4C420D665802FB10100AE1D466038BD8C2301641840CB074A976A0432F0A01860A505320
E993041E4A51881928A1007898802DEC300121040012E0D042162811B081480011E2EAC1F9D2A0805964A1004C608025E81039B79C42145F00E2072E110639A0
82107EF8C21DFC02182D4842201ED0C6053E21105CDCA0032E98443130B18D44AC601025C003611981005D38C10989306C2C144085234C822017208315063280
219D0CA41D69A8411A8443073E080419F41A0801C8A018641CA12C6AA08502BE000210883508371088046AFA8F0A1000080D60003311858D0A4081041328C401
F020903D2063783808842484618642982014BB184F2860F382066081195F30032CD681850494010300082F062A00034D8CA1105350C21E8431880780420D8160
C021E2E1024A28A2104150021045C14BF975E11A419840261E2AD012FB2920003B}}
\par\par \b \uc2 Usana Health Sciences, Inc\uc2 . \uc2 USANA\uc2  Unveils New and Reformulated Products\b0\par\par\uc2 212 \uc2 words\par \uc2 7 September 2013\par \uc2 Marketing Weekly News\par \uc2 MRKWN\par 209\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2013 Marketing Weekly News via VerticalNews.com   \par \par \uc2 2013 SEP 7 (VerticalNews) -- By a News Reporter-Staff News Editor at Marketing Weekly News -- \uc2 USANA Health Sciences, Inc\uc2 . (NYSE: USNA), an international nutritional company, announced exciting \b \highlight22\uc2 new products\b0 \highlight\uc2  and upgrades to their low-glycemic Foods line during its 21st International Convention. \uc2 USANA\uc2  unveiled four \b \highlight22\uc2 new products\b0 \highlight\uc2 : a mild-flavored meal replacement shake called Nutrimeal(TM) Free and three protein snacks--Choco Chip(TM), Peanutty Bliss(TM) and Fudge Delite(TM). The company also \b \highlight22\uc2 introduced\b0 \highlight\uc2  customers to reformulated Nutrimeal flavors and a new, upgraded probiotic supplement.\par \par \uc2 "\uc2 USANA\uc2 's new protein snacks, along with Nutrimeal Free and our other product upgrades, are major steps forward in the continued development of our Foods product line," says USANA Chief Marketing Officer \uc2 Doug Braun\uc2 . "The markets for diet, weight-management, and health-related products are constantly changing, and \uc2 USANA\uc2  understands the need to evolve with these marketing trends. It's important for us to stay relevant and listen to what our consumers want in order to continue our worldwide growth and success for years to come."\par \par \uc2 Keywords for this news article include: Marketing, Advertising, \uc2 Usana Health Sciences Inc\uc2 .\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC\par \par \uc2 Document MRKWN00020130830e9970005h\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 The X-Change Corporation\uc2  To Announce Corporate Name Change Next Week; New Industry-Driven Branding to Commence For Global Activities, Services, Product Lines, and Website\b0\par\par\uc2 719 \uc2 words\par \uc2 6 September 2013\par 07:49\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2013  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 \f2 \par Motivated by Industry-Specific Branding For Operational \f28 \b \highlight22\uc2 \f2 Launch\f28 \b0 \highlight\uc2 \f2  of the Company's \f28 \uc2 \f2 Medbox, Inc\f28 \uc2 \f2 . Multi-Year, Multi-State Medical Cannabis Dispensary and Cultivation Agreement, \f28 \b \highlight22\uc2 \f2 New Product\f28 \b0 \highlight\uc2 \f2  Releases, International Operating Subsidiaries' Establishment, and Website \par  \f28 \par \par \uc2 \f2 COLORADO SPRINGS, Colo., Sept. 6, 2013 /PRNewswire/ -- \f28 \uc2 \f2 The X-Change Corporation\f28 \uc2 \f2  (NASDAQ OTC: XCHC), a U.S. Company specializing primarily in cannabinoid formulation-based health and wellness solutions, is pleased to announce that the Company's Board of Directors has carefully considered and affirmatively decided to change the name of the Company. The company share structure will remain the same, as there will be no consolidation or share split in this corporate action. The new Brand name will be announced next week and will better position the Company in the global medical cannabis market.\f28 \par \par \uc2 The new Company name will serve as the enhanced brand and refined image to be used in conjunction with all of its activities, products, and services. Dispensary owners will be licensed to use the Company's brands and formulations for retail distribution through licensing agreements.\par \par \uc2 Through the current Medbox agreement, the Company expects to enter into ten additional management agreements with the owners of dispensary and cultivation operations in the states of Arizona, California, Illinois, Massachusetts, Nevada, and Washington State. Building on the new Company name, this brand will also serve as the primary name of international subsidiaries and their operations globally, for products already set for release, for various new products and services under study or development, and for worldwide website and social media modalities.\par \par \uc2 Specifically, initial regulatory steps to effectuate the name change have begun in order to maximize the branding of the Company's launch of its Arizona dispensary management and of its management operations pursuant to the agreement with \uc2 Medbox, Inc\uc2 . regarding legal medical cannabis dispensary and cultivation facilities around the country.\par \par \uc2 "We are very excited about the upcoming corporate name change. The Company's branding is a critical component in our messaging and will provide an enhanced platform for the important work that the Company is undertaking for the benefit of science, solutions for patients, and the integrity of the markets," stated \uc2 Robert Kane\uc2 , CFO and Senior Vice President for Business Development of XCHC. Mr. Kane continued, "We expect to announce the new name and branding campaign next week."\par \par \uc2 About \uc2 The X-Change Corporation\par \par \uc2 The X-Change Corporation\uc2  is currently developing new natural cannabinoid containing products based on innovative formulations to utilize the unique and potent benefits of the cannabis and hemp plants. Medicinal properties of cannabis and hemp have been known and applied for thousands of years. With the aid of scientific research, \uc2 The X-Change Corporation\uc2  is translating such knowledge into development of effective cannabinoid formulation-based health and wellness solutions as well as cosmeceutical, nutraceutical, and food brands throughout the world. The Company's health and wellness, nutritional, and cosmetics lines will address personal needs and will evolve with the introduction of new formulations and products, advancing the Company within the expanding multibillion-dollar global market.\par \par \uc2 Forward Looking Statements\par \par \uc2 This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. \uc2 X-Change Corp\uc2 . does not undertake any duty nor does it intend to update the results of these forward-looking statements.\par \par \uc2 The X-Change Corporation\par \par \uc2 President\par \par \uc2 Dr. Dorothy Bray\par \par \uc2 info@xchangecorp.com\par \par {\field{\*\fldinst{HYPERLINK "http://www.xchangecorp.com"}}{\fldrslt{\cf2 \uc2 www.xchangecorp.com}}}\par \par \uc2 +1.866.326.5595\par \par \uc2 Investment Inquiries\par \par \uc2 Robert Kane\par \par \uc2 CFO, Sr VP of Business Development\par \par \uc2 rkane@xchangecorp.com\par \par \uc2 +1.561.420.4824\par \par \uc2 SOURCE \uc2 The X-Change Corporation\par \par \uc2 Web site: {\field{\*\fldinst{HYPERLINK "http://www.xchangecorp.com"}}{\fldrslt{\cf2 \uc2 http://www.xchangecorp.com}}}\par \par \uc2 Document PRN0000020130906e9960001n\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ Agenus Inc Files 8K - Other Events >AGEN\b0\par\par\uc2 256 \uc2 words\par \uc2 5 September 2013\par 06:18\par \uc2 Dow Jones Newswires\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright (c) 2013, Dow Jones & Company, Inc.   \par \par \uc2 Agenus Inc\uc2 . (AGEN) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on September 05, 2013.\par \par \uc2 Agenus Inc\uc2 . announced today that \uc2 GlaxoSmithKline\uc2 's (NYSE: GSK) DERMA i study, a Phase 3 randomized, blinded, placebo-controlled MAGE-A3 cancer immunotherapeutic ii (CI) trial, which contains Agenus'QS-21 Stimulon (R) adjuvant iii, a component of GSK's novel adjuvant system AS15, did not meet its first co-primary endpoint. In an independent analysis, the study did not significantly extend the disease-free survival (DFS) iv period when compared to placebo in the overall MAGE-A3 positive trial population.\par \par \uc2 In line with the Independent Data Monitoring Committee's (IDMC) unanimous recommendation, GSK will continue the study until the second co-primary endpoint is assessed. This co-primary endpoint is based on predefined criterion that was agreed upon by regulatory authorities. This analysis, which is based on gene\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1098972/000115752313004338/a50703018.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1098972/000115752313004338/a50703018.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1098972/000115752313004338/0001157523-13-004338-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1098972/000115752313004338/0001157523-13-004338-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 September 05, 2013 06:18 ET (10:18 GMT)\par \par \uc2 Document DJDN000020130905e99500231\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ Ariad Pharmaceuticals Files 8K - Other Events >ARIA\b0\par\par\uc2 287 \uc2 words\par \uc2 4 September 2013\par 16:39\par \uc2 Dow Jones Newswires\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright (c) 2013, Dow Jones & Company, Inc.   \par \par \uc2 Ariad Pharmaceuticals Inc\uc2 . (ARIA) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on September 04, 2013.\par \par \uc2 On September 4, 2013, \uc2 ARIAD Pharmaceuticals, Inc\uc2 . (the "Company") issued a press release announcing enrollment of fifty percent of the patients planned in its randomized Phase 3 trial of Iclusig (R) (ponatinib) in adult patients with newly diagnosed chronic myeloid leukemia (CML). The trial, formally known as EPIC (Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia), is designed to provide definitive clinical data to support regulatory approval of ponatinib in treatment-na ve CML patients.\par \par \uc2 An interim analysis of efficacy focused on the primary endpoint of major molecular response rate (MMR) at twelve months will be performed in the third quarter of 2014 based on the patients enrolled to date. Approximately 264 patients have been enrolled in the EPIC trial, and full patient enrollment of approximately 500 patients in the trial is anticipated by the end of 2013.\par \par \uc2 A copy of the press release is being filed herewith as Exhibit 99.1 and is incorporated by reference herein.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/884731/000115752313004333/a50702571.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/884731/000115752313004333/a50702571.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/884731/000115752313004333/0001157523-13-004333-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/884731/000115752313004333/0001157523-13-004333-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 September 04, 2013 16:39 ET (20:39 GMT)\par \par \uc2 Document DJDN000020130904e99400594\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ \uc2 Pfizer\uc2  Files 8K - Other Events >PFE\b0\par\par\uc2 185 \uc2 words\par \uc2 3 September 2013\par 16:05\par \uc2 Dow Jones Newswires\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright (c) 2013, Dow Jones & Company, Inc.   \par \par \uc2 Pfizer Inc\uc2 . (PFE) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on September 03, 2013.\par \par \uc2 On September 3, 2013, \uc2 Esperion Therapeutics, Inc\uc2 . issued a press release titled, "\uc2 Esperion Therapeutics\uc2  Announces Positive Top-Line Results from Phase 2 Clinical Study of ETC-1002 as an Add-On to Statin Therapy in Patients with Hypercholesterolemia."\par \par \uc2 A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1434868/000110465913067732/a13-20094_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1434868/000110465913067732/a13-20094_18k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1434868/000110465913067732/0001104659-13-067732-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1434868/000110465913067732/0001104659-13-067732-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 September 03, 2013 16:05 ET (20:05 GMT)\par \par \uc2 Document DJDN000020130903e993004cy\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw222\pich44\picscaley100\picscalex100\picwgoal3330\pichgoal660
47
4946383961DE002C00C4000044448FDA44448888B8F1BBBBE78888BBBBD6CF1111EEEEF5E06666D32222EB9999F8DDDD22227AF5CCCCFCEEEE111170DDDDEB33
33856666A3AAAACCEEAAAA7777AD9999C2D63333E47777CCCCE0DD5555555599CC0000000066FFFFFF00000021F90400000000002C00000000DE002C000005FF
A0278E64699E68AAAE6CEBBE702CCF746DDF78AEEF7CEFFFC0A070482C1A8FC8A472C96C3A9F31884500A84A0405A8763B0474BE60F0284C16980A5E3298616E
A5D570705B17570538F83C07511AE8F5035C396F6A6371732215716411072C848B653C7529777F780E247E971C818237906186708812918C8E2AA1A71D883894
289697049A9C9D9FA08BA36A7316AC64152BABA7AE37B027B27F09B59C9EB834C31DBB92220FBF6410AAD761C536C726C97F0A239B97CECF32D1D3DC22BEDB72
DAEFAD937076B61C01E4B6E7E830EA228BDA9882B3A180803800E2BDEB56E35B89707F3C958BD86FC63F0F01453088936A2099070AC9B01140B224C92C3B1CFF
9280A8878F8789802AA6D305F050CD7A220EE244312C218B03023644F80240C28414028676886046E508967A16BCDC57C201010D17F00440408144030260C312
6830422CD8110BCC82CD24C281020D09F25CC0D0D5C5C58C18E3A0D45928454F1602ACC1618072C401A5613C92B1778F032D9879CE1130602B81A7059C6889B8
54F6D285B2946D5D20FB88665E5222107FCCE0014281D7B05F870CE33385E2381648A866C5F89E81A9CD4620688C679C87D02D4534B8449AC02597C3891B203D
5BD44D5E89223114865085A25F473DB8DBD6FB9E02C8783C61209EA72BC47CC0F5D485488B027B3CCBB8C3C25BE014E1187FA100C1360C88108D532240A5C7FF
05E8DD82D97D1C2CE3DC1FBF7930A11E9A65F507597141689C5FA6E1E5C1815F6C908A1B718C64D208B77D11C1466A1C258F3495DC772145D1FD7141877F5060
1F671EACF7874B9C78B0DC251A10A06172D589711D35AD0916C903E19576CD08308611416B705470001C0F40C0D76235B2C7234567E2F1D9837F60C0664CEF19
79493E0A70221564F081B89F4D2364206524C158F9CB3A1DF8044742873EE9642C1052C5097C8F1E774957C8E5F11B64187850E72CF1E9A1DF4E228AE0E72F12
08CA9B075FAA61A8AAA7D1A6E817E5351A9903917A10297DB67262D525E33448005BFE84C827090790F8456E4DEE49C6AACBB60A06B364323A67A5F704526BFF
A437E28140830308A90769BEFD1AACB2D89D10D8290F9C7882B18BCA8328ABCE2E8ACCA3D93A2A6B3E3FEA1140BEE28453A107397262C087A6461B6A09076C40
4CB2A0BEF36EB3F1C25AE61F01BC596DAE8DE663310706D48B070169E6E900B57302CB30A15F6C27C2047F42CC538A269184F2220FBB1A318DD2520C307BD6DE
2B02C9DE561AF0C75EA5798901527DDAD7CDF31814B3CCADED66DDCB89A2004704B165CD5AD5087AC0523E4736D6B38E03946DB6D9A441845CC024D735820343
7B56F0D4190D33C28071644335BC27549D02D73BCD3B6782C48DAD2F0B1EE791781E4997B040DC7A10BC6E8A339B31E6D423C6C1DADE2E9B50750555840E40FF
30802F2DB8CE9A168EF1E14106E0FAEB997AC0EF251BEB911F0A8FDBA281D2646431C122595C0E4661524BCCB9CD26A40A7128353FFB2ACEA7B3EE81D180D03A
B8D7D7D78EDFEA488E80C1EBAF8FD300C9B7A320FC36D9FC7EF50406C5B1A59E7C7B0E6F281228AF25AA5D7FDDD9C5B542E492A4B7BA876676F607CD786C05EA
9B5181B834A30E04EA78CE83E0032C309E30E4260E1BC852B4A2970791890D7B1452C0A6C4F1145BD00272E9D91FEB34703D1568701B7360971AF40641A2A4A0
82ACC846F122112BAD900085B718E17D1A97B8712C0E5861B31DC91CC382046E235D2370E2351E58C342B9F01AA5F2C077C83331E9C9892AD383D0FF644795E7
067D86044B928EC952B0C56B5449042D8A4423781741148C0A5DA9C05B1C5A063D70D4AA84C131D212296432ED89407B63EC546324A782F381E98D2CBA0600D4
55C5DAD8F18522D95C3BE2208116F5101F2510624C9443BD3C24803A2320DF084C6802050C120F038B421CC1F080FAA5000D916000B2E666C3150005936CA0A4
0726F0C26008EF93791A01F5CE6115A325405C7E441D0829628205608064064040E36270000B804E74029880304F20A66F860E0B49700DFB0A304E12A8939D5B
58C0002850B6350E419EF31C002A65C2CF7EFAF39F000DA840074AD0821AF4A0084DA8429F1102003B}}
\par\par \b \uc2 FORM 8-K: \uc2 ARENA PHARMACEUTICALS\uc2  FILES CURRENT REPORT\b0\par\par\uc2 824 \uc2 words\par \uc2 30 August 2013\par \uc2 US Fed News\par \uc2 INDFED\par \uc2 English\par \uc2 Copyright 2013. HT Media Limited. All rights reserved.   \par \par \uc2 WASHINGTON, Aug. 30 -- \uc2 Arena Pharmaceuticals Inc\uc2 ., San Diego, files Form 8-K (current report) with \uc2 Securities and Exchange Commission\uc2  on Aug. 29.\par \par \uc2 State or other jurisdiction of incorporation: Delaware\par \par \uc2 In this report, "\uc2 Arena Pharmaceuticals\uc2 ," "Arena," "Company," "we," "us" and "our" refer to \uc2 Arena Pharmaceuticals, Inc\uc2 ., and our wholly owned subsidiaries, unless the context otherwise provides. \uc2 Arena Pharmaceuticals\uc2  and Arena are registered service marks of \uc2 Arena Pharmaceuticals, Inc\uc2 . BELVIQ is a registered trademark of \uc2 Arena Pharmaceuticals GmbH\uc2 .\par \par \uc2 Other Events.\par \par \uc2 On August 28, 2013, we filed a Form 8-K regarding the completion of a Phase 1b clinical trial for APD811, an investigational oral prostacyclin, or IP, receptor agonist intended for the treatment of pulmonary arterial hypertension, or PAH. We are filing this Form 8-K to revise the information previously disclosed regarding adverse events.\par \par \uc2 The randomized, double-blind and placebo-controlled Phase 1b clinical trial evaluated the safety, tolerability and pharmacokinetics of multiple-ascending doses of APD811. We previously evaluated single-ascending doses of APD811 in a Phase 1a clinical trial.\par \par \uc2 In the Phase 1b clinical trial, 40 healthy volunteers received APD811 and 15 received placebo, and the safety profile of APD811 was characteristic of IP receptor agonists. The most frequent treatment-emergent adverse events were headache, nausea and jaw pain. One serious adverse event, transient atrial fibrillation, occurred in a single patient, and the study investigator considered it to be possibly treatment related.\par \par \uc2 We plan to initiate a Phase 2 clinical trial for APD811 in the first quarter of 2014. The results of the Phase 1 program led to the decision to proceed with Phase 2 development of APD811, which will include further exploration of dosing regimens in PAH patients.\par \par \uc2 Forward-Looking Statements\par \par \uc2 Certain statements in this Form 8-K are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the advancement, therapeutic indication, safety, efficacy, mechanism of action and potential of APD811; and the initiation of a Phase 2 clinical trial for APD811 and the further exploration of dosing regimens. For such statements, we claim the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from our expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: APD811 may not be sufficient for further development or regulatory review or approval; risks related to commercializing drugs, including regulatory, manufacturing and supply issues and the availability and use of BELVIQ; cash and revenues generated from BELVIQ, including the impact of competition; our revenues will be based in part on estimates, judgment and accounting policies, and incorrect estimates or disagreement regarding estimates or accounting policies may result in changes to our guidance or previously reported results; the timing and outcome of regulatory review is uncertain, and BELVIQ may not be approved for marketing when expected or ever in combination with another drug, for another indication or using a different formulation or in any other territory for any indication; regulatory decisions in one territory may impact other regulatory decisions and our business prospects; government and commercial reimbursement and pricing decisions; risks related to relying on collaborative arrangements; the timing and receipt of payments and fees, if any, from collaborators; the entry into or modification or termination of collaborative arrangements; unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than us or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to any of our research and development may not meet regulatory requirements\par \par \uc2 or otherwise be sufficient for further research and development, regulatory review or approval or continued marketing; our ability to obtain and defend patents; the timing, success and cost of our research and development; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by our forward-looking statements are disclosed in our filings with the \uc2 Securities and Exchange Commission\uc2 . These forward-looking statements represent our judgment as of the time of the filing of this Form 8-K. We disclaim any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.\par \par \uc2 More information can be viewed at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1080709/000119312513350814/d591143d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1080709/000119312513350814/d591143d8k.htm}}}\par \par \uc2 Document INDFED0020130830e98u0007i\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ \uc2 BioTime\uc2  Files 8K - Other Events >BTX\b0\par\par\uc2 350 \uc2 words\par \uc2 28 August 2013\par 09:00\par \uc2 Dow Jones Newswires\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright (c) 2013, Dow Jones & Company, Inc.   \par \par \uc2 BioTime Inc\uc2 . (BTX) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on August 26, 2013.\par \par \uc2 On August 26, 2013, we received notice of approval from The \uc2 Spanish Agency of Medicines and Medical Devices\uc2  (AEMPS) to begin human clinical trials of Renevia(tm), as a delivery matrix for autologous adipose derived cells. This AEMPS approval follows the earlier approval this year from the Balearic Island Ethics Committee Approval for the first of a multiphase clinical investigation of Renevia(tm). The clinical studies will be conducted at The Stem Center in Palma de Mallorca, Spain, a patient therapy center, laboratory, and professional research facility located within the Clinica USP Palma Planas hospital in Palma. The Medical Director of The Stem Center and Principal Investigator for the Renevia(tm) studies, Ramon Lull, MD, PhD, is a leading expert on advanced regenerative therapies based on adipose technology.\par \par \uc2 We expect that the first clinical investigation, a study in 10 volunteers to demonstrate the safety of Renevia(tm) in humans, will be completed before the end of the year. Subsequent clinical studies are being planned to document the efficacy of Renevia(tm) as a delivery matrix for autologous adipose cells to restore normal skin contours in patients where the subcutaneous adipose tissue had been lost due to trauma, surgical resection, congenital defects or disease.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/876343/000115752313004271/a50698384.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/876343/000115752313004271/a50698384.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/876343/000115752313004271/0001157523-13-004271-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/876343/000115752313004271/0001157523-13-004271-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Order free Annual Report for \uc2 BioTime, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://djnewswires.ar.wilink.com/?link=BTX"}}{\fldrslt{\cf2 \uc2 http://djnewswires.ar.wilink.com/?link=BTX}}}\uc2  or call 1-888-301-0513\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 August 28, 2013 09:00 ET (13:00 GMT)\par \par \uc2 Document DJDN000020130828e98s003al\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Orexigen Therapeutics\uc2  Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee\b0\par\par\uc2 1,164 \uc2 words\par \uc2 27 August 2013\par 07:31\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2013  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 SAN DIEGO, Aug. 27, 2013 /PRNewswire/ -- Orexigen(R) \uc2 Therapeutics, Inc\uc2 . (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Light Study independent Data Monitoring Committee has recently confirmed that sufficient major adverse cardiovascular events (MACE) are expected to occur within the next two months, enabling the interim analysis to be conducted by early December and the potential resubmission of the Contrave(R) \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (NDA) by year end. The DMC also recommended that the Light Study continue as planned with no changes to the protocol.\par \par \uc2 "I'm proud of the progress made by our Light Study team," said \uc2 Michael Narachi\uc2 , Chief Executive Officer of Orexigen. "We remain focused on trial execution and \b \highlight22\uc2 launch\b0 \highlight\uc2  preparation and look forward to the interim analysis and upcoming regulatory submissions."\par \par \uc2 Orexigen also today reiterated its plan to submit a Marketing Authorization Application (MAA) for Contrave(R) to the \uc2 European Medicines Agency\uc2  (EMA) in advance of the Light Study interim analysis and to have cardiovascular outcomes data from the Light Study available for the Committee for Medicinal Products for Human Use (CHMP) Day 120 List of Questions.\par \par \uc2 About Contrave (32 mg naltrexone sustained--release (SR)/360 mg bupropion SR) for the treatment of obesity: In 2012, Orexigen screened more than 13,000 patients, enrolled more than 10,400 and ultimately completed recruitment of the Light Study with approximately 8,900 randomized patients. The primary objective of the double--blind, randomized, placebo--controlled Light Study, which Orexigen is conducting under a Special Protocol Assessment with the \uc2 U.S. Food and Drug Administration\uc2  (FDA), is to rule out excess cardiovascular risk in overweight and obese patients receiving Contrave. An interim analysis and NDA resubmission is planned once the DMC has determined that sufficient information has been gathered for the analysis that would include at least 87 adjudicated MACE.\par \par \uc2 Orexigen has licensed North American commercial rights to \uc2 Takeda Pharmaceuticals\uc2 . Orexigen owns Contrave rights throughout the rest of the world and intends to license commercial rights outside North America.\par \par \uc2 About \uc2 Orexigen Therapeutics\par \par \uc2 Orexigen Therapeutics, Inc\uc2 . is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave, which has completed Phase 3 clinical trials and for which a NDA has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a SPA for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic, has completed Phase 2 clinical trials. Further information about the Company can be found at {\field{\*\fldinst{HYPERLINK "http://www.orexigen.com"}}{\fldrslt{\cf2 \uc2 www.orexigen.com}}}\uc2 .\par \par \uc2 Forward--Looking Statements\par \par \uc2 Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward--looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "should," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward--looking statements. These statements are based on the Company's current beliefs and expectations. These forward--looking statements include statements regarding: the potential for, and timing of, the interim analysis and submission of a Contrave NDA; the potential for, and timing of, the accrual and adjudication of MACE; the expected retention rate for patients in the Light Study; the probability of success of the Light Study; the possibility of resubmitting the Contrave NDA with the independent DMC report on the interim analysis and without the clinical study report for the interim analysis; the potential to accelerate the timing of the review of the Contrave NDA; the safety and effectiveness of Contrave; the potential for past Contrave clinical trials to predict the outcome of future Contrave clinical trials; the SPA and the protocol for the Contrave(R) cardiovascular outcomes trial, or Light Study; the potential for and timing of a submission of an MAA in the \uc2 European Union\uc2 ; the potential for approval of the Contrave MAA by the EMA; and the potential to license commercial rights to Contrave outside North America. The inclusion of forward--looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ materially from those expressed or implied in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: the possibility that the FDA determines not to initiate review of the Contrave NDA until it has received the complete study report for the interim analysis; the SPA is not binding on the FDA if public health concerns unrecognized at the time the SPA agreement was entered into become evident, other new scientific concerns regarding product safety or efficacy arise, or if Orexigen fails to comply with the agreed upon trial protocol; Orexigen's ability to conduct the Light Study and the progress and timing thereof, including risks associated with enrolling and retaining the appropriate patients in the Light Study; Orexigen's ability to demonstrate in the Light Study that the risk of MACE in overweight and obese patients treated with Contrave does not adversely affect Contrave's benefit--risk profile; the potential that earlier clinical trials may not be predictive of future results in the Light Study; the potential for the FDA to not approve Contrave even after the resubmission with the MACE data; the potential for the Light Study to cost more than what is projected; the potential for early termination of Orexigen's North American collaboration agreement with \uc2 Takeda Pharmaceutical Company Limited\uc2 ; the costs and time required to complete additional clinical, non--clinical or other requirements prior to any resubmission of the Contrave NDA; the therapeutic and commercial value of Contrave; Orexigen's ability to maintain sufficient capital to fund our operations through potential approval of Contrave in 2014; Orexigen's ability to enter into a collaborative partnership for Contrave outside North America on acceptable terms, if at all; and other risks described in Orexigen's filings with the \uc2 Securities and Exchange Commission\uc2 . You are cautioned not to place undue reliance on these forward--looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in Orexigen's Annual Report on Form 10--K filed with the \uc2 Securities and Exchange Commission\uc2  March 14, 2013 and its other reports, which are available from the SEC's website ({\field{\*\fldinst{HYPERLINK "http://www.sec.gov"}}{\fldrslt{\cf2 \uc2 www.sec.gov}}}\uc2 ) and on Orexigen's website ({\field{\*\fldinst{HYPERLINK "http://www.orexigen.com"}}{\fldrslt{\cf2 \uc2 www.orexigen.com}}}\uc2 ) under the heading "Investor Relations." All forward--looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.\par \par \uc2 \f2 \par  \par Orexigen Contact:                                      Media Contact: \par McDavid Stilwell                                       Denise Powell \par VP, Corporate Communications and Business Development  BrewLife \par (858) 875-8629                                         (510) 703-9491 \par  \f28 \par \par \uc2 \f2 SOURCE \f28 \uc2 \f2 Orexigen Therapeutics, Inc\f28 \uc2 \f2 .\f28 \par \par \uc2 \f2 Web site: \f28 {\field{\*\fldinst{HYPERLINK "http://www.orexigen.com"}}{\fldrslt{\cf2 \uc2 http://www.orexigen.com}}}\par \par \uc2 Document PRN0000020130827e98r0003l\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ Orexigen Files 8K - Other Events >OREX\b0\par\par\uc2 904 \uc2 words\par \uc2 27 August 2013\par 08:36\par \uc2 Dow Jones Newswires\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright (c) 2013, Dow Jones & Company, Inc.   \par \par \uc2 Orexigen Therapeutics Inc\uc2 . (OREX) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on August 27, 2013.\par \par \uc2 On August 27, 2013, \uc2 Orexigen Therapeutics, Inc\uc2 . (the "Company" or "Orexigen") announced that the independent Data Monitoring Committee ("DMC") for its Light Study, a long-term research study of Contrave (R) (naltrexone SR/bupropion SR), has recently confirmed that sufficient major adverse cardiovascular events ("MACE") are expected to occur within the next two months, enabling the interim analysis to be conducted by early December and the potential resubmission of the Contrave (R) New Drug Application ("NDA") by year end.\par \par \uc2 Orexigen also reiterated its plan to submit a Marketing Authorization Application ("MAA") for Contrave (R) to the \uc2 European Medicines Agency\uc2  ("EMA") in advance of the Light Study interim analysis and to have cardiovascular outcomes data from the Light Study available for the Committee for Medicinal Products for Human Use Day 120 List of Questions.\par \par \uc2 * * *\par \par \uc2 Orexigen cautions you that statements included in this report that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "should," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding: the potential for, and timing of, the interim analysis and submission of a Contrave NDA; the potential for, and timing of, the accrual and adjudication of MACE; the expected retention rate for patients in the Light Study; the probability of success of the Light Study; the possibility of resubmitting the Contrave NDA with the independent DMC report on the interim analysis and without the clinical study report for the interim analysis; the potential to accelerate the timing of the review of the Contrave NDA; the safety and effectiveness of Contrave; the potential for and timing of a submission of an MAA in the \uc2 European Union\uc2 ; and the potential for approval of the Contrave MAA by the EMA. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ materially from those expressed or implied in this report due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: the possibility that the FDA determines not to initiate review of the Contrave NDA until it has received the complete study report for the interim analysis; the SPA is not binding on the FDA if public health concerns unrecognized at the time the SPA agreement was entered into become evident, other new scientific concerns regarding product safety or efficacy arise, or if Orexigen fails to comply with the agreed upon trial protocol; Orexigen's ability to conduct the Light Study and the progress and timing thereof, including risks associated with enrolling and retaining the appropriate patients in the Light Study; Orexigen's ability to demonstrate in the Light Study that the risk of MACE in overweight and obese patients treated with Contrave does not adversely affect Contrave's benefit-risk profile; the potential that earlier clinical trials may not be predictive of future results in the Light Study; the potential for the FDA to not approve Contrave even after the resubmission with the MACE data; the potential for the Light Study to cost more than what is projected; the potential for early termination of Orexigen's North American collaboration agreement with \uc2 Takeda Pharmaceutical Company Limited\uc2 ; the costs and time required to complete additional clinical, non-clinical or other requirements prior to any resubmission of the Contrave NDA; the therapeutic and commercial value of Contrave; Orexigen's ability to maintain sufficient capital to fund our operations through potential approval of Contrave in 2014; Orexigen's ability to enter into a collaborative partnership for Contrave outside North America on acceptable terms, if at all; and other risks described in Orexigen's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this report to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in Orexigen's Annual Report on Form 10-K filed with the Securities and Exchange Commission March 14, 2013 and its other reports, which are available from the SEC's website ({\field{\*\fldinst{HYPERLINK "http://www.sec.gov"}}{\fldrslt{\cf2 \uc2 www.sec.gov}}}\uc2 ) and on Orexigen's website ({\field{\*\fldinst{HYPERLINK "http://www.orexigen.com"}}{\fldrslt{\cf2 \uc2 www.orexigen.com}}}\uc2 ) under the heading "Investor Relations." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1382911/000119312513347273/d590139d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1382911/000119312513347273/d590139d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1382911/000119312513347273/0001193125-13-347273-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1382911/000119312513347273/0001193125-13-347273-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 August 27, 2013 08:36 ET (12:36 GMT)\par \par \uc2 Document DJDN000020130827e98r002aq\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw166\pich40\picscaley100\picscalex100\picwgoal2490\pichgoal600
47
4946383961A6002800F7000095A4CEF0F2F8768BBFD1D8EA4964AA677EB85871B12A4A9CA4B1D5E1E5F18598C63957A3C2CBE3B3BEDCF2F4F9FBFBFDF4F6FAEC
EFF6F8F9FCC6CFE5E0E4F0F1F3F8DFE3F0F5F7FBC5CDE4E1E6F1D5DBEBD9DEEDEEF0F7D4DAEBE3E7F2D7DDECF7F8FB9DABD1F6F7FBCED5E8FAFAFCEBEEF6FDFE
FEFBFCFDF3F5FADBE0EEE4E8F2AEBAD99EACD2BFC8E1BBC5DFE7EBF4E7EAF4CFD6E9B0BBDA90A0CB9DABD2D3DAEBD9DFEDEEF1F7ADB9D94F69AEF9FAFCC9D1E6
C1CAE2AFBBDAE6EAF3A1AFD3D9DFEE94A3CDFEFEFFE4E8F3AFBADA7D8FC2E5E9F3F3F5F9F5F7FAF5F6FA798CC04E68ADBAC4DFCBD2E7FCFDFE93A2CCDCE0EED0
D6E991A1CC6C81BBEDEFF6A8B5D7ABB7D7D6DCECB7C1DEC0C9E1DDE2F0B6C0DD6E83BCCCD4E8D8DEECFAFAFDE2E7F2AEBADAEDEFF7D2D9EAA7B4D6D3DAEACBD3
E798A7D0566EB1D5DBECC2CBE2FEFEFE8597C6AFBAD98395C5DADFEDA6B3D5DEE3F0EFF1F8BEC7E17388BFDDE2EFCCD3E7E8EBF4D1D7EAD0D7E9A5B2D599A8D0
DCE1EFC9D1E5DADFEEE9EDF5FEFFFFE2E6F2798DC0D1D7E9FDFDFED2D8E93A56A3ECEEF6C7CFE59FADD3E6E9F3E9ECF5B7C2DE99A8CF899AC8C2CAE3B9C3DFEF
F1F71B3D95FFFFFF0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000021F90400000000002C00000000A60028000008FF0027091C48B0A0C18308132A5CC8B0A1C38710234A9C244092A4020A0B5C5448
C062828920438A1C49D220038B0702200C605192CA83032C622C49B3A6CD9B931658448010404B000815586C80B3A8D1A30B7D6E3CD8D1A201843A0F209D4AF5
6882962F099E94A453D2C7825B1514D4F852634B941F599E9529B0E3008342D74A7A3BC9805C0103EDAEC5DB5312D0810DFC0A8CBB7640E099930E203EF0B4EE
5D887AFF12AC7820A6E08215E78E752990EC400482594A65AAB9A050C904598A1D08E0AF6A82AD132A6D3C29F0DFD34C534E52FA11348349AF59A366085A126D
81010E4812DB718141E5040C7A9E347D1268A0A211BA857BB9A0DABDC8E54AFFE27BD0A75D026F6D0FEE0E5B3001BB620D38072E9E7CC3E41E09167FABF43760
8BC351C799806B1D90D65A440DB49D69674547905E678DE65881B2CD551C02EA4D4298240E2277007A7315B0C0559241D892840E6586DA79E18D4790595FBD38
20590174C453782812B42041B8193440017475C6D98F410A9855413EBD35804E1DDDC6DE64C645171801BA4D42A48C4732B455875775A75195F81D37D0749ED5
785976A415B95E80D689375A7114F645570091AD89906537EA441E9C114AD4155D4A65159824375E781099039A594000DF35D8965C186DD812516682075C5367
D987646902F9E4A45C094E42C07CBB49E2DFA58F4514D76A3A21069C728DD9FF55E544849820901E204CD2C12255F5DAAB65CE6D15AA409925A096A61161E05F
08224CB2051FBE463B55530C50661280FD8934020693B020C124525C300907186420EDB9362995D96A0531D91C4821C0700323931C5283047B8851C2237038E0
04BA0093D4A857E59DC566432C4480C20A9304A1C2241F5D60EE0E1AD4A166C0183B649671087599DF445D5CC0831D09811180032864ACF24383129A905E6236
F483239314A18207362CB441141644B0F2CF0A2937AB418646048506937CE083430F38F000D0509F9B07158D40E29D00CA5924C05B205090C21751873D951093
708134581FDEF8A3600F9C2CF6DB3835614812935CF1F44031058800010120FF5101DC80D754810B933C90C3100F7618F8E2484D5186772E2BE422415DB534DF
C6F999686A41934FE2A2522D21CB784D4AA80116A708750E71773E09B4005F016C5D17A902E9C553E79F134C51CCA393E4C6139314828656A81FA43A89AC4952
FB5ABF417823E7E4E59E69EF379D41C6242FF4919A24C31A6F1FF29D2A1FFB5757F1249FE4D1E3E5538CD41765051D0619C03B416B3D55B945F3DDBFB9E6A73E
7A164FEB6BDF51FCE0020A4C802079231ADF262181BB09F0810779431826E1051A9C8E00FE19805D8062010A400082202CC81CD86082311C240199D11A5D2AC0
810F86F0850221C11222D1860332240E16E0800E6008C33534AB051E5808046F1C40441EF2F0038200440F5A1081441C84049348410780600423C2F0044798C4
060201023C9C00068880984A64300839B8D08A4654040E2631831540C00C1118C008EE90B40C6C008D56F400112651820E482006589884162690053C1A722055
4803F69820903F1CF29190B4494000003B}}
\par\par \b \uc2 Moberg Pharma \highlight22\uc2 Launches \highlight\uc2  Kerasal NeuroCream at \uc2 Walmart\uc2  and U.S. Drugstores\b0\par\par\uc2 290 \uc2 words\par \uc2 25 August 2013\par \uc2 Wireless News\par \uc2 WLNW\par \uc2 English\par \uc2 (c) 2013. Close-Up Media, Inc. All rights reserved.   \par \par \uc2 Moberg Pharma AB\uc2  announced its U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of Kerasal NeuroCream, an over the counter pain relieving foot cream.\par \par \uc2 According to a release, the \b \highlight22\uc2 new product\b0 \highlight\uc2  will be sold in over 3,800 \uc2 Walmart\uc2  stores and in CVS, Walgreens, and \uc2 Rite Aid\uc2  drug stores starting late August.\par \par \uc2 Moberg Pharma\uc2  noted that approximately 30 million Americans experience frequent foot pain and many simultaneously suffer from cold feet and dry skin. Painful, cold, dry feet may be associated with various conditions, including diabetes, fibromyalgia, shingles, arthritis, joint pain, muscle strain, or trauma. Kerasal NeuroCream is a triple action formula that relieves stabbing, burning, tingling foot pain, warms cold feet, and soothes and moisturizes dry skin. Kerasal NeuroCream is applied with a "no mess" foam applicator.\par \par \uc2 The company said the active ingredients of Kerasal NeuroCream, capsaicin and camphor, have a well-established use as topical pain relievers, are naturally occurring and derived from plants. \uc2 Moberg Pharma\uc2  added it has utilized its Fusome skin delivery system, currently used in Moberg's JointFlex Pain Relieving Cream, to formulate Kerasal NeuroCream, enabling a rapid delivery of effective pain relievers to the pain source.\par \par \uc2 "Kerasal NeuroCream is an innovative addition to our product portfolio. It leverages one of our existing drug delivery technologies along with proven active ingredients, to provide a solution that meets an unmet consumer need. Kerasal NeuroCream further strengthens the Kerasal brand, our leadership in the topical OTC foot care space in the U.S. and our value to retail partners", said \uc2 Peter Wolpert\uc2 , CEO of Moberg Pharma AB.\par \par \uc2 Moberg Pharma AB\uc2  is a pharmaceutical company.\par \par \uc2 More information:\par \par {\field{\*\fldinst{HYPERLINK "http://www.mobergpharma.se"}}{\fldrslt{\cf2 \uc2 www.mobergpharma.se}}}\par \par \uc2 ((Comments on this story may be sent to newsdesk@closeupmedia.com))\par \par \uc2 Document WLNW000020130825e98p00021\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ \uc2 ChemoCentryx\uc2  Files 8K - Other Events >CCXI\b0\par\par\uc2 369 \uc2 words\par \uc2 23 August 2013\par 09:33\par \uc2 Dow Jones Newswires\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright (c) 2013, Dow Jones & Company, Inc.   \par \par \uc2 ChemoCentryx Inc\uc2 . (CCXI) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on August 23, 2013.\par \par \uc2 On August 23, 2013, GSK announced that the first of four Phase III studies, the SHIELD-1 study, investigating vercirnon - an investigational CCR9 antagonist - in adult patients with moderate-to-severe Crohn's disease did not achieve the primary endpoint of improvement in clinical response and the key secondary endpoint of clinical remission. The rates of serious adverse events and withdrawals due to adverse events were similar among the treatment groups, including the placebo group, with a trend in dose-dependent increases in overall adverse event rates. GSK has indicated that it intends to continue to explore the safety and efficacy results to inform decisions about the clinical development program for vercirnon. New recruitment and dosing in the ongoing clinical program has been suspended pending further review of the SHIELD-1 results.\par \par \uc2 In accordance with General Instruction B.2 of Form 8-K, the information furnished under Item 7.01 in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1340652/000119312513344579/d588575d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1340652/000119312513344579/d588575d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1340652/000119312513344579/0001193125-13-344579-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1340652/000119312513344579/0001193125-13-344579-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 August 23, 2013 09:33 ET (13:33 GMT)\par \par \uc2 Document DJDN000020130823e98n003cx\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw189\pich40\picscaley100\picscalex100\picwgoal2835\pichgoal600
47
4946383961BD002800F7FF00FF6767FF0000FF5252FF0606FF0101FF0E0EFF0202FF1010FF1717FFFEFEFF0B0BFF1C1CFFF7F7FFB4B4FF5454FF4545FFC6C6FF
7D7DFFFFFFFF9393FF3838FF7272FF2626FFC9C9FF8888FFDEDEFFF2F2FFF4F4FF1616FF6B6BFF0A0AFF0505FF4D4DFF2C2CFF4F4FFFF3F3FF1818FF8080FFDF
DFFFFDFDFF2222FFC4C4FF4242FF2929FFF0F0FFEBEBFF0303FF0404FF3434FFADADFF0F0FFFF5F5FFE0E0FF2A2AFF4B4BFF1A1AFF3D3DFF1919FF1212FF9292
FF8D8DFF6565FFEAEAFFE1E1FF7B7BFFF6F6FFFCFCFF2D2DFFF1F1FF5959FF3E3EFFF8F8FFE2E2FF0808FF0909FF0D0DFF1515FF0707FF2727FFA2A2FF5A5AFF
F9F9FF7E7EFF3A3AFF1111FFD2D2FF2020FF1F1FFFE4E4FF7676FFBDBDFF1313FFFBFBFFC7C7FF1B1BFFA1A1FFEEEEFFA6A6FFDCDCFF6060FF0C0CFF2424FF7C
7CFFB6B6FF2B2BFFB0B0FFE3E3FF6161FFD1D1FF2121FF2323FF5353FF6C6CFFC2C2FF6262FFEFEFFF5757FFFAFAFFE6E6FFC5C5FFA0A0FF3535FFA7A7FF1414
FF1D1DFFACACFFECECFFB9B9FF5050FF5E5EFF9797FF3737FF8383FFE5E5FFDBDBFFCCCCFFEDEDFF5151FF6969FF5D5DFFE7E7FFD0D0FFD4D4FF4040FF8686FF
5B5BFF8E8EFFB7B7FF5555FFB5B5FF4141FFCDCDFF4949FFD5D5FFA5A5FF4E4EFF7F7FFFE9E9FF6D6DFF9090FFAAAAFF5F5FFFC0C0FF4848FF2525FF9D9DFF2F
2FFF7373FFAEAEFF3030FF3131FF7474FF3333FF6F6FFFBBBBFF7171FFCFCFFF7777FFD9D9FFDDDDFFD7D7FFDADAFFE8E8FF7A7AFFD6D6FF4A4AFF6868FF5656
FF3636FF1E1EFF9A9AFF9191FF8A8AFF6363FF8989FF7979FFA9A9FF6A6AFFABABFFB8B8FF4C4CFFA3A3FFCECEFF9C9CFFBFBFFFBEBEFF3C3CFF5C5CFF3B3BFF
7070FF6E6EFF9999FF9494FF3939FF2E2EFF3232FF3F3FFF9F9FFF8484FF9595FF8181FFD8D8FF4343FFD3D3FFA4A4FFCBCBFFBABAFF5858FFCACAFF2828FF9E
9EFFB2B2FF4646FF4747FF8B8BFFAFAFFFC3C3FF8787FFBCBCFF8C8CFF4444FF6464FF9696FF7575FF8282FF9B9BFF9898FFB3B3FF7878F8F7F7FFB1B1FA4747
FC7C7CFED9D9FFC8C8FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A45374239373346443531423531314536383342314337334644453946314437322220786D704D4D3A446F63756D656E7449443D22786D702E6469643A4537
423937334645353142353131453638334231433733464445394631443732223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A4537423937334642353142353131453638334231433733464445394631443732222073745265663A646F63756D656E744944
3D22786D702E6469643A4537423937334643353142353131453638334231433733464445394631443732222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000BD00280040
08FF00FFFD93606BDBA21C0512A6F2C548A0C38710234A9C48B1A2C58B181F76D383E7C9932FE782083CE1AE6336654204DA42D5F149291A09324A4C60A894C7
52B862420CD2A0E3173D8E3016084094A803812C96147D41C961A558020450FA54CBA1B8183140B99220449A003A9A540A8BCAA9DBBF23A8FAC43016450890A8
4094FD4B104713D6187EFE352216A3CFBA14C71AD0291A408E26665C044E1A165500355902B934001583582321B33A08D0B580B0B57F3FA6100E90E51F2C0E45
A9101A782650D43569A240CC14E64D5439E136FC9BD183309411FF3401E114E15DA61A450DC0A9A4161C8413732B19EB2B6A28E1A3127D38284A42CB3F108479
C0FF208C814104C20F3464E84CD4C0840345115C3041817009118421FCEB50744005812A10B643022DD8505401D4FCF3CA00458D71435104A4F110230F16F508
2045C94094077010509437AE10C6811A239052940559C047D414FF54D14651140840980846148543503F84405825128047541E970C5154182758575424913141
D8384570D7CC77E18D575479E71595DE7AC9BD17DF7CF515755F7EFFC0D1DF7FFF0458D4800516758030FFD843D82E5E40D8004473C8315A0079FC93012F7702
F04F0A84B971C93F83A4760A1545B1188E91A424425812DA204714141A8CB042510A9C2210381E8C06433F12C972061EC93C014B0613D901C11D9930201345AE
28FF50540E2944F10D04833ED4421C5D1CF12A442D5C90822C22FD6AEC43B5A490C20F1375F2431C10D471AC445C0053D407403C34C19D013048980B294C2BAE
B80C1CB2CC2E35E89198B851BC419801A0086446A7442D91C93F412842182F4189BB416F45FD16518E984A21D468D8097141175D40D0851A92108602254AA486
C4188F52E021615EC84AD82F8816758529A309E32351FAF147D400A338C16D00BC2C4218029128459412D958F0B23C4010464217B06C3CEB1CAF103685814519
6126519B88A1735198B04258075512F586049E100606184F13D54718457930271CDE060086914609B401268F3C828D25520C4654775016251E79E6A1A71E7B01
B8FFA76200F2D1671F7E45A53C268002128834513A5870451B28A0E0862724C8F9900476BCFC0535DC2EB10D3384114002299147FEC02D460E60050A90476EDB
CB016823C13F26E8489402FF616145514EE8409427AE32821AEC44A912451C84955DBC184D4E99B7957B67F937B72F80B238B703BC2290080614E5C006098872
A70B45A131492F9643D4051AA3F92090F8845DD1C83F5CF47CED68D3D451236115B7574A058479C606D84186A28CC20FECBB9DC1FE51070016C5143418970425
F2870F1445071798A00637C8416395E04ED94889434E6088DDC18E04E4804E0757C8428784A30C8479010B04D28038FDC810024903FF6031AE7FF90638102198
02FF3162C3A2C80109FFD0829288F28240B4B0858A7841517E21AD7141A209C981C33F4E6086D1848B06FB238A1966272EDEFC3022B52B0A198671B0EB20C566
62FC07289457943DC88201422A0A344633087ADC691E0D205E006E11854B15EE1F00208C25AEF0322B24A082DC6AC32CC4E0B100A0A16B3BB05DF1C0E00A3E8C
C61B2738046142A00628BC0C103364811BB845804F1C21188409C41CE28045A23C8008920AC00782211AA22CE00CFF4843F788120CB405003B11E984A388C281
3BFC631C51228C24EA60ADA280600319405F7BB444941C54C107610CC0970EA9B26EC54220B9204C32FEB101C205A0005FF8C72DCA16881C106601F870841888
80FF8BD061A08BA329C0249C5194052CC28244E1031634608DA294211A1A228A25FEA10613066010182A8A22F49084A27C820B603064003C308D146833007010
42D68862032C18139910410425B8E39D9305E06ECEAB5A00AEC437BF6D49705E7267000CB732322D2D00685A9C126A20002B94CD41E913C8088AF12D6F8D22A3
A37941114057140E5C0307F6240A8AFEA603011821A20188D1CB0A800A810831004B68C53F9641AF02B4829101288328FEF1D23712A608CD0B00DD6C8A53A250
496F58DAE6DF02D725A28C1365FB395C99129726A224E1090319C11C5840844B6C21AA0269442AEEE4813A30825B24F8C71D08638543E08B052C980303BE30CC
00FF5443AA9B25C206ECF43219408606B9544069FE1188DA5A5642841A4D13CC51889916C5053D9011519810867F7CB028BE20684E11DB536E06E00629288476
89C209A186EB19923D2A064ED0094C10E65E66A8A42E3C491402CC0922EE306E00F0F18F3984E24ECE24C71E8A5283E7ACA128BD68C5DF72F18F42AC9228D088
0461D630832C084D0CB670D9ED38219004E095282EE007445250003AFA9210B249002E78D151C2C8E014B32B60518611049DDEB216DDFD9B0B069C2171FCE31E
15224A192A20C56E254220C9F05D51683117134C815E45D90227122086BF11C01811D9C02608638A2A08440F7C0B802EC0E09030944168BEC432BE08415FC2E4
41FF0D12F86FC066F00F0D074009B7C8630014200D87B060944F14D724101A001D9023D0884EB4B18E400454746D0BBE52F4ABCE40681DE847D298CE3444AE1B
002B7C818C1091001B9679A772E843D3A8BE88202A491487C421AC01C0841D0422885A12A51EA036D606E46C350D44840630ACEF3C30B281420972103A49F5B8
7C90EB63D9A1A1C9898340EC11B2BC064502DB2A8A158ED143804D0A880F79AB021668114B8C860CD578460E6A3B805B28FB5840D04112180409D98C6B17E4DB
A64062D1BE7FD842BA4401445EFCE5ED00082C889A5400872F62CC553864780178413CDE6D2C3310DA17132406C409F0807F44C1A60190C73F68D1B501984382
66FF0C18B81DC2800406A0091868A3F7FCCA44100C84104CE81F0164700D3D080405084000076ED0820A6091004C98C408E8601D0560A31387580007820E8937
D0CB0316A081102CC184A023C09959E83A0716308E2990C0D611DFC2147423080E40F900A688C13F665183A93321161718028322D0E6B4FE23EFA341522184B6
075CF8A10308C8F70B1030062CE8C40E165862C47B110D211CA1E00E38410250E0010528E00A8570B90736C18AA0EFC1086C18390AA6CE8144F4F51F445881EC
57E0842FF880D5A3294617D221486EF1A114C61C8D0CCE7054A276AB652FC3C11F247FA745B00101F72BCA3602411834FCA1129F250C05C0A00EC220A39A2FEB
83FF04A8DA5B36E862C21A9004A1EB6108918A3391CC14C43F7CD1E200F4E1F51109C27688F28127F8001E84D10036B50662004B4531047FA00E68E553F59206
87602245610658355491B5323D70157A561831E00B5B0662920006BC4514ABF022A3B1076E80077810435DB00E77720341C06B1F60092870416C60076D660140
805621600777D03F016004FA722476008178C20023904B4A9006970065198403F9E60588807F10A11DB3F22484252544210C4760631B800439B62519D058E224
54C6E71F88732609E007E9441407F009FF200DF5170A411600522042B087661D5070B7F30B1F5603F643143720067E20526395287AF16017456A015001E7C744
A9FF8705E5901CC460087A960E09706044D10A4420850F4185735353D1B45DD093587DE35D8C353860524E66385968585980237FAB2063010055F5054C0E8108
A3C03152D369A3A54BD5B03104100A6AC06555F00361548844F108B4E3726A5514372079DC901234A0491F0009FF9082448102E6F0341E800B7C85300E3103E2
288E48B00B345537445158017058A3F88544718A41958AE94559D7C32D505044F6F51051C003AC0404A7C02D4AA00DF0033B39B00AD5C62D43A088C933090231
8D98922D7A007D01C0713664044CF67A2C807674105883158A86F53CB6143D8AF55362F85814A88A46458F84410D88600258800448800529907D13795F0E8105
3EFF981C62204A77220355803CA971068C400330F90388B00CF98627B340038500936AE00318937C4141037AA6001D301038D01FC3F424DFE846FF3002701400
80758E578837362692A5B8585C828AE4348FADB838AAF10FFE300A388003D8300C12599310410300381A6DF00FCA504445910A7F421865C00EFFE0007589038B
2005B29827B54007750984EEE233B248248860670A1001FB4647A4608BC60402D0C1025016001BE98C7B457D45010CBBF89167498A0C0838B0A006D5C0964411
41D1E09644210809E0036B180064300DFF10067FA36EA0351011331A6BF00F8CE05EA3F10EAA25346E90410F7022ABF037CAC8068898071D4814DEC0008F1065
5CFFB0019A49269D109601B00FF92010EDD07BDD72064118002E6003BF908185B052AEC95DD2A346E81009104787DD190030B0067939009AC28A443106273003
F04714C5D0002120349FD035F908115F709001700F5BC40DCAD502FF70092EB705592009249856C4D9550D10019544077F18008AF00318507F705005C1B54033
800E2EC6990EF10DA5C92D95007BC8003B29C000BD989FEDB89FB0630144E047A3919403A0456F686B21A01B473081A3D1087E606536E910DDD04BCC64023484
36988005026102B0E697EE13066846188B900051491445C00041106465800409B74027000A84710D12710EADA00A57B0057BB007D65003E7106902410B664001
2BE9500EAA900BCBB02E9ED01802800A75A00794CA0D41D009D1D518BFA06401B0003B900EBC207B6121105F000D16B002E8D00C201815BBE086FF8008F140A9
CCE010B30009CE50034EC00AC8000E31610863D0186FE05A11710C948A0173201086100D949A0C552410C7B00830E0044E4001EDE00A0F31030D000D14B0AA0F
50011E7A048240A992E02BD3D018944008AFD01845E07303A10CC9810C14371177909407907AF5BAAF2B5434C7C5AF1001498C9341005BB0D3020C0580762290
6C052BB08546B0061BB1324108A3618D12FB95DF50051A9B09C572B11E4B1155A009A5D005B5A042101110003B}}
\par\par \b \uc2 Certara\uc2 ; \uc2 Certara \highlight22\uc2 Launches \highlight\uc2  Cardiac Safety Simulator to Determine Likelihood That  \highlight22\uc2 New Drug \highlight\uc2  Candidates Could Cause Potentially-Fatal Arrhythmias\b0\par\par\uc2 548 \uc2 words\par \uc2 22 August 2013\par \uc2 Computer Weekly News\par \uc2 COMWKN\par 238\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2013 Computer Weekly News via via VerticalNews.com   \par \par \uc2 2013 AUG 22 (VerticalNews) -- By a News Reporter-Staff News Editor at Computer Weekly News -- \uc2 Certara\uc2 (TM), a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, \b \highlight22\uc2 announced the launch\b0 \highlight\uc2  of its Cardiac Safety Simulator(TM) (CSS), based on an in-silico model of human ventricular heart cells. When the CSS is integrated with \uc2 Certara\uc2 's Simcyp(TM) Population-based Simulator, it allows for the in-vitro to in-vivo extrapolation of the pharmacokinetic and pharmacodynamic data to predict the likelihood that a drug candidate will exhibit cardiac toxicity.\par \par \uc2 "Our Cardiac Safety Simulator can help to determine whether a drug candidate is likely to cause disruption of the electrical potential in the left ventricular cardiac cells and QT prolongation, which are surrogates for potentially-fatal arrhythmias, before the drug candidate enters clinical trials. This is possible because the tool's mechanistic modeling is based on human data," said Dr. Sebastian Polak, principal scientist at \uc2 Certara\uc2 's Simcyp, associate professor at the \uc2 Jagiellonian University\uc2  in Cracow, Poland, and chief architect of the CSS. "This model incorporates not only information about the chemical structure of the molecule, but also independent parameters including in-vitro study settings," he added. QT is an electrocardiogram (ECG) marker, which represents the ventricular repolarization that occurs when the heart beats.\par \par \uc2 As the CSS includes a virtual population generator, it allows sponsors to model variability between individuals as well as within them. Sponsors are no longer looking at average individuals, but at entire populations in which they can determine the number, gender and age of participants. The CSS can predict differences in response based on demographic, physiological, and genetic variations. It also factors in chronopharmacology and the fact that individuals can respond differently to a drug dose at different times of the day. Results are displayed as pseudo ECGs.\par \par \uc2 Sponsors can continue to use the CSS throughout the drug development process, further refining their cardiac risk analysis as clinical data becomes available. The CSS can also be used to help determine safe drug doses for specific patient populations.\par \par \uc2 The CSS' initial focus will be on QT prolongation. However, there are already plans underway to include additional electrophysiology endpoints, and also heart contractility and heart muscle cell metabolism modules in the CSS. About \uc2 Certara\uc2 Certara\uc2  is dedicated to improving human health by delivering a broad spectrum of software products and consulting services, spanning molecular discovery to clinical development, with special focus on supporting translational approaches to drug development. A leading provider of model-based drug development tools, \uc2 Certara\uc2  was formed by the acquisition and integration of industry leaders \uc2 Tripos\uc2 (R), Simcyp(TM), and Pharsight(R) Corporation. Each \uc2 Certara\uc2  family brand focuses on a key phase within the drug discovery and development process; combined, they offer a unique set of scientific modeling, analysis, and simulation capabilities that can enable the cross-disciplinary approaches necessary for translational science initiatives. For more information, visit {\field{\*\fldinst{HYPERLINK "http://www.certara.com"}}{\fldrslt{\cf2 \uc2 www.certara.com}}}\uc2 .\par \par \uc2 Keywords for this news article include: \uc2 Certara\uc2 , Therapy, Software, Cardiology, Drug Development, Clinical Trials and Studies.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC\par \par \uc2 Document COMWKN0020130816e98m0003m\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Mylan confirms FDA approval of sANDA for Bupropion Hydrochloride tablets\b0\par\par\uc2 89 \uc2 words\par \uc2 22 August 2013\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2013. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Mylan confirmed that the company has received approval from the U.S. FDA for its supplemental Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application providing bioequivalence study results requested by FDA for Bupropion Hydrochloride Extended-release Tablets USP, 300 mg. Bupropion HCl ER Tablets USP are the generic version of WELLBUTRIN XL and are indicated for the treatment of major depressive disorder. Mylan \b \highlight22\uc2 launched\b0 \highlight\uc2  its Bupropion HCl ER Tablets USP, 150 mg and 300 mg, to the U.S. market in September 2010. \par \par \uc2 Document FLYWAL0020130822e98m006he\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 USANA\uc2  Unveils New and Reformulated Products\b0\par\par\uc2 759 \uc2 words\par \uc2 20 August 2013\par 08:20\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2013  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 \f2 \f28 \b \highlight22\uc2 \f2 New products\f28 \b0 \highlight\uc2 \f2  include three protein snacks and allergy-free meal replacement, along with Nutrimeal and Probiotic upgrades \par  \f28 \par \par \uc2 \f2 SALT LAKE CITY, Aug. 20, 2013 /PRNewswire/ -- \f28 \uc2 \f2 USANA Health Sciences, Inc\f28 \uc2 \f2 . (NYSE: USNA), an international nutritional company, announced exciting \f28 \b \highlight22\uc2 \f2 new products\f28 \b0 \highlight\uc2 \f2  and upgrades to their low-glycemic Foods line during its 21st International Convention. \f28 \uc2 \f2 USANA\f28 \uc2 \f2  unveiled four \f28 \b \highlight22\uc2 \f2 new products\f28 \b0 \highlight\uc2 \f2 : a mild-flavored meal replacement shake called Nutrimeal(TM) Free and three protein snacks--Choco Chip(TM), Peanutty Bliss(TM) and Fudge Delite(TM). The company also \f28 \b \highlight22\uc2 \f2 introduced\f28 \b0 \highlight\uc2 \f2  customers to reformulated Nutrimeal flavors and a new, upgraded probiotic supplement.\f28 \par \par \uc2 (Logo: {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20120807/LA53885LOGO"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20120807/LA53885LOGO}}}\uc2 )\par \par \uc2 "\uc2 USANA\uc2 's new protein snacks, along with Nutrimeal Free and our other product upgrades, are major steps forward in the continued development of our Foods product line," says USANA Chief Marketing Officer \uc2 Doug Braun\uc2 . "The markets for diet, weight-management, and health-related products are constantly changing, and \uc2 USANA\uc2  understands the need to evolve with these marketing trends. It's important for us to stay relevant and listen to what our consumers want in order to continue our worldwide growth and success for years to come."\par \par \uc2 USANA\uc2 's new Foods line now includes:\par \par \uc2 \f2 \par    -- Reformulated Nutrimeal product line. These meal replacement shakes now \par       come in four varying gluten-free flavors, including Dutch Chocolate, \par       French Vanilla, Chocolate Whey, and Wild Strawberry. The formulas were \par       updated to improve the flavor and to cater to consumers with gluten \par       intolerances. Packaging was also updated to reflect \f28 \uc2 \f2 USANA\f28 \uc2 \f2 's visual \par       rebranding, which was launched last year at International Convention. \par       Nutrimeal Free. Nutrimeal Free is a meal replacement shake made with \par       plant-based protein. It is a gluten-, soy-, fructose- and dairy-free \par       alternative for those with food allergies or those looking to reduce the \par       daily intake of sugar in their diet. \par  \par    -- Three new protein snacks. The low-glycemic, gluten-free Choco Chip, \par       Peanutty Bliss and Fudge Delite protein snacks are intended to serve as a \par       healthy alternative for those who have weight-loss or weight-management \par       issues due to their craving for sweets. They are the first products in \par       the line that will eventually make up \f28 \uc2 \f2 USANA\f28 \uc2 \f2 's new weight management \par       program. \par  \par    -- Reformulated Probiotic. \f28 \uc2 \f2 USANA\f28 \uc2 \f2 's probiotic food supplement supports \par       digestive health with a unique blend of healthy bacteria that brings \par       balance to the gut. The reformulated \f28 \uc2 \f2 USANA\f28 \uc2 \f2  Probiotic is dairy and sugar \par       free, making it a great option for those with dairy sensitivities and for \par       those limiting sugar in their daily diets. \f28 \par \par \uc2 \f2 "This year's additions to our Foods line and our other product reformulations show our dedication and commitment to health at every level," says USANA CEO \f28 \uc2 \f2 Dave Wentz\f28 \uc2 \f2 . "These products are in line with \f28 \uc2 \f2 USANA\f28 \uc2 \f2 's promise to our consumers, which is that 'Everything we do helps you love life and live it.' With these new product offerings and gluten-free upgrades, we can help people lead healthier lifestyles and ultimately make the world a better place, one individual at a time."\f28 \par \par \uc2 \f2 About \f28 \uc2 \f2 USANA\f28 \par \par \uc2 \f2 Founded in 1992, \f28 \uc2 \f2 USANA Health Sciences\f28 \uc2 \f2  (NYSE: USNA) is a U.S.-based nutritional company that manufactures high-quality supplements and personal care, energy and weight-management products in its FDA-registered facility in Salt Lake City. \f28 \uc2 \f2 USANA\f28 \uc2 \f2 's products, used by more than 600 professional athletes, are developed by the company's award-winning team of scientists and sold directly to Preferred Customers and Associates in 19 international markets. \f28 \uc2 \f2 USANA\f28 \uc2 \f2  has earned NSF Certified for Sport(R) certification for its SportsPak, Essentials(TM) (Chelated Mineral and Mega Antioxidant), Proflavanol(R) C100, Active Calcium(TM), Procosa(R) and BiOmega(TM) products. It has also earned NSF dietary supplement certification for its HealthPak(TM).\f28 \par \par \uc2 \f2 USANA\f28 \uc2 \f2  is the No. 1 Rated Brand in Direct Sales Based on Customer Satisfaction in ConsumerLab.com's 2013 Survey of Vitamin and Supplement Users. Named one of Outside magazine's "Best Places to Work" for five consecutive years, \f28 \uc2 \f2 USANA\f28 \uc2 \f2  has received more than 100 state, national and international accolades, including Utah Best of State, Stevie Awards, Australian Business Awards, NutriSearch Editor's Choice and others. Learn more about \f28 \uc2 \f2 USANA\f28 \uc2 \f2  (\f28 {\field{\*\fldinst{HYPERLINK "http://www.USANA.com"}}{\fldrslt{\cf2 \uc2 www.USANA.com}}}\uc2 \f2 ) and the \f28 \uc2 \f2 USANA\f28 \uc2 \f2  True \f28 \uc2 \f2 Health Foundation\f28 \uc2 \f2  (\f28 {\field{\*\fldinst{HYPERLINK "http://www.USANAfoundation.org/"}}{\fldrslt{\cf2 \uc2 www.USANAfoundation.org/}}}\uc2 \f2 ), stay current with the official \f28 \uc2 \f2 USANA\f28 \uc2 \f2  blog (\f28 {\field{\*\fldinst{HYPERLINK "http://www.whatsupUSANA.com"}}{\fldrslt{\cf2 \uc2 www.whatsupUSANA.com}}}\uc2 \f2 ), like us on the \f28 \uc2 \f2 USANA\f28 \uc2 \f2 Facebook\f28 \uc2 \f2  page (\f28 {\field{\*\fldinst{HYPERLINK "http://www.facebook.com/USANAhealthsciences"}}{\fldrslt{\cf2 \uc2 www.facebook.com/USANAhealthsciences}}}\uc2 \f2 ), or follow \f28 \uc2 \f2 USANA\f28 \uc2 \f2  on \f28 \uc2 \f2 Twitter\f28 \uc2 \f2  (@USANAinc).\f28 \par \par \uc2 \f2 Media Contact: \f28 \uc2 \f2 Ashley Collins\f28 \par \par \uc2 \f2 Executive Director of PR, Social Media and Communications\f28 \par \par \uc2 \f2 USANA Health Sciences, Inc\f28 \uc2 \f2 .\f28 \par \par \uc2 \f2 (801) 954-7629\f28 \par \par \uc2 \f2 media(at)us.usana(dot)com\f28 \par \par \uc2 \f2 SOURCE \f28 \uc2 \f2 USANA Health Sciences, Inc\f28 \uc2 \f2 .\f28 \par \par \uc2 \f2 Web site: \f28 {\field{\*\fldinst{HYPERLINK "http://www.USANA.com"}}{\fldrslt{\cf2 \uc2 http://www.USANA.com}}}\par \par \uc2 Document PRN0000020130820e98k0006y\par }\page {\par\fs20\b \uc2 General Mills\uc2  innovates to spark growth.(CORPORATES PROFILES: TSE 2013)\b0\par\par\uc2 1,000 \uc2 words\par \uc2 19 August 2013\par \uc2 Chain Drug Review\par \uc2 CHDR\par 120\par \uc2 ISSN: 0164-9914; Volume 35; Issue 13\par \uc2 English\par \uc2 Copyright 2013 Gale Group Inc. All rights reserved.   \par \par \uc2 MINNEAPOLIS -- The consumer packaged goods giant \uc2 General Mills Inc\uc2 . has once again demonstrated its innovation and responsiveness to the market with the rollout of more than 200 \b \highlight22\uc2 new products\b0 \highlight\uc2 , including such favorites as cereals, snack bars, yogurt, and breakfast and gluten-free items.\par \par \uc2 "Product innovation is the fuel that creates category growth," said General Mills chairman and chief executive officer \uc2 Ken Powell\uc2  at the company's annual Investor Day, held at the New York Stock Exchange in July. "We also have a robust \b \highlight22\uc2 new product\b0 \highlight\uc2  plan, with more than 200 new items being \b \highlight22\uc2 introduced\b0 \highlight\uc2  in the first half of the year alone."\par \par \uc2 Every day, consumers look to \uc2 General Mills\uc2  to provide such mainstays as 60 million servings of ready-to-eat cereal, 27 million servings of \uc2 Yoplait\uc2  dairy products, 14 million Nature Valley bars and 5 million Pillsbury cookies.\par \par \uc2 The company has also responded to changing demographics with new meal offerings that deliver convenience as well as taste. Since on-the-go consumers now spend, on average, less than 30 minutes to prepare and cook the evening meal, \uc2 General Mills\uc2  is meeting that need with such new dinner options as Ultimate Helper premium dinner kits, Old E1 Paso Mexican Cooking Sauces, Old El Paso Frozen Entrees, Old E1 Paso Stand 'n Stuff Soft Flour Tortillas and Progresso Heart Healthy soups.\par \par \uc2 Consumers are also eating more snacks and mini-meals throughout the day. In 2012, for example, snacking accounted for 53% of all eating occasions in the United States, up from 49% in 2010, according to \uc2 General Mills\uc2 . Consumers also view snacking as an integral part of a healthy lifestyle and are increasingly seeking such ingredients as protein or fiber within convenient, portable food items that will fill them up and give them energy, notes a 2012 study released by the Hartman Group, a brand advisor that provides global research on consumer culture, behaviors and demand.\par \par \uc2 In response, \uc2 General Mills\uc2  is engaging in a global launch of such convenient, tasty and protein- and fiber-rich SKUs as Nature Valley Protein Granola cereal, Nature Valley Greek Yogurt Protein bars and Fiber One Protein Peanut Butter bars in the U.S.; \uc2 Yoplait\uc2  Yopa! yogurt in Canada; and Liberte Greek yogurt in the United Kingdom.\par \par \uc2 "Our business portfolio gives us confidence that we can keep growing at an attractive rate," noted Powell. "In recent years we've taken important strategic actions to focus and enhance our business mix. We now compete in five global product categories where sales are growing at a healthy clip. We've got a $4 billion cereal business worldwide; that's including our half of CPW [\uc2 Cereal Partners Worldwide\uc2 ] sales. We're the world's second-largest yogurt company with nearly $3 billion in net sales worldwide."\par \par \uc2 The company has changed the geographic mix of its business, adding international markets and, in particular, emerging markets. Five years ago, for example, just about 25% of \uc2 General Mills\uc2 ' total sales came from markets outside the U.S., compared with more than one-third today. The company's cereal joint venture sales in markets outside of Western Europe and Australia, along with consolidated sales in China, India and Latin America, now account for about $2 billion of revenue, according to Powell.\par \par \uc2 General Mills\uc2  has also maintained its promotional support for such key products as cereals. "While cereal share of total food and beverage spending has declined, our share of cereal advertising is up to 41% of total category spending over the latest 12-month period," notes Ian Friendly, the company's executive vice president and chief operating officer of U.S. retail. "We have some great new advertising coming in 2014. We are particularly excited about our Cheerios campaign."\par \par \uc2 The company also plans to invest in product innovation, expanding such lines as Chex with a vanilla variety and, in the cooking segment, introducing several gluten-free refrigerated dough products. \uc2 General Mills\uc2 ' frozen food Totino's Bold Rolls have been successful in the club channel, and the company plans to expand distribution to other channels. It will also add a Jalapeno Popper SKU. Availability of the company's Pillsbury breakfast items--which can be microwaved in the package -will also grow as \uc2 General Mills\uc2  adds grocery stores to the current food service channel distribution.\par \par \uc2 "We also have some great dessert mixes featuring the irresistible taste of Hershey's chocolate," notes Friendly, adding that the baking business will be supported with a new advertising campaign aligned with the Pillsbury brand.\par \par \uc2 The success of these and other efforts is reflected in \uc2 General Mills\uc2 ' sales, which continue to post gains despite an uncertain economy. Fiscal 2013 net sales rose 7% to $17.8 billion, while total segment operating profit increased 6% to $3.2 billion.\par \par \uc2 The company reports that products that made the strongest contributions to the U.S. retail segment's net sales growth in fiscal 2013 included such new items as Honey Nut Cheerios Medley Crunch cereal, \uc2 Yoplait\uc2  Greek 100-calorie yogurt and Nature Valley Protein Bars, along with such established brands as Lucky Charms cereal, Progresso ready-to-serve soup, Fiber One snack bars, Totino's frozen snacks and Pillsbury refrigerated baked goods.\par \par \uc2 International contributions to the overall sales increase were led by double-digit growth in such lines as Haagen Dazs ice cream and Wanchai Ferry frozen dim sum in China, and the newly acquired Yoki and Kitano brands in Brazil. In the bakeries and food service segment, such items as Chex Mix snack varieties, Pillsbury heat-and-serve breakfast items and Yoplalt Parfait Pro Greek yogurt made strong contributions to fiscal 2013 sales.\par \par \uc2 "Our business plans for 2014 include strong levels of innovation on established product lines and a high-quality lineup of new products," Powell said.\par \par \uc2 General Mills Inc\uc2 .\par \par \uc2 P.O. Box 9452\par \par \uc2 Minneapolis, Minn. 55440\par \par \uc2 Website: generalmills.com\par \par \uc2 Phone: (800) 248-7310\par \par \uc2 Primary business:\par \par \uc2 CONSUMABLES\par \par \uc2 Cereal, snack bars, yogurt, breakfast items and other food products\par \par \uc2 Total Store Expo booth #2868\par \par \uc2 Document CHDR000020130903e98j00031\par }\page {\par\fs20\b \uc2 Product  \highlight22\uc2 launches \highlight\uc2  augment Wrigley line.(CORPORATE PROFILES: TSE 2013)\b0\par\par\uc2 854 \uc2 words\par \uc2 19 August 2013\par \uc2 Chain Drug Review\par \uc2 CHDR\par 114\par \uc2 ISSN: 0164-9914; Volume 35; Issue 13\par \uc2 English\par \uc2 Copyright 2013 Gale Group Inc. All rights reserved.   \par \par \uc2 CHICAGO -- For more than a century, \uc2 Wm. Wrigley Jr. Co\uc2 . has been a recognized leader in confections with such product offerings as gum, mints, hard and chewy candies, and lollipops. The company--a subsidiary of \uc2 Mars Inc\uc2 ., with operations in some 50 countries and distribution in more than 180--offers a portfolio of popular brands that includes the Extra, Orbit, Doublemint, and five chewing gum lines, as well as such confectionery brands as Skittles, Starburst, Altoids and Life Savers.\par \par \uc2 This summer Wrigley bolstered its selection with a series of \b \highlight22\uc2 new product\b0 \highlight\uc2  introductions. The Extra gum brand expanded its Extra Dessert Delights line with a Raspberry Vanilla Cupcake flavor. Available at retailers nationwide in a 15-count slim pack for $1.19 and a three-pack multi-pack containing three 15-stick slim packs for $2.69, the new Dessert Delights flavor "rides on the wave of the nation's cupcake craze," says Caroline Sherman, Wrigley's U.S. manager of marketing communications.\par \par \uc2 Wrigley is also adding to its five gum line with two new mint-influenced SKUs: spearmint and peppermint. "Both include a blast of menthol to shock chewers' senses and awaken their minds," notes Sherman. "They are available at retailers nationwide in a resealable 15-piece pellet pouch for a suggested retail pace of $1.49."\par \par \uc2 In 2013 "new and unusual spices and flavors, comfort foods, and little tastes" are emerging as the top trends to meet the evolving appetites of consumers, according to the \uc2 National Confectioners Association\uc2 , which hosted the 2013 Sweets and Snacks Expo in Chicago in May.\par \par \uc2 "In 2013 confectionery and snacks are spicing up life," says Larry Graham, president of the National Confectioners Association. "We've seen tangy flavors in sweets and snacks before, but the variations are becoming more daring each year.\par \par \uc2 "Consumers are excited by new flavors and formulas, and the confectionery and snack industries have obliged. We're looking across borders and cultures for inspiration, we're borrowing flavors historically not found in the category, and we're taking consumers along for a wild and satisfying ride."\par \par \uc2 In an August introduction tied to the upcoming Halloween holiday, Wrigley's Starburst line is unveiling Candy Corn, infusing the bright, juicy flavors and colors found in Starburst Original fruit chews with the iconic shape and texture of candy corn. The new product features such flavors as cherry, orange, strawberry and lemon. It is available from August through October in 12-ounce lay-down bags that carry a suggested retail pace of $2.49, while 2-ounce single-serve bags are available for 69 cents.\par \par \uc2 Wrigley is known for its policy of constant innovation, but these and other introductions are also part of a broad-based response to a competitive market. "During the past year the gum category has continued to decline at a rate that is faster than we anticipated," Sherman says. "As a leader in gum, Wrigley is committed to helping restore the category to health.\par \par \uc2 "To do this, we must understand what's happening--why fewer people are chewing gum, and why those who chew are chewing less."\par \par \uc2 Explaining the decline, she points to such factors as a decrease in discretionary income that is affecting all consumers, including the pivotal teen category; a noticeable increase in competition for consumer spending from such categories as technology, which leaves less pocket space for gum; and new brand and flavor entries that are complicating the gum category even as spending options at the front end increase, increasing the complexity of consumer purchase decisions.\par \par \uc2 Wrigley has not been daunted by the challenges, however. "In order to revitalize the category, we're focused on the bigger picture," comments Sherman. "For sustained growth, it's critical for gum to be a part of people's daily routines.\par \par \uc2 "We're focused on several key ways to address these challenges. For example, in 2012 we introduced Orbit and five gum Micro Packs, a six-tab pack at a suggested retail price of 69 cents. This new pack size delivers a significant under-S1 opening pace option and fits easily into pockets or small purses."\par \par \uc2 The company is also reminding consumers about the functional benefits of chewing sugar-free gum. "One way we're communicating this is via Orbit gum's current 'Eat Drink Chew' campaign, which reminds consumers to chew after meals for oral care benefits," explains Sherman. "This summer we launched Orbit for Kids, a new innovation aimed at giving parents a fun and convenient way to help protect kids' teeth."\par \par \uc2 Wrigley has also responded to the changes in the way consumers shop, as they increasingly turn to online and mobile transactions.\par \par \uc2 "We're confident in our current retail presence, but in order to maximize possibilities in these newer locations, we must get distribution in these spaces as well," she adds. "We support multiple brands through a variety of channels, including TV, print, digital, mobile and in-store."\par \par \uc2 Wm. Wrigley Jr. Co\uc2 .\par \par \uc2 600 West Chicago Ave.\par \par \uc2 Chicago, Ill. 60610\par \par \uc2 Website: wrigley.com\par \par \uc2 Phone: (800) WRIGLEY\par \par \uc2 Primary business:\par \par \uc2 CONSUMABLES\par \par \uc2 Chewing gum, mints and other confections\par \par \uc2 Document CHDR000020130903e98j0002x\par }\page {\par\fs20\b \uc2 Maybelline\uc2  New York on cutting edge.(CORPORATE PROFILES: TSE 2013)\b0\par\par\uc2 459 \uc2 words\par \uc2 19 August 2013\par \uc2 Chain Drug Review\par \uc2 CHDR\par 55\par \uc2 ISSN: 0164-9914; Volume 35; Issue 13\par \uc2 English\par \uc2 Copyright 2013 Gale Group Inc. All rights reserved.   \par \par \uc2 NEW YORK -- With the introduction this year of a round of \b \highlight22\uc2 new products\b0 \highlight\uc2  that continue to appeal to fashion-conscious consumers, \uc2 Maybelline\uc2  New York has again demonstrated how it consistently remains at the top of the color cosmetics category.\par \par \uc2 Earlier this year, the company \b \highlight22\uc2 introduced\b0 \highlight\uc2  Falsies Big Eyes by Volum' Express, a mascara designed to address the different needs of top and bottom lashes, just as makeup artists do backstage.\par \par \uc2 "The big-eyed beauty look has become a bold statement unto itself and is sure to remain a trend for seasons to come," vice president of marketing Ali Goldstein says. "With Big Eyes, we've simplified the technique and redefined the very goal of mascara. It's not just about the lashes, but also about the eyes."\par \par \uc2 Building further on the dramatic eye trend, \uc2 Maybelline\uc2  has added two new items to its popular Eye Studio collection: Color Tattoo Pure Pigments eye shadow and Master Smoky liner. Goldstein says both products are professionally inspired and sure to keep eyes in the spotlight for seasons to come.\par \par \uc2 Meanwhile, \uc2 Maybelline\uc2  has engineered what marketers say is "a heavy hitter in the war on shine" with the launch of Fit Me shine-free stick foundation.\par \par \uc2 With its convenient stick format, lightweight gel-based formula and anti-shine properties, Fit Me shine-free stick foundation makes it easy to achieve the matte skin look that has taken over the runways.\par \par \uc2 Goldstein explains that the product's secret weapon is an anti-shine core with ultra-absorbent powder, which is designed to perfectly balance skin and absorbs excess oil.\par \par \uc2 The company's Baby Lips Electro lip balm is the latest addition to its popular Baby Lips lip care franchise. The new collection of six neon shades includes electric-colored pigments created to give lips an instant pop of can't-miss color in addition to a surge of renewing moisture.\par \par \uc2 As the official nail color sponsor of \uc2 Mercedes-Benz\uc2  Fashion Week in New York, \uc2 Maybelline\uc2 's Color Show nail lacquer is locked into what's happening backstage and poised to present on-trend shades, effects and techniques, the company says.\par \par \uc2 With the recent introduction of The Polka Dot Line and The Holographics by Color Show, the company has taken the latest trends from the catwalk to the sidewalk, keeping fingers and toes "runway ready from morning to night."\par \par \uc2 Maybelline\uc2  New York\par \par \uc2 575 Fifth Ave. New York, N.Y. 10017\par \par \uc2 Key contacts: Nicole Schwend, Vice President of National Sales, \uc2 Maybelline\uc2  and essie\par \par \uc2 Dan Kuzdro, Vice President of National Sales, Garnier\par \par \uc2 Websites: maybelline.com, garnierusa.com, essie.com\par \par \uc2 Phone: (212) 984-1500\par \par \uc2 Primary business: BEAUTY CARE\par \par \uc2 Color cosmetics, hair care, nail care\par \par \uc2 Total Store Expo booth #5235\par \par \uc2 Document CHDR000020130903e98j0001a\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ Chimerix Files 8K - Regulation FD >CMRX\b0\par\par\uc2 276 \uc2 words\par \uc2 14 August 2013\par 06:05\par \uc2 Dow Jones Newswires\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright (c) 2013, Dow Jones & Company, Inc.   \par \par \uc2 Chimerix Inc\uc2 . (CMRX) filed a Form 8K - Regulation FD Disclosure - with the U.S Securities and Exchange Commission on August 14, 2013.\par \par \uc2 On August 14, 2013, we announced top line data from our exploratory Phase 2 study of CMX001 as preemptive therapy for adenovirus infection and the acceptance of the proof-of-concept data as an oral late-breaker presentation at the upcoming 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy meeting, in the press release attached hereto as Exhibit 99.2 and incorporated herein by reference.\par \par \uc2 The information in this Item 7.01 and the attached Exhibit 99.2 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 7.01 and the attached Exhibit 99.2 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1117480/000114420413045333/v352925_8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1117480/000114420413045333/v352925_8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1117480/000114420413045333/0001144204-13-045333-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1117480/000114420413045333/0001144204-13-045333-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 August 14, 2013 06:05 ET (10:05 GMT)\par \par \uc2 Document DJDN000020130814e98e00288\par }\page {\par\fs20\uc2 MI News\par \b \uc2 Local business; Perrigo gets OK to  \highlight22\uc2 launch \highlight\uc2  3 new generic drugs\b0\par\par\uc2 Brian.VanOchten   \par \uc2 256 \uc2 words\par \uc2 13 August 2013\par \uc2 The Holland Sentinel\par \uc2 HOLLND\par 4\par \uc2 English\par \uc2 Copyright 2013 The Holland Sentinel, All Rights Reserved. Distributed by NewsBank, inc.   \par \par \uc2 @hollandsentinel.com (616) 546-4279\par \par \uc2 Perrigo Company\b \highlight22\uc2 announced the launch\b0 \highlight\uc2  of three \b \highlight22\uc2 new products\b0 \highlight\uc2  Monday.\par \par \uc2 The Allegan-based drug manufacturer is partnering with \uc2 Teva Pharmaceutical Industries Inc\uc2 . on the generic equivalent of Temodar (temozolomide), which is used in the treatment of adult patients with some newly diagnosed forms of cancer.\par \par \uc2 It also was granted final \uc2 U.S. Food and Drug Administration\uc2  approval for its abbreviated new drug applications for Derma-Smoothe/FS Scalp Oil (fluocinolone acetonide topical oil, 0.01 percent) and Derma Smoothe/FS Body Oil (fluocinolone acetonide topical oil 0.01 percent).\par \par \uc2 "We are excited to begin shipments of these products," said Joseph C. Papa, Perrigo chairman, president and CEO, in a news release.\par \par \uc2 Teva will manufacture, market and distribute generic Temodar, which had sales of about $423 million in the U.S last year. The Jerusalem-based company has marketing exclusivity for 180 days because it was first to file for a new drug application.\par \par \uc2 Both companies will share equally in the cost and profitability of Temodar throughout the U.S, the release said.\par \par \uc2 The generic equivalent Derma-Smoothe/FS products, which had combined sales of almost $25 million last year, are used for the topical treatment of atopic dermatitis in adult patients and moderate to severe atopic dermatitis in children 3 months and older for up to four weeks.\par \par \uc2 It plans to begin shipments of both products next month.\par \par \uc2 \u8212\'20\'14 Follow this reporter on \uc2 Twitter\uc2  @BizHolland.\par \par \uc2 Document HOLLND0020130814e98d0000p\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ \uc2 Osiris Therapeutics\uc2  Files 8K - Regulation FD >OSIR\b0\par\par\uc2 196 \uc2 words\par \uc2 13 August 2013\par 08:01\par \uc2 Dow Jones Newswires\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright (c) 2013, Dow Jones & Company, Inc.   \par \par \uc2 Osiris Therapeutics Inc\uc2 . (OSIR) filed a Form 8K - Regulation FD Disclosure - with the U.S Securities and Exchange Commission on August 13, 2013.\par \par \uc2 On August 13, 2013, \uc2 Osiris Therapeutics, Inc\uc2 . issued a press release announcing the results of the planned interim analysis of the data from its multi-center, randomized, controlled clinical trial (Protocol 302) comparing the safety and efficacy of Grafix(R) to standard of care. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1360886/000110465913062980/a13-18544_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1360886/000110465913062980/a13-18544_18k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1360886/000110465913062980/0001104659-13-062980-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1360886/000110465913062980/0001104659-13-062980-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 August 13, 2013 08:01 ET (12:01 GMT)\par \par \uc2 Document DJDN000020130813e98d002ix\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ \uc2 Osiris Therapeutics\uc2  Files 8K - Other Events >OSIR\b0\par\par\uc2 409 \uc2 words\par \uc2 13 August 2013\par 08:01\par \uc2 Dow Jones Newswires\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright (c) 2013, Dow Jones & Company, Inc.   \par \par \uc2 Osiris Therapeutics Inc\uc2 . (OSIR) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on August 13, 2013.\par \par \uc2 On August 13, 2013, \uc2 Osiris Therapeutics, Inc\uc2 . reported that its multi-center, randomized, controlled clinical trial (Protocol 302) comparing the safety and effectiveness of Grafix to standard of care in patients with chronic diabetic foot ulcers (DFU) was halted after the data monitoring committee conducted a planned interim analysis of the data and found that Grafix had reached the pre-specified stopping rules for overwhelming efficacy. For the primary endpoint, 62% of patient receiving Grafix had complete closure compared to 21% (p<0.0001) of patients who received conventional treatment for their wounds a relative improvement of 191%. A total of 131 patients were enrolled, with the interim analysis being conducted on the first 97 to complete the trial.\par \par \uc2 The trial also reached statistical significance in favor of Grafix on all available secondary endpoints, demonstrating faster wound closure and a reduction in the number of treatments needed to achieve wound closure. In the crossover phase of the trial, patients whose wounds failed to close after 12 weeks of standard of care had an 80% closure rate when switched to Grafix. Patients randomized to receive standard of care were 74% more likely to experience a Treatment Emergent Adverse Event (TEAE) than those receiving Grafix (p=0.008). As a result, the blinded phase of the trial is being discontinued immediately and all patients randomized to the control arm will be offered treatment with Grafix.\par \par \uc2 Top-Line Data from the Interim Analysis of Protocol 302\par \par \uc2 Grafix\par \par \uc2 (n=50)\par \par \uc2 Control\par \par \uc2 (n=47)\par \par \uc2 P Value\par \par \uc2 Primary\par \par \uc2 Complete Would Closure at 12 Weeks\par \par \uc2 62.0%\par \par \uc2 21.3%\par \par \uc2 p\par \par \uc2 *Patients attending all 12 treatments visits (n=79)\par \par \uc2 **n=20 at time of the interim analysis\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1360886/000110465913062980/a13-18544_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1360886/000110465913062980/a13-18544_18k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1360886/000110465913062980/0001104659-13-062980-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1360886/000110465913062980/0001104659-13-062980-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 August 13, 2013 08:01 ET (12:01 GMT)\par \par \uc2 Document DJDN000020130813e98d002dr\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 AcelRx Pharmaceuticals\uc2  Reports Second Quarter 2013 Financial Results\b0\par\par\uc2 2,754 \uc2 words\par \uc2 12 August 2013\par 16:05\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2013  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 REDWOOD CITY, Calif., Aug. 12, 2013 /PRNewswire/ -- \uc2 AcelRx Pharmaceuticals, Inc\uc2 . (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and six months ended June 30, 2013.\par \par \uc2 "With the successful completion of our Zalviso(TM) clinical program that includes data from all three Phase 3 studies, each of which met its primary endpoint, we are preparing to submit our \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (NDA), by the end of the third quarter," stated \uc2 Richard King\uc2 , president and CEO of AcelRx. "We were pleased with the financing completed last month in which we raised almost $48 million in net proceeds. This additional cash provides the resources to fund operations at least through the end of 2014 including commercial preparation activities for, and the potential \b \highlight22\uc2 launch\b0 \highlight\uc2  of, Zalviso in the United States."\par \par \uc2 Second Quarter Financial Results\par \par \uc2 Net loss for the second quarter of 2013 was $17.4 million, or $0.47 per share, compared with a net loss of $7.2 million, or $0.35 per share for the second quarter of 2012. Adjusted net loss for the second quarter of 2013 was $8.1 million, or $0.22 per share and excludes the $9.3 million non-cash expense resulting from the liability accounting related to warrants issued in connection with the PIPE financing completed in June 2012. There was no such expense recorded in the second quarter of 2012.\par \par \uc2 During the second quarters of 2013 and 2012, AcelRx recognized revenue of $407,000 and $224,000, respectively, as reimbursement for work completed under a research grant from the \uc2 U.S. Army\uc2  Medical Research and Materiel Command (USAMRMC), for development of ARX-04, a sufentanil NanoTab product candidate for the treatment of moderate-to-severe acute pain in a range of ambulatory environments.\par \par \uc2 Research and development (R&D) expenses for the quarter ended June 30, 2013 totaled $6.1 million, compared with $5.4 million for the quarter ended June 30, 2012. Phase 3 clinical costs for Zalviso, AcelRx's lead product candidate designed to improve the management of moderate-to-severe acute pain in patients in the hospital setting, were very similar in the quarters ending June 30, 2013 and 2012. The increase over the quarter ended June 30, 2012 was primarily due to personnel related costs, including stock compensation expenses. R&D expenses in the preceding quarter ended March 31, 2013 were $9.3 million, and the decrease to $6.1 million in R&D expenses in the quarter ended June 30, 2013 reflects lower Zalviso Phase 3 costs as we completed the Phase 3 clinical program.\par \par \uc2 General and administrative expenses were $2.1 million for the second quarter of 2013, compared with $1.8 million for the second quarter of 2012, due primarily to an increase in market research activities.\par \par \uc2 Other income and expense includes the $9.3 million non-cash charge in the second quarter of 2013 resulting from the liability accounting related to the warrants issued in connection with the PIPE financing completed in June 2012. The primary determinant of this charge was an increase in share price during the second quarter of 2013 and its resulting impact on the Black-Scholes valuation of these warrants.\par \par \uc2 For the six months ended June 30, 2013, AcelRx reported a net loss of $30.2 million, or $0.81 per share, compared with a net loss of $14.3 million, or $0.71 per share for the same period in 2012. Adjusted net loss for the six months ended June 30, 2013 was $19.2 million, or $0.52 per share. Adjusted net loss excludes the $11.0 million non-cash expense resulting from the liability accounting related to the warrants issued in connection with the PIPE financing completed in June 2012.\par \par \uc2 R&D expenses for the six months ended June 30, 2013 totaled $15.4 million, compared with $10.2 million for the six months ended June 30, 2012. The increase over the six months ended June 30, 2012 was primarily due to expenses associated with Phase 3 clinical studies of Zalviso. General and administrative expenses were $4.3 million for the six months of 2013, compared with $3.9 million for the six months ended June 30, 2012 due primarily to an increase in stock based compensation.\par \par \uc2 As of June 30, 2013, AcelRx had cash, cash equivalents and investments of $36.8 million, compared to $59.8 million at December 31, 2012 and $48.2 million at March 31, 2013. In July 2013, we raised approximately $47.9 million in net proceeds through the issuance of 4.37 million shares of common stock in an underwritten public offering.\par \par \uc2 Review of Recent Accomplishments and Corporate Update\par \par \uc2 \f2 \par    -- On July 23, 2013, AcelRx completed an underwritten public offering of \par       4,370,000 shares of common stock, including 570,000 shares which were \par       issued pursuant to the exercise of the underwriters' option to purchase \par       additional shares, at a price of $11.65 per share. The total net proceeds \par       of this offering were approximately $47.9 million after deducting \par       underwriting discounts and commissions and other estimated expenses \par       payable by AcelRx. AcelRx intends to use the net proceeds from this \par       offering to fund potential regulatory approval of Zalviso both in the \par       United States and Europe, our continuing preparation for and the \par       potential commercial launch of Zalviso in the United States, and for \par       working capital and other general corporate purposes. \par  \par    -- On June 27, 2013, AcelRx held an investor day in New York City, \par       introducing the trade name of Zalviso for the sufentanil NanoTab PCA \par       System. Presentations delivered at the meeting covered a range of topics, \par       including insights from an anesthesiologist and an orthopedic surgeon on \par       the potential role of Zalviso in the management of post-operative \par       patients and additional data from the Zalviso Phase 3 clinical program. \par       We also discussed AcelRx's intent to pursue a broad label for Zalviso for \par       the treatment of moderate-to-severe acute pain in the hospital setting in \par       the United States. \par  \par    -- On May 21, 2013, AcelRx announced top-line data demonstrating that \par       Zalviso met its primary endpoint in a pivotal Phase 3 trial comparing the \par       efficacy and safety of Zalviso to placebo in the management of acute \par       post-operative pain after major orthopedic surgery. Utilizing a \par       randomized, double-blind, placebo-controlled design, this pivotal Phase 3 \par       trial enrolled 426 adult patients at 34 U.S. sites. The primary endpoint \par       evaluated pain intensity difference to baseline over the 48-hour study \par       period, or SPID-48, in patients following major orthopedic surgery, \par       specifically knee or hip replacement. Patients receiving Zalviso \par       demonstrated a significantly greater SPID-48 (pain reduction) compared to \par       placebo-treated patients during the trial period (p<0.001). \par       Treatment-emergent adverse events were generally mild-to-moderate in \par       nature and similar for the majority of adverse events between Zalviso and \par       placebo treated patients, with the exception of nausea, vomiting, itching \par       and dizziness, which were higher in the sufentanil treated group. Two \par       patients (one each in the Zalviso group and placebo group) experienced a \par       severe adverse event considered possibly or probably related to the trial \par       drug by the investigator. \par  \par    -- On May 2, 2013 AcelRx presented five posters relating to clinical and \par       pharmacokinetic data from the Phase 3 Zalviso clinical program, as well \par       as data from design and human factors studies relating to the Zalviso \par       delivery system at the American Society of Regional Anesthesia and Pain \par       Medicine (ASRA) annual meeting in Boston. In one of these posters, new \par       analyses from the Phase 3 trial comparing Zalviso to intravenous \par       patient-controlled analgesia (IV PCA) with morphine demonstrated that \par       Zalviso had a significantly faster reduction in pain intensity compared \par       to IV PCA morphine (p<0.01). In addition, fewer patients experienced \par       oxygen desaturation events below 95% in the Zalviso-treated group \par       compared to the IV PCA morphine-treated group (p=0.028). Overall, adverse \par       events were similar between groups, and most were generally \par       mild-to-moderate in nature in both groups. \par  \par    -- On April 24, 2013, AcelRx reported top-line data showing that the primary \par       endpoint was achieved in a placebo-controlled, dose-finding, Phase 2 \par       clinical trial of ARX-04 for moderate-to-severe acute pain. This trial \par       randomized 101 patients following bunionectomy surgery in a 2:2:1 ratio \par       to 30 mcg sufentanil, 20 mcg sufentanil or placebo treatment. Results \par       demonstrated that patients receiving 30 mcg sufentanil NanoTab doses, \par       administered by a healthcare professional, no more frequently than once \par       per hour, had significantly greater pain reduction as measured by Summed \par       Pain Intensity Difference to baseline during the 12-hour trial period \par       (SPID-12) than placebo-treated patients (p=0.003). The clinical study and \par       associated research activities for ARX-04 are funded by a grant from \par       USAMRMC. \f28 \par \par \uc2 \f2 Financial Outlook\f28 \par \par \uc2 \f2 AcelRx records as revenue the reimbursement received pursuant to the $5.6 million USAMRMC grant received in 2011. To date, revenue from this grant has been the only source of revenue recognized by AcelRx and we have recorded revenues of $4.8 million through June 30, 2013. We expect the remaining $0.8 million to be recorded as revenue over the remaining life of the grant, which is scheduled to end on January 31, 2014.\f28 \par \par \uc2 \f2 We anticipate that the quarterly R&D expenses in the second half of 2013 will be lower than the expense recorded in Q2 of 2013, due to lower clinical development costs associated with the Zalviso and ARX-04 programs. These decreases in clinical R&D expenses will be partially offset by costs associated with the preparation of an NDA filing for Zalviso, expected to be submitted to the FDA by the end of the third quarter of 2013.\f28 \par \par \uc2 \f2 Additionally, AcelRx anticipates continued increases in 2013 in general and administrative expense due to costs associated with commercial preparations for the launch of Zalviso in the U.S. and expansion of its corporate infrastructure to support a commercial launch.\f28 \par \par \uc2 \f2 Total operating expenses for 2013 are anticipated to be modestly higher than they were in 2012.\f28 \par \par \uc2 \f2 Other income and expense in future periods is expected to include non-cash charges that result from the liability accounting related to the warrants we issued in connection with the PIPE financing completed in the second quarter of 2012. The primary determinant of this charge is stock price change over each quarter and its impact on the Black-Scholes valuation of these warrants. For this reason, the impact in future periods is very difficult to predict and is not included in the company's guidance.\f28 \par \par \uc2 \f2 AcelRx believes its current cash, cash equivalents and investments, including funding from the recently completed public equity offering, are sufficient to fund operations at least through the end of 2014. We expect our use of cash will decrease during the second half of 2013 compared to the first half of the year as expenditures, primarily R&D expenditures, decline for clinical activity and final payments are made to contract research organizations.\f28 \par \par \uc2 \f2 Conference Call\f28 \par \par \uc2 \f2 AcelRx will conduct a conference call and webcast today, August 12, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss its financial results and program updates. To listen to the conference call, dial in approximately ten minutes before the scheduled call to (800) 860-2442 for domestic callers, (866) 605-3852 for Canadian callers, or (412) 858-4600 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting the Investors section of the company's website at \f28 {\field{\*\fldinst{HYPERLINK "http://www.acelrx.com"}}{\fldrslt{\cf2 \uc2 www.acelrx.com}}}\uc2 \f2  and selecting the Webcast link for the Q2 2013 earnings conference call. A webcast replay will be available on the AcelRx website for 90 days following the call by visiting the Investors section of the company's website at \f28 {\field{\*\fldinst{HYPERLINK "http://www.acelrx.com"}}{\fldrslt{\cf2 \uc2 www.acelrx.com}}}\uc2 \f2 .\f28 \par \par \uc2 \f2 About \f28 \uc2 \f2 AcelRx Pharmaceuticals, Inc\f28 \uc2 \f2 .\f28 \par \par \uc2 \f2 AcelRx Pharmaceuticals, Inc\f28 \uc2 \f2 . is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, Zalviso, is designed to solve the problems associated with IV PCA which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the complexity of infusion pumps. AcelRx has announced positive results from each of the three Phase 3 clinical trials for Zalviso and AcelRx anticipates submitting a New Drug Application with the FDA in the third quarter of 2013. AcelRx also announced positive top-line results for a Phase 2 trial for ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from USAMRMC. The company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development. For additional information about AcelRx's clinical programs, please visit \f28 {\field{\*\fldinst{HYPERLINK "http://www.acelrx.com"}}{\fldrslt{\cf2 \uc2 www.acelrx.com}}}\uc2 \f2 .\f28 \par \par \uc2 \f2 Forward Looking Statements\f28 \par \par \uc2 \f2 This press release contains forward-looking statements, including, but not limited to, statements related to future financial results, including 2013 financial guidance and cash forecast, use of proceeds from recently completed financing, the process and timing of anticipated future development of AcelRx's product candidates, the potential submission of an NDA for Zalviso and the timing thereof, therapeutic and commercial potential of Zalviso and the anticipated timing and therapeutic and commercial potential of other AcelRx product candidates. These forward-looking statements are based on AcelRx's current expectations and inherently involve significant risks and uncertainties. AcelRx's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: AcelRx's ability to submit an NDA and receive regulatory approval for Zalviso, that fact that FDA may dispute or interpret differently positive clinical results obtained to date; any delays or inability to obtain and maintain regulatory approval of its product candidates, including Zalviso, in the United States and Europe; its ability to attract funding partners or collaborators with development, regulatory and commercialization expertise; its ability to obtain sufficient financing to commercialize Zalviso; the market potential for its product candidates; the accuracy of AcelRx's estimates regarding expenses, capital requirements and needs for financing; and other risks detailed in the "Risk Factors" and elsewhere in AcelRx's \f28 \uc2 \f2 U.S. Securities and Exchange Commission\f28 \uc2 \f2  filings and reports, including its Quarterly Report on Form 10-Q filed with the SEC on August 12, 2013. AcelRx undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.\f28 \par \par \uc2 \f2 \par  \par                                SELECTED FINANCIAL DATA \par                         (in thousands, except per share data) \par                                      (unaudited) \par  \par                                        Three Months Ended          Six Months Ended \par                                             June 30,                   June 30, \par                                 -------------------------------  -------------------- \par                                     2013            2012           2013       2012 \par                                 ------------  -----------------  ---------  --------- \par Statement of Operations Data \par Research grant revenue            $      407    $           224   $  1,347    $   553 \par  \par Operating expenses: \par  Research and development (1)          6,108              5,394     15,426     10,165 \par  General and administrative \par   (1)                                  2,070              1,776      4,261      3,880 \par      Total operating expenses          8,178              7,170     19,687     14,045 \par                                 ------------  -----------------  ---------  --------- \par Loss from operations                 (7,771)            (6,946)   (18,340)   (13,492) \par  \par Interest expense                       (403)              (598)      (857)    (1,192) \par Other income (expense), net(2)       (9,273)                350   (11,012)        425 \par                                 ------------  -----------------  ---------  --------- \par Net loss                        $   (17,447)  $         (7,194)  $(30,209)  $(14,259) \par                                 ============  =================  =========  ========= \par  \par Basic and diluted net loss per \par  common share                   $     (0.47)  $          (0.35)  $  (0.81)  $  (0.71) \par  \par Shares used in computing basic \par  and diluted net loss per \par  common share                         37,263             20,627     37,198     20,115 \par                                 ============  =================  =========  ========= \par  \par  \par  \par (1)  Includes the following non-cash, stock-based compensation \par expense: \par  \par            Research and \par             development           $      411    $           254    $   766    $   505 \par            General and \par             administrative               391                276        793        566 \par                   Total \par                    non-cash, \par                    stock-based \par                    expense        $      802    $           530   $  1,559   $  1,071 \par                                 ============  =================  =========  ========= \par  \par (2) Other income and expense includes a $9.3 million and $11.0 million and non-cash \par charge in the for the three and six months ended June 30, 2013, respectively, related \par to warrants issued in connection with a private placement equity financing, completed \par in June 2012. \par  \par                                   June 30, \par                                     2013      December 31, 2012 \par                                 ------------  ----------------- \par Selected Balance Sheet Data \par Cash, cash equivalents and \par  investments                     $    36,844   $         59,763 \par Total assets                          40,797             64,520 \par Total liabilities                     34,756             30,673 \par Total stockholders' equity             6,041             33,847 \par  \f28 \par \par \uc2 \f2 (Logo: \f28 {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20130226/MM67303LOGO"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20130226/MM67303LOGO}}}\uc2 \f2 )\f28 \par \par \uc2 \f2 SOURCE \f28 \uc2 \f2 AcelRx Pharmaceuticals, Inc\f28 \uc2 \f2 .\f28 \par \par \uc2 \f2 /\f28 \par \par \uc2 Document PRN0000020130812e98c000it\par }\page {\par\fs20\b \uc2 Otsuka Pharmaceutical; Otsuka Pharmaceutical Announces A Revamped Website on Aug 1, 2013\b0\par\par\uc2 449 \uc2 words\par \uc2 12 August 2013\par \uc2 Pharma Business Week\par \uc2 PHBW\par 119\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2013 Pharma Business Week via NewsRx.com    \par \par \uc2 2013 AUG 12 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- \uc2 Otsuka Pharmaceutical Co., Ltd\uc2 . \b \highlight22\uc2 launched\b0 \highlight\uc2  a newly designed English corporate website that was collaborated with an Amsterdam-based creative agency to reflect our philosophy: "Otsuka-people creating \b \highlight22\uc2 new products\b0 \highlight\uc2  for better health worldwide." With additional new content designed creatively, the new website adopts an innovative, personal design to attract people from around the world.\par \par \uc2 To view the multimedia assets associated with this release, please click: {\field{\*\fldinst{HYPERLINK "http://www.multivu.com/mnr/62657-otsuka-pharmaceutical-new-global-website"}}{\fldrslt{\cf2 \uc2 http://www.multivu.com/mnr/62657-otsuka-pharmaceutical-new-global-website}}}\par \par \uc2 This is a great chance for inquisitive internet users everywhere to discover who we are. At Otsuka Pharmaceutical, we are committed to a holistic approach to health and well-being of people and are striving to create innovative, thoroughly-original products based on our corporate philosophy. Otsuka Pharmaceutical and affiliated companies have products in more than 80 countries and nearly 28,100 employees, of which around 70% are based outside of Japan(1) (about 20,000 employees), and consolidated revenues of about USD 12 billion(2) (in FY2012).\par \par \uc2 Otsuka's business for better health is driven on two wheels: pharmaceuticals and neutraceuticals.(3) The creator of ABILIFY(R), the world's first antipsychotic drug with a dopamine D(2) receptor partial agonist mechanism is prescribed for schizophrenia, bi-polar and major depression in the US. A maker of many nutritional food products, such as SOYJOY, a baked soy bar with either real fruits, or peanuts as well as POCARI SWEAT, a health beverage that smoothly replenishes body fluids and ions (electrolytes), fall under our nutraceuticals category.\par \par \uc2 New content on the site includes Otsuka People Talk, video interviews with Otsuka employees in Japan and overseas, and WHATS & WHOS, an English-language global journal focusing on unique global initiatives pioneered by Otsuka. The website also incorporates comprehensive health information related to specific Otsuka business areas including tuberculosis, dry-eye and metabolic syndrome. The new Otsuka Pharmaceutical website, like the company overall, aims to contribute to the well-being of people everywhere.\par \par \uc2 The Otsuka Pharmaceutical culture encourages each and every employee to embody a spirit of innovation, as emphasized in our chairman \uc2 Akihiko Otsuka\uc2 's words "People make the company run, people do the thinking." To communicate this stance to our customers throughout the world, the new website is designed to convey an intimate, personal experience.\par \par \uc2 (1) Product presence by country and employee count current as of March 31, 2013\par \par \uc2 Keywords for this news article include: Asia, Otsuka Pharmaceutical, Japan.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC\par \par \uc2 Document PHBW000020130809e98c0002o\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw166\pich40\picscaley100\picscalex100\picwgoal2490\pichgoal600
47
4946383961A6002800F700002A4A9CD1D8EA95A4CE4964AAF0F2F85871B18598C6768BBF3957A3E1E5F1677EB8B3BEDCA4B1D5C2CBE3F2F4F9FBFBFDF4F6FAEC
EFF6F8F9FCC6CFE5C5CDE4E0E4F0F1F3F8F5F7FBE1E6F1D5DBEBF7F8FBD9DEEDEEF0F7DFE3F0D4DAEBE3E7F2D7DDECBFC8E1BBC5DFFDFEFEEBEEF6FBFCFDCED5
E8DBE0EEFAFAFC9DABD1AEBAD99EACD2E4E8F2F6F7FBF3F5FAE7EAF4E7EBF4D2D9EAE8EBF4C2CBE2E6E9F3AFBAD9C9D1E6AFBADAA8B5D74F69AE90A0CBCCD4E8
DADFED9FADD3E6EAF3DADFEEAFBBDAD5DBECD9DFEEA1AFD3DDE2EFEEF1F7D2D8E9EFF1F8E9ECF5F5F6FA798DC0798CC0DEE3F0BAC4DFE4E8F3DCE0EEA6B3D5D0
D6E9CBD2E791A1CC7388BFEDEFF7ABB7D73A56A3BEC7E1566EB1C2CAE3F3F5F9B7C1DED3DAEB6C81BBCCD3E7ECEEF6C1CAE2EDEFF6D3DAEA9DABD2D6DCECEFF1
F7C9D1E5C7CFE5C0C9E1FDFDFE94A3CDF5F7FAD0D7E9B7C2DE899AC8E2E6F2D1D7E9FEFFFFA5B2D5D1D7EAB0BBDAFCFDFEA7B4D6E9EDF5FAFAFDD8DEECAEBADA
ADB9D9DCE1EFCBD3E793A2CC8597C6CFD6E9FEFEFEE5E9F37D8FC298A7D0B9C3DFB6C0DDD9DFEDF9FAFCE2E7F2FEFEFFDDE2F06E83BC4E68AD8395C599A8D099
A8CF1B3D95FFFFFF0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000021F90400000000002C00000000A60028000008FF0027091C48B0A0C18308132A5CC8B0A1C38710234A1428491280041019549434
B1A3C78F204336DC38E06102001B45AA5CC9B2E5C18D920C381C00D3A5CD9B3821564429690143033B2BE61C4AB468C502052C624C18A0E2019E071148125010
C080A50207001048C022C105310502855931C04001921010207892ACA40393D0BAED3989A659AE924A0AE409536F5399939A1620D8558140B06ED53A3CDAA0A2
DE8304A4AA4D595000800200D60E4409C067D6AD93BA823E1C761250AA901128282D102DEAD079AB8ECE2AE92EECC756091EA81DB874D3BC4B0B0B5C6D3BAE01
AC0B8F9A768A70355DCA034F1A2000C0F0E60152016BC53B1B2CE0D3089F12FF006ADB3541060601CCAECB1B2FEEC793769BFD2B50B045F4C22711F7A89CFD54
831A9506DD7008B446D75E0A10905401046C075B77A58D55D16BBD5115D963E60D749C6C05D9355057B8B9E5976F530520D501F9ED8758459E31D45F5BED09D4
9662930CB8E246052228D06E0820009A685F45F89F413491855A86B771489087EE5D17180008D8465F85A125459375FB6978A08B920C465A5A9AF967DB80AA05
895A750331C0D966737D372441681587DD5A729105DF24EA159494884E3ED9597D24BE361696736D995C97040D2A5645805124D4A20D740880596846E7607C73
45BA1C859324808097038165188C30A147509EE7CDF55A6EF5A144D5944D51FFB840A50192452397A0D2566245390E34E0446A8C20D01C1A4CE2011245253B54
7FD1F124558C8E72F411059AA6D0C22487F4A1ECB636311B2A4C9CD6F8A847265030C90A124C32C5059370400106DCC61B92B703ED169B41BF3E94C20B45B831
09185D48004915246801850376C8AB7047F472251572BE8E1BD10A11B8A0C2246BB0D0E92417C06B43064414B7F0C80A355C5F8B05E5EBD00E1784F145428A10
E0800B24D75C32A211A9ACD0106F4C42080B1F20B2D00651741081CD481364F2A1D23EF444069380E083430F38F040D258C7DB861891185210014F6D7480591A
5470421E59A73DD42293340275410D58656A00AB51F580CC6AE7ED92145724FF314919570F142B800310C086057A27BE9205224CF2400E4E1054C09D8A577E93
17637C2D89A909BD55D0B3380E4716467B6EA4A9AF705104579DCC597ED31233C00DED4BA9CBF8265A0221903AD86615D0AB407BA2E7B9EA7149B2D401B9BAAE
D2237F4C62441604352632BEB5777ABBB4A5571469E99C2B5DBBE7AC0FAFFC4A85DC31090C67106628ED6C5D1FDA014B25B0F924BE97FCFDEAC68F9F93155418
8414D3CA011DAF724796ED15B04364410F5A20A63F96FC40041598004106571006146E1212085C033778101EEC61127A2083EC06A0A90024852A1DA8000438C8
C2826001102388C14112602FA7DCC5021C58610B7728101438C20C359020437F98D0010E2482873C14C4B542F0818540C0015044221241A0043900210411E8C1
41503089137840088390220F4BB085496C000E1AA043095E80864EADA50E7138820EC528451AF061123A500104FC10810098400651C3C006E828C60FDC601224
F0800402C185493062026920A424078283209CAF0902C1C32437C949960404003B}}
\par\par \b \uc2 Globus Medical\uc2  Updates on 2013 Second Quarter Results\b0\par\par\uc2 400 \uc2 words\par \uc2 10 August 2013\par \uc2 Manufacturing Close-Up\par \uc2 MFGCLU\par \uc2 English\par \uc2 (c) 2013. Close-Up Media, Inc. All rights reserved.   \par \par \uc2 Globus Medical, Inc\uc2 ., a musculoskeletal implant manufacturer, announced its financial results for the quarter ended June 30.\par \par \uc2 David Paul\uc2 , Chairman and CEO noted, , "We are very pleased with our performance this quarter and for the first half of 2013. Our revenue growth and profitability margins remain at industry leading levels, driven by our focus on rapid product innovation, expanding our sales footprint, and efficient operational execution. This quarter we \b \highlight22\uc2 launched\b0 \highlight\uc2  six \b \highlight22\uc2 new products\b0 \highlight\uc2 , including LATISTM, the first laterally expanding unitary interbody fusion spacer on the market to offer the benefits of a traditional anterior implant through a posterior approach."\par \par \uc2 In a release on August 1, the Company noted that second quarter net sales were $107.0 million, compared to $96.0 million last year, representing an 11.5 percent increase. Sales in the US and international grew by 10.8 percent and 20.3 percent, respectively, over the same quarter in 2012. International sales currently represents 8.3 percent of total sales.\par \par \uc2 Net income for the quarter was $7.4 million, or $0.08 per diluted share, as compared to $19.0 million, or $0.21 per diluted share, for the second quarter of 2012. Non-GAAP earnings per diluted share were $0.21 and $0.20 for the quarters ending June 30, and 2012, respectively. The non-GAAP earnings per diluted share excludes the after-tax effect of the provisions for litigation losses. Non-GAAP Adjusted EBITDA for the quarter was 34.0 percent of net sales, compared to 36.1 percent for the same period last year. The Medical Device Excise Tax, which was not in effect in 2012, reduced Adjusted EBITDA by 1.6 percent for the second quarter of 2013.\par \par \uc2 Cash, cash equivalents and marketable securities for the quarter increased by $7.6 million, ending the second quarter of 2013 at $231.7 million. The company remains debt free.\par \par \uc2 The company reiterated its revenue outlook and non-GAAP diluted earnings per share guidance for 2013. For 2013, the company continues to expect full-year revenue to be approximately $432 million and non-GAAP annual diluted earnings per share, which excludes provisions for litigation losses, to be approximately $0.81.\par \par \uc2 Globus Medical\uc2  is a musculoskeletal implant company based in Audubon, PA.\par \par \uc2 More Information:\par \par {\field{\*\fldinst{HYPERLINK "http://www.globusmedical.com"}}{\fldrslt{\cf2 \uc2 http://www.globusmedical.com}}}\par \par \uc2 ((Comments on this story may be sent to newsdesk@closeupmedia.com))\par \par \uc2 Document MFGCLU0020130810e98a0005o\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Second Quarter 2013 Financials\b0\par\par\uc2 2,102 \uc2 words\par \uc2 9 August 2013\par 07:30\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2013  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 \f2 \par BUNAVAIL NDA submitted to FDA; first buccal film to compete in growing opioid dependence marketplace \par  \par Phase 3 studies for BEMA Buprenorphine for chronic pain on track for completion and data read out by early 2014 \par  \par Clonidine Topical Gel for Painful Diabetic Neuropathy to initiate Phase 2b study by year-end \par  \par Cash runway through end of 2014 \par  \f28 \par \par \uc2 \f2 RALEIGH, N.C., Aug. 9, 2013 /PRNewswire/ -- \f28 \uc2 \f2 BioDelivery Sciences International, Inc\f28 \uc2 \f2 . (NASDAQ: BDSI) announced that it has filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2013, with the \f28 \uc2 \f2 U.S. Securities and Exchange Commission\f28 \uc2 \f2  and, in connection therewith, is providing a review of BDSI's recent achievements and an update on business operations and upcoming milestones for 2013.\f28 \par \par \uc2 (Logo: {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20110217/CL49801LOGO"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20110217/CL49801LOGO}}}\uc2  )\par \par \uc2 Business Highlights\par \par \uc2 As recently announced, a significant milestone was achieved by BDSI with the submission of a New Drug Application (NDA) to the \uc2 U.S. Food and Drug Administration\uc2  (FDA) for BUNAVAIL (buprenorphine naloxone buccal film) for the maintenance treatment of opioid dependence. Under the 505(b)(2) regulatory statute, the NDA for BUNAVAIL, which was submitted on July 31, 2013, will be subject to a ten month review. If approved, BUNAVAIL will be the first buccal film dosage form containing buprenorphine for the treatment of opioid dependence that will compete with the market leader Suboxone, which achieved sales in excess of $1.5 billion in 2012 according to data from \uc2 Wolters Kluwer\uc2 .\par \par \uc2 BDSI also remains on track to report data, expected in early 2014, from two pivotal Phase 3 studies of BEMA Buprenorphine for the treatment of chronic pain, a product with peak U.S. sales potential of $500 million. These trials, one in opioid naive and the other in opioid experienced patients, are being conducted along with BDSI's partner, Endo Health Solutions. Both trials are expected to complete in late 2013 or early 2014, and with database lock for each trial, BDSI expects milestone payments from Endo which, along with a milestone payment for NDA filing, total an aggregate of $30 million to BDSI.\par \par \uc2 In addition to the advancement of BDSI's two BEMA products containing buprenorphine, BDSI strengthened its pain portfolio by entering into a worldwide license agreement with \uc2 Arcion Therapeutics\uc2  (Arcion) under which BDSI will develop and commercialize Clonidine Topical Gel (formerly ARC4558) for the treatment of painful diabetic neuropathy (PDN) and potentially other indications. Nearly 26 million people in the U.S. have diabetes, according to the \uc2 American Diabetes Association\uc2 , and a substantial number of these people have neuropathy as manifest by impaired sensation and pain in the extremities, most commonly the feet. Currently available oral treatments have been shown to be modestly effective in relieving symptoms and are limited by systemic side effects and drug interactions. There are no topical products approved for the treatment of this painful condition. BDSI estimates annual peak U.S. sales potential for this product to be in excess of $300 million and plans to initiate a Phase 2b clinical trial program for Clonidine Topical Gel for the treatment of painful diabetic neuropathy by the end of this year.\par \par \uc2 In addition, BDSI announced that \uc2 Adrian Hepner\uc2 , MD, PhD, joined the company as Vice President of Clinical Research and Regulatory Affairs, and will initially concentrate his efforts on the clinical development of Clonidine Topical Gel for the treatment of PDN.\par \par \uc2 During the second quarter of 2013, BDSI further added to its Board of Directors with the appointment of \uc2 Thomas W. D'Alonzo\uc2 . Mr. D'Alonzo has held a number of high-level executive positions and board appointments at large and specialty pharmaceutical companies, including being current Chairman of \uc2 Salix Pharmaceuticals, Inc\uc2 . (NASDAQ:SLXP) and previously served on BDSI's Board of Directors from August 2006 through June 2008.\par \par \uc2 Financial Highlights\par \par \uc2 At June 30, 2013, BDSI had $37.4 million in cash (not including proceeds received in early July 2013, from a $20.0 million senior secured loan from an affiliate of \uc2 MidCap Financial\uc2 ), as compared to $63.2 million at December 31, 2012 and $43.0 million at June 30, 2012.\par \par \uc2 Cash used in operations for the first six months of 2013 totaled $25.8 million, driven largely by the expense associated with the aforementioned Phase 3 pivotal trials and completion of work on BUNAVAIL.\par \par \uc2 During the six months ended June 30, 2012, BDSI received $45.0 million in milestone payments in connection with the Endo license, of which $30.7 million was recognized as revenue. Cash flow contributed to operations in the prior year's first six months was $33 million.\par \par \uc2 Research and development costs were $12.8 million in the second quarter of 2013, compared to a corresponding $6.5 million in the second quarter of 2012. For the six month periods ended June 30, 2013 and 2012, research and development costs totaled $24.8 million and $11.3 million, respectively. The increase in research and development expenses in 2013 compared to 2012 can be attributed to the two pivotal pain trials and one safety trial underway pursuant to BDSI's collaboration with Endo for the BEMA Buprenorphine chronic pain program. Also contributing to the first half 2013 increase was the near completion of the BUNAVAIL program for the treatment of opioid dependence and compilation of its NDA as well as $2.1 million of in-process research and development (paid in common stock) associated with the aforementioned license agreement with Arcion. The two Phase 3 pivotal trials for BEMA Buprenorphine for chronic pain are scheduled to complete later this year or early 2014, as will final development work associated with the completion of the BUNAVAIL NDA. As such, R&D spending is expected to be significantly reduced starting in the fourth quarter of 2013 as these two programs wind down.\par \par \uc2 Including the recently closed MidCap loan and the addition of the anticipated Endo database lock milestones, BDSI believes that it has sufficient resources to fund intended operations through the end of 2014.\par \par \uc2 "Tremendous progress has been made in the first half of 2013 as we continue to build value in BDSI by both advancing our "home grown" products while strengthening and diversifying the pipeline through targeted in-licensing opportunities," said \uc2 Dr. Mark A. Sirgo\uc2 , President and Chief Executive Officer. "BDSI has made significant strides with the submission of an NDA for our second BEMA product, BUNAVAIL, for the maintenance treatment of opioid dependence. And, we simultaneously moved toward completion of the Phase 3 clinical studies for BEMA Buprenorphine for chronic pain, while expanding and diversifying the product pipeline with the acquisition of Clonidine Topical Gel."\par \par \uc2 Anticipated 2013 Milestones\par \par \uc2 BDSI is focusing its resources on achievement of the following key milestones and activities:\par \par \uc2 \f2 \par    -- Phase 3 study results for BEMA Buprenorphine in chronic pain.  BDSI and \par       Endo expect to continue toward completion of the two Phase 3 efficacy \par       studies for BEMA Buprenorphine for the treatment of chronic pain.  The \par       two efficacy studies, one in opioid naive patients and one in opioid \par       experienced patients, are currently expected to report data in early \par       2014.  Upon achievement of database lock for each trial, and the \par       acceptance of filing of the NDA with the FDA, BDSI expects to receive \par       milestone payments from Endo totaling $30 million. \par  \par    -- BUNAVAIL NDA review: BDSI anticipates ongoing interaction with the FDA \par       regarding the NDA for BUNAVAIL, which was submitted on July 31, 3013. \par  \par    -- Initiation of Phase 2b Study for Clonidine Topical Gel.  BDSI plans to \par       initiate a Phase 2b study of Clonidine Topical Gel for the treatment of \par       painful diabetic neuropathy in the latter part of 2013.   This study \par       could report data by year-end 2014. \par  \par    -- Commercialization strategy for BUNAVAIL.  As the FDA's review of the NDA \par       for BUNAVAIL progresses, BDSI will continue to evaluate its strategic \par       options for the commercialization of BUNAVAIL in the U.S.-  Such options \par       include partnership, internal approaches or a combination thereof.  BDSI \par       plans to provide updates on its strategic direction as the year \par       progresses. \par  \par    -- Exploration of potential new products and technologies.  In addition to \par       advancing its lead products in development, BDSI is also, as in the past, \par       exploring the application of its BEMA drug delivery technology to \par       additional pharmaceuticals.  In addition, BDSI continues to investigate \par       potential new products and technologies to complement and diversify its \par       existing portfolio. \f28 \par \par \uc2 \f2 About \f28 \uc2 \f2 BioDelivery Sciences International\f28 \par \par \uc2 \f2 BioDelivery Sciences International\f28 \uc2 \f2  (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics. BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and addiction.\f28 \par \par \uc2 \f2 BDSI's pain franchise currently consists of three products, two of which utilize the patented BioErodible MucoAdhesive (BEMA) drug delivery technology. ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, E.U. (where it is marketed as BREAKYL) and Taiwan (where it is marketed as PAINKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer. The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and South Korea (licensed to \f28 \uc2 \f2 Kunwha Pharmaceutical Co\f28 \uc2 \f2 .).\f28 \par \par \uc2 \f2 BDSI's second pain product using the BEMA technology, BEMA Buprenorphine, is in Phase 3 clinical trials for the treatment of moderate to severe chronic pain and is licensed on a worldwide basis to Endo Health Solutions. BDSI's third pain product in development is Clonidine Topical Gel for the treatment of painful diabetic neuropathy and was recently licensed from \f28 \uc2 \f2 Arcion Therapeutics\f28 \uc2 \f2 .\f28 \par \par \uc2 \f2 In August 2013, BDSI filed an NDA for BUNAVAIL, a high dose formulation of buprenorphine in combination with naloxone for the maintenance treatment of opioid dependence. Under the 505(b)(2) regulatory statute, the NDA for BUNAVAIL is subject to a ten month review.\f28 \par \par \uc2 \f2 BDSI's headquarters is located in Raleigh, North Carolina. For more information visit \f28 {\field{\*\fldinst{HYPERLINK "http://www.bdsi.com"}}{\fldrslt{\cf2 \uc2 www.bdsi.com}}}\uc2 \f2 .\f28 \par \par \uc2 \f2 Cautionary Note on Forward-Looking Statements\f28 \par \par \uc2 \f2 This press release, the presentation referred to herein, and any statements of representatives and partners of \f28 \uc2 \f2 BioDelivery Sciences International, Inc\f28 \uc2 \f2 . (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes, " "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the \f28 \uc2 \f2 Securities and Exchange Commission\f28 \uc2 \f2  and those that relate to the Company's ability to leverage the expertise of employees and partners to assist the Company in the execution of its strategy. Actual results (including, without limitation, the timing for and results of the clinical trials and proposed NDA submissions for, and FDA review of, the Company's products in development) may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.\f28 \par \par \uc2 \f2 Readers are cautioned that peak sales and market size estimates have been determined on the basis of market research and comparable product analysis, but no assurances can be given that such estimates are accurate or that such sales levels will be achieved, if at all.\f28 \par \par \uc2 \f2 BDSI(R) and BEMA(R) are registered trademarks of \f28 \uc2 \f2 BioDelivery Sciences International, Inc\f28 \uc2 \f2 . The BioDelivery Sciences logo and BUNAVAIL(TM) are trademarks owned by \f28 \uc2 \f2 BioDelivery Sciences International, Inc\f28 \uc2 \f2 . ONSOLIS(R) is a registered trademark of \f28 \uc2 \f2 Meda Pharmaceuticals, Inc\f28 \uc2 \f2 . BREAKYL(TM) is a trademark owned by Meda Pharma GmbH & Co. KG. PAINKYL(TM) is a trademark owned by TTY Biopharm. All other trademarks and tradenames are owned by their respective owners.\f28 \par \par \uc2 \f2 (c) \f28 \uc2 \f2 BioDelivery Sciences International, Inc\f28 \uc2 \f2 . All rights reserved.\f28 \par \par \uc2 \f2 SOURCE \f28 \uc2 \f2 BioDelivery Sciences International, Inc\f28 \uc2 \f2 .\f28 \par \par \uc2 \f2 /\f28 \par \par \uc2 Document PRN0000020130809e9890001o\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 PRESS RELEASE: \uc2 Keryx Biopharmaceuticals \highlight22\uc2 Announces  \highlight \highlight22\uc2 New \highlight \highlight22\uc2  Drug \highlight\uc2  Application Submission for Zerenex(TM) for the Treatment of Hyperphosphatemia in Chronic Kidney Disease Patients on Dialysis\b0\par\par\uc2 1,335 \uc2 words\par \uc2 8 August 2013\par 08:31\par \uc2 Dow Jones Newswires\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright (c) 2013, Dow Jones & Company, Inc.   \par \par \uc2 Keryx Biopharmaceuticals\b \highlight22\uc2 Announces \b0 \highlight\b \highlight22\uc2 New\b0 \highlight\b \highlight22\uc2  Drug\b0 \highlight\uc2  Application Submission for Zerenex(TM) for the Treatment of Hyperphosphatemia in Chronic Kidney Disease Patients on Dialysis\par \par \uc2 PR Newswire\par \par \uc2 NEW YORK, Aug. 8, 2013\par \par \uc2 NEW YORK, Aug. 8, 2013 /PRNewswire/ -- \uc2 Keryx Biopharmaceuticals, Inc\uc2 . (Nasdaq:KERX) today announced the submission of a New Drug Application (NDA) to the \uc2 U.S. Food and Drug Administration\uc2  (FDA) seeking approval for the marketing and sale of Zerenex(TM) (ferric citrate coordination complex), the Company's drug candidate for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with chronic kidney disease (CKD) on dialysis. The Company's NDA submission is based primarily on the datasets derived from its Phase 3 registration program, which was conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA, and is also supported by efficacy and safety data from several additional studies, including four Phase 3 studies conducted in Japan in CKD patients on dialysis.\par \par \uc2 Ron Bentsur\uc2 , the Company's Chief Executive Officer, said, "The submission of the Zerenex NDA marks a major milestone for the Company. With approximately 1,500 patients exposed to the drug in the clinical development programs conducted by us and our Japanese partner, JT/Torii, we believe that Zerenex is a safe, effective and highly-differentiated drug candidate and today's submission brings us one step closer to potentially bringing this drug to patients who can benefit from it." Mr. Bentsur continued, "We are grateful to Dr. Julia Lewis, the Study Chair for the Zerenex Phase 3 program, and to our highly skilled internal team of clinical, manufacturing and regulatory professionals, for the time and effort they have dedicated towards this tremendous achievement."\par \par \uc2 The Company also plans to submit a Marketing Authorization Application (MAA) to the \uc2 European Medicines Agency\uc2  (EMA) for regulatory approval of Zerenex in the \uc2 European Union\uc2 .\par \par \uc2 Keryx holds a worldwide license (except for certain Asian Pacific countries) to Zerenex from \uc2 Panion & BF Biotech, Inc\uc2 . The Japanese rights are sublicensed by Keryx to \uc2 Japan Tobacco Inc\uc2 . (JT) and \uc2 Torii Pharmaceutical Co., Ltd\uc2 . (Torii). On January 7, 2013, JT announced the filing of its NDA with the \uc2 Japanese Ministry of Health, Labour and Welfare\uc2  for marketing approval of ferric citrate in Japan for the treatment of hyperphosphatemia in patients with CKD.\par \par \uc2 Zerenex is also in Phase 2 development in the U.S. for the management of phosphorus and iron deficiency in anemic patients with Stage 3 to 5 non-dialysis dependent CKD.\par \par \uc2 About Special Protocol Assessments\par \par \uc2 The Special Protocol Assessment (SPA) process is a procedure by which the FDA provides official evaluation and written guidance on the design and size of proposed protocols that are intended to form the basis for a new drug application. Final marketing approval depends on the efficacy and safety results, including the adverse event profile, and an evaluation of the benefit/risk of treatment demonstrated in the Phase 3 clinical program. The SPA agreement may only be changed through a written agreement between the sponsor and the FDA, or if the FDA becomes aware of a substantial scientific issue essential to product efficacy or safety. For more information on Special Protocol Assessment, please visit: {\field{\*\fldinst{HYPERLINK "http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm080571.pdf"}}{\fldrslt{\cf2 \uc2 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm080571.pdf}}}\uc2 .\par \par \uc2 About Hyperphosphatemia\par \par \uc2 In the United States, according to data from the U.S. Renal Data System, there are approximately 630,000 patients with Chronic Kidney Disease Stage 5, also referred to as End Stage Renal Disease (ESRD), and the number of CKD Stage 5 patients is projected to rise in the future. The majority of CKD Stage 5 patients in the United States, over 400,000, require dialysis. These patients are referred to as CKD patients on dialysis.\par \par \uc2 Worldwide, there are approximately 2.8 million patients with CKD Stage 5, with the majority of such patients, over 2 million, requiring dialysis. Phosphate retention and the resulting hyperphosphatemia in CKD patients on dialysis are usually associated with secondary hyperparathyroidism, renal osteodystrophy, soft tissue mineralization and the progression of renal failure. CKD patients on dialysis usually require treatment with phosphate-binding agents to lower and maintain serum phosphorus at acceptable levels. The need for alternative phosphate-binding agents has long been recognized, especially given the increasing prevalence of dialysis as well as shortcomings with current therapies. Zerenex has the potential to be an effective and safe treatment in lowering and/or maintaining normal serum phosphorus levels in CKD patients on dialysis.\par \par \uc2 About \uc2 Keryx Biopharmaceuticals, Inc\uc2 .\par \par \uc2 Keryx Biopharmaceuticals\uc2  is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate coordination complex), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Keryx has completed a U.S.-based Phase 3 clinical program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with chronic kidney disease on dialysis, conducted pursuant to a Special Protocol Assessment (SPA) agreement with the Food and Drug Administration (FDA), and the Company has submitted a New Drug Application to the FDA. The Marketing Authorization Application filing with the \uc2 European Medicines Agency\uc2  (EMA) is pending submission. Zerenex is also in Phase 2 development in the U.S. for the management of phosphorus and iron deficiency in anemic patients with Stages 3 to 5 non-dialysis dependent chronic kidney disease. In addition, Keryx's Japanese partner, \uc2 Japan Tobacco Inc\uc2 . and \uc2 Torii Pharmaceutical Co., Ltd\uc2 . has filed its New Drug Application for marketing approval of ferric citrate in Japan for the treatment of hyperphosphatemia in patients with chronic kidney disease. Keryx is headquartered in New York City.\par \par \uc2 Cautionary Statement\par \par \uc2 Some of the statements included in this press release, particularly those relating to the results of clinical trials, the clinical benefits to be derived from Zerenex (ferric citrate coordination complex), regulatory submissions and approvals, the commercial opportunity and competitive positioning, and any business prospects for Zerenex, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: the risk that the NDA and MAA will not be accepted for review by the FDA and EMA, respectively, due to deficiencies in the application or for other reasons; the risk that the FDA and EMA ultimately deny approval of the NDA and MAA, respectively; the risk that SPAs are not a guarantee that the FDA will accept an NDA for filing or ultimately approve a product candidate following submission; whether the FDA and EMA will concur with the our interpretation of our Phase 3 study results or the conduct of the study; whether, if Zerenex receives approval, it will be successfully distributed and marketed; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at {\field{\*\fldinst{HYPERLINK "http://www.keryx.com"}}{\fldrslt{\cf2 \uc2 http://www.keryx.com}}}\uc2 . The information found on our website, and the FDA website, is not incorporated by reference into this press release and is included for reference purposes only.\par \par \uc2 KERYX CONTACT:\par \par \uc2 Lauren Fischer\par \par \uc2 Director - Investor Relations\par \par \uc2 Keryx Biopharmaceuticals, Inc\uc2 .\par \par \uc2 Tel: 212.531.5965\par \par \uc2 E-mail: lfischer@keryx.com\par \par \uc2 SOURCE \uc2 Keryx Biopharmaceuticals, Inc\uc2 .\par \par \uc2 /Web site: {\field{\*\fldinst{HYPERLINK "http://www.keryx.com"}}{\fldrslt{\cf2 \uc2 http://www.keryx.com}}}\par \par \uc2 Order free Annual Report for \uc2 Keryx Biopharmaceuticals, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://djnweurope.ar.wilink.com/?ticker=US4925151015"}}{\fldrslt{\cf2 \uc2 http://djnweurope.ar.wilink.com/?ticker=US4925151015}}}\uc2  or call +44 (0)208 391 6028\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 August 08, 2013 08:31 ET (12:31 GMT)\par \par \uc2 Document DJDN000020130808e988003cm\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Stryker Interventional Spine  \highlight22\uc2 Launches \highlight\uc2  Two  \highlight22\uc2 New Products \highlight\uc2  to Expanding Portfolio: The Venom(TM) Cannula and Electrode combination and 11g iVAS(R) Balloon System\b0\par\par\uc2 674 \uc2 words\par \uc2 7 August 2013\par 08:00\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2013  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 KALAMAZOO, Mich., Aug. 7, 2013 /PRNewswire/ -- Stryker Interventional Spine announced the clearance of 510(k)s for two additional products to its portfolio. Venom RF Cannula and Venom Electrode are designed to provide an effective and minimally invasive treatment for facet joint pain. The \b \highlight22\uc2 launch\b0 \highlight\uc2  of the 11g iVAS Balloon System, one of the least invasive vertebral augmentation options available on the market, addresses the surgical trend of shifting toward less invasive treatment options.\par \par \uc2 The additions of these products enhance Stryker's position as being a single source for minimally invasive spine solutions.\par \par \uc2 Venom RF Cannula and Electrode\par \par \uc2 The Venom Electrode addresses technical challenges that exist for the effective use of radiofrequency treatment for spinal pain. The Venom cannula and electrode features a "V" shape active tip, which increases the lesion volume and provides an optimized configuration to target lesion zones. "The target for radiofrequency lesioning is not a point, it's a volume. It's important to produce a lesion that fills the target zone," says Dr. Aaron Calodney*, MD, Texas Spine and Joint.\par \par \uc2 "Venom is not only smaller, but has the potential for less burning time, " says Dr. Paul Lynch*, MD, owner of Boost Medical and co-founder of Arizona Pain Specialists. On average, the 20-gauge Venom electrode and cannula combination created a lesion of 92% greater volume than the 20-gauge standard RF cannula, and the 18-gauge Venom cannula created a lesion of 76% greater volume than the 18-gauge standard RF cannula[i].\par \par \uc2 11g iVAS Balloon System\par \par \uc2 In vertebral augmentation procedures, physicians must skillfully navigate their access cannulas through a small bridge of bone known as the pedicle, the anatomical formation that grants access to the vertebral body. The 11g iVAS Balloon System has a 20% smaller cross-sectional area than a traditional 10g system and a 47% smaller cross-sectional area than the original 8g vertebral augmentation equipment. "In today's day and age, if I was going to treat my mom and dad, I would want to use the least invasive cannula to give me an adequate fracture repair. The 11g iVAS balloon system is just as efficacious (as previously available balloon systems) but less invasive, which is exciting," says Dr. Paul Lynch, MD.\par \par \uc2 Physicians presented with the concept of a smaller vertebral augmentation system reacted with excitement and optimism for future compression fracture treatments. Dr. Wayne Olan*, Director of Minimally Invasive Neurosurgery at \uc2 George Washington University\uc2  Medical Center in Washington, DC, says, "With the release of the 11g iVAS Balloon System, a less invasive option is now available that affords physicians the opportunity to treat the same fractures that they currently see and opens the possibility of treating more challenging fractures."\par \par \uc2 About Stryker\par \par \uc2 Stryker Corporation\uc2  is one of the world's leading medical technology companies that has a broadly based range of products in orthopedics and a significant presence in other medical specialties. Stryker works with respected medical professionals to help people lead more active and more satisfying lives. Our Interventional Spine business manufactures minimally invasive solutions for relieving chronic back pain. Developed with respectful medical professionals, Stryker offers a wide range of innovative products for spinal procedures and pain management treatments that reduce patient pain, shortens recovery time and improve quality of life. For more information about our Interventional Spine business, please visit {\field{\*\fldinst{HYPERLINK "http://www.StrykerIVS.com"}}{\fldrslt{\cf2 \uc2 www.StrykerIVS.com}}}\uc2 .\par \par \uc2 [i] Effect of the Stryker Venom(TM) Cannula and Venom(TM) Electrode combination on Lesion Size and Anesthesia Delivery During Radiofrequency Ablation Stryker Instruments, 4100 East Milham Avenue, Kalamazoo, Michigan 49001.\par \par \uc2 * Drs. Lynch, Calodney and Olan have a consulting relationship with \uc2 Stryker Instruments\uc2 .\par \par \uc2 1000-025-252 Rev None\par \par \uc2 SOURCE Stryker Interventional Spine\par \par \uc2 /\par \par \uc2 Document PRN0000020130807e98700057\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Otsuka Pharmaceutical Announces A Revamped Website on Aug 1, 2013\b0\par\par\uc2 467 \uc2 words\par \uc2 1 August 2013\par 09:01\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2013  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 \f2 \par A Brand New English Site for Viewers Worldwide: \f28 {\field{\*\fldinst{HYPERLINK "http://www.otsuka.co.jp/en"}}{\fldrslt{\cf2 \uc2 http://www.otsuka.co.jp/en}}}\par \par \uc2 \f2 TOKYO, Aug. 1, 2013 /PRNewswire/ -- \f28 \uc2 \f2 Otsuka Pharmaceutical Co., Ltd\f28 \uc2 \f2 . \f28 \b \highlight22\uc2 \f2 launched\f28 \b0 \highlight\uc2 \f2  a newly designed English corporate website that was collaborated with an Amsterdam-based creative agency to reflect our philosophy: "Otsuka-people creating \f28 \b \highlight22\uc2 \f2 new products\f28 \b0 \highlight\uc2 \f2  for better health worldwide." With additional new content designed creatively, the new website adopts an innovative, personal design to attract people from around the world.\f28 \par \par \uc2 To view the multimedia assets associated with this release, please click: {\field{\*\fldinst{HYPERLINK "http://www.multivu.com/mnr/62657-otsuka-pharmaceutical-new-global-website"}}{\fldrslt{\cf2 \uc2 http://www.multivu.com/mnr/62657-otsuka-pharmaceutical-new-global-website}}}\par \par \uc2 (Photo: {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20130801/MM50225-INFO"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20130801/MM50225-INFO}}}\uc2 )\par \par \uc2 This is a great chance for inquisitive internet users everywhere to discover who we are. At Otsuka Pharmaceutical, we are committed to a holistic approach to health and well-being of people and are striving to create innovative, thoroughly-original products based on our corporate philosophy. Otsuka Pharmaceutical and affiliated companies have products in more than 80 countries and nearly 28,100 employees, of which around 70% are based outside of Japan(1) (about 20,000 employees), and consolidated revenues of about USD 12 billion(2) (in FY2012).\par \par \uc2 Otsuka's business for better health is driven on two wheels: pharmaceuticals and neutraceuticals.(3) The creator of ABILIFY(R), the world's first antipsychotic drug with a dopamine D(2) receptor partial agonist mechanism is prescribed for schizophrenia, bi-polar and major depression in the US. A maker of many nutritional food products, such as SOYJOY, a baked soy bar with either real fruits, or peanuts as well as POCARI SWEAT, a health beverage that smoothly replenishes body fluids and ions (electrolytes), fall under our nutraceuticals category.\par \par \uc2 New content on the site includes Otsuka People Talk, video interviews with Otsuka employees in Japan and overseas, and WHATS & WHOS, an English-language global journal focusing on unique global initiatives pioneered by Otsuka. The website also incorporates comprehensive health information related to specific Otsuka business areas including tuberculosis, dry-eye and metabolic syndrome. The new Otsuka Pharmaceutical website, like the company overall, aims to contribute to the well-being of people everywhere.\par \par \uc2 The Otsuka Pharmaceutical culture encourages each and every employee to embody a spirit of innovation, as emphasized in our chairman \uc2 Akihiko Otsuka\uc2 's words "People make the company run, people do the thinking." To communicate this stance to our customers throughout the world, the new website is designed to convey an intimate, personal experience.\par \par \uc2 (1) Product presence by country and employee count current as of March 31, 2013\par \par \uc2 (2) 1USD = 79.8 yen\par \par \uc2 (3) Nutraceuticals: nutrition + pharmaceuticals\par \par \uc2 SOURCE Otsuka Pharmaceutical\par \par \uc2 /\par \par \uc2 Document PRN0000020130801e981000b2\par }\page {\par\fs20\uc2 MI News\par \b \uc2 Annual sales of $19 million; Perrigo  \highlight22\uc2 launches \highlight\uc2  another  \highlight22\uc2 new drug \highlight\b0\par\par\uc2 Brian.VanOchten   \par \uc2 182 \uc2 words\par \uc2 1 August 2013\par \uc2 The Holland Sentinel\par \uc2 HOLLND\par 4\par \uc2 English\par \uc2 Copyright 2013 The Holland Sentinel, All Rights Reserved. Distributed by NewsBank, inc.   \par \par \uc2 @hollandsentinel.com (616) 546-4279\par \par \uc2 The \uc2 U.S. Food and Drug Administration\uc2  has granted final approval to \uc2 Perrigo Company\uc2  for the Allegan-based drugmaker's abbreviated \b \highlight22\uc2 new drug\b0 \highlight\uc2  application of the generic equivalent of Cutivate Lotion 0.05%, the company announced this morning.\par \par \uc2 Perrigo said it plans to begin shipments immediately of the topical steroid cream, which boasts annual sales of approximately $19 million, according to Symphony Health Solutions.\par \par \uc2 \u8220\'20\'1CThis is another example of our Rx team's commitment to launching difficult-to-manufacture topicals, lotions and foams,\u8221\'20\'1D Perrigo Chairman and CEO Joseph C. Papa said in a news release. \u8220\'20\'1CWe are excited to market this product and are dedicated to making quality healthcare more affordable for all consumers around the globe.\u8221\'20\'1D\par \par \uc2 Fluticasone propionate lotion, which is marketed under the brand name Cutivate, is used to reduce itching, redness and swelling associated with several skin conditions. It has been proven effective for the treatment of children ages 1 and older.\par \par \uc2 \u8212\'20\'14 Follow this reporter on \uc2 Twitter\uc2  @BizHolland\par \par \uc2 Document HOLLND0020130801e98100009\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ BioDelivery Sciences Files 8K - Other Events >BDSI\b0\par\par\uc2 193 \uc2 words\par \uc2 1 August 2013\par 17:28\par \uc2 Dow Jones Newswires\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright (c) 2013, Dow Jones & Company, Inc.   \par \par \uc2 BioDelivery Sciences International Inc\uc2 . (BDSI) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on August 01, 2013.\par \par \uc2 On August 1, 2013, \uc2 BioDelivery Sciences International, Inc\uc2 . (the "Company") issued a press release announcing the Company's submission of a New Drug Application ("NDA") to the \uc2 U.S. Food and Drug Administration\uc2  ("FDA") for the Company's BUNAVAIL (buprenorphine naloxone buccal film) product for the maintenance treatment of opioid dependence. A copy of such press release is attached as Exhibit 99.1 hereto.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1103021/000119312513315326/d577903d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1103021/000119312513315326/d577903d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1103021/000119312513315326/0001193125-13-315326-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1103021/000119312513315326/0001193125-13-315326-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 August 01, 2013 17:28 ET (21:28 GMT)\par \par \uc2 Document DJDN000020130801e98100657\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ Omeros Files 8K - Other Events >OMER\b0\par\par\uc2 184 \uc2 words\par \uc2 1 August 2013\par 16:02\par \uc2 Dow Jones Newswires\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright (c) 2013, Dow Jones & Company, Inc.   \par \par \uc2 Omeros Corp\uc2 . (OMER) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on August 01, 2013.\par \par \uc2 On August 1, 2013, we issued a press release announcing that Omeros recently submitted a New Drug Application to the \uc2 U.S. Food and Drug Administration\uc2  for approval of OMS302 for use in patients undergoing intraocular lens replacement surgery. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1285819/000119312513315015/d576760d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1285819/000119312513315015/d576760d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1285819/000119312513315015/0001193125-13-315015-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1285819/000119312513315015/0001193125-13-315015-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 August 01, 2013 16:02 ET (20:02 GMT)\par \par \uc2 Document DJDN000020130801e981005kj\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ ViroPharma Files 8K - Other Events >VPHM\b0\par\par\uc2 270 \uc2 words\par \uc2 1 August 2013\par 08:03\par \uc2 Dow Jones Newswires\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright (c) 2013, Dow Jones & Company, Inc.   \par \par \uc2 ViroPharma Inc\uc2 . (VPHM) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on August 01, 2013.\par \par \uc2 On August 1, 2013, the Company issued a press release to announce that, following discussions with the Center for Biologics Evaluation and Research (CBER) division of the \uc2 U.S. Food and Drug Administration\uc2 , the Company is going to discontinue its Phase 2 study of the combination of Cinryze(R) (C1 esterase inhibitor [human]) and recombinant human hyaluronidase enzyme (rHuPH20). The discontinuation of the study is a precaution related to the emergence of and unexpected incidence and titer of non-neutralizing anti-rHuPH20 antibodies in a number of patients with the formulation being used in this study.\par \par \uc2 The full text of a press release issued by the Company in connection with the announcement is set forth as Exhibit 99.2 attached hereto.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/946840/000110465913058647/a13-17761_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/946840/000110465913058647/a13-17761_18k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/946840/000110465913058647/0001104659-13-058647-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/946840/000110465913058647/0001104659-13-058647-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Order free Annual Report for \uc2 ViroPharma Incorporated\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://djnewswires.ar.wilink.com/?link=VPHM"}}{\fldrslt{\cf2 \uc2 http://djnewswires.ar.wilink.com/?link=VPHM}}}\uc2  or call 1-888-301-0513\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 August 01, 2013 08:03 ET (12:03 GMT)\par \par \uc2 Document DJDN000020130801e981002zc\par }\page {\par\fs20\b \uc2 Pacamor Kubar Bearings\uc2 ; \uc2 Pacamor Kubar Bearings\uc2  PKB  \highlight22\uc2 Introduces \highlight\uc2  Four New Ball Bearing Products for the Aerospace & Robotics Industries\b0\par\par\uc2 783 \uc2 words\par \uc2 31 July 2013\par \uc2 Defense & Aerospace Week\par \uc2 DEFAER\par 56\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2013 Defense & Aerospace Week via VerticalNews.com   \par \par \uc2 2013 JUL 31 (VerticalNews) -- By a News Reporter-Staff News Editor at Defense & Aerospace Week -- \uc2 Pacamor Kubar Bearings\uc2  (PKB) has expanded its factory capabilities and is introducing four important \b \highlight22\uc2 new product\b0 \highlight\uc2  lines. PKB is now producing Full Complement Ball Bearings, Thin Section Ball Bearings, Separable Angular Contact Ball Bearings, and Nonseparable Angular Contact Bearings alongside such legacy bearing products as Radial Ball Bearings, Cryogenic Ball Bearings, Metric Ball Bearings, FAA TSO-C149 Aircraft Bearings, and Specialty Ball Bearings. PKB ball bearings are manufactured at the ISO 9001:2008 and AS9100:2009 certified factory in Troy, NY.\par \par \uc2 Pacamor Kubar Bearings\uc2  (PKB) is pleased to present DFARS approved Angular Contact Bearings. PKB is manufacturing Separable Inner Ring Relieved Angular Contact Ball Bearings and Nonseparable Outer Ring Relieved Angular Contact Ball Bearings. \uc2 Pacamor Kubar Bearings\uc2  (PKB) Angular Contact Ball Bearings are produced to sustain significant axial loads in one direction, in addition to radial loads. PKB Angular Contact Ball Bearings are designed for increased thrust in the axial direction and are designed for high precision at very high speeds, often found in aerospace applications, medical and dental devices, and chemical processing systems. PKB Angular Contact Ball Bearings are available as discreet bearings or as preloaded duplex pairs. Optional retainer & ball materials, lubricants, closures, and special processing and unique configurations are available.\par \par \uc2 PKB's new Thin Section Ball Bearings are available in radial (deep groove) and angular contact designs. PKB Thin Section Ball Bearings are extremely low profile bearings, often found in aerospace and defense applications, industrial machinery, medical systems, semiconductor manufacturing, robotics, and renewable energy. PKB's Thin Section Bearings are available with a variety of retainer types and materials as well as optional ceramic balls. \uc2 Pacamor Kubar Bearings\uc2  (PKB) manufactures a standard line of Thin Section Bearings with sizes up to 1.125" Outer Diameter.\par \par \uc2 PKB's new Full Complement Ball Bearings (both fill-slot and angular contact) utilize the space normally shared with the retainer to increase the ball complement and load capacity compared to standard deep groove type or radial ball bearings. Bearing capacity in both the radial and axial direction is increased by the maximized ball complement. \uc2 Pacamor Kubar Bearings\uc2  (PKB) Full Complement Ball Bearings are available with steel or ceramic balls. As with the Angular Contact Ball Bearings and the Thin Section Ball Bearings, optional lubricants, closures, special processing and unique configurations are available.\par \par \uc2 Ed Osta\uc2 , EVP, stated, "Product quality from PKB is excellent. We're a very customer focused business. Customers have made it known that these four products are desirable to them. Our customers are our greatest asset and our existence depends on responding to their ever changing needs. These four new products that we're introducing today are a direct result of specific customer requests."\par \par \uc2 Pacamor Kubar Bearings\uc2  (PKB) continues to invest in its factory with the recent addition of a Cincom A32 lathe to its primary turn capabilities. This state of the art lathe expands machine capacity and production efficiencies within the Troy, NY ball bearing factory. The Cincom A32 is reputed to be the world's fastest Swiss type CNC automatic Lathe. The new lathe enables PKB to shorten its uniquely compact factory lead time of 8-10 weeks for standard bearings and respond more quickly to new and unique ball bearing requests from the aerospace community. Enhanced products, as a result of this new lathe, will include shaft and bearing assemblies and expedited responses to time sensitive prototype requests.\par \par \uc2 Pacamor Kubar Bearings\uc2  (PKB) manufactures high performance DFARS compliant miniature and instrument ball bearings for the aerospace, defense, medical, industrial, and commercial industries. Customers include major aerospace manufacturers and key resellers as well as various national laboratories and prestigious government organizations such as the \uc2 National Aeronautics and Space Administration\uc2  (NASA). PKB provides these industries with precision ball bearings, including those with unique designs and materials used at sub-cryogenic temperatures.\par \par \uc2 The entire line of PKB products is available direct from the manufacturer by contacting 518-283-8002 ({\field{\*\fldinst{HYPERLINK "http://www.pacamor.com"}}{\fldrslt{\cf2 \uc2 www.pacamor.com}}}\uc2 ). \uc2 Pacamor Kubar Bearings\uc2  (PKB) offers the right bearing at the right price for all your miniature, precision, and instrument applications. \uc2 Pacamor Kubar Bearings\uc2  is a domestic manufacturer of high precision miniature & instrument bearings and offers over 40 years of expertise in radial ball bearings. Located in Troy, NY, \uc2 Pacamor Kubar Bearings\uc2  is one of the few American owned and operated miniature & instrument ball bearing manufacturers.\par \par \uc2 Keywords for this news article include: Aerospace, \uc2 Pacamor Kubar Bearings\uc2 .\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC\par \par \uc2 Document DEFAER0020130726e97v0001b\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw112\pich40\picscaley100\picscalex100\picwgoal1680\pichgoal600
47
494638396170002800E60000DB858AAC0000B61318C3313CD6747AE1969CFEFBFBB80B1DB50113F9EAECCA4C51F0C9CDC53943D2666CC22D3AEDC2C4F4D9DCC8
444ABB1C22D36C72D05C66BA1021B3010CDF9197CE6365BF2331BD1B29F2D2D4BE212DC12936F7E3E4E9B1B6EAB4BAC02735FDF5F6E5A4A9BE3538EAB9BCC435
3FBB1524D87C82F7E1E4CC535AC9484DE29CA0E3A1A5AC1618B50B11B00004F4D5D9F6DDE0E5A8ADECBDC1E7ADB2B7091AB60417A40000DD8B90CC5B5CCC5054
FCF1F1BB2225C54045EFC8C9F9E7E9F1CCCFB90E1FC3393DBC282BB3080CEFC4C7FBF2F1FBEDEFC65554FCF3F4BF262EC8424CD07373C23037C64A4ABE4443B3
2525BA13239B0000BD1529E7B0B1BB1726AD0B0DE9B7B6AE0507FDF7F8C73C46C5514FC84147BA1222AA2021B82D2DB41B1DBE192DF3D8D6C73E44EDC8C6A70C
0DB70E17B70719F7E0DFAF0F11F2CFD0FDF6F3BC1327BE1D2DC83F4BA50608BA171FB63131F8E5E7CE5660DB9090BD2F31BE3C3EE7ADAFCB5F61FBEFEEFBF1F4
B81F25CA5059C9585BFFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633133382037392E3135393832342C20323031362F30392F31342D30313A30393A30312020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A63336632323837622D623131352D343930372D623635352D6563336432633038356536632220786D704D4D3A
446F63756D656E7449443D22786D702E6469643A44423230463231453343433131314538424441434143323846354633383935442220786D704D4D3A496E7374
616E636549443D22786D702E6969643A44423230463231443343433131314538424441434143323846354633383935442220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313720284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265
663A696E7374616E636549443D22786D702E6969643A64653264316633332D666534622D343138342D386365662D383033353430303139376134222073745265
663A646F63756D656E7449443D22786D702E6469643A63336632323837622D623131352D343930372D623635352D656333643263303835653663222F3E203C2F
7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFD
FCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBD
BCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D
7C7B7A797877767574737271706F6E6D6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D
3C3B3A393837363534333231302F2E2D2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F9
0400000000002C00000000700028000007FF800A6E2119030E1921211D1C2103898A1985878A8B1D8E891D91261D98211C0E0E8F998D9C8A840EA51D9597A685
A9A7A18F88AC99AE8FB0A2918E1A5B2615374B11273652523642641D075E524237035D4207C568275D1C42CC07365B430742525E371C642715D442111D36E7BF
0E0C42E72737562B1C36CC42362603CB52150842AC38314DCA810A6432106B86005A05705E6C68E8A261E1811B0C4C7C0B61E246060515A50C3B10A1DF396703
14443C21E5869415CABC10444326828D0327C47158E166DA0934425630006AEE860361E05A9E50D0E146851342D09820F3F01F820C3B38A0D186AC9F4C210D15
102C66C34A84250B6DDCD8120D5CA3100AFFAC2060898664472150A5AEB86845A982103764DA40D325C28DB25E10700059EDA710050C101CB002D0C18A0A3658
D2DBD10141052BCE4C743980136008151A1048B1F2ADCB00A7A0C3FE3AD1A6EC8A0C2E87DDA889865885106F5668B87162DE811577732A8EF0CBCA09048F3B7B
C16CA33002341A122F961BAF6E0427162A68006BD959F1C04CA11BC418A18805E558E55A6963E106938E15A8D880E16087332B545CA74E6E6A1576584E3600F7
D379C799001D6D30BCD041005988A15B1C6A9D6085050198B04211011C10205C6A0460220C563871C6896A39B1C30B01DCD006761D588080182BA2F1860F5904
004300160C10010C45F444A10412E023C5FF8F12106181441550B844163050A15B048665A6534699B57480020E4EB6241F556C40401137A08140033330514405
2FBC81C21016B841C000306440111D17B0C0021D1D3480020B2D9010808B4530008009453C06001D1658C040036F3891C51320D0F0221926503000877DC4F043
0F30B401431C33F050471616B411C01D0FC8304116C7DC80659A7D29B6C2000C50D3A0649421C0C7034AD4F0070B019CC1010B7F80A086053054A1C40A3828F0
871F59D0710507298860440258BC50C01F46002102064B1C10000D7FA0A0C610446C3007115310F0870E38A8C04310341800400049FC81C11418349B420C7CC0
20010473B4F0470D16E010010F1BD42002FFB2846599EB621AB8D12B50C84117AC0418E8D1000E4DECC1C01915E4F0C71C6004D04309C7E2B0C21F1348904100
4368814187445C41431038B8B0410C020470C203473CE0441C022C80F31475FC214700109461C61563C400F01F49E010031638F0010401705C30470F5334F147
1E380421431838A0908009C11CB631483784C0C031BB8A0CD0004E98E0C11D387030430301F051021E0928C08706E3C600C31D7FFCAB6ECF79C47142006A1861
040E016031870436D3D002101386B1C61F3304E072147C20D1070C3DA850000C5CFCE143187F108083050048AE07D9328FE00309C19B28C0112C44D4A5627C7B
614905253D08564A6720E0410901147148FF005CCC41C10F057000C30C6B8CD107E67904404500242801801A30DCA0C6D03ECE9000EA4D90010A52E080001061
0D6548C31D0A06861E2081001D7083055E00036B4D200055F843CCB2D003C355417E3778411C4C700414C0E03D4A284088E0533D29F8CD074EB8015EB6B78288
C0400506C0420F9E14809449A10635E85109085585085C2B006238D41E72A0010708E10A35D083133490001044AC00697002047E162F166C6002019383041290
8333D4C50601D801CE70D00319F060093020011F20003EEC90E105B503000C60C00425A02000C1FAC870F2918137A0E52960F15054C211803CFC210802D82300
D2F0822A04A14434B8C00A36D08704304EFF0815E441025260040964815931F8030DE2E0A335CCE00A10502111E630011454A1014090831D944001189CE30030
B0D70E7CB4B03F304E0032009F0656100203FA31004B50C0335B124D2BB8C4205E188009B2D18C1B28120D22014A1C18A0052398E8036BC0411D4440840094A0
044E9041012070322A48400147004021101087318080097F68020E6C30840408EF013408C016DE068534B4600D4488800128101E1BD840021338A2BA7A30062D
70400D32F8000CEC810067A240034BD0801EFE850681CC4324ECE8020318F04B6FEE454BD398620074F007C419410F1308C21FDA5982325C615C4048421A05B0
045E0269091D3002F81680050B8C50063FFF40011020C98007E2C008069803093480840658601B1D7881B57410BE217040006900800B20F0009D2160451C4840
0B3460010DF0E05F1D588152A400B20170A0571761C00A2CDA173511000B2B629E1FA2A08531B000AC5B0840C5F2F5072030A0070CE0991618E78421BCA0040B
C081BD5480031FE8E107230882078810850400600A28F8830CBE503B0AF8480725B040EFB890851234E04763A8820B6210041385E1035C280212FE78AA070AA0
86C469C9635EE3B7C4AE000D68C8951B964087043C4162F7F2C1B5A6500408B0E00C0F005F182080330BA041B414F00219F4F700A241217353008006A7A080BB
4541043998C213FE0081305840062DC842FF11462003DEFD010A7CF8430E4827830BEC0F02579842C08EFBBD2BE0400748A0C012E6E11C192A60009EB1041AB6
1081DEE44A033BB0020C1EC00314C8200D45C8A8A102B00008B8A0043F30D105EE85035791600F7558829AD4F0830504400241F0DA0C2020000944C08F51C85C
001CB00176AAD60020C0828671D087E655ED0220980313BCF0843DC4800048D88009609007340340046B70C201C2FB9C0AECC0099E390147140B5EF1EE003756
1D419E11D780029C01065EB880BB2630810861A0054BB080182C60850F4CE049523843032E40060BA860065E6840031C3080330080020240C1AC2DF0693EF808
0047D3237F8CC0B800D8ED077D58C2CE86FF108439CC20025658910EE4F601F04C661E8646F4532A9081159061D0CEB180175620010B48C10D30C8C212C21080
36ACC8020E5041D210B0473128A00738B88118C092010920C0A283B6C0123800AD2C00730943700F0C1070D72E48E044FA6600887E0403342CC1DF0798B855E3
10188A67E6263730D119CE109E36D05B082AF894104063830E6C81347DB9C1013800221315A10DE019281560808330F44103A4E3501622608213814500517286
8F38722291BFE1E17BA490907A042D1CC4E1C5EA225D0004D08310C128006170C2C4DBE085F0BD003A1CA2907BDC6DF31E70FC3328E1145EA4F06F006021072D
60411EB2C0010C1480053E280201685000FF7C47600634589C002C408107E8910408A5431656D002143881022CB840016670812EBCA00705A0C1077410872E64
C10E5578000876D08310A0C102741881E6AB80070220800E25288013DE708111A000012FC841105A001E0070BE0A58A04311B28001102CE003EDA402404CA08E
5EB5C40B4B60D61FB66F80160800A001C501BB8C0007120061FB7FE0C11DCC30839749408D7FD8800BDC96862C3400FDDB87020C8C807E03FC71007A807FBE65
0359E030F8F70016E0323C10057D20027F900002400206B07D172435E8370370D00013B87D1BD07508407D4270582DC10143622F7BA002CC620002C0007FA005
7EA006AF033E55E301289006B01300E3C2FF0376503FDB670774600065100019850405D002FFE2365A4001ECB2010120600B400152F3016A7003F6C102F4C503
23A00030C02C32E0027EE0804A400746B47D3FC37F0294037D20001BF0077840014AD03C4E1001FAD00143E1060AF070B995062ED0677FA0012C684C2F20541F
1000CCB200F3B7017A342E5D78070E883313A0050F1000F632074380033D322E7310062A1004056001E3023E3B00042C200092A10102503532402F02F000BAA5
890E782EF0772D59904A786006A4930147F00775300505E0013F4706FAA06886251C1C925B402001F6820471B050CD03027F003E02163C66A0064550040EB388
5AB07DB5A704E634844F100068642F6C28FF0066900559B06499830366807452310457B06432D0754EC08A73A3020EA80500905B1418076B288515D70532D059
0AA08E4EC004DBC012C041061A5017C6B67D6310803F632D060037EC023E7E908D06F0010FA70134B38806C0065A0061E524842D98006C70324410907FB00086
5241E84703BE86060CD00504A8880CF00237D07E73D3807AA0043FF00006C003011500ACA8040910040A2078E807009F670C2C210485640599A12EFA682E22A0
020140077F60003FC32E6B50741380040E596BD7E80298833E7A908B0F9005FAF8861714641EB07D48302412D004D9F80729600712008C685004E39200580903
1FC0602EA081655094251090F1F3035B29FF021E300001F0022CB0810F104954E00568E031DB241225B56448C0070563005BE0485CB92E7F1003448003384002
42F5072310004B06016AF05F34100163B07D95E932099086564038382000CEF8073F600267300560B086AAE42442200445B0641E6002C33398A7A3811F805417
904A3F23350BC019CB1900F9D2889F340EC8D12B3F8106CBD2595F1005E7870126B0957033982050049D12066A405F91189B67D03B48C32E7FB0062F707F6920
0753E0654CD007EDA4664030004B40012E7005FC8730EFC19C8AD801D1997E51B0024AF00105232BF4959DCFE8023850041CD0074CF00249908D23B04758E106
1E836D1170061935075F000542C90419B0FF95180007AC380216309823600678F04830B0643CE004CC93002EA08F9198511E200757A00101E08C63307FA72904
23F0072D10600CB6437427001994024EE023C6626417090203209C0E9002021300FC578B3ED29EED3205FCF79A12801A3740873274680DA90504109C0310070E
68041730811780030E33071710971F84897C80394AF005242096E6642F225003580031B9E57F4B08032E030104205425B07837A0011C70A5293000214A332910
061769040EC0861A908DF1F33A73500023D00071707E2040000E480015C401AA713D60C2212ED37F055004C1847FA78A03773007E8970277000757DA85FF0504
7C200171D95CE2887E5C609ADB2702F163FF38E827023BB0701910012FB0647989030340AB5F70917A60076B90036126303D6083E8F7006140006FB87D25C001
6E8500CC408721B30D26300139700113F0216AF20213C002330000ED74514F90039C3704D084B01320001C40000DC0045EF628F0C60200202828D04C44B07905
F004F913005D300223C002187B1520A15639400171300496910313700656500028F002BD1007ABD6002740072830010D40002830214FD0023330011D04AC5E00
1AE7EA0032A4014B22003A66222F60031EC3213F12232BB0053D32B64BB0032B522A49D341EAE22336C0010F6722018000E355733122045BD075636B01822423
1133746F406F26E2117100030760236824FF011C7003639B2C1C0027745B044E40B5522904BC720CB1E1047BE11952B9144D810654780385411A6AE1B720011D
987900AE214306F1818BE5140021050AE00008F024DB50131751046AF2B72271188183173610247B510D89816354FB130830040C20737DA1303BE006022B9507
4006BD8048B2411C56004E7FE1B9CEC01BE0B4BD7F5BB5161501CD8B13E230002B101556604D56F017B0811964B05F65F11C1C1318C610140EB2723484199A61
053B1002D37B1164301AE81B10A831BD83417419D02B98A1BEE6310CF500188854BD5D005E64B113836410D8D31105610371881964A101F0DB0E7ABB0575F10F
16D742E05012329417EA5B01E06410249CC001020B153640063E605108120239A61A0421045D6002689001BE70004BD005BF500CD9D00514FC0F07E00464C0C3
341C016EB015CD200419217364A1275E5010D3E0C44E110E0790B9492111568CBF0FC100AF710E98190C98190E4F21C6CC101103F06DD3E00542E00611301C4C
7C006C0C1421F073BC32009630008660020CD001B46608BC820A886C0819C1C8884C6B0C00C995CCC687ECC89BD0C8887CC99EEC00FC40C98EBCC88D6CC9989C
C89B10C9A8BCC9EFE008ACACC88C5C488100003B}}
\par\par \uc2 Stem cells\par \b \uc2 StemCells  \highlight22\uc2 launches \highlight\uc2  Alzheimer's program with CIRM cash\b0\par\par\uc2 Ron Leuty   \par \uc2 598 \uc2 words\par \uc2 30 July 2013\par \uc2 San Francisco Business Times Online\par \uc2 SFBJO\par \uc2 English\par \uc2 \u169\'00\'A9 2013 American City Business Journals, Inc. All rights reserved.   \par \par \uc2 StemCells Inc\uc2 . formally \b \highlight22\uc2 launched\b0 \highlight\uc2  its Alzheimer's disease program, which already has been fraught with drama, with the help of a $19.3 million loan from California's stem cell research funding agency.\par \par \uc2 The Newark company (NASDAQ: STEM) said Tuesday that it received $3.8 million from the California Institute for Regenerative Medicine with the goal of filing an investigational \b \highlight22\uc2 new drug\b0 \highlight\uc2  application with the Food and Drug Administration within four years for its purified neural stem cells.\par \par \uc2 An investigational new drug application would set the stage for human clinical trials of StemCells' experimental treatment \u8212\'20\'14 known as HuCNS-SC cells \u8212\'20\'14 which are extracted from fetal brain tissue of surgical abortions.\par \par \uc2 StemCells, which is led by CEO \uc2 Martin McGlynn\uc2 , is working with \uc2 University of California\uc2 , Irvine, researchers Frank LaFerla and Matthew Blurton-Jones on the Alzheimer's program.\par \par \uc2 The forgivable loan was awarded by San Francisco-based CIRM in the second round of its disease team program, which aims to help companies get to the point where they can test stem cell therapies in humans.\par \par \uc2 When StemCells received the award, CIRM officials raised concerns about the agency taking on too much risk in one company. CIRM had earlier won a $20 million forgivable loan to expand its spinal cord injury program.\par \par \uc2 StemCells opted in March {\field{\*\fldinst{HYPERLINK "http://www.bizjournals.com/sanfrancisco/blog/biotech/2013/04/stemcells-alzheimers-cirm-stem-cells.html"}}{\fldrslt{\cf2 \uc2  not to accept CIRM's spinal cord program loan}}}\uc2 .\par \par \uc2 CIRM's Alzheimer's program loan will be disbursed over four years, but the term of the loan is 10 years. It bears interest at the one-year LIBOR rate plus 2 percent, but the rate will increase by 1 percent each year after the fifth year.\par \par \uc2 StemCells must make milestone payments, the size of which have not been disclosed, if a product hits the Alzheimer's disease market.\par \par \uc2 StemCells' Alzheimer's work also {\field{\*\fldinst{HYPERLINK "http://www.bizjournals.com/sanfrancisco/print-edition/2011/05/20/orphan-disease-still-stands-alone.html"}}{\fldrslt{\cf2 \uc2  caught the ire of parents}}}\uc2  in 2011 whose children have a deadly malady called Batten disease.\par \par \uc2 The company ditched a planned trial after saying it couldn't identify a single patient with the disease early enough to prove that StemCells' therapy might work. But parents and patient advocates questioned whether StemCells was interested in finding a treatment for Batten disease or using safety data from an earlier trial to feed its work in more lucrative neurodegenerative diseases such as Alzheimer's.\par \par \uc2 Ten days after StemCells shelved the trial in Batten disease, which occurs in about three of every 100,000 children born in the United States, it said it would pursue an Alzheimer's program.\par \par \uc2 Alzheimer's patient advocates say the disease's ranks could swell from today's roughly 5.4 million people to more than 30 million by 2025. There are no drugs approved that halt the progression of the brain disease and several once-promising treatments have failed in recent years in late-stage trials.\par \par \uc2 StemCells' head of research and development, \uc2 Dr. Eliseo Salinas\uc2 , said preclinical work indicated that HuCNS-SC cells could help restore memory in Alzheimer's disease brains.\par \par \uc2 "Even a modest slowing of disease progression could translate into substantial improvements in quality of life for patients and families as well as significant economic savings for society," Salinas said {\field{\*\fldinst{HYPERLINK "http://investor.stemcellsinc.com/phoenix.zhtml?c=86230&p=irol-newsArticle&ID=1842446&highlight="}}{\fldrslt{\cf2 \uc2 in a press release}}}\uc2 .\par \par \uc2 StemCells also has programs in spinal cord injury, a blinding eye disease known as dry age-related macular degeneration and a rare brain disease, called Pelizaeus-Merzbacher Disease, that kills young boys.\par \par \uc2 Did you find this article useful? Why not {\field{\*\fldinst{HYPERLINK "https://secure.bizjournals.com/subscribe/selectTerm?market=sanfrancisco&ana=cstpd&csrc=6355"}}{\fldrslt{\cf2 \uc2 subscribe}}}\uc2  to San Francisco Business Times for more articles and leads? Visit bizjournals.com/subscribe or call 1-866-853-3661.\par \par \uc2 Document SFBJO00020130730e97u0005o\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ Synta Pharmaceuticals Files 8K - Other Events >SNTA\b0\par\par\uc2 192 \uc2 words\par \uc2 29 July 2013\par 07:07\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2013, Dow Jones & Company, Inc.   \par \par \uc2 Synta Pharmaceuticals Corp\uc2 . (SNTA) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on July 29, 2013.\par \par \uc2 On July 29, 2013, Synta issued a press release announcing plans to progress into the second stage of the on-going ENCHANT-1 trial evaluating its lead drug candidate, ganetespib, for treatment of metastatic breast cancer. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1157601/000110465913057169/a13-17439_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1157601/000110465913057169/a13-17439_18k.htm  }}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1157601/000110465913057169/0001104659-13-057169-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1157601/000110465913057169/0001104659-13-057169-index.htm  }}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 July 29, 2013 07:07 ET (11:07 GMT)\par \par \uc2 Document DJDN000020130729e97t001zd\par }\page {\par\fs20\b \uc2 Pharmaceutical Companies; Mylan  \highlight22\uc2 Launches \highlight\uc2  One of the First Generic Versions of Trilipix(R) Capsules\b0\par\par\uc2 417 \uc2 words\par \uc2 29 July 2013\par \uc2 Pharma Business Week\par \uc2 PHBW\par 57\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2013 Pharma Business Week via NewsRx.com    \par \par \uc2 2013 JUL 29 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- \uc2 Mylan Inc\uc2 . (Nasdaq: MYL) announced that its U.S.-based subsidiary \uc2 Mylan Pharmaceuticals Inc\uc2 . has \b \highlight22\uc2 launched\b0 \highlight\uc2  Fenofibric Acid Delayed-release Capsules, 45 mg and 135 mg.\par \par \uc2 Fenofibric Acid Delayed-release Capsules, 45 mg and 135 mg, are the generic version of Abbott's Trilipix(R) Capsules, which are indicated as an adjunct to diet in combination with a statin to reduce triglyceride and increase high-density lipoprotein cholesterol in patients with mixed dyslipidemia and CHD or a CHD risk equivalent who are on optimal statin therapy to achieve their low-density lipoprotein cholesterol goal. Mylan received final approval from the \uc2 U.S. Food and Drug Administration\uc2  (FDA) for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for this product.\par \par \uc2 Fenofibric Acid Delayed-release Capsules, 45 mg and 135 mg, had U.S. sales of approximately $553.6 million for the 12 months ending March 31, 2013, according to \uc2 IMS Health\uc2 .\par \par \uc2 Currently, Mylan has 174 ANDAs pending FDA approval representing $83.2 billion in annual sales, according to \uc2 IMS Health\uc2 . Thirty-six of these pending ANDAs are potential first-to-file opportunities, representing $22.9 billion in annual brand sales, for the 12 months ending Dec. 31, 2012, according to \uc2 IMS Health\uc2 .\par \par \uc2 Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com\par \par \uc2 Keywords for this news article include: Pharmaceutical Companies, Generics, \uc2 Mylan Inc\uc2 ., Government Agencies, Offices and Entities.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC\par \par \uc2 Document PHBW000020130726e97t00016\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 ERBA Diagnostics\uc2  exhibits at AACC Houston\b0\par\par\uc2 126 \uc2 words\par \uc2 28 July 2013\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2013. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 ERBA Diagnostics\uc2  is pleased to announce \uc2 ERBA Diagnostics\uc2  will be exhibiting the full range of products from \uc2 ERBA Diagnostics\uc2  group including not only the Autoimmune and Infectious Elisa product lines, but also the \b \highlight22\uc2 new product\b0 \highlight\uc2  lines from its Drew Scientific and Jas Diagnostics subsidiaries of hematology and Hb1AC equipment and reagents. \uc2 ERBA Diagnostics\uc2  will also be displaying its full line of biochemistry, clinical chemistry and urine analysis products of the parent company, \uc2 ERBA Diagnostics Mannheim GmbH\uc2  and group companies in India, Czech Republic, France and Italy. Another product being \b \highlight22\uc2 launched\b0 \highlight\uc2  is the ERBA Automated Chemistry Analyzer XL-400 with very advanced features and a wide test menu of over 50 analytes. It can test up to 400 tests per hour. \par \par \uc2 Document FLYWAL0020130728e97s000gp\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Mylan announces STALEVO settlement agreement\b0\par\par\uc2 118 \uc2 words\par \uc2 25 July 2013\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2013. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Mylan confirmed that Mylan Pharmaceuticals and Orion Corporation have entered into a settlement and license agreement settling the parties litigation in connection with Mylan's filing of an Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application with the FDA for Carbidopa/Levodopa/Entacapone Tablets. This product is the generic version of STALEVO, which is indicated to treat patients with idiopathic Parkinson's disease to substitute for immediate-release Carbidopa/Levodopa and Entacapone previously administered as individual products. Under the terms of the settlement and license agreement, Mylan may \b \highlight22\uc2 launch\b0 \highlight\uc2  an authorized generic version of STALEVO immediately and its own ANDA product upon receiving final FDA approval. Pursuant to the agreement, the parties pending litigation will be dismissed. \par \par \uc2 Document FLYWAL0020130725e97p0018q\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw145\pich40\picscaley100\picscalex100\picwgoal2175\pichgoal600
47
494638396191002800F7FF00716A5D2C210E5A6D71112D33E5E4E2DAD8D5C5C2BDCCC9C4787165A6A2997B8A8E4D443452666BADB6B9675F51D0CEC9B0ACA580
7A6EABA79FF2F2F0889699DADEDF3227153D3321281E0AD4D2CEEDECEA55696E64767B8A8479BEBBB56B7C8061594A2E23104B4231A6B0B38190948E887EB3BC
BF41575D8781763E555A352B199B968DCAD0D27C766A6D6558847E72B8B4AE2D464C3A515766787C30484E665E50564D3E5148385D55465F72767A74684C6166
585041696153465B60E4E3E14E63682942483A301E413826A0ABAD4A5F64364D53403624342917443A29766F63C8C6C12B444AF1F1EFBBB7B1ADA9A19F9A92F0
F2F295A1A5928C82C3CACB869498F6F6F5D6D4D0D2D7D877878B68797EFAFAF9FCFBFBDDDBD8FDFDFDC1BEB90F2B325B5344271C08F7F7F61D373E544B3CE0DF
DCA19C94302613AAA59DF9F9F8C8CFD0A4A097C3C0BBDBDFE0BDC5C6BFBCB6A8A39BFCFCFC18333A98A4A7433928261B07E9E8E6FBFBFA5047371E383F6F685B
E1E4E5F0EFEDD9D7D4E3E1DF382E1CF2F3F4CFCDC86C65571B363CE7E6E4F5F4F3E6E9EA635B4C274046E2E0DEFBFCFCBFC6C8C1C8CA324A50ECEBEACAC7C2D3
D0CC374E545C5344849296B7B4AD8983788C867BFCFCFD98938A88827719343BEAE9E8463D2CEAE9E7DEDCD9B4B0A9FAFBFBC5CCCE756E61A49F97979188918B
81CDD3D4A2ADB0C7C5C0E3E6E7EEF0F07F786DA9B3B5CECCC7D8D6D28B989CBBB8B2B3AFA8938E849CA7AA8C877C948F85DFDEDBA9A49CB5B2AB384F55A39E96
453C2BECEEEFEFEEECDFE3E46F8084E8EBEC574F40777064867F74C3CACCF8F8F7AFABA4AEB7BAE8E7E5F9FAFA9C978E5B6E73B7C0C2AFABA3736C5FC7C4BF75
6E62728387C4CBCD5F5748BCB9B3645C4EC9C6C1969187EDEFF0C7CECFEBEDEE97A3A6483F2ECED4D5A29D95F5F6F6F6F5F4142F36243D44C2C9CAA09B934C43
33F6F7F8CCD2D3F3F4F4CBC8C393A0A3929FA2C0C7C97E776C96A2A574848849402FBAC2C49E99909E9A919FAAADDCE0E1BAB6B0B5B1AA284148E5E8E9E7EAEB
ACA8A00E2A31251A06FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633036372037392E3135373734372C20323031352F30332F33302D32333A34303A34322020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34423235433037343633384331314535384231344433354232383933364645392220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3442
323543303735363338433131453538423134443335423238393336464539223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3442323543303732363338433131453538423134443335423238393336464539222073745265663A646F63756D656E744944
3D22786D702E6469643A3442323543303733363338433131453538423134443335423238393336464539222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C000000009100280000
08FF00950854E2EA9FC183FFCE0CB46230C3C0870333FC4B339000C27F04049EB9F86FC542835CE294096067080A0D07230D84C3F185121D1CBF0C14F4AFCDC0
2E06BB4054D2A2048C311729EEFC78F0160221FE4250F370D09F537F79BC70ECF1B48941274FB33E75F24FC2D32717BDFA3BC211895311060D4DD2EA4F88C47F
779EBAB8C8E9294E84009E5A84F27489C1256C9F5AE0875049E0AA07610460DBC2A0D6635311FFC37AD81FD7B84E875D1CF6B410423F4F5118CC1B5888D57F0B
9C02BA98EB699C8B179CC633C8D7A9DF7F802BFB2B77D070E5D3AF1607CEF44FEB05A008A93A3D4DD95F000BD0A3B344EDB4CEC53A4F4121DCF5D4C0BF2B4FC5
ECFFD161D6690983979E7E4218E1E928848A9E12A3DDF7EFD3E7163064C5B0FE9F6F7FD105388141833CC54B04613C15C2046C95729172FE30F7154707A5E754
32077992550408EDE154086AFC838D6B06152086539D1804C9536920945A75083DD11D7DB6D9E7D41406E1F1C5104F35E69F641CC921DC100CFD439A3FB2B085
C623C949D61C5814FEB3A253DA19044A560B200488530E18D4C2537F1CE4C2020BE421C73F5C58E0D47B06356147569EF4F66188FFD4E6CF6DB9F983E3418AE8
E7CF1006FD771A471AAE791034642EC0C653C2A8E90F2B4D2E77D58451A6E9943B07B517DE80FF7CF2540206B1F254255112E8145906C1A1552E0761E74F9734
DEFF69A39E17D9E01406810279912F4F897026474FF5B0C2AD77FD03A1844E41196581FEA06590084EC5E6CF1706A501A6418B3A65411C747224963F16FDD341
B44EBD6050214FED72909D783EB5E74165A896ABA4516EE994357E00EB540F6A1CC1E541C74EEAD42C57146CF0AF5D3DE5CB3F7DBC894629E619F48C53BC1CC4
8970DA4673004798F9038141B6FAF38D53791894A4538AAC5B1F6EEE2264869F20CCEB8F3A06176CC6419A6895C73C8306FB0F3E4F5D6350C093E93668C75C79
E014088238158641FEFA63EE41D6B205C20F17BDD89815FA056085596218F2CF97FE54AC728D2CDF68D018B144ED0F2E32B3F5B4411340AB95056C38B62FC84E
DDFF30B4934623648E53F359E254265B2C16C0163F3C452D423020A5951037578862DA3CFC5383536DFCD349B908B13BEB73686895C416716B35B7417DECF1A6
56F3F9FC8F2B4F7D4C7473810D2A6EDFFFC4EBCFC66BF92388334E05600C475BC8C28356362034A53F1ACC12F1B0FE98A281E3A1AF9C676080E49B7A56AB17F5
820A5AB521FB3F1E8E35C6ED4FE9F0C4FBF0A37E506E623CD235EAA638B58C0E4E2152EA3F0580903F2271104BF9A31238E0DC3F9AE60F1C54A278C88955BB02
13021DDCA1304F6103FCDEF7388EA82101F6F20722CEF707E164827DC9FADF3FF0503A7F18AE810631C0BE5CB511154ECC2935FC9B3F2210027F60406C5C584C
08FF34E5BFECA12D4F7B100E065EC11141A9F0225DF093A3FCD103848C0B40C2005C0A55A89C16EE291CFA69A13F2AF78F472CE18C64FC472A5A46B50F39A50C
0749A03F5A984309CE6A0A76CA83FCE4442F8E44E28C4BC003428297952A1E6402E4D30AB2FCA1AC52556D65BDCB8A750EB2C6A521E40B4FA10742D095154D1C
640A5A49639DB4E72E2F2CCF299EC4601F2F9220A714E420594CCAF9B0C5964536324A9CBC5591FE81820D21A40F7EC2C003D6764A5921C46E4E614A0CB302A8
8B882E6DB4FA430F9DE21D3E46284A577CD5AF30E9B459A2A91B8A14987302049DE91C935108894556947990230540091170DB10B870916CDA61505C7B0A879C
49FF4AB5FD83144F11024A64464EE80C288A4F5900317A7022A7C4C19BFF505556161918AED4F329B5F8E57D76691002243230D5E0489EB28410DFF9839D6733
669EDE0582A7D4C09AB933482D2A53062E40F41F72A417EED8625184E4A983CFB2A41FA5B59FD7708485A043C80BBDC69167AEF42004102329BE375183784153
5AB90127FCA3110AF9E1214572C85004F21684E0010102111B427021909E5EA409B6100106C470011D148B231E51C2C610F20081D882423611C85D74D25684DC
63202D008A50C6CAD1250C827C21E0411CF6F8C4CA5AF6B298CDAC6637CBD9CE7AF6B3A00DAD68474BDAD29AF6B4A84DAD6A577B5926B896093400022D168190
0AFFE4800CFD980303D670901D30410A06390513E8601016B87615FF0B846B5970903530600EFD20430E2A701054302106D43508037E6B100ABCF6B50A380811
7401867E48A21EACCD6C3FD6CBDE7E30402AFFA80021DADB8F0190C3201CE807330C42827EF8C02074E84722541885F552C1208D18007D09E106834861BD4538
880CFA5105836481BEFDD08241DE816158A4F7B2EB15051618A185F53600BFFDD003320EF18618F4E3040659473F6260105DD4B717FFF8403F364060031B2405
337EC3211A805B0E3898BD4430C8842BFC8F0BA7000B50C6822A0C22891DFFC20D1BE8C7263E6CD9F546E1204006864168D00F4A1C6404FD008354A6B1DE40F0
81FFBD23F8079029D0E37E1C1813E56DC54128D10F471C79BD6408C63F966CE17E4498236416F33FCEC1073E70B9B25E3E8800326C1026F403B806A142A4D351
5E510478BDCC088538FA218F3A1FB8C0763EC8839970E44418A11F391834850B3D0E2DD85A0B38CEF17AF3A1851104E2D190EEC7970D32690DFFC3D298FE87A6
856D9057D30108FAD5F229D6BB0D53FF03D5073E32ABFFB1EA3594B719846E32861DFD8F6CF8A0BD9B4006B05518696253FAD8973EC8B2873D03588FDA1EF9E8
477E83F0446C5FDBC7DA0EB834FA11043233F9C24CA882C2AB306C83A003163B50F01CE0BB6E0AB55BCEFD503499CD6C1034ABD920DCA86F3F74F10F78887CBF
14EFC202151AEC6F3CF743CF06E1B39FB9DD0F56072211EC3DB8A139B2882C64411B06F1C67A9551F1288578C425EEC789FF915F15B3D8C530368836D86BE676
B0D7C314CAB2247E4184F5A2E3C7411E729103FE0F13E4BCD04F8EF294FF41661A1423189F0E45D12D8EE1F71A44BEF41D40230E020E05F7030BFFC0841ED6FB
8628A1B9BD3190FB3F12BCE006D37CDBFF98F4ACC54D5F639BC0EFEC35C2DC29F4DDD8CEB6B6B7CDED6E2F020426FCD7C2C72D153B82D00F7130C0F106712E74
A59BDD7F58F7F4FFD08723B8FB0FEF7E9709E135082376306A3D68611F9B4FBEF297CFFCE63BFFF9D08FBEF4A76FD98000003B}}
\par\par \uc2 Market Movers\par \b \uc2 Boston Scientific\uc2  Shows Sales Momentum; Shares Soar\b0\par\par\uc2 By JOSEPH WALKER and NATHALIE TADENA \par \uc2 718 \uc2 words\par \uc2 25 July 2013\par 19:08\par \uc2 Dow Jones Top North American Equities Stories\par \uc2 DJTNAE\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2013 Dow Jones & Company, Inc. \par \par \uc2 --\uc2 Boston Scientific\uc2  raises full-year outlook as declines in core business stabilize\par \par \uc2 --\b \highlight22\uc2 New product launches\b0 \highlight\uc2  help company beat Wall Street sales expectations\par \par \uc2 --Shares hit their highest point since 2009; recently up 11%\par \par \uc2 Boston Scientific Corp\uc2 . (BSX), attempting to rebound from years of struggles, swung to a second-quarter profit as cost-cutting and new product launches helped the medical device maker turn in better-than-expected results despite a challenging health-care market.\par \par \uc2 Overall sales fell 1% to $1.81 billion as the company continued to suffer declines in its implanted defibrillator and pacemaker unit, which were partially offset by higher sales in its endoscopy and neuromodulation units. The company also reported a profit of $130 million, or 10 cents a share, which exceeded the company's expectations.\par \par \uc2 Chief Financial Officer \uc2 Jeffrey Capello\uc2  attributed the company's earnings growth to lessening pricing pressure as the company has released product improvements. He specifically cited a new device that he says alleviates back pain and can help patients return to work sooner.\par \par \uc2 "In this economic environment of austerity, people are willing to pay a premium for products that are helpful in addressing the broader costs of health care," Mr. Capello said in an interview.\par \par \uc2 Wall Street analysts focused on the company's adjusted sales figures, which, excluding the impact of foreign currency exchange, rose 1%. Many analysts had projected that the company wouldn't return to organic top-line growth until next year.\par \par \uc2 "The surprise in the quarter was that they finally returned to positive organic revenue growth," said Glenn Novarro, an \uc2 RBC Capital Markets\uc2  analyst. "The last two years have been disappointments on the revenue front."\par \par \uc2 The company also raised its full-year outlook, helping to lift shares to their highest point since 2009. In recent trading, shares were up 9.6% at $10.53.\par \par \uc2 Boston Scientific\uc2  now expects 2013 per-share earnings between 67 cents and 71 cents on revenue of $7.05 billion to $7.17 billion. Its prior outlook called for per-share earnings of 65 cents to 70 cents and revenue of $6.95 billion to $7.15 billion.\par \par \uc2 For the third quarter, \uc2 Boston Scientific\uc2  expects an adjusted per-share profit of 14 cents to 16 cents and revenue of $1.7 billion to $1.76 billion. Analysts polled by Thomson Reuters had predicted nine cents and $1.72 billion, respectively.\par \par \uc2 Like other medical-equipment companies, \uc2 Boston Scientific\uc2  has suffered in recent years from economic austerity measures in Europe and a weakened U.S. economy, which has led health insurers and hospitals to seek lower prices and bigger discounts. Meanwhile, the company also has grappled with a slowdown in surgical procedures in developed markets as well as a failure in recent years to bring new products to market as quickly as its peers.\par \par \uc2 Costs related to its $28 billion acquisition of \uc2 Guidant Corp\uc2 . in 2006, a purchase widely seen as a failure, also have hampered recent results and battered its stock price.\par \par \uc2 Chief Executive \uc2 Mike Mahoney\uc2  has pledged to continue the company's cost-cutting measures and beef up its new product pipeline. Those efforts appeared to pay dividends in the second quarter, as its gross margin widened to 70.7% from 68.4%.\par \par \uc2 The company also benefited from increased output from its manufacturing facilities, which have been consolidated in recent years. "Our manufacturing team did a very good job of running the factories efficiently, both in terms of volume and cost," Mr. Capello said.\par \par \uc2 Earlier this year, \uc2 Boston Scientific\uc2  said it would cut as many as 1,000 jobs, which would bring the company's total headcount reduction to 2,400 since 2011. It is also in the process of moving its headquarters into a cheaper location.\par \par \uc2 "The company has executed on the restructuring and cost-cutting, so it's a very lean organization, and it's starting to fall to the bottom line," Mr. Novarro said.\par \par \uc2 Revenue from neuromodulation products jumped 21%. Sales of endoscopy products rose 8.1%, while sales of peripheral interventional-cardiology products increased 4.6%.\par \par \uc2 Meanwhile, sales of cardiac-rhythm management products fell 1.8%, and sales of interventional-cardiology products decreased 2.5%.\par \par \uc2 Write to Joseph Walker at joseph.walker@wsj.com\par \par \uc2 Document DJTNAE1120130725e97p000b2\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ Arena Pharmaceuticals Files 8K - Other Events >ARNA\b0\par\par\uc2 829 \uc2 words\par \uc2 25 July 2013\par 16:41\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2013, Dow Jones & Company, Inc.   \par \par \uc2 Arena Pharmaceuticals Inc\uc2 . (ARNA) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on July 25, 2013.\par \par \uc2 On July 25, 2013, we announced that our wholly owned subsidiary, Arena Pharmaceuticals GmbH, has entered into an exclusive marketing and supply agreement with CY Biotech Company Ltd., or CYB, for BELVIQ in Taiwan. Under the agreement, we granted CYB the rights to market and distribute BELVIQ in Taiwan for weight loss or weight management in obese and overweight patients, subject to regulatory approval of BELVIQ by the Taiwan Food and Drug Administration, or TFDA.\par \par \uc2 We will manufacture BELVIQ at our facility in Switzerland, and sell finished product to CYB for a purchase price at 45% of CYB's annual net sales. In addition, we received from CYB a net upfront payment of $2 million, and are eligible to receive purchase price adjustment payments based on CYB's annual net sales, as well as a milestone payment upon approval of the first additional indication for BELVIQ by the TFDA. CYB is responsible for the development, regulatory approval and, ultimately, marketing and distribution of BELVIQ in Taiwan, including related costs and expenses.\par \par \uc2 Forward-Looking Statements\par \par \uc2 Certain statements in this Form 8-K are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the advancement, therapeutic indication and use, and regulatory review and approval of BELVIQ; marketing of lorcaserin hydrochloride outside of the United States; rights and obligations under the marketing and supply agreement with CYB; and expectations and future activities related to such agreement, including the development, regulatory approval, manufacture, sale, marketing and distribution of BELVIQ and upfront, milestone and other payments. For such statements, we claim the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from our expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: risks related to the implementation and continuation of the marketing and supply agreement with CYB and relying on collaborative arrangements; risks related to commercializing drugs, including regulatory, manufacturing and supply issues and the availability and use of BELVIQ; cash and revenues generated from BELVIQ, including the impact of competition; our revenues will be based in part on management's estimates, judgment and accounting policies, and incorrect estimates or disagreement regarding our estimates or accounting policies may result in changes to our guidance or previously reported results; the timing and outcome of regulatory review is uncertain, and BELVIQ may not be approved for marketing when expected or ever in combination with another drug, for another indication or using a different formulation or in any other territory for any indication; regulatory decisions in one territory may impact other regulatory decisions and our business prospects; government and commercial reimbursement and pricing decisions; the timing and receipt of payments and fees, if any, from collaborators; the entry into or modification or termination of collaborative arrangements; unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than us or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to any of our research and development may not meet regulatory requirements or otherwise be sufficient for further research and development, regulatory review or approval or continued marketing; our ability to obtain and defend patents; the timing, success and cost of our research\par \par \uc2 and development; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by our forward-looking statements are disclosed in our filings with the Securities and Exchange Commission. These forward-looking statements represent our judgment as of the time of the filing of this Form 8-K. We disclaim any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1080709/000119312513302781/d576148d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1080709/000119312513302781/d576148d8k.htm  }}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1080709/000119312513302781/0001193125-13-302781-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1080709/000119312513302781/0001193125-13-302781-index.htm  }}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 July 25, 2013 16:41 ET (20:41 GMT)\par \par \uc2 Document DJDN000020130725e97p005vr\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ UPDATE: \uc2 Boston Scientific\uc2  Shows Sales Momentum; Shares Soar\b0\par\par\uc2 652 \uc2 words\par \uc2 25 July 2013\par 12:32\par \uc2 Dow Jones Newswires\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright (c) 2013, Dow Jones & Company, Inc.   \par \par \uc2 --\uc2 Boston Scientific\uc2  raises full-year outlook as declines in core business stabilize\par \par \uc2 --\b \highlight22\uc2 New product launches\b0 \highlight\uc2  help company beat Wall Street sales expectations\par \par \uc2 --Shares hit their highest point since 2009; recently up 12.2% to $10.79\par \par \uc2 (Adds details and company comments beginning in first paragraph.) \par \par \uc2 \f2 \par  \par    By Joseph Walker and Nathalie Tadena \par  \f28 \par \par \uc2 \f2 Boston Scientific Corp\f28 \uc2 \f2 . (BSX), attempting to rebound from years of struggles, swung to a second-quarter profit as cost-cutting and new product launches helped the medical device maker turn in better-than-expected results despite a challenging health-care market.\f28 \par \par \uc2 \f2 Overall sales fell 1% to $1.81 billion as the company continued to suffer declines in its implanted defibrillator and pacemaker unit, which were partially offset by higher sales in its endoscopy and neuromodulation units. The company also reported a profit of $130 million, or 10 cents a share, which exceeded the company's expectations.\f28 \par \par \uc2 \f2 Wall Street analysts focused on the company's adjusted sales figures, which, excluding the impact of foreign currency exchange, rose 1%. Many analysts had projected that the company wouldn't return to organic top-line growth until next year.\f28 \par \par \uc2 \f2 "The surprise in the quarter was that they finally returned to positive organic revenue growth," said Glenn Novarro, an \f28 \uc2 \f2 RBC Capital Markets\f28 \uc2 \f2  analyst. "The last two years have been disappointments on the revenue front."\f28 \par \par \uc2 \f2 The company also raised its full-year outlook, helping to lift shares to their highest point since 2009. In recent trading, shares were up 12% to $10.79.\f28 \par \par \uc2 \f2 Boston Scientific\f28 \uc2 \f2  now expects 2013 per-share earnings between 67 cents and 71 cents on revenue of $7.05 billion to $7.17 billion. Its prior outlook called for per-share earnings of 65 cents to 70 cents and revenue of $6.95 billion to $7.15 billion.\f28 \par \par \uc2 \f2 For the third quarter, \f28 \uc2 \f2 Boston Scientific\f28 \uc2 \f2  expects an adjusted per-share profit of 14 cents to 16 cents and revenue of $1.7 billion to $1.76 billion. Analysts polled by Thomson Reuters had predicted nine cents and $1.72 billion, respectively.\f28 \par \par \uc2 \f2 Like other medical-equipment companies, \f28 \uc2 \f2 Boston Scientific\f28 \uc2 \f2  has suffered in recent years from economic austerity measures in Europe and a weakened U.S. economy, which has led health insurers and hospitals to seek lower prices and bigger discounts. Meanwhile, the company also has grappled with a slowdown in surgical procedures in developed markets as well as a failure in recent years to bring new products to market as quickly as its peers.\f28 \par \par \uc2 \f2 Costs related to its $28 billion acquisition of \f28 \uc2 \f2 Guidant Corp\f28 \uc2 \f2 . in 2006, a purchase widely seen as a failure, also have hampered recent results and battered its stock price.\f28 \par \par \uc2 \f2 Chief Executive \f28 \uc2 \f2 Mike Mahoney\f28 \uc2 \f2  has pledged to continue the company's cost-cutting measures and beef up its new product pipeline. Those efforts appeared to pay dividends in the second quarter, as its gross margin widened to 70.7% from 68.4%.\f28 \par \par \uc2 \f2 Earlier this year, \f28 \uc2 \f2 Boston Scientific\f28 \uc2 \f2  said it would cut as many as 1,000 jobs, which would bring the company's total headcount reduction to 2,400 since 2011. It is also in the process of moving its headquarters into a cheaper location.\f28 \par \par \uc2 \f2 "The company has executed on the restructuring and cost-cutting, so it's a very lean organization, and it's starting to fall to the bottom line," Mr. Novarro said.\f28 \par \par \uc2 \f2 Revenue from neuromodulation products jumped 21%. Sales of endoscopy products rose 8.1%, while sales of peripheral interventional-cardiology products increased 4.6%. Meanwhile, sales of cardiac-rhythm management products fell 1.8%, and sales of interventional-cardiology products decreased 2.5%.\f28 \par \par \uc2 \f2 Write to Joseph Walker at joseph.walker@wsj.com\f28 \par \par \uc2 \f2 Order free Annual Report for \f28 \uc2 \f2 Boston Scientific Corp\f28 \uc2 \f2 .\f28 \par \par \uc2 \f2 Visit \f28 {\field{\*\fldinst{HYPERLINK "http://djnweurope.ar.wilink.com/?ticker=US1011371077"}}{\fldrslt{\cf2 \uc2 http://djnweurope.ar.wilink.com/?ticker=US1011371077}}}\uc2 \f2  or call +44 (0)208 391 6028\f28 \par \par \uc2 \f2 (END) Dow Jones Newswires\f28 \par \par \uc2 \f2 July 25, 2013 12:32 ET (16:32 GMT)\f28 \par \par \uc2 Document DJDN000020130725e97p004dn\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ \uc2 ARCA biopharma Inc\uc2  Files 8K - Other Events >ABIO\b0\par\par\uc2 241 \uc2 words\par \uc2 25 July 2013\par 06:04\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2013, Dow Jones & Company, Inc.   \par \par \uc2 ARCA biopharma Inc\uc2 . (ABIO) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on July 24, 2013.\par \par \uc2 On July 22, 2013, \uc2 ARCA biopharma, Inc\uc2 . ("ARCA") announced that it has expanded the clinical trial leadership team with three new hires in clinical development and quality assurance. The press release is furnished as Exhibit 99.1 hereto, the contents of which are incorporated herein by reference.\par \par \uc2 Additionally, on July 24, 2013, ARCA announced the Steering Committee for GENETIC-AF, ARCA's Phase 2B/3 trial evaluating Gencaro as a potential treatment for atrial fibrillation. The Steering Committee is comprised of experts in the field of cardiology and electrophysiology, particularly in clinical development. The press release is furnished as Exhibit 99.2 hereto, the contents of which are incorporated herein by reference.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/907654/000119312513300792/d573228d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/907654/000119312513300792/d573228d8k.htm  }}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/907654/000119312513300792/0001193125-13-300792-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/907654/000119312513300792/0001193125-13-300792-index.htm  }}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 July 25, 2013 06:04 ET (10:04 GMT)\par \par \uc2 Document DJDN000020130725e97p0023e\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw95\pich40\picscaley100\picscalex100\picwgoal1425\pichgoal600
47
49463839615F002800F7FF00ACD19CD5E8F3A5A6A9E0EEF6C8E1EEB2D4A3C4DEB975B25BFDFEFEFAFCF9B3D6E82C8DC03391C289898D66666BD1D0D2E1EEDCB6
B6B8A3CB78A3CC91D2E6C9CEE4F0DDDDDE929296A1A1A462A74484BCDAEDF5FAD0E6F191C3DE757579C9E2F09595999B9B9EF5FAFCC5E0EE858589E6F1E168AD
D2F0F7EE3E96C58DC2DD818185BABABC8D8D914C9ECAB8B8BB6D6D71C6C6C8CDCDCFF9FCFD4299C7B9D9EAD9E9D1529E32C2DEED0E7CB70276B4ACD3E7E6F1F8
A0CCE3F7FAF5CFCFD1D4D4D598C5857CB8D892C27DD8D8DAAAD1E6BCBCBE59A23AEDF5EA95C6E05CA43D9D9DA1FAFAFA69AB4D9AC8E1E8F3F8F7F7F7117FB818
82BA6CAD50469BC81480B965ACD1E1E1E2EAF3E6E3F0F87EB765EAF4F90578B578787CB2B2B5BEDCED72B3D551A1CBC7E0BC88BC71717176D6E8CEBEBEC081B9
69F8F8F92589BEF4F4F4C9C9CAF2F2F2AAAAAC49992661A9D078B35EDEEDD8C0C0C2E6E6E6DDECD6097AB6A5CFE41E85BCB4B4B77BB561D5E7CDECECEDBAD8AD
8DBF77B7D7A9AFAFB1F8FBFDF3F8F0F0F7FB9FCBE2DFEEF7ACACAE60A6420071BD56A03564A846A9CF995AA6CEA0CA8EC4C4C68AC0DCD0E5BFBCDBEBC3DDB871
AF563A94C488BFDC9EC88B96C482A7A7AAE4F0DFE2EFF78ABD745FA540DAEAD386BB6F57A4CD288BBF8EC0795FA8CF7B7B7F67AA4B509D2F0076B10075B3DFEE
F5A0A0A3DEEDF597C7E0E5E5E6EBF4E7DADADB2086BD9CC9E1CACACC76B5D6EFF6ECF5F9F4C3C3C5DBDBDC9DCAE2CDE3C39BC788DBECF4D8EAF3A4A4A7E3E3E4
FBFDFBD3D3D472B057A7CE96AFD29FDCEBD52F8EC11A83BBBDDAB054A2CCE7E7E8E8E8E9F2F8FB98989BCAE1C0E4E4E5B6D7E9CDE3C49EC7EA78B6D77BB5DDDC
DBDCC5DEF0DEDEDFEFEFF0D9EAF4DDECCDF1F7F0F4F3F36CB0D39CC8E6EDF5F0CBE3F0B6B8BBDDEBB79FCBDE0072B8B7D7AAA2CBE7A2CDE3D0E5C7D3E6CB87BC
700C7BB7F8FBF753A2CCB2B2B4EBEBECF9FBF8E1EED5F5F5F5F6F5F5EBF4E890C07A93C37F97C57B9B9B9FDDEDF582B6E5D8D8D9E8F2E3DBEBC571B2D3D7D7D8
5DA6D1AED3E7CFE4C5FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F626520496D61676552656164792220786D704D4D3A496E7374616E636549443D22786D702E6969643A3142304236354442353046303131453639
3838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A314230423635444335304630313145363938384645
4531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E636549443D22786D702E6969643A3142304236
354439353046303131453639383846454531364331343335353638222073745265663A646F63756D656E7449443D22786D702E6469643A314230423635444135
3046303131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D70
6D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDA
D9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A
999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D6C6B6A696867666564636261605F5E5D5C5B5A
595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D2C2B2A292827262524232221201F1E1D1C1B1A
191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C000000005F0028004008FF00FF091C48B0A0C18308132A3468EB9FBF
70F0566D5A48B1A2C58B0365919B902583478F59801430400ECE2500470CC4E2255059128F9A34650056A0D01B60B130EA24C80BC001299420EC1C4AF4DF1B31
0A71942A35C5C4962D60FE4933540AC73F3B4BBD68588A6229121A4B5BE05A4A76E9BF5C4BE92C9DF20FD452494B053979ABB4D48E7F41967650546A060E1CB5
942A0A40F69F27B2A4B40D00476ACBD26245234B9E4CB9724565323300F188E04AA443496C24096399F29CCD19442D9A5894429251870A5CC20707C2112136E6
1C3C2226C3A28AB552094FD544C70682C438CD6B575AE70041E388FCDB30AE7A857F23AADF4858200F42B25BD42EFF9D34B7548E0564EB2CC00106139A520C9A
2C75836A69AB7F3396D69BB474442A4FAD10D00A156EECD00A538D94D20A2AE32C358E406E9015C53F5F48F80F61A550F14F57A5E820105C5B5490C202ADDC95
D0340EDC310606FF2801822E242473813A2C0CC182032E10A2C20B6AC431861F0DFC50840A212CF1CF0B67C4F182121E4460893A4AA8C1C6055CB05086034538
5086002FA8E383034FFC330417EAD0430221BA701141115D14D1801F1160008207C990100706B38C914C737CFEB38A1419BC51093EFF20C08728854871429F8C
52144B3061149048098518914112661820D0047BCC01071C7C18D1E864BC9473CB474CDC12C62A155D234F1827C4FF524209918C62840D9A2092410102959088
AE5278372A41C164E25125BA35D7C31EB77CB2071964B04A1131199046590200BC614643C396360125099D13D6176A81C3CF358E6CD3AD45C32C25422A644962
D852DB21248B370655F1455D41A0925F29D960C8007E4B7103EF526898B081024B9930C0520377B2542DEF3946560AAE90B580099804D06E588208A4C55254A8
C5C114A54491432923C860DF3F2897D2CF854B59BC540AFF38B1C3CE3B388100411F7C50282698FCF14F20043CC28DD1C810BD01025860E2C43F5A101D884001
78318216036931020DDCC8305000343C820A410898A236D77F0C32882957FF61CA2058E43CB708045540C30DC751FF3484032CFE73CA05244440CD1D7A0CC106
178CC0D04B0C023810871C1158A0CE3D2BFC20D018AF5C70012D654CE34117178030CD132B3CEE0E0C6B0C0143113E0CF1040CFF3CE0810F18ACE1070C4BACE0
C22C2E9C110321AAA4E1821C72ECAEC63B1658B06E69AFA871910B0915E1CEF392C5F2061305B4110F3A79BCF1C611D8974FD0011E5D41862CFF8413C6279A14
8287F9E59B93994700F0120E1E35005080F8F4B3CC250CB0888E7CC423063083108CF00B8218C0178790820D3251807204238018810000F0F0114450B01CE43B
481F0AD083125C4116808884A53EA2093E4080131FC91F0609D20C63794408B0DA091FDA208F725C211635C80227FF80F186244821010449401FF057BE6B14C0
171960C2229235993C40B00D3690C726CA418E5B40422100C840031B65803764000F5F1C1602D0C10E8C24220348AC4C027E218503EC61861801440684121900
98A112ACC1E34E00B108961CA42C6481420010900F0948C01A82E44061FA4116B6086329554888233485B69DD56504FF804B29F4F1876F68C319FF1087063430
B5261443186E904E2E56C98C40D012176E50C42304928B20A0A0054818482AD2C10013CCEC1F15800503663089BEC5EC0379411826DA458500346212A9F80711
26910202D88300FFE0003466D0893AFCA3094DA80B7840F18F0F406C430E82422984518D0E0882007568D8C3AAD2FF0F062C85006028051444A0030751A11428
40450A9A908B672C8519DC68842BB8C68CA580E19229B8A422D492823F2CC50E305B0A0E5040047F464106192BC575EAE28A7F486C9E0C830F3C4BA18040A422
08B058D90252EAB0A52CE01F2D588A0E2E4985472820151D18C1063A10047D2C6518C8F0022C1AC1211E08043D69F9075FC82283F2DC2766CCF8C70E96120566
1001091DE0C63FA09083959967182610485011FA2F0E30C3AD29AB8017F4E953A02EE53AFF6AD83F9050962854E00F58B5A8D8FE2108B20C8CB016FD07379E4A
3099096407FE244B3604C9D98A80E00102C19D25A2511001FC4C203DFAC73BBA711036D4EE0E03C1C63F5660248CD9C060468DA2920AAE478853B02102F40885
004870810638A0172CB8000694E0B908808004200805098C44821090C0122E1883254000B90B9C22062A60810AB8440F42B0610C0DD0050B4EF10F0C9040200D
B0C4702FC08206AC37192E084111B830B80684C003BA00012D14120DD01E837672B84304FE91605544C318CB88C60AD410831FA862193EB0C23EF4708608F840
203158821C1E108322AC63082B60C531AC00BA18BC03066778C51A1E50045594C1030361050658F10F36C0001BACD88515761103E1EAC1184518422F54B10F77
7061169DE56C4000003B}}
\par\par \b \uc2 Verso  \highlight22\uc2 Introduces \highlight\uc2  VersoRx(TM) Pharmaceutical Inserts, Adding to its Specialty Papers Product Line\b0\par\par\uc2 547 \uc2 words\par \uc2 23 July 2013\par 07:55\par \uc2 Business Wire\par \uc2 BWR\par \uc2 English\par \uc2 (c) 2013  Business Wire. All Rights Reserved.   \par \par \uc2 \f2 \par MEMPHIS, Tenn.--(BUSINESS WIRE)--July 23, 2013-- \f28 \par \par \uc2 \f2 Verso Paper Corp\f28 \uc2 \f2 . (NYSE:VRS) \f28 \b \highlight22\uc2 \f2 announces the launch\f28 \b0 \highlight\uc2 \f2  of a new pharmaceutical insert grade: VersoRx(TM). This \f28 \b \highlight22\uc2 \f2 new product\f28 \b0 \highlight\uc2 \f2  offering, engineered to deliver outstanding print fidelity while providing excellent sheeting and folding performance, is an exciting addition to Verso's growing specialty papers product portfolio.\f28 \par \par \uc2 "Our introduction of VersoRx(TM) pharmaceutical inserts is a great example of our continued focus in the specialty papers market segment," says \uc2 Mike Weinhold\uc2 , Verso's Senior Vice President of Sales, Marketing and Product Development. "By adding the VersoRx(TM) products to our portfolio, we have enhanced the wide range of product solutions that Verso offers converters, printers, and end-users."\par \par \uc2 Available in 27#, 30# and 35# basis weights, VersoRx(TM) pharmaceutical inserts are produced on the No. 1 paper machine at Verso's mill in Bucksport, Maine. "The No. 1 paper machine at Bucksport plays a key role in Verso's plan to diversify its product line and expand in the specialty papers market segment," Weinhold explains. "Thanks to the expertise and ingenuity of our manufacturing team and to strategic investments made at the Bucksport Mill, we are pleased to announce this important, new commercial component of our product diversification plan. The VersoRx(TM) products are integral to the success of our diversification efforts, both now and in the future," he says.\par \par \uc2 VersoRx(TM) is offered certified, upon request, to meet our customers' PEFC (BV-PEFCCOC-US005202-1), SFI(R) , or FSC(R) (BV-COC-301978) needs. For more information on VersoRx(TM) pharmaceutical inserts or other Verso products, please visit versopaper.com or contact Verso at 1-800-258-8852.\par \par \uc2 About Verso\par \par \uc2 Based in Memphis, Tennessee, \uc2 Verso Paper Corp\uc2 . is a leading North American producer of coated papers, including coated groundwood and coated freesheet, and specialty products. Verso's paper products are used primarily in media and marketing applications, including magazines, catalogs and commercial printing applications such as high-end advertising brochures, annual reports and direct-mail advertising. Additional information about Verso is available on the Company's website at {\field{\*\fldinst{HYPERLINK "http://www.versopaper.com"}}{\fldrslt{\cf2 \uc2 www.versopaper.com}}}\uc2 .\par \par \uc2 Forward-Looking Statements\par \par \uc2 In this press release, all statements that are not purely historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by the words "believe," "expect," "anticipate," "project," "plan," "estimate," "intend" and similar expressions. Forward-looking statements are based on currently available business, economic, financial and other information and reflect management's current beliefs, expectations and views with respect to future developments and their potential effects on Verso. Actual results could vary materially depending on risks and uncertainties that may affect Verso and its business. For a discussion of such risks and uncertainties, please refer to Verso's filings with the \uc2 Securities and Exchange Commission\uc2 . Verso assumes no obligation to update any forward-looking statement made in this press release to reflect subsequent events or circumstances or actual outcomes.\par \par \uc2 Document BWR0000020130723e97n00048\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw222\pich44\picscaley100\picscalex100\picwgoal3330\pichgoal660
47
4946383961DE002C00C4000044448FDA44448888B8F1BBBBE78888BBBBD6CF1111EEEEF5E06666D32222EB9999F8DDDD22227AF5CCCCFCEEEE111170DDDDEB33
33856666A3AAAACCEEAAAA7777AD9999C2D63333E47777CCCCE0DD5555555599CC0000000066FFFFFF00000021F90400000000002C00000000DE002C000005FF
A0278E64699E68AAAE6CEBBE702CCF746DDF78AEEF7CEFFFC0A070482C1A8FC8A472C96C3A9F31884500A84A0405A8763B0474BE60F0284C16980A5E3298616E
A5D570705B17570538F83C07511AE8F5035C396F6A6371732215716411072C848B653C7529777F780E247E971C818237906186708812918C8E2AA1A71D883894
289697049A9C9D9FA08BA36A7316AC64152BABA7AE37B027B27F09B59C9EB834C31DBB92220FBF6410AAD761C536C726C97F0A239B97CECF32D1D3DC22BEDB72
DAEFAD937076B61C01E4B6E7E830EA228BDA9882B3A180803800E2BDEB56E35B89707F3C958BD86FC63F0F01453088936A2099070AC9B01140B224C92C3B1CFF
9280A8878F8789802AA6D305F050CD7A220EE244312C218B03023644F80240C28414028676886046E508967A16BCDC57C201010D17F00440408144030260C312
6830422CD8110BCC82CD24C281020D09F25CC0D0D5C5C58C18E3A0D45928454F1602ACC1618072C401A5613C92B1778F032D9879CE1130602B81A7059C6889B8
54F6D285B2946D5D20FB88665E5222107FCCE0014281D7B05F870CE33385E2381648A866C5F89E81A9CD4620688C679C87D02D4534B8449AC02597C3891B203D
5BD44D5E89223114865085A25F473DB8DBD6FB9E02C8783C61209EA72BC47CC0F5D485488B027B3CCBB8C3C25BE014E1187FA100C1360C88108D532240A5C7FF
05E8DD82D97D1C2CE3DC1FBF7930A11E9A65F507597141689C5FA6E1E5C1815F6C908A1B718C64D208B77D11C1466A1C258F3495DC772145D1FD7141877F5060
1F671EACF7874B9C78B0DC251A10A06172D589711D35AD0916C903E19576CD08308611416B705470001C0F40C0D76235B2C7234567E2F1D9837F60C0664CEF19
79493E0A70221564F081B89F4D2364206524C158F9CB3A1DF8044742873EE9642C1052C5097C8F1E774957C8E5F11B64187850E72CF1E9A1DF4E228AE0E72F12
08CA9B075FAA61A8AAA7D1A6E817E5351A9903917A10297DB67262D525E33448005BFE84C827090790F8456E4DEE49C6AACBB60A06B364323A67A5F704526BFF
A437E28140830308A90769BEFD1AACB2D89D10D8290F9C7882B18BCA8328ABCE2E8ACCA3D93A2A6B3E3FEA1140BEE28453A107397262C087A6461B6A09076C40
4CB2A0BEF36EB3F1C25AE61F01BC596DAE8DE663310706D48B070169E6E900B57302CB30A15F6C27C2047F42CC538A269184F2220FBB1A318DD2520C307BD6DE
2B02C9DE561AF0C75EA5798901527DDAD7CDF31814B3CCADED66DDCB89A2004704B165CD5AD5087AC0523E4736D6B38E03946DB6D9A441845CC024D735820343
7B56F0D4190D33C28071644335BC27549D02D73BCD3B6782C48DAD2F0B1EE791781E4997B040DC7A10BC6E8A339B31E6D423C6C1DADE2E9B50750555840E40FF
30802F2DB8CE9A168EF1E14106E0FAEB997AC0EF251BEB911F0A8FDBA281D2646431C122595C0E4661524BCCB9CD26A40A7128353FFB2ACEA7B3EE81D180D03A
B8D7D7D78EDFEA488E80C1EBAF8FD300C9B7A320FC36D9FC7EF50406C5B1A59E7C7B0E6F281228AF25AA5D7FDDD9C5B542E492A4B7BA876676F607CD786C05EA
9B5181B834A30E04EA78CE83E0032C309E30E4260E1BC852B4A2970791890D7B1452C0A6C4F1145BD00272E9D91FEB34703D1568701B7360971AF40641A2A4A0
82ACC846F122112BAD900085B718E17D1A97B8712C0E5861B31DC91CC382046E235D2370E2351E58C342B9F01AA5F2C077C83331E9C9892AD383D0FF644795E7
067D86044B928EC952B0C56B5449042D8A4423781741148C0A5DA9C05B1C5A063D70D4AA84C131D212296432ED89407B63EC546324A782F381E98D2CBA0600D4
55C5DAD8F18522D95C3BE2208116F5101F2510624C9443BD3C24803A2320DF084C6802050C120F038B421CC1F080FAA5000D916000B2E666C3150005936CA0A4
0726F0C26008EF93791A01F5CE6115A325405C7E441D0829628205608064064040E36270000B804E74029880304F20A66F860E0B49700DFB0A304E12A8939D5B
58C0002850B6350E419EF31C002A65C2CF7EFAF39F000DA840074AD0821AF4A0084DA8429F1102003B}}
\par\par \b \uc2 FORM 8-K: \uc2 BIOCRYST PHARMACEUTICALS\uc2  FILES CURRENT REPORT\b0\par\par\uc2 1,042 \uc2 words\par \uc2 23 July 2013\par \uc2 US Fed News\par \uc2 INDFED\par \uc2 English\par \uc2 Copyright 2013. HT Media Limited. All rights reserved.   \par \par \uc2 WASHINGTON, July 23 -- \uc2 BioCryst Pharmaceuticals Inc\uc2 ., Durham, N.C., files Form 8-K (current report) with \uc2 Securities and Exchange Commission\uc2  on July 22.\par \par \uc2 State or other jurisdiction of incorporation: Delaware\par \par \uc2 Regulation FD Disclosure.\par \par \uc2 On July 22, 2013, \uc2 BioCryst Pharmaceuticals, Inc\uc2 . ("BioCryst") issued a news release announcing the results of its BCX4161 Phase 1 clinical trial for the treatment of hereditary angioedema ("HAE"), as further described in Item 8.01 below. A copy of the news release is attached hereto as Exhibit 99.1 and is incorporated into this Item 7.01 by reference.\par \par \uc2 BioCryst's management will host a conference call and webcast on July 22, 2013 at 8:30 a.m. Eastern Time to discuss the results of the BCX4161 Phase 1 clinical trial and other aspects of BioCryst's HAE development program. The webcast can be accessed by logging onto {\field{\*\fldinst{HYPERLINK "http://www.biocryst.com"}}{\fldrslt{\cf2 \uc2 www.biocryst.com}}}\uc2 , and slides that will be used in connection with the conference call and webcast are available for viewing, downloading and printing on the website.\par \par \uc2 The information in this Item 7.01 is furnished and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, is not subject to the liabilities of that section and is not deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.\par \par \uc2 Other Events.\par \par \uc2 On July 22, 2013, BioCryst announced that the randomized, placebo-controlled, Phase 1 clinical trial of orally-administered BCX4161 in healthy volunteers successfully met all of its objectives. The safety, tolerability, drug exposure and on-target kallikrein inhibition results of this Phase 1 trial strongly support advancing the development program into a Phase 2a study in HAE patients.\par \par \uc2 Overall, 87 healthy volunteers completed the study; 30 received a single dose of BCX4161 from 50 mg up to 1000 mg, 40 subjects received 100 mg, 200 mg, 400 mg, or 800 mg BCX4161 every eight hours for seven days and 17 received placebo.\par \par \uc2 Oral administration of BCX4161 was generally safe and well tolerated. There were no serious adverse events and no dose limiting adverse events. Laboratory tests of coagulation remained normal. Drug exposure was dose proportional through 400 mg three times a day. Steady state (day seven) blood levels were 30% higher compared to the first day of dosing. At 400 mg three times a day, pre-dose geometric mean (coefficient of variance, CV) drug levels on day 7 were 28.6 ng/mL (CV 77%) and post-dose maximum drug levels were 152 ng/mL (CV 57%). Kallikrein inhibition was observed throughout the dosing interval, p<0.0001 compared to placebo.\par \par \uc2 The Phase 2a clinical trial in patients with HAE is expected to begin in the fourth quarter of 2013. This trial will test 400 mg of BCX4161 administered three times daily for 28 days in a randomized, placebo-controlled, two-period cross-over design. Approximately 25 HAE patients who have a high frequency of attacks ( LOGO 1 per week) will be enrolled. The main goals for this clinical trial are to evaluate the safety and tolerability of BCX4161 and to estimate the degree of efficacy in reducing the frequency of attacks. This study is designed to provide proof of concept for oral kallikrein inhibition as a treatment strategy for hereditary angioedema.\par \par \uc2 As a part of BioCryst's strategy to become a leader in the treatment of HAE, BioCryst is finalizing its evaluation of multiple potent and specific second generation oral kallikrein inhibitors. Oral bioavailability of these compounds ranges between 20% and 60% in animals. One or more candidates are expected to enter preclinical development by the end of 2013.\par \par \uc2 Financial Statements and Exhibits.\par \par \uc2 (d) Exhibits\par \par \uc2 Exhibit No. - Description\par \par \uc2 99.1 - Press release dated July 22, 2013 entitled "Biocryst Successfully Completes its Phase 1 Clinical Trial of BCX4161 for the Treatment Of Hereditary Angioedema"\par \par \uc2 Forward-Looking Statements\par \par \uc2 This Current Report on Form 8-K contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst's actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect BioCryst's current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: that BioCryst may not be able to enroll the required number of subjects in the Phase 2a clinical trial of BCX4161; that the Phase 2a trial of BCX4161 may not have a favorable outcome or may not be successfully completed; that the FDA or similar regulatory agency may refuse to approve subsequent studies, or delay approval of clinical studies which may result in a delay of planned clinical studies and increase development costs of a product candidate; that the FDA may withhold market approval for product candidates; that ongoing and future preclinical and clinical development of HAE second generation candidates may not have positive results; that BioCryst or its licensees may not be able to continue future development of current and future development programs; that such development programs may never result in future product, license or royalty payments being received; that BioCryst may not be able to retain its current pharmaceutical and biotechnology partners for further development of its product candidates or may not reach favorable agreements with potential pharmaceutical and biotechnology partners for further development of product candidates. Please refer to the documents BioCryst files periodically with the \uc2 Securities and Exchange Commission\uc2 , specifically BioCryst's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and current reports on Form 8-K, all of which identify important factors that could cause the actual results to differ materially from those contained in BioCryst's projections and forward-looking statements.\par \par \uc2 More information can be viewed at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/882796/000119312513296443/d571693d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/882796/000119312513296443/d571693d8k.htm}}}\par \par \uc2 Document INDFED0020130723e97n00061\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ \uc2 BioCryst Pharmaceuticals\uc2  Files 8K - Other Events >BCRX\b0\par\par\uc2 507 \uc2 words\par \uc2 22 July 2013\par 06:13\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2013, Dow Jones & Company, Inc.   \par \par \uc2 BioCryst Pharmaceuticals Inc\uc2 . (BCRX) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on July 22, 2013.\par \par \uc2 On July 22, 2013, BioCryst announced that the randomized, placebo-controlled, Phase 1 clinical trial of orally-administered BCX4161 in healthy volunteers successfully met all of its objectives. The safety, tolerability, drug exposure and on-target kallikrein inhibition results of this Phase 1 trial strongly support advancing the development program into a Phase 2a study in HAE patients.\par \par \uc2 Overall, 87 healthy volunteers completed the study; 30 received a single dose of BCX4161 from 50 mg up to 1000 mg, 40 subjects received 100 mg, 200 mg, 400 mg, or 800 mg BCX4161 every eight hours for seven days and 17 received placebo.\par \par \uc2 Oral administration of BCX4161 was generally safe and well tolerated. There were no serious adverse events and no dose limiting adverse events. Laboratory tests of coagulation remained normal. Drug exposure was dose proportional through 400 mg three times a day. Steady state (day seven) blood levels were 30% higher compared to the first day of dosing. At 400 mg three times a day, pre-dose geometric mean (coefficient of variance, CV) drug levels on day 7 were 28.6 ng/mL (CV 77%) and post-dose maximum drug levels were 152 ng/mL (CV 57%). Kallikrein inhibition was observed throughout the dosing interval, p<0.0001 compared to placebo.\par \par \uc2 The Phase 2a clinical trial in patients with HAE is expected to begin in the fourth quarter of 2013. This trial will test 400 mg of BCX4161 administered three times daily for 28 days in a randomized, placebo-controlled, two-period cross-over design. Approximately 25 HAE patients who have a high frequency of attacks ( 1 per week) will be enrolled. The main goals for this clinical trial are to evaluate the safety and tolerability of BCX4161 and to estimate the degree of efficacy in reducing the frequency of attacks. This study is designed to provide proof of concept for oral kallikrein inhibition as a treatment strategy for hereditary angioedema.\par \par \uc2 As a part of BioCryst's strategy to become a leader in the treatment of HAE, BioCryst is finalizing its evaluation of multiple potent and specific second generation oral kallikrein inhibitors. Oral bioavailability of these compounds ranges between 20% and 60% in animals. One or more candidates are expected to enter preclinical development by the end of 2013.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/882796/000119312513296443/d571693d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/882796/000119312513296443/d571693d8k.htm  }}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/882796/000119312513296443/0001193125-13-296443-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/882796/000119312513296443/0001193125-13-296443-index.htm  }}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 July 22, 2013 06:13 ET (10:13 GMT)\par \par \uc2 Document DJDN000020130722e97m001t3\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ \uc2 BioCryst Pharmaceuticals\uc2  Files 8K - Regulation FD >BCRX\b0\par\par\uc2 320 \uc2 words\par \uc2 22 July 2013\par 06:13\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2013, Dow Jones & Company, Inc.   \par \par \uc2 BioCryst Pharmaceuticals Inc\uc2 . (BCRX) filed a Form 8K - Regulation FD Disclosure - with the U.S Securities and Exchange Commission on July 22, 2013.\par \par \uc2 On July 22, 2013, \uc2 BioCryst Pharmaceuticals, Inc\uc2 . ("BioCryst") issued a news release announcing the results of its BCX4161 Phase 1 clinical trial for the treatment of hereditary angioedema ("HAE"), as further described in Item 8.01 below. A copy of the news release is attached hereto as Exhibit 99.1 and is incorporated into this Item 7.01 by reference.\par \par \uc2 BioCryst's management will host a conference call and webcast on July 22, 2013 at 8:30 a.m. Eastern Time to discuss the results of the BCX4161 Phase 1 clinical trial and other aspects of BioCryst's HAE development program. The webcast can be accessed by logging onto {\field{\*\fldinst{HYPERLINK "http://www.biocryst.com"}}{\fldrslt{\cf2 \uc2 www.biocryst.com}}}\uc2 , and slides that will be used in connection with the conference call and webcast are available for viewing, downloading and printing on the website.\par \par \uc2 The information in this Item 7.01 is furnished and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, is not subject to the liabilities of that section and is not deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/882796/000119312513296443/d571693d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/882796/000119312513296443/d571693d8k.htm  }}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/882796/000119312513296443/0001193125-13-296443-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/882796/000119312513296443/0001193125-13-296443-index.htm  }}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 July 22, 2013 06:13 ET (10:13 GMT)\par \par \uc2 Document DJDN000020130722e97m001o1\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ Synergy Pharmaceuticals Files 8K - Other Events >SGYP\b0\par\par\uc2 254 \uc2 words\par \uc2 17 July 2013\par 11:25\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2013, Dow Jones & Company, Inc.   \par \par \uc2 Synergy Pharmaceuticals Inc\uc2 . (SGYP) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on July 17, 2013.\par \par \uc2 On July 17, 2013, \uc2 Synergy Pharmaceuticals Inc\uc2 . (the "Company") issued a press release announcing that it has reached the halfway mark for total enrollment in its ongoing plecanatide Phase 2b clinical trial in patients with irritable bowel syndrome with constipation. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.\par \par \uc2 The information disclosed under this Item 8.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1347613/000110465913054836/a13-16737_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1347613/000110465913054836/a13-16737_18k.htm  }}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1347613/000110465913054836/0001104659-13-054836-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1347613/000110465913054836/0001104659-13-054836-index.htm  }}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 July 17, 2013 11:25 ET (15:25 GMT)\par \par \uc2 Document DJDN000020130717e97h003ya\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 PRESS RELEASE: \uc2 OxySure \highlight22\uc2 Launches New Product \highlight\uc2  - Double Wall Cabinet for AED/\uc2 OxySure\uc2  Combination Set\b0\par\par\uc2 902 \uc2 words\par \uc2 17 July 2013\par 09:10\par \uc2 Dow Jones Newswires\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright (c) 2013, Dow Jones & Company, Inc.   \par \par \uc2 OxySure\b \highlight22\uc2 Launches New Product\b0 \highlight\uc2  - Double Wall Cabinet for AED/\uc2 OxySure\uc2  Combination Set\par \par \uc2 FRISCO, TX--(Marketwired - July 17, 2013) - \uc2 OxySure Systems, Inc\uc2 . (OTCQB: OXYS) ("\uc2 OxySure\uc2 ," or the "Company"), a medical device innovator of life-saving, easy-to-use emergency oxygen solutions with its "oxygen from powder" technology today announced that the Company \b \highlight22\uc2 launched\b0 \highlight\uc2  a new double wall mounted cabinet to house a combination AED/\uc2 OxySure\uc2  system.\par \par \uc2 This new product allows customers to house and display an AED of their choosing, along with an \uc2 OxySure\uc2  Model 615 unit in the same wall cabinet, allowing easy, one-step access, reducing response time when seconds count, in a cardiac arrest or other medical emergency. In addition, by housing both their AED and \uc2 OxySure\uc2  units in the same cabinet, the Company believes that customers will save wall space and expense, and will reduce installation and maintenance requirements. The cabinet comprises a powder coated finish and clear impact resistant acrylic window that provides durability and protection. The unit also comes fully alarmed with a key switch conveniently located in the front. A magnetic door latch provides solid closure and trouble free opening.\par \par \uc2 The Company has previously announced the addition of six AED brands to its product portfolio, including Zoll, Philips, Cardiac Science, Physio Control, \uc2 Defibtech\uc2  and Heartsine. In a cardiac arrest emergency the \uc2 OxySure\uc2  Model 615 is intended to be used post-resuscitation. In most other medical emergencies the \uc2 OxySure\uc2  Model 615 is intended for general emergency use, prior to the arrival of the first responders.\par \par \uc2 One of the first customers to take delivery of ten of the new \uc2 OxySure\uc2  double cabinet systems is the First Baptist Church of Dallas. Ron Cresswell of First Baptist Church stated: "We are very excited to be deploying the new AED/\uc2 OxySure\uc2  combination wall cabinets. This unit creates a compact way to pre-position both an AED and an \uc2 OxySure\uc2  unit, and it eliminates the need for multiple keys and multiple access points in an emergency, reducing response time and risk."\par \par \uc2 Julian T. Ross\uc2 , CEO of OxySure Systems, Inc. stated: "We are pleased to be offering our customers and distributors this new combination wall cabinet. We have developed this product based on customer feedback, and we believe it enhances the appeal of the AED and \uc2 OxySure\uc2  Model 615 as a combination set, and our product portfolio in general."\par \par \uc2 For a video demonstration of the new AED/\uc2 OxySure\uc2  wall box, please click here: {\field{\*\fldinst{HYPERLINK "http://www.youtube.com/watch?v=VgQ4VDNqKKo"}}{\fldrslt{\cf2 \uc2 http://www.youtube.com/watch?v=VgQ4VDNqKKo}}}\par \par \uc2 The AED/\uc2 OxySure\uc2  combination wall cabinet has a manufacturer suggested retail price of $369. For order information, please email ehuntsberry@oxysure.com or call Ed Huntsberry at (+1) 972-294-6559.\par \par \uc2 About \uc2 OxySure Systems, Inc\uc2 .\par \par \uc2 OxySure Systems, Inc\uc2 . (OTCQB: OXYS) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. \uc2 OxySure\uc2 's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health" (IDLH) environments. {\field{\*\fldinst{HYPERLINK "http://www.OxySure.com"}}{\fldrslt{\cf2 \uc2 www.OxySure.com}}}\par \par \uc2 Forward-Looking Statements\par \par \uc2 This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts, including, without limitation, statements that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development, may be deemed to be forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import also identify forward-looking statements. These statements are subject to risks and uncertainties. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Except as may be required under applicable law, we assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of \uc2 OxySure Systems, Inc\uc2 . can be found in the filings of \uc2 OxySure Systems, Inc\uc2 . with the \uc2 U.S. Securities and Exchange Commission\uc2 .\par \par \uc2 The following files are available for download: \par \par \uc2 \f2 \par    -- \f28 \uc2 \f2 OxySure\f28 \uc2 \f2  Emergency Oxygen Cabinet \f28 \par \par \uc2 \f2 Investor Relations Contacts:\f28 \par \par \uc2 \f2 Barwicki Investor Relations\f28 \par \par \uc2 \f2 Andrew Barwicki\f28 \par \par \uc2 \f2 President\f28 \par \par \uc2 \f2 Tel: +1-516-662-9461\f28 \par \par \uc2 \f2 Email: andrew@barwicki.com\f28 \par \par \uc2 \f2 Investor Relations WS\f28 \par \par \uc2 \f2 Chris Hagerman\f28 \par \par \uc2 \f2 Tel: +1-208-361-6624\f28 \par \par \uc2 \f2 Email: jamespr@oxysure.com\f28 \par \par \uc2 \f2 (END) Dow Jones Newswires\f28 \par \par \uc2 \f2 July 17, 2013 09:10 ET (13:10 GMT)\f28 \par \par \uc2 Document DJDN000020130717e97h003fk\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Mylan  \highlight22\uc2 Launches \highlight\uc2  Generic Nor-Q.D.(R) Tablets, 0.35 mg (28-Day Cycle)\b0\par\par\uc2 358 \uc2 words\par \uc2 16 July 2013\par 11:43\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2013  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 PITTSBURGH, July 16, 2013 /PRNewswire/ -- \uc2 Mylan Inc\uc2 . (Nasdaq: MYL) today announced that its U.S.-based subsidiary \uc2 Mylan Pharmaceuticals Inc\uc2 . has \b \highlight22\uc2 launched\b0 \highlight\uc2  Norethindrone Tablets USP, 0.35 mg. Norethindrone Tablets USP, 0.35 mg, are the generic version of \uc2 Watson Laboratories\uc2 ' (now \uc2 Actavis, Inc\uc2 .) Nor-Q.D.(R) Tablets, 0.35 mg (28-Day Cycle), which are indicated for the prevention of pregnancy. Mylan's partner, \uc2 Famy Care Ltd\uc2 ., received final approval from the \uc2 U.S. Food and Drug Administration\uc2  (FDA) for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for this product.\par \par \uc2 Norethindrone Tablets USP, 0.35 mg, had U.S. sales of approximately $39 million for the 12 months ending March 31, 2013, according to \uc2 IMS Health\uc2 .\par \par \uc2 Currently, Mylan has 174 ANDAs pending FDA approval representing $83.2 billion in annual sales, according to \uc2 IMS Health\uc2 . Thirty-six of these pending ANDAs are potential first-to-file opportunities, representing $22.9 billion in annual brand sales, for the 12 months ending Dec. 31, 2012, according to \uc2 IMS Health\uc2 .\par \par \uc2 Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com\par \par \uc2 SOURCE \uc2 Mylan Inc\uc2 .\par \par \uc2 /\par \par \uc2 Document PRN0000020130716e97g000g8\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ Rexahn Pharm Files 8K - Regulation FD >RNN\b0\par\par\uc2 341 \uc2 words\par \uc2 15 July 2013\par 16:14\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2013, Dow Jones & Company, Inc.   \par \par \uc2 Rexahn Pharmaceuticals Inc\uc2 . (RNN) filed a Form 8K - Regulation FD Disclosure - with the U.S Securities and Exchange Commission on July 15, 2013.\par \par \uc2 On July 15, 2013, \uc2 Rexahn Pharmaceuticals, Inc\uc2 . (the "Company") issued a press release announcing that that \uc2 Teva Pharmaceutical Industries\uc2  ("Teva") has submitted an Investigational New Drug application to the \uc2 US Food and Drug Administration\uc2  for RX-3117, a novel oral small molecule chemotherapy agent. The Company has a Research and Exclusive License Option Agreement with Teva for the development of RX-3117, dated June 26, 2009.\par \par \uc2 In August 2012, the Company reported the completion of an exploratory Phase I clinical trial of RX-3117 in cancer patients conducted in Europe. The clinical trial demonstrated that RX-3117 is orally bioavailable and that no adverse events were reported over the dose range tested. A further Phase I clinical trial in cancer patients is expected to be initiated in the second half of 2013.\par \par \uc2 A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.\par \par \uc2 Information contained herein, including Exhibit 99.1, shall not be deemed filed for the purposes of the Securities Exchange Act of 1934, as amended, nor shall such information and Exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1228627/000114036113028098/form8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1228627/000114036113028098/form8k.htm  }}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1228627/000114036113028098/0001140361-13-028098-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1228627/000114036113028098/0001140361-13-028098-index.htm  }}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 July 15, 2013 16:14 ET (20:14 GMT)\par \par \uc2 Document DJDN000020130715e97f004fy\par }\page {\par\fs20\b \uc2 Pharmaceutical Companies; Breckenridge Announces Approval of Rizatriptan Benzoate ODT Orally Disintegrating Tablets\b0\par\par\uc2 284 \uc2 words\par \uc2 15 July 2013\par \uc2 Pharma Business Week\par \uc2 PHBW\par 45\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2013 Pharma Business Week via NewsRx.com    \par \par \uc2 2013 JUL 15 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- \uc2 Breckenridge Pharmaceutical, Inc\uc2 . announces the immediate \b \highlight22\uc2 launch\b0 \highlight\uc2  of Rizatriptan Benzoate Orally Disintegrating Tablets. The \uc2 U.S. Food and Drug Administration\uc2  granted finalapproval for the Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for this product on July 1, 2013, approximately nine (9) months prior to expiration of the pediatric-exclusivity period for the challenged Orange Book patent (April 1, 2014). Breckenridge's ANDA to Maxalt-MLT(R) contained a Paragraph IV certification patent challenge, permitting \b \highlight22\uc2 launch\b0 \highlight\uc2  after the 180-day exclusivity period of the first filer.\par \par \uc2 Breckenridge's Rizatriptan Benzoate ODT is manufactured and supplied by \uc2 Natco Pharma Limited\uc2 , the ANDA holder, and will be supplied in both 5mg and 10mg strengths. Rizatriptan Benzoate Orally Disintegrating Tablets are AB rated to Maxalt-MLT(R), a $200 million dollar brand drug marketed by \uc2 Merck & Co., Inc\uc2 . Maxalt-MLT(R) is a prescription medicine indicated for the acute treatment of migraines. Breckenridge and Natco also launched Rizatriptan Benzoate Tablets on December 31, 2012.\par \par \uc2 Breckenridge's patent challenge regarding Rizatriptan Benzoate Orally Disintegrating Tablets is a continuing part of its larger aggressive Paragraph IV strategy commenced a few years ago. Since the beginning of 2011, Breckenridge has filed twelve (12) Paragraph IV patent challenges and intends to continue that trend in the next several years, focusing on niche Paragraph IV opportunities with certain barriers to entry.\par \par \uc2 Keywords for this news article include: \uc2 Breckenridge Pharmaceutical Inc\uc2 ., Pharmaceutical Companies, Benzoates, Benzoic Acids, Carboxylic Acids, Organic Chemicals.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC\par \par \uc2 Document PHBW000020130712e97f0000n\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Actavis\uc2 ' generic version of Lamictal ODT receives FDA approval\b0\par\par\uc2 183 \uc2 words\par \uc2 15 July 2013\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2013. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Actavis\uc2  (ACT) announced that it has received approval from the U.S. FDA on its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application for Lamotrigine Orally Disintegrating Tablets, 25 mg, 50 mg, 100 mg and 200 mg, a generic equivalent to \uc2 GlaxoSmithKline\uc2 's (GSK) Lamictal ODT. \uc2 Actavis\uc2  intends to \b \highlight22\uc2 launch\b0 \highlight\uc2  the product immediately. As a "first applicant" to submit a substantially complete ANDA, \uc2 Actavis\uc2  may be eligible for 180 days of generic market exclusivity. While the company failed to obtain tentative approval of its ANDA within 40 months after the date on which it was filed, the FDA is not making a formal determination on \uc2 Actavis\uc2 ' eligibility for 180-day exclusivity at this time. It will do so only if another paragraph IV applicant becomes eligible for full approval within 180 days after \uc2 Actavis\uc2  begins commercial marketing of its product. Lamictal ODT is an antiepileptic drug indicated for the treatment of epilepsy and bipolar disorder. For the 12 months ending May 31, 2013, Lamictal ODT had total U.S.\par \par \uc2  sales of approximately $51M, according to \uc2 IMS Health\uc2  data. \par \par \uc2 Document FLYWAL0020130715e97f007vn\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw237\pich40\picscaley100\picscalex100\picwgoal3555\pichgoal600
47
4946383961ED002800F7000095A4CED1D8EA677EB88598C64964AAF0F2F8B3BEDCC2CBE33957A32A4A9CE1E5F1A4B1D5768BBF5871B1F2F4F9F9FAFCFAFBFDEA
EDF5E9ECF5F3F5FAFDFDFEDDE2EFFBFBFDF1F3F8F5F7FAFCFDFEA5B2D5E6E9F3F4F6FAE7EAF4E2E6F2FEFEFFF8F9FCF6F7FBD2D9EAECEFF6F7F8FBE6EAF38597
C6C1CAE2D9DFEECCD3E7DADFEEDEE3F0F3F5F9D3D9EAC9D1E6CFD6E9C3CCE3EFF1F86077B5CED5E8EEF0F7EEF1F7E8EBF4FBFCFDFDFEFEDAE0EEC0C9E2D4DAEB
FCFCFDA9B6D85F76B5B7C2DEB0BCDBCDD4E7D4D9EA9CAAD1F6F7FA697FB9697FB85E75B5D0D6E9C6CEE4C5CDE4E3E7F2D4DAEAD9DFEDBCC6E0BEC8E1BFC8E162
79B7FAFAFDC6CEE5677EB9EFF1F7E4E8F2D1D7E9A0AED3ACB8D9EDEFF6B7C1DDCBD3E78597C7B1BCDBB5C0DDE5E8F29BAAD0788CC08C9DC9DFE4F0FEFEFED3DA
EBD8DEEDAAB7D86F84BDE2E7F2E3E7F1E0E5F19BA9D0FAFAFCA6B3D5D9DEECF3F4F9B6C1DDBAC4DF657BB79AA9D0EBEEF68394C5BEC7E1E0E4F092A1CCC8D0E5
D7DDED8496C6DEE3EF97A7CF4F69AEA6B3D6CAD2E6B2BDDB7387BEC4CCE3C5CEE4DBE1EF1B3D95FFFFFF00000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000021F90400000000002C00000000ED0028000008FF0013091C48B0A0C18308132A5CC8B0A1C38710234A9C48B1A2434418336ADC88
9180018B20438A1C49B2A4C98B1C536EFC78B2A5CB97306356544913A300993873EADC4932E381850508606CC0B3A8D1A34805FA6408002302824D392E10B840
E5D4444237264834206500810D38DE14D875E3538109080CCCBA516DA20088880E2C8068ECC0A6080A10EC0AA0A101AF6401C3E5C820D10144670722C89B4800
22BD5839BAFDCBB12F578E891B2E5D18357353968914D415E8F8EB40B885239BDE8BC87241D103A0BA46E056A0810190D30A846B973422056F3B024F44B77701
048E630FE4DB90C1E3D3034C33370857B940045B2FBB6E7AD5B15EDE0485EAFFFDDB9B206D82B7216BC6F893B353A888408B1E5B9A2078D506A7BF4E993A1102
C903E9165C79F5C115560253154710030914D0D56AFA29E49C56C345781A22D6F9979D867A15206063CFDD67DB40E421F45F5B106DA65067F049E5DB6A030AC4
1622106A541B581C6D58D646A60928E28BC10110C07F0C28B85B6BC49D17986B0A51B691653B2272E3601BF557A273AB7917E35D2C3989917A977104E3422A22
14D450F07DE4587F20C2789F50636A77500002C0A8A5834C7E86965B3FB6192471610965D78C18418924531956B7E49C1826D254036082D854865AFE285E2225
1A84679A0FD544536F7A82281788FCC948637E871654558E02890658223ED2FF041C5CAE953556533012C0988526A6642893172AD71401C309E421626056AAD2
78A319E4AA989D7A9A12688EC63790630D7CB52A47EDC1892A471F9D59E5B500EEB9564A72D18A5E02372990C0A8B68D1625461B161495460954386D70D6E175
95404D01AB6564E3629A92728EA118ADB41979945444197C9088044008B447060F67ACB152EC6D5C9206122412410F89E0B0000F1EA76C54992A5784C6082304
92C8066D2472430D5B60DCF2CE2FB1CC734312D49188204D2472081B6468108708737C81C1CF509BE473D409451046222FB4F080098984B0C1CC1780E042000A
A040F5D9144D8D76412CA49008160E20F4801A0E4C40C2DA78A384487B7917FF5404173688914810712B9482191D4CD0F7E206A98DF7090E5050881B0E718001
058C67AE794249B04088160505302122091499881D397420C5E6AC6F1EC11128DB5B97690B1090C04F17385078EBBCAFDD0715893CA082EC7C0FC440612358D0
FBF2689F8144224CF840908719326FFDE255C84044417F157BD061FF56BBD15487695458F919C15BED704D01179646E15F2F7F225618B13BC0F57E8F48F8CE11
846455C359405FC057908C28A07D00FB4D221A901804006B7ECC03041C1271872140257F0621A0F110E1BF016E8428E8CBCC5D14B8BE058E0F82F34B43051261
0830A0E73909D1A040FA3790FFB986014F91A14110584206A2F0870389C209ED0AE2A10712047D85BA5746A6A2C4B818E683DC330B58440844F979A10230F000
7C8A37C3D4604079550CA34E0661B637CC40760208A0ED0E70831C948003628CA34CBAE0841AF8E17B09239DE91211031AC0518E807C8910E85086315C80210F
A8800226F080403AF22410800005B20001857CC0011798C0D31EC94992FC410E8930010D9E3005835040793B78410942D6C9568224040FC0811220B0060F64C0
051D48041F1261831F8820046074A5304182871D2442061158420B40A003155452042B88C030A75911287C250F2B488406B4A883195C819AE004C907F4008244
C0608524884138D7C9CEA80504003B}}
\par\par \b \uc2 Breckenridge  \highlight22\uc2 Launches \highlight\uc2  Rizatriptan Benzoate ODT (Orally Disintegrating Tablets)\b0\par\par\uc2 269 \uc2 words\par \uc2 15 July 2013\par \uc2 Professional Services Close-Up\par \uc2 PSVCLU\par \uc2 English\par \uc2 (c) 2013. Close-Up Media, Inc. All rights reserved.   \par \par \uc2 Breckenridge Pharmaceutical, Inc\uc2 . announced the immediate \b \highlight22\uc2 launch\b0 \highlight\uc2  of Rizatriptan Benzoate Orally Disintegrating Tablets.\par \par \uc2 According to a release, the \uc2 U.S. Food and Drug Administration\uc2  granted final approval for the Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for this product on July 1, approximately nine (9) months prior to expiration of the pediatric-exclusivity period for the challenged Orange Book patent (April 1, 2014). Breckenridge's ANDA to Maxalt-MLT contained a Paragraph IV certification patent challenge, permitting \b \highlight22\uc2 launch\b0 \highlight\uc2  after the 180-day exclusivity period of the first filer.\par \par \uc2 Breckenridge's Rizatriptan Benzoate ODT is manufactured and supplied by \uc2 Natco Pharma Limited\uc2 , the ANDA holder, and will be supplied in both 5mg and 10mg strengths. Rizatriptan Benzoate Orally Disintegrating Tablets are AB rated to Maxalt-MLT, a $200 million dollar brand drug marketed by \uc2 Merck & Co., Inc\uc2 . Maxalt-MLT is a prescription medicine indicated for the acute treatment of migraines. Breckenridge and Natco also launched Rizatriptan Benzoate Tablets on December 31, 2012.\par \par \uc2 Breckenridge's patent challenge regarding Rizatriptan Benzoate Orally Disintegrating Tablets is a continuing part of its larger aggressive Paragraph IV strategy commenced a few years ago. Since the beginning of 2011, Breckenridge has filed twelve (12) Paragraph IV patent challenges and intends to continue that trend in the next several years, focusing on niche Paragraph IV opportunities with certain barriers to entry.\par \par \uc2 Breckenridge is a privately-held pharmaceutical marketing, research and development company that markets a broad range of generic prescription products and Medical Foods in many therapeutic categories.\par \par \uc2 ((Comments on this story may be sent to newsdesk@closeupmedia.com))\par \par \uc2 Document PSVCLU0020130715e97f0009q\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw112\pich40\picscaley100\picscalex100\picwgoal1680\pichgoal600
47
494638396170002800E60000004A8E5989B62B66A19BB8D300146DE3ECF3ABC2DA326BA4F5FAFCB8CFE16487B5DAE9F11C5B9A739BC13B73A9A5BAD5D7E3EEFA
FEFE26619EB3C7DD4677AB135193D3DCE9004D900041896792BC013A855475A996A9C9CCDBE9EDF5F9015294002B7B175B99215C9A7AA3C6134D91899CC13658
98193B85E9F0F68BABCB7794BD0B448B17468C83ABCB456CA4F1F6F9BFD3E4E4F4F818539599B0CE386DA600448A013481233A8500478C718CB80D4C9009498E
001F74EDFAFC002F7EE5EFF5CED4E521478D37609C8BB0CE2B5E9C8398BF90A1C544599980A0C54B639E82A5C8CCDFEC07478C1A5998172779234D91C8CFE12B
51931F609CC5DAE80026785B7FAF556AA2093A85C2C6DC3167A26C78AB3B66A1C0D7E7013E8704418920509305448B0D35820B2E7D364D91CAD8E71758973040
890F1D7010559688A5C82D70A7222C7B004088396FA70005625181B191B2D00D40891B5697EEF2F70924772757974B7EAFC9E6F0E8F8FBDFEFF59FC0D903448A
E1E6F0403C84366FA7FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633133382037392E3135393832342C20323031362F30392F31342D30313A30393A30312020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A31333464646664372D333863352D343931342D393763642D6536323166353162393836332220786D704D4D3A
446F63756D656E7449443D22786D702E6469643A42434235393642363343433231314538424441434143323846354633383935442220786D704D4D3A496E7374
616E636549443D22786D702E6969643A42434235393642353343433231314538424441434143323846354633383935442220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313720284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265
663A696E7374616E636549443D22786D702E6969643A31333464646664372D333863352D343931342D393763642D653632316635316239383633222073745265
663A646F63756D656E7449443D22786D702E6469643A31333464646664372D333863352D343931342D393763642D653632316635316239383633222F3E203C2F
7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFD
FCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBD
BCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D
7C7B7A797877767574737271706F6E6D6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D
3C3B3A393837363534333231302F2E2D2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F9
0400000000002C00000000700028000007FF80026521650C522188884D87898452528388858C9265520C918E94848B8D8E0C8D6522908993A196A0A58F99658B
A9928FA18684026817353A5965350017381812123800C41872073A3817B74C82C3BE35120238CA00181559C9BD354C590CBCC4350C124CBDD6150715BCBECDDF
CBD622593BD5B85915CAB7350222CF00354D02983CC3A0E3009A616842D4D87140C43A006C24C81B664D461B19EBB86511D6EB978403F32E9CA3212723930302
6A54C3C000D9CA0A6D9AACC3D18CA32F0C22DAE800878B64C63D02048059D9C4A54882341C12235450049B8E110F300187C1620536CBB81D9080A163341A606A
2CBBE60063D69302BA8A6423C2CF0EB1E7FF1CC8E9D2114C16017BA0E6DC9955871F3918B2DA15E0852832B117083A1041576488261B9FFA8AE867EA51AB586F
813940C44B470C52A43E05D08544D92EC3306C16D0A5711711A2C75638BDCDCB5D2F544538D08141250EBF7224D7F022200B866A6C9AF8E10B51C7E2C6D44230
403393F2D45E55DB54089C588784153CA880C0C0A48C8E3D357C80A062034D05F5EB41A03960833D081F521C84E1E1838A0F190EB0C0C3051FD440451D6AD4D7
1F154DEC660308F5D9E0871436F850CC0E6558465A133A21C686732268E095250A41254165DC5D43830CDC71F3110523B4E0021568BCF1461732B4D0C01B030C
E05C0B1928F0801220D091010C2AACC0C0FF0E4264D0420E41348106116F5CA0811719D861431D01B450C4163ABC27460606CCD0461C1A48F106001A1C800411
1A88D4851C0E90C0DD878B89F8010E6C04D5440826B6C1448A30B178961F1A54F187056420A042176FF450C70913F0F1071F09301000141144B004123C341081
012FC0B01F177F60814002E0C1F1030B6EB8F0470604CC906A01085441800D03FC31010A2F3CC1430605A0C186037F703060170DDA39168874EDD9C547E501EA
118AB25DA4163734084040117F1CE186AA363880C016E1A9F0C706037A4107107C884185097F94E0461A7F5841C012069C4141040AB831C0025EF8E007020D10
F0EB155F2C3105011BFC91030F24F03101FF010AA0E0000651FC31030FCCD69919063BB4C15847D31E101622D69C38E85824B401D836274950030FE08E410012
7380E1800744D8D00505EB125083061AC00004153C2421B11B22E8B105151D4CD04518733CE0C6100550A8C30F09CFF0830EC32E00420E7F4CCD430E23D04101
0A6D50D1B11104349BD9427E9C3C19B56211B207DFB2AD080E4D5B754585BA148010C00F4C383087411A58F1870220E8A383011660A041184B2CE1030F1A6060
43070910E0C41F46B8D102024410408207093FF08318048C000115689B00C2075D6860430305784180191194E083C8DB30C4805A7C0A20155C8F496459628532
DF0D57CAACFD870B0A7BE0C3BF5568C043FFC4555021800420180081066CB0F1EF046280DC85051D68318301715031F00A04C8E04106549840019E6082511100
0E08F802847800820B200105346081152200071CD8297907F8C6678A139665E0403A22B845B630420C1CEC200B2238CE3278A0803F00010805A0000FDEF0822D
80000411DBC00EF0E2830958C0062DA1C2113C00812080A00C309803145E900210306102106042FF5090021BA4E1050BC81A0B343080089CE00A70484300E240
0104A0800F28F803122A87410DFA022859408F0775008A7E5C435B1D69865244723425A0AE0A4D0041171A300722A827620D500D0E6C30810E9040003B10DF13
16000111F8A003067042107EF0002AA4A0FF00FC23C10F52C083194060031E78830D6AD0803F9C200C5D5CC219EC80020A3CA1854518D02D94373838CA313165
D807A02E834776A07026C0F082BAC6003A1DA021031EC8827A2497032A28C30706E0431976E08530E0800092D355D58A340120F04009A02400111040AB0740C0
0964E8407F94108127F827010B70421582C7832CA08E0A89511EF37C0997AAD0A0028320268B68B611649E487B4200013A86F6822C88076D1B682000B0C907DF
1D20014250670432C0034CD2E10A4AE3C11020F03901BC2076F11A41015840801678F10A1A30000AF45900484601011CA002C9F236D0E2A8102232F0833A5856
95B208E77A79B9890468B0039CFDC1041AFFF0830C7C40432280000019F84315BECA062F58C0021AF081ACECB585C911C0027AF0010B16000502B492086E686B
000820BB0A0801756E68A10278C00328C87203B5A4C218924500BFA4B02340494B35E6E480ED000011D991C1DD362301CF4895062BC0010F8C90363904C70601
F08000481087882940A80CA840070A80341BE821024800420F9E40800EFCE10130F0000508F0D305E4000231E0ED042210073A4C610954A003AA8A6080080C37
033F68020FE8A5ACE74056227B982C9DAEB20C4260E62C28290C34A63A950FD8600B0FB0C35B1223801450000D2010821EB20082B65C210023C00006BAC08007
E0810B51A082064690001818C0053ED843FF17DA00831E4CC09E714082127AE70738D401471C88C102D8C5820CA4C14A3248411544E014007C0000BEC4C18B29
7B958E14421023EB820088102D6B30200B2BE0450D7A538632F4AE2BD70811352054949D54A8062450431C40D71F26A88104E1518F0624A0062A10C07754708E
0E40308CF570D906A0437305A4FCD50F68800A2190401754326011E08518BE2B03052AD0050F7E30046F814A05C04305F6EC410415608F9B41A7063430B04220
78447F6C00001B5CE1033EA046A1652080377B990756C672A1A9A0E303C487003C98CDF2E043EA82B917D55210C0E77CF0010C44387417500F153CD3E737FBC0
0B158803627021011184E01935B001051EFF908614A4400157685C03D240011FD861002920020FA29086090C40013B28D7001AA08127E861008913808EA44001
0DB7000E0D38000682A08404E8C1052B38800FA230002E0C40085F68C280DF900225C0E10133B043170230EE3AD000092978830F4800070334200E2C1881B30D
900209F8E00A2A98000C7220C802AD800612904308B2328F3744E00F308F00192AF00504FC960043F8031E6E208629C0FC0F08D840EDFED083281CE1E53D5883
A2681B809FC3FC085480C1CF3DA0021E08C1E63F7700997D0004A7FF61003630C01FA67006B42D4A7130EF8119CC807598BF810E62FF39127CA00126A0BC0609
255C1C84E0013566E0057F38C009E6803AFF1EE8E10F0B10430B110681450DEB0F1138C209F20073131C00011040FB0BE0908211680F010A20830B55FA8704BC
A1F170A03B1BEC30044B8D720B61FF83010860F60234A1953A37C30D62E02B1534400644F8C3FF52407413F0C00F36FB334DEE62F5BE1FC1060BF8831D4E5080
3FA440030FF803046C00AE39ACC1050998810FC21A831BDC80F27F68801D5EF0C3A67B807BFD81C31F0AE0840D24800339FD3A0B21308238D0650757D02B5C00
026ED030B2B7362F870202807B79700263607301E00685D6740DB80677600026F005C9770184703D3500025BD0772E200269E40771507D1FD3028827065A0073
45400727E503AD547EBB077309F077ED07FF74426720EAE23162400796D62BB3420074B003B7506C62907D53501F02E05B0680807F30076F9073C2570726D077
00F46B4D277B61400057A0065270548F713EBC00827D47492F9006364002D5473739B700611005BC372AC2B202B6428331800073300703800016E0034D17017C
C0077BF505D1277BF6C4553F370361604D41E1055720766480067B000613207B181301C0024508D0296330797FF00316300015C00252B72842100765400D22F1
41527010BD905F7DF7022FF03F54200384E786F3E70754B00196327F5BB0607F40833D600170300780D7013610567F00780DC00336A000D5377F86440245F072
7F400641F048831289DA97053C80527FA0FF075695008D87020FF0023B5783088000301007205007BE0573002416D4800687D00F54E00236B762D517004D9046
BA380734C00304100409007350F07834E88707308F64A00348207C0A100415606C3C700209F90730200257E00644D0785F4702228203DEB80455B5025297001A
002E157729F4D403E6C77B03B022FEC00362602BDAF7043E708402000A75C1066F607349D05BB2F70596622F2A58442BE000271040DA875A7F90072C402F1E40
027117454D170363E0062BA006592078E9337F0CF0050E40079CF3071D700236700B6120765370337120755CA078113002616501ADB48EBC472B3C500321E007
4F60031C00731B4005D19005D522552440FF043FF00749C0034BF00770307880A5820BA00185C90567002E10C0064D870042C002BC770355F0721D807631607C
632676B2A42816000097C801F7F2074B100471A2012420751D205A5790907A407B11D0007EF0072D40033A677E94B757FD11567960037D60983CC03788E01171
73043637032960732A7006A8020169107D30400025007329207A164005618500BA87077F60062BF0982C159A133001091006E5F90745909040000287370501E0
5B7A10061A500315C00009B90452C4023E37013CA02E29200008F0067FB5736CA7963D92056DF5024850983F100571E0071D4408C040553CE002D8087330C002
FB984631F706041007F3287C42B7973740FF3C57A50193C907E3E7755640051B297CBAB20584077335E403C9910594A2965DD04FD1573AEA020375F00314D056
1EF0044EE374231006419A7ED1305F1CD804EC55033520036FD00070A0021B802638000214900270A0045EA50138B0051910A733B202671A002BB0020110004A
950519F0066CC0004AA0040A90011910023CF0052D30004AE00236800120D0064300A975E00304A6131A40010D40014C20014DE0A914B0256274050E80066590
030D40032410008A9AA801C00461A0000330042EB00352C01B1E640912C0AB6E466B6F062100B003120006FEA11E362001FA91AC54B00375C21F2FC6033BB403
EAE10350A603FD711F6C400232A00137E4FF0324F3ABE2711F1AC021242016E22306C8D705CA8A03DB64038B74343E8006C6724385E64C9586AF5EB0ABC3B603
75840FDDAA55742A127B701760206035C016BB41671AE0174DC006BC8003D38217F6382754851AA4B10213D21ABC0006C5C1046CD01B18C02196951827A13747
E33C1D8454CB411710611B2DB6275BE21629C269C6860F18601A02E7158F881CBAA10399F11B7ED0B393C1B288610CCBF1AF26A31630561CE1B50C6C305EDBB2
037923197C0238155159C2C159510B632E43282B3208E10013C1610E3810144371147BC11DBF7100320159503B6C724003CCD1134E510D38200D6BEB0F72A01D
CCD314CC130DCFC347327050D65338D5F0843785EB0F8502986800006F1BB1682B05C7AAB7C7C0AB22B143462BB9D2F04B38800D3BD11127F45825C40001410F
E870B20010AA8FC547F1A021A16B0F6E9BB652A012AD0819D3F3B6248406821002ABE00952D00491300897C00AC12B09E340BCAA400ACA0B099900BCCC9B08C9
8B088610BDD21BBDD56B09D09B08AE80BCA4104C8100003B}}
\par\par \b \uc2 Mylan  \highlight22\uc2 launches new product \highlight\b0\par\par\uc2 Kris B. Mamula   \par \uc2 167 \uc2 words\par \uc2 15 July 2013\par \uc2 Pittsburgh Business Times Online\par \uc2 PITBJO\par \uc2 English\par \uc2 \u169\'00\'A9 2013 American City Business Journals, Inc. All rights reserved.   \par \par \uc2 Mylan Pharmaceuticals Inc\uc2 . has \b \highlight22\uc2 launched\b0 \highlight\uc2  two strengths of fenofibric acid delayed-release capsules, a generic version of Abbott's Trilipix capsules. Release of the product follows Food and Drug Administration approval.\par \par \uc2 The drug is used with dietary changes to control high cholesterol and also with a statin drug to prevent heart problems in some patients. The two capsule strengths had U.S. sales of approximately $553.6 million for the year ending March 31, according to Danbury, Conn.-based consultant \uc2 IMS Health Inc\uc2 .\par \par \uc2 Mylan has 174 applications pending FDA approval, representing $83.2 billion in annual sales, according to \uc2 IMS Health\uc2 . Thirty-six of the pending applications are potential first-to-file opportunities, representing $22.9 billion in annual brand sales for the year ending Dec. 31, 2012, according to \uc2 IMS Health\uc2 .\par \par \uc2 Did you find this article useful? Why not {\field{\*\fldinst{HYPERLINK "https://secure.bizjournals.com/subscribe/selectTerm?market=pittsburgh&ana=cstpd&csrc=6355"}}{\fldrslt{\cf2 \uc2 subscribe}}}\uc2  to Pittsburgh Business Times for more articles and leads? Visit bizjournals.com/subscribe or call 1-866-853-3661.\par \par \uc2 Document PITBJO0020130715e97f0002v\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Natural Quit Smoking Aid Nicotame is Released by Defiant Innovations, LLC\b0\par\par\uc2 595 \uc2 words\par \uc2 11 July 2013\par 11:00\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2013  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 \f2 \par The Revolutionary \f28 \b \highlight22\uc2 \f2 New Product\f28 \b0 \highlight\uc2 \f2  Helps to Alleviate Nicotine Withdrawals through a Combination of Vitamins, Minerals and Amino Acids \par  \f28 \par \par \uc2 \f2 NORFOLK, Va., July 11, 2013 /PRNewswire-iReach/ -- Defiant Innovations, LLC, a supplement company that offers top-notch products that provide solutions to common problems, is announcing the \f28 \b \highlight22\uc2 \f2 launch\f28 \b0 \highlight\uc2 \f2  of a natural quit smoking aid called Nicotame. The product takes a unique approach to helping people quit smoking by curbing nicotine cravings.\f28 \par \par \uc2 (Photo: {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20130711/CG45936"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20130711/CG45936}}}\uc2 )\par \par \uc2 In honor of the 4th of July, Defiant Innovations is currently running a special promotion called "The Independence from Smoking Sale." Throughout the entire month of July, Nicotame is available for just $27.00, instead of its regular price of $37.00.\par \par \uc2 As anybody who has ever tried to quit smoking knows quite well, it can be an incredibly difficult thing to accomplish. Nicotine cravings can be constant, and often leave people feeling stressed, crabby and overwhelmed. Even prescription medications, gums, patches and other approaches don't always make it easy to quit smoking; in many cases, people resume smoking after a matter of days or weeks.\par \par \uc2 Thanks to Nicotame, people are finding they have a fighting chance to quit smoking naturally. The secret is in the innovative combination of ingredients that are found in the product. In order to help people overcome their withdrawal cravings for nicotine, the stop smoking aid alleviates these often-overpowering urges by introducing a variety of vitamins, minerals and amino acids into the body. These are the very nutrients the nicotine in tobacco typically displaces from the body.\par \par \uc2 "The problem is nicotine messes with your brain's reward system and wreaks havoc on your brain's circuitry by posing as an important neurotransmitter called acetylcholine, which disrupts several others, namely dopamine, serotonin, and norepinephrine," an article on the Defiant Innovations, LLC website noted, adding that these chemical messengers are directly responsible for the "feel good" sensations people experience after doing certain things like eating and exercising.\par \par \uc2 "On top of that, nicotine destroys supplies of vitamins and minerals necessary to manufacture neurotransmitters, making your brain dependent on nicotine...since the brain essentially thinks it is one."\par \par \uc2 Fortunately, the article noted, endless nicotine cravings can be significantly reduced thanks to the natural ingredients found in the Nicotame quit smoking aid. By supplying needed nutrients like niacin, L-theanine, L-tyrosine, riboflavin, vitamin C, gamma-amino butyric acid, and many more, the body can begin to restore the brain's natural reward system.\par \par \uc2 Anybody who would like to learn more about Nicotame is welcome to visit Defiant Innovations' website at any time; there, they can read about how the product works, its various ingredients, and positive reviews from former smokers who successfully used Nicotame.\par \par \uc2 For example, Erin G. from Norfolk, Virginia, wrote in her review that Nicotame was "amazing," and helped to cut her almost pack a day habit down to four or less cigarettes--in just three days.\par \par \uc2 "Thanks to Nicotame I finally quit smoking," she said.\par \par \uc2 About Defiant Innovations, LLC:\par \par \uc2 Defiant Innovations, LLC is a dietary supplement and information product company with one goal: redefine mainstream solutions to common problems by offering innovative alternatives. Defiant Innovations, LLC was founded in February 2013 and is based out of Norfolk, Virginia. For more information, please visit {\field{\*\fldinst{HYPERLINK "http://www.nicotame.com/"}}{\fldrslt{\cf2 \uc2 http://www.nicotame.com/}}}\par \par \uc2 Media Contact: Waylon Coulter, Defiant Innovations, LLC, (949) 555-2861, waylon@defiantinnovations.com\par \par \uc2 News distributed by PR Newswire iReach: {\field{\*\fldinst{HYPERLINK "https://ireach.prnewswire.com"}}{\fldrslt{\cf2 \uc2 https://ireach.prnewswire.com}}}\par \par \uc2 SOURCE Defiant Innovations, LLC\par \par \uc2 Web site: {\field{\*\fldinst{HYPERLINK "http://www.nicotame.com"}}{\fldrslt{\cf2 \uc2 http://www.nicotame.com}}}\par \par \uc2 Document PRN0000020130711e97b000dw\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ \uc2 Rockwell Medical\uc2  Files 8K - Other Events >RMTI\b0\par\par\uc2 235 \uc2 words\par \uc2 11 July 2013\par 16:51\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2013, Dow Jones & Company, Inc.   \par \par \uc2 Rockwell Medical Inc\uc2 . (RMTI) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on July 11, 2013.\par \par \uc2 On July 11, 2013, \uc2 Rockwell Medical, Inc\uc2 . (the "Company") issued a press release announcing top-line results from the long-term CRUISE-1 Phase 3 efficacy study of SFP. SFP is the Company's late-stage investigational iron-delivery drug for the treatment of iron deficiency in chronic kidney disease patients receiving hemodialysis. This long-term study is the first of two identical Phase 3 efficacy studies to provide clinical data required for the Company to file a New Drug Application with the U.S. FDA. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1041024/000110465913054095/a13-16516_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1041024/000110465913054095/a13-16516_18k.htm  }}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1041024/000110465913054095/0001104659-13-054095-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1041024/000110465913054095/0001104659-13-054095-index.htm  }}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 July 11, 2013 16:51 ET (20:51 GMT)\par \par \uc2 Document DJDN000020130711e97b004dc\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ Cempra Files 8K - Entry Into Definitive Agreement >CEMP\b0\par\par\uc2 755 \uc2 words\par \uc2 9 July 2013\par 16:41\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2013, Dow Jones & Company, Inc.   \par \par \uc2 Cempra Inc\uc2 . (CEMP) filed a Form 8K - Entry Into a Definitive Agreement - with the U.S Securities and Exchange Commission on July 02, 2013.\par \par \uc2 On July 2, 2013, \uc2 Cempra Pharmaceuticals, Inc\uc2 ., our wholly owned subsidiary, entered into a development and supply agreement with the One2One contract manufacturing group of Hospira Worldwide, Inc. whereby Hospira will assist us in the development of an intravenous form of solithromycin (in glass vials) and will provide our supply of that product for development purposes. If we receive regulatory approval for such form of solithromycin, we will purchase from Hospira at least 80% of our and our affiliates' requirements of such product for commercial sale as a human pharmaceutical product in the United States, the \uc2 European Union\uc2 , Canada, Norway and Switzerland (the "Territory").\par \par \uc2 We will pay one price for clinical supplies of solithromycin and another price for commercial supplies. Beginning in 2014, Hospira may increase the price of the product for commercial use once annually by the increase in Hospira's manufacture of the product or the annual increase of a specified inflation index. The per unit price of our commercial supply will decrease if we purchase specified volumes in a given year. Additionally, we will pay Hospira certain development fees, with specified amounts becoming payable at defined stages of the development of the product.\par \par \uc2 Each year during which we or our affiliates commercially sell the product, we are required to purchase a specified minimum percentage of our forecasted amount of product required for that year. We must supply Hospira at no cost the active pharmaceutical ingredient for the product. If Hospira fails to supply a specified percentage of product, we may purchase all or a portion of our or our affiliates' requirements of the product from an alternative supplier until Hospira remedies the supply failure. However, if Hospira's failure to supply the product is a result of our failure to supply Hospira with the active pharmaceutical ingredient for the product, we will remain liable for the purchase order, regardless of whether Hospira produces the product.\par \par \uc2 Unless earlier terminated, the agreement will remain in effect until the end of the third year after we, our affiliate, or our licensee first commercially sells the product in the Territory. Thereafter, the agreement will automatically renew for an indefinite period. Beginning one year after our, our affiliate's or any licensee's first commercial sale of the product in the Territory, either party may terminate the agreement at will upon 24 months' notice. Prior to the completion of the development of the product or the submission of an application for regulatory approval in the Territory, either party may terminate the development project or the agreement if such party determines the development of intravenous solithromycin under the agreement is not clinically, commercially or technically feasible. Either party may terminate the agreement if the other party becomes involved in bankruptcy, insolvency or similar proceedings, materially breaches the agreement and such breach remains uncured for a period of 60 days following notice of the breach, or is unable to perform its obligations for 180 days by reason of force majeure. If we or our affiliate licenses or grants a third party exclusive rights to sell, offer for sale, or otherwise commercialize the products in one or more countries, we may terminate the agreement in respect of such products and countries upon 24 months' notice given at any time following the end of the first commercial year.\par \par \uc2 The development and supply agreement is otherwise subject to such terms and conditions as are reasonably customary for supply agreements of similar type. The description of the supply\par \par \uc2 agreement with Hospira provided above is qualified in its entirety by reference to the full and complete terms contained in the agreement, which will be filed as an exhibit to our Quarterly Report on Form 10-Q for the quarter ending September 30, 2013.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1461993/000119312513286118/d565651d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1461993/000119312513286118/d565651d8k.htm  }}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1461993/000119312513286118/0001193125-13-286118-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1461993/000119312513286118/0001193125-13-286118-index.htm  }}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 July 09, 2013 16:41 ET (20:41 GMT)\par \par \uc2 Document DJDN000020130709e97900496\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Tria Beauty\uc2  Completes New Equity And Debt Financings\b0\par\par\uc2 592 \uc2 words\par \uc2 9 July 2013\par 07:41\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2013  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 \f2 \par Proceeds to Fuel Multiple \f28 \b \highlight22\uc2 \f2 New Product Launches\f28 \b0 \highlight\uc2 \f2  and Expansion of Distribution \par  \f28 \par \par \uc2 \f2 DUBLIN, Calif., July 9, 2013 /PRNewswire/ -- Today, \f28 \uc2 \f2 Tria Beauty, Inc\f28 \uc2 \f2 . announced the closing of $45.5 million in new equity financing and a new structured debt facility. This latest round of equity financing was led by \f28 \uc2 \f2 Bay City Capital\f28 \uc2 \f2 , and joined by new investors, AmorePacific Ventures and Athyrium Capital Management. All major existing investors including Aisling Capital, DeNovo Ventures, Morgan Stanley Alternative Investment Partners, \f28 \uc2 \f2 Vivo Ventures\f28 \uc2 \f2  and Technology Partners all participated in the equity financing. These funds will be used to \f28 \b \highlight22\uc2 \f2 launch\f28 \b0 \highlight\uc2 \f2  multiple new laser devices for skincare, including the company's first device in the largest skincare segment - anti-aging. The funds will also allow the company to selectively expand distribution and accelerate its growth and operating plans.\f28 \par \par \uc2 "We are thrilled to welcome \uc2 Bay City Capital\uc2 , AmorePacific Ventures and Athyrium Capital as new investors, and appreciate the continued and unwavering support of our existing investors. This new financing reflects investor confidence and support of the company, our breakthrough skincare products built upon a proprietary portfolio of medical laser technologies, and our team's ability to build the Tria brand and drive consumer adoption and advocacy," commented \uc2 Kevin Appelbaum\uc2 , CEO of \uc2 Tria Beauty, Inc\uc2 . "In less than five years and in the midst of a troubled economy, Tria has grown from a nascent start-up generating its first revenues to the world's largest marketer of medical lasers for treating multiple skincare concerns. This financing will provide Tria with capital needed to continue to create breakthrough skincare products that deliver results never before available outside of a physician's office."\par \par \uc2 "\uc2 Tria Beauty\uc2 's high growth, professional-quality products and excellent management team attracted us to this global business. We are excited to support the company as it introduces multiple new products into large market segments worldwide," said Dayton Misfeldt, Investment Partner, \uc2 Bay City Capital\uc2 .\par \par \uc2 Tria Beauty\uc2  also announced today the completion of an up to $45 million structured lending facility provided by Athyrium Capital. This new debt facility refinances existing debt and provides incremental, non-dilutive capital to the company. Wedbush Securities acted as strategic advisor to the company in the debt refinancing.\par \par \uc2 "We have been investors in innovative companies bringing disruptive medical technologies and services to the market for some time. We see in Tria a unique combination of best-in-class technology, superior product design and a management team capable of scaling Tria into a dominant, global skincare brand," said Dick Pines, Partner, Athyrium Capital Management.\par \par \uc2 About \uc2 Tria Beauty, Inc\uc2 .\par \par \uc2 Tria Beauty, Inc\uc2 . creates laser and light-based skin care products that deliver professional results at home. The clinically proven Tria Hair Removal Laser is the first and only FDA-cleared hair removal system available for at-home use. It is also the only at-home hair removal device on the market that uses diode laser technology, the same leading technology used by thousands of physicians for delivering safe and effective hair removal in-office. The Tria Skin Perfecting Blue Light treats the bacteria in the skin that causes acne, and is clinically proven to rapidly clear acne breakouts and improve overall complexion. The Tria Skin Rejuvenating Laser treats multiple signs of a facial aging, is \uc2 Health Canada\uc2  licensed and CE marked for sale in Europe. Learn more about \uc2 Tria Beauty\uc2 's devices and other skin care products by visiting {\field{\*\fldinst{HYPERLINK "http://www.triabeauty.com"}}{\fldrslt{\cf2 \uc2 www.triabeauty.com}}}\uc2 .\par \par \uc2 Contact: Megan Driscoll\par \par \uc2 Behrman Communications\par \par \uc2 212-986-7000\par \par \uc2 SOURCE \uc2 Tria Beauty, Inc\uc2 .\par \par \uc2 Web site: {\field{\*\fldinst{HYPERLINK "http://www.triabeauty.com"}}{\fldrslt{\cf2 \uc2 http://www.triabeauty.com}}}\par \par \uc2 Document PRN0000020130709e9790003t\par }\page {\par\fs20\b \uc2 Pharmaceutical Companies; Mylan  \highlight22\uc2 Launches \highlight\uc2  Generic Micronor(R) Tablets, 0.35 mg 28-Day Cycle\b0\par\par\uc2 376 \uc2 words\par \uc2 8 July 2013\par \uc2 Pharma Business Week\par \uc2 PHBW\par 89\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2013 Pharma Business Week via NewsRx.com    \par \par \uc2 2013 JUL 8 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- \uc2 Mylan Inc\uc2 . (Nasdaq: MYL) announced that its U.S.-based subsidiary \uc2 Mylan Pharmaceuticals Inc\uc2 . has \b \highlight22\uc2 launched\b0 \highlight\uc2  Norethindrone Tablets USP, 0.35 mg. Norethindrone Tablets USP, 0.35 mg, are the generic version of Janssen Pharmaceuticals, Inc.'s Micronor(R) Tablets, 0.35 mg (28-Day Cycle), which are indicated for the prevention of pregnancy. Mylan's partner, \uc2 Famy Care Ltd\uc2 ., received final approval from the \uc2 U.S. Food and Drug Administration\uc2  (FDA) for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for this product.\par \par \uc2 Norethindrone Tablets USP, 0.35 mg, had U.S. sales of approximately $57.2 million for the 12 months ending March 31, 2013, according to \uc2 IMS Health\uc2 .\par \par \uc2 Currently, Mylan has 176 ANDAs pending FDA approval representing $83 billion in annual sales, according to \uc2 IMS Health\uc2 . Thirty-four of these pending ANDAs are potential first-to-file opportunities, representing $22.5 billion in annual brand sales, for the 12 months ending December 31, 2012, according to \uc2 IMS Health\uc2 .\par \par \uc2 Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com\par \par \uc2 Keywords for this news article include: Pharmaceutical Companies, \uc2 Mylan Inc\uc2 ., Government Agencies, Offices and Entities.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC\par \par \uc2 Document PHBW000020130705e9780001s\par }\page {\par\fs20\uc2 Generics News\par \b \uc2 Breckenridge  \highlight22\uc2 Launches \highlight\uc2  Generic Maxalt-MLT\b0\par\par\uc2 144 \uc2 words\par \uc2 3 July 2013\par \uc2 MPR, Monthly Prescribing Reference\par \uc2 MPRMPR\par \uc2 English\par \uc2 \u169\'00\'A9 2013 Haymarket Media. All Rights Reserved.   \par \par \uc2 Breckenridge \b \highlight22\uc2 announced the launch\b0 \highlight\uc2  of Rizatriptan Benzoate Orally-Disintegrating Tablets, the generic version of Merck's Maxalt-MLT.\par \par {\field{\*\fldinst{HYPERLINK "http://www.empr.com/breckenridge-pharmaceutical-inc/manufacturer/27632/"}}{\fldrslt{\cf2 \uc2 Breckenridge}}}\uc2  announced that the FDA has approved its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for Rizatriptan Benzoate Orally-Disintegrating Tablets, the generic version of {\field{\*\fldinst{HYPERLINK "http://www.empr.com/merck--co-inc/manufacturer/11448/"}}{\fldrslt{\cf2 \uc2 Merck's}}}{\field{\*\fldinst{HYPERLINK "http://www.empr.com/maxalt-mlt/drug/2833/"}}{\fldrslt{\cf2 \uc2 Maxalt-MLT}}}\uc2 .\par \par {\field{\*\fldinst{HYPERLINK "http://www.empr.com/pain-management/section/1991/"}}{\fldrslt{\cf2 \uc2 RELATED: Pain Management Resource Center}}}\par \par \uc2 Maxalt-MLT is a selective 5-HT(1B/1D) receptor agonist indicated for the acute treatment of {\field{\*\fldinst{HYPERLINK "http://www.empr.com/migraine-and-headache-treatments/article/169358/"}}{\fldrslt{\cf2 \uc2 migraine}}}\uc2 . Rizatriptan binds with high affinity to human cloned 5-HT(1B/1D )receptors. Maxalt-MLT presumably exerts its therapeutic effects in the treatment of migraine headache by binding to 5-HT(1B/1D )receptors located on intracranial blood vessels and sensory nerves of the trigeminal system.\par \par \uc2 Rizatriptan Benzoate Orally Disintegrating Tablets are available in 5mg and 10mg strengths.\par \par \uc2 For more information call (561) 443 - 3314 or visit {\field{\*\fldinst{HYPERLINK "http://www.bpirx.com/"}}{\fldrslt{\cf2 \uc2 Bpirx.com}}}\uc2 .\par \par \uc2 Document MPRMPR0020130704e97300002\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ \uc2 Array BioPharma\uc2  Files 8K - Other Events >ARRY\b0\par\par\uc2 172 \uc2 words\par \uc2 2 July 2013\par 08:12\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2013, Dow Jones & Company, Inc.   \par \par \uc2 Array BioPharma Inc\uc2 . (ARRY) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on July 02, 2013.\par \par \uc2 On July 2, 2013, \uc2 Array BioPharma\uc2  issued a press release titled, "ARRAY BIOPHARMA INITIATES MEK162 PHASE 3 MILO STUDY TRIGGERING MILESTONE PAYMENT."\par \par \uc2 A copy of the press release is attached to this Form 8-K as Exhibit 99.1 and incorporated herein by reference.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1100412/000110041213000012/a8k7213.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1100412/000110041213000012/a8k7213.htm  }}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1100412/000110041213000012/0001100412-13-000012-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1100412/000110041213000012/0001100412-13-000012-index.htm  }}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 July 02, 2013 08:12 ET (12:12 GMT)\par \par \uc2 Document DJDN000020130702e972002r9\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ Threshold Pharmaceuticals Files 8K - Other Events >THLD\b0\par\par\uc2 202 \uc2 words\par \uc2 1 July 2013\par 15:34\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2013, Dow Jones & Company, Inc.   \par \par \uc2 Threshold Pharmaceuticals Inc\uc2 . (THLD) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on July 01, 2013.\par \par \uc2 On July 1, 2013, \uc2 Threshold Pharmaceuticals, Inc\uc2 . issued a press release regarding the announcement of a protocol amendment to the company's pivotal Phase 3 trial of TH-302, an investigational hypoxia-targeted drug, in patients with advanced soft tissue sarcoma. The \uc2 U.S. Food and Drug Administration\uc2  has agreed to the amendment under the existing Special Protocol Agreement.\par \par \uc2 The press release is attached as Exhibit 99.1 to this Form 8-K.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1183765/000114420413037528/v349128_8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1183765/000114420413037528/v349128_8k.htm  }}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1183765/000114420413037528/0001144204-13-037528-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1183765/000114420413037528/0001144204-13-037528-index.htm  }}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 July 01, 2013 15:34 ET (19:34 GMT)\par \par \uc2 Document DJDN000020130701e971004ii\par }\page {\par\fs20\uc2 News\par \b \uc2 Covidien \highlight22\uc2 launches \highlight\uc2  two new lines to stop infections\b0\par\par\uc2 RICK FOSTER SUN CHRONICLE STAFF   \par \uc2 152 \uc2 words\par \uc2 30 June 2013\par \uc2 The Sun Chronicle\par \uc2 ATTLSC\par \uc2 English\par \uc2 Copyright 2013 The Sun Chronicle. All Rights Reserved. Distributed by NewsBank, inc.   \par \par \uc2 MANSFIELD - \uc2 Covidien\uc2  is launching two \b \highlight22\uc2 new product\b0 \highlight\uc2  lines designed to improve infection prevention.\par \par \uc2 Through an agreement with Excelsior Medical, \uc2 Covidien\uc2  will begin selling the Kendall luer access disinfectant cap and the Kendall prefill syringe with removable luer access disinfectant cap.\par \par \uc2 Through a separate agreement with NP Medical, \uc2 Covidien\uc2  also is launching the Kendall neutral displacement needleless connector. Both product lines will be available for sale in the United States this summer.\par \par \uc2 The devices are designed to work in tandem with a syringe to prevent pathogens from entering and possibly leading to infection.\par \par \uc2 "These additions to our growing portfolio of products aimed at catheter care will significantly benefit our customers," said Tim Moran, vice president and general manager, SharpSafety, \uc2 Covidien\uc2 .\par \par \uc2 "These products offer advantages to both caregivers and patients by promoting standardization and compliance in vascular access device maintenance."\par \par \uc2 Document ATTLSC0020130630e96u0000s\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw237\pich40\picscaley100\picscalex100\picwgoal3555\pichgoal600
47
4946383961ED002800F7000095A4CED1D8EA677EB88598C64964AAF0F2F8B3BEDCC2CBE33957A32A4A9CE1E5F1A4B1D5768BBF5871B1F2F4F9F9FAFCFAFBFDEA
EDF5E9ECF5F3F5FAFDFDFEDDE2EFFBFBFDF1F3F8F5F7FAFCFDFEA5B2D5E6E9F3F4F6FAE7EAF4E2E6F2FEFEFFF8F9FCF6F7FBD2D9EAECEFF6F7F8FBE6EAF38597
C6C1CAE2D9DFEECCD3E7DADFEEDEE3F0F3F5F9D3D9EAC9D1E6CFD6E9C3CCE3EFF1F86077B5CED5E8EEF0F7EEF1F7E8EBF4FBFCFDFDFEFEDAE0EEC0C9E2D4DAEB
FCFCFDA9B6D85F76B5B7C2DEB0BCDBCDD4E7D4D9EA9CAAD1F6F7FA697FB9697FB85E75B5D0D6E9C6CEE4C5CDE4E3E7F2D4DAEAD9DFEDBCC6E0BEC8E1BFC8E162
79B7FAFAFDC6CEE5677EB9EFF1F7E4E8F2D1D7E9A0AED3ACB8D9EDEFF6B7C1DDCBD3E78597C7B1BCDBB5C0DDE5E8F29BAAD0788CC08C9DC9DFE4F0FEFEFED3DA
EBD8DEEDAAB7D86F84BDE2E7F2E3E7F1E0E5F19BA9D0FAFAFCA6B3D5D9DEECF3F4F9B6C1DDBAC4DF657BB79AA9D0EBEEF68394C5BEC7E1E0E4F092A1CCC8D0E5
D7DDED8496C6DEE3EF97A7CF4F69AEA6B3D6CAD2E6B2BDDB7387BEC4CCE3C5CEE4DBE1EF1B3D95FFFFFF00000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000021F90400000000002C00000000ED0028000008FF0013091C48B0A0C18308132A5CC8B0A1C38710234A9C48B1A2434418336ADC88
9180018B20438A1C49B2A4C98B1C536EFC78B2A5CB97306356544913A300993873EADC4932E381850508606CC0B3A8D1A34805FA6408002302824D392E10B840
E5D4444237264834206500810D38DE14D875E3538109080CCCBA516DA20088880E2C8068ECC0A6080A10EC0AA0A101AF6401C3E5C820D10144670722C89B4800
22BD5839BAFDCBB12F578E891B2E5D18357353968914D415E8F8EB40B885239BDE8BC87241D103A0BA46E056A0810190D30A846B973422056F3B024F44B77701
048E630FE4DB90C1E3D3034C33370857B940045B2FBB6E7AD5B15EDE0485EAFFFDDB9B206D82B7216BC6F893B353A888408B1E5B9A2078D506A7BF4E993A1102
C903E9165C79F5C115560253154710030914D0D56AFA29E49C56C345781A22D6F9979D867A15206063CFDD67DB40E421F45F5B106DA65067F049E5DB6A030AC4
1622106A541B581C6D58D646A60928E28BC10110C07F0C28B85B6BC49D17986B0A51B691653B2272E3601BF557A273AB7917E35D2C3989917A977104E3422A22
14D450F07DE4587F20C2789F50636A77500002C0A8A5834C7E86965B3FB6192471610965D78C18418924531956B7E49C1826D254036082D854865AFE285E2225
1A84679A0FD544536F7A82281788FCC948637E871654558E02890658223ED2FF041C5CAE953556533012C0988526A6642893172AD71401C309E421626056AAD2
78A319E4AA989D7A9A12688EC63790630D7CB52A47EDC1892A471F9D59E5B500EEB9564A72D18A5E02372990C0A8B68D1625461B161495460954386D70D6E175
95404D01AB6564E3629A92728EA118ADB41979945444197C9088044008B447060F67ACB152EC6D5C9206122412410F89E0B0000F1EA76C54992A5784C6082304
92C8066D2472430D5B60DCF2CE2FB1CC734312D49188204D2472081B6468108708737C81C1CF509BE473D409451046222FB4F080098984B0C1CC1780E042000A
A040F5D9144D8D76412CA49008160E20F4801A0E4C40C2DA78A384487B7917FF5404173688914810712B9482191D4CD0F7E206A98DF7090E5050881B0E718001
058C67AE794249B04088160505302122091499881D397420C5E6AC6F1EC11128DB5B97690B1090C04F17385078EBBCAFDD0715893CA082EC7C0FC440612358D0
FBF2689F8144224CF840908719326FFDE255C84044417F157BD061FF56BBD15487695458F919C15BED704D01179646E15F2F7F225618B13BC0F57E8F48F8CE11
846455C359405FC057908C28A07D00FB4D221A901804006B7ECC03041C1271872140257F0621A0F110E1BF016E8428E8CBCC5D14B8BE058E0F82F34B43051261
0830A0E73909D1A040FA3790FFB986014F91A14110584206A2F0870389C209ED0AE2A10712047D85BA5746A6A2C4B818E683DC330B58440844F979A10230F000
7C8A37C3D4604079550CA34E0661B637CC40760208A0ED0E70831C948003628CA34CBAE0841AF8E17B09239DE91211031AC0518E807C8910E85086315C80210F
A8800226F080403AF22410800005B20001857CC0011798C0D31EC94992FC410E8930010D9E3005835040793B78410942D6C9568224040FC0811220B0060F64C0
051D48041F1261831F8820046074A5304182871D2442061158420B40A003155452042B88C030A75911287C250F2B488406B4A883195C819AE004C907F4008244
C0608524884138D7C9CEA80504003B}}
\par\par \b \uc2 Bond Labs  \highlight22\uc2 Introduces \highlight\uc2  SirenLabs\b0\par\par\uc2 260 \uc2 words\par \uc2 29 June 2013\par \uc2 Professional Services Close-Up\par \uc2 PSVCLU\par \uc2 English\par \uc2 (c) 2013. Close-Up Media, Inc. All rights reserved.   \par \par \uc2 Bond Laboratories, Inc\uc2 ., an international provider of proprietary nutritional supplements for health conscious consumers \b \highlight22\uc2 introduced\b0 \highlight\uc2  SirenLabs, the Company's new line of nutritional supplements available exclusively at GNC.\par \par \uc2 "SirenLabs is committed to providing high quality, performance enhancing supplements with an emphasis on superior ingredients, precision formulation and true innovation for anyone striving for an edge in health, fitness and training results," stated Patrick Ryan, VP of Retail Sales at Bond Labs. "With exciting \b \highlight22\uc2 new products\b0 \highlight\uc2  like SHOCK'D, a powerful pre-workout powder, and ULTRA KARBS, an amazing new carbohydrate complex, SirenLabs is an exciting new brand for us and we are thrilled to \b \highlight22\uc2 introduce\b0 \highlight\uc2  it to our GNC family."\par \par \uc2 "The launch of SirenLabs provides Bond Labs with a second full line of high quality products marketed exclusively through the GNC franchise system. Building on the tremendous success of our NDS brand, SirenLabs enables the Company to build on its position with GNC by adding brand and product differentiation as well as economies of scale that are expected to drive organic growth and cost synergies starting in the second half of 2013. I am truly excited about the opportunity to leverage our strong relationship with GNC to both offer a broader suite of effective solutions to our loyal customers, enhance shareholder value with anticipated top line and profitability growth, and position the company for future brand and product line expansion opportunities," concluded Wilson.\par \par \uc2 More Information:\par \par {\field{\*\fldinst{HYPERLINK "http://www.sirenlabs.com"}}{\fldrslt{\cf2 \uc2 http://www.sirenlabs.com}}}\par \par {\field{\*\fldinst{HYPERLINK "http://www.bond-labs.com"}}{\fldrslt{\cf2 \uc2 http://www.bond-labs.com}}}\par \par \uc2 ((Comments on this story may be sent to newsdesk@closeupmedia.com))\par \par \uc2 Document PSVCLU0020130629e96t0006o\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw300\pich40\picscaley100\picscalex100\picwgoal4500\pichgoal600
47
49463839612C012800C40000E74C40EF8880F7C4C0E11F10FDF1F0EB6A60F3A6A0E53D30FBE2E0E32E20F9D3D0ED7970E95B50F5B5B0F19790DF1000FFFFFF00
000000000000000000000000000000000000000000000000000000000000000000000000000000000000000021F90400000000002C000000002C0128000005FF
20248E64699E68AAAE6CEBBE702CCF746DDF78AEEF7CEFFFC0A070482C1A8FC8A472C96C3A9FD0A8744AAD5AAFD8AC76CBD53DBEE0B078FC2838C8E8C7A1D068
05D269054B007F08448CF41DF28E2701685D5C0A7575010B856409062B7989616E7504220969238096496809825B068F680298A061052A07A46A2D8E68032369
9C22036907490868009D5A7DA96004BD62A628BD0C2DA869B91074B822BF69C247CB6301BA5906010195C1D8DC010561AED8DF6209DC0CB3680E2708DCC75FE8
A5D87B2BD8A36005017B0ADEDB7BEC88E0E42511806D4C9B6A5AC89C38032619840663A08930000FDC2414042AF202C328064431F3468C037390C4C607D49CFF
8C918310CB2D7227007E5930E2244A130A2A724C711281363029614803A38EC4CB304147FC7C30E02293A15F5A6681FAA098097B1D21D8FB1272C4A731564D64
2CA5554C5818D34AD84C0AE12BD0130AAE6173D075850007DC1A2050E1F64B2DA957D69E004098304B084BBF382DA153D5899E10587D71084367D2B1664BB863
BA9840363203D89A1030520C80BA22647E11B63533602492BF946C31C6158AD60F4E605E2DC2E68CAD94FB362401356983C6620E2C1E4140359AAC24B6A634F4
1AC9E62F87E78CA15C02F763317B21300CB3BC45E90794134F8E6E7184F334679B5D4F335B16480884E0D4AF2EA4502C14E38141D36D0A95B05B192350851AFF
3DC979950904477D11947075CC46C07CB01838C624148A911D7F41E407477C25BC075D7763FC651278098E51140C1F4122026E5189505A532288D8501B045064
1A09CE85260702B13D001D54B61114C0750C600362111D8A211A7BF7A1A01E77077297560C54894055187B3923E008D749F4D0865EAE846218679D4499732F3E
49844D06A9D0980A640C5813398511B6DD0C63EC55DA567740D6164C268CB187742604881E09E70D88C066032C28E70FAD1DD02700E1AD33C67FA39101DD8189
A858194811567A5F45D000D70D378A4238C602AFF2230609D731725C180094776910EAF98A025524BA47C6627416F21B48AAE523A570E18999CA1D8E3E629BFF
088A9E34E5AF4048FB0E0C82E9D61865A43ED2E90BB105000F8E522E05CD9789DC5164220EE9381939C272EB0355DCAD70DE03FBF526EA8A480960F0C1A4C51A
C349AC621B46629D26AB2C04181612568C5F24D09A9EFA0A512DC72CCCF7A108083406EA81A0128C940C517E119E7AF7A8EC17C234D3EC701874D55C73C466D9
8B5DC7439888D618BA61389BB6285008720BF02238631AE7BA3974189612B8B24DA602ED436B5597E073BF179271D681389EC0AF0CDE527D091A6632BC0E000E
9C0B814E4BB7C58001E52576D07CDB6A8DC39D2F60CCDB08FB20A79CCC4E7B8A680CCCEC4986DC82DF448202EE1C90D556037C186001E7AA891F1923FB4D03FF
01859151589C251840987A1A0350B15F1715A693A6001C46BA9FDB0170E20AB81D4D869910A45D4603023450804E2F563BC00206AB2E068E05B89E7B3136B52E
FA0D4DAF8CC2BCA01C1EFCC469D6D1750945A6DCA1DC02832251B969647E333304C09CF5F531544B86A5AFD7111A7175806A3F8B2FB0C989A8023CF93C6269D9
03074B7C2686017DA958F473C1BF8E950260946339FF1B8EB1EA1003E15C8B70814A01E9FAB7A05DC1A1004E69D917B2F29EBE4570050BD8940C09930205CCF0
8600C047E8DA8243C24027863DAC9B0A6CD827D4CDA84F2E9CC87C06C0808091A039265B80DC54D743DB316053E37BA116A5400084A16F05084058BEB648C616
329AF18C684CA31AD7C8C636BAF18D708CA31C671002003B}}
\par\par \b \uc2 PhRMA\uc2 , BIO  \highlight22\uc2 Launch \highlight\uc2  Database To Collect Real-Time Data On User Fee Programs\b0\par\par\uc2 551 \uc2 words\par \uc2 28 June 2013\par \uc2 FDA Week\par \uc2 IFDAW\par \uc2 Vol. 19, No. 26\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2013, Inside Washington Publishers.  All rights reserved.  Also available in print and online as part of   \uc2 www.InsideHealthPolicy.com\uc2 .   \par \par \uc2 Pharmaceutical Research and Manufacturers of America\uc2  and the \uc2 Biotechnology Industry Organization\uc2  said Tuesday (June 25) that all their members will participate in a new industry-generated database collecting information on new molecular entity, \b \highlight22\uc2 new drug\b0 \highlight\uc2  application and biologics license application submissions. The two groups headed industry negotiations with FDA for the fifth reauthorization of the Prescription Drug User Fee Act and are joining forces to monitor the progress of these programs, potentially identifying trends that should be corrected before the next reauthorization.\par \par \uc2 CEOs and regulatory heads at member companies signed off on the idea, which is intended to generate high quality data that the groups can share with the agency, said Sascha Haverfield, vice president of scientific and regulatory affairs at \uc2 PhRMA\uc2 . The groups plan to analyze the data and publicly share conclusions, he said.\par \par \uc2 The database will track company interactions with the agency, such as when discussions about a Risk Evaluation and Mitigation Strategy program emerge, Haverfield said. If new components of the user fee program are not having their intended effect, industry could suggest a change of course in advance of reauthorization, which occurs every five years. "If the trend emerges earlier there's no reason to wait," Haverfield said.\par \par \uc2 Some aspects of the fifth PDUFA program cannot change as they were prescribed by Congress in last year's FDA Safety and Innovation Act. But other components dependent on FDA and company actions could shift, such as whether FDA is raising certain concerns later in the review process, rather than earlier, said \uc2 Sara Radcliffe\uc2 , executive vice president of health at BIO.\par \par \uc2 Companies will enter the data into a secure Internet platform, a process expected to take one to three hours per application throughout the review process, Haverfield said. Companies will be able to monitor aggregated data in real-time, down to the review division level. The database guards against confidentiality and antitrust issues, and includes internal checks to monitor the data quality, such as alerting the submitter to dates that do not match up, Haverfield said.\par \par \uc2 BIO and \uc2 PhRMA\uc2  officials said previous attempts at obtaining similar data were labor intensive and retrospective, whereas the current effort is intended to generate real-time data. Previous efforts included data requests from FDA that required analysis and retrospective surveys of member companies that involved looking back through old files, they said.\par \par \uc2 A key part of the recent PDUFA reauthorization was a revamp of the review program that includes new mid- and late-cycle communications and adds two months to the review with a 60-day administrative filing period. FDA and industry envision the increased communication and transparency measures outlined in the new review model will increase the number of first cycle drug reviews. The program is also subject to an evaluation by an independent contractor.\par \par \uc2 Radcliffe said one goal of the database is to better prepare for the next negotiation process with more consensus and input.\par \par \uc2 "We think of it as a sustained engagement approach," she said, noting the effort takes a life cycle, rather than intermittent, approach to monitoring the PDUFA programs. Industry will also have myriad opportunities to discuss the data through the public meetings scheduled for the PDUFA program, she said. -- Alaina Busch\par \par \uc2 Document IFDAW00020130628e96s00008\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Positive Clinical Study Results,  \highlight22\uc2 New Product Launches \highlight\uc2 , and Leadership Changes - Research Report on \uc2 Allergan\uc2 , Isis, \uc2 Covidien\uc2 , BD, and \uc2 DaVita HealthCare Partners\b0\par\par\uc2 1,454 \uc2 words\par \uc2 27 June 2013\par 08:02\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2013  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 \f2 \par Editor Note: For more information about this release, please scroll to bottom. \par  \f28 \par \par \uc2 \f2 NEW YORK, June 27, 2013 /PRNewswire/ --\f28 \par \par \uc2 Today, Wall Street Reports announced new research reports highlighting \uc2 Allergan, Inc\uc2 . (NYSE: AGN), \uc2 ISIS Pharmaceuticals, Inc\uc2 . (NASDAQ: ISIS), \uc2 Covidien plc\uc2  (NYSE: COV), \uc2 Becton, Dickinson and Co\uc2 . (NYSE: BDX) and \uc2 DaVita Healthcare Partners Inc\uc2 . (NYSE: DVA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.\par \par \uc2 Allergan, Inc\uc2 . Research Report\par \par \uc2 On June 24, 2013, \uc2 Allergan, Inc\uc2 . (\uc2 Allergan\uc2 ) announced that \uc2 David E.I. Pyott\uc2 , Chairman of the Board and Chief Executive Officer of Allergan, and the Company's Board of Directors, have named \uc2 Douglas S. Ingram\uc2  as President of Allergan. Ingram will lead \uc2 Allergan\uc2 's global commercial operations, with responsibility for the Company's broad portfolio of pharmaceutical, consumer, and medical device products, including its leading ophthalmology products (e.g. RESTASIS, LUMIGAN, ALPHAGAN, COMBIGAN, GANFORT, OPTIVE and OZURDEX), facial aesthetics products (e.g. BOTOX and JUV\u201\'00\'C9DERM), and medical dermatology products (e.g. ACZONE). \uc2 Allergan\uc2  stated that Ingram has been with the Company for 17 years, and for the past three years, Ingram has served as the Company's Executive Vice President and President, Europe, Africa and Middle East (EAME), where he was responsible for \uc2 Allergan\uc2 's regional pharmaceutical and medical device operations, with a focus on strategic planning, sales and marketing, development and general management. Full Research Report on \uc2 Allergan, Inc\uc2 . - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [{\field{\*\fldinst{HYPERLINK "http://www.wsreports.com/r/full_research_report/1c25_AGN"}}{\fldrslt{\cf2 \uc2 http://www.wsreports.com/r/full_research_report/1c25_AGN}}}\uc2 ]\par \par \uc2 --\par \par \uc2 ISIS Pharmaceuticals, Inc\uc2 . Research Report\par \par \uc2 On June 23, 2013, \uc2 ISIS Pharmaceuticals Inc\uc2 . (Isis) announced data from Phase 2 study of ISIS-APOCIII in patients with high triglycerides and type 2 diabetes. In the study, patients treated with ISIS-APOCIII experienced an 88% reduction in apolipoprotein C-III (apoC-III), a 72% reduction in triglyceride levels, a 40% increase in high-density lipoprotein cholesterol (HDL-C), the 'good' cholesterol, and improvements in other atherogenic lipid parameters. Further, patients dosed with ISIS-APOCIII(Rx) showed consistent trends towards enhanced insulin sensitivity with improvements in multiple measures of glucose control. The Company also stated that it is evaluating ISIS-APOCIII in a separate Phase 2 study in patients with moderate to high triglycerides and expects to report data from the study in the summer of 2013. The Full Research Report on \uc2 ISIS Pharmaceuticals, Inc\uc2 . - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [{\field{\*\fldinst{HYPERLINK "http://www.wsreports.com/r/full_research_report/f5f5_ISIS"}}{\fldrslt{\cf2 \uc2 http://www.wsreports.com/r/full_research_report/f5f5_ISIS}}}\uc2 ]\par \par \uc2 --\par \par \uc2 Covidien plc\uc2  Research Report\par \par \uc2 On June 20, 2013, \uc2 Covidien plc\uc2  (\uc2 Covidien\uc2 ) announced that an independent study called CLOTS 3, conducted by the University of Edinburgh, successfully demonstrated the effectiveness of \uc2 Covidien\uc2 's Kendall SCD system with Vascular Refill Detection Technology on immobile stroke patients. The study showed a 29.9% decrease in the development of proximal deep vein thrombosis (DVP) in immobile stroke patients who received intermittent pneumatic compression (IPC) using the Kendall SCD system with Vascular Refill Detection Technology, which as per the Company, delivers sequential, circumferential, gradient compression through thigh-length sleeves. Compared to the routine care group, the IPC group showed a 14% mortality risk reduction (p = 0.042) during the first six months after admission for stroke. The results of the CLOTS 3 trial were presented at the European Stroke Conference and were also published in the medical journal, The Lancet. The Full Research Report on \uc2 Covidien plc\uc2  - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [{\field{\*\fldinst{HYPERLINK "http://www.wsreports.com/r/full_research_report/a748_COV"}}{\fldrslt{\cf2 \uc2 http://www.wsreports.com/r/full_research_report/a748_COV}}}\uc2 ]\par \par \uc2 --\par \par \uc2 Becton, Dickinson and Co\uc2 . Research Report\par \par \uc2 On June 24, 2013, BD Diagnostics, a segment of \uc2 Becton, Dickinson and Co. (BD)\uc2 , together with Diagenode SA, an international biotech company based in Belgium, announced the European-only launch of the Diagenode Bordetella pertussis/parapertussis real-time polymerase chain reaction (PCR) kit for use on the BD MAX System. According to the Company, Bordetella pertussis is responsible for 30-50 million annual cases of pertussis, or the "whooping cough." Timely detection of the infection through the PCR is essential in preventing the spread of disease and reducing the risk of widespread outbreaks. BD further stated that PCR testing is ideal in enabling the prompt differential diagnosis of pertussis from other respiratory diseases such as atypical pneumonia, bronchitis, or respiratory viruses. Through BD's collaborations with leading in vitro diagnostic (IVD) developers such as Diagenode, the Company is rapidly expanding its molecular testing menu by offering syndrome specific and clinically relevant IVD assays across a number of disease syndromes. The Full Research Report on \uc2 Becton, Dickinson and Co\uc2 . - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [{\field{\*\fldinst{HYPERLINK "http://www.wsreports.com/r/full_research_report/0978_BDX"}}{\fldrslt{\cf2 \uc2 http://www.wsreports.com/r/full_research_report/0978_BDX}}}\uc2 ]\par \par \uc2 --\par \par \uc2 DaVita Healthcare Partners Inc\uc2 . Research Report\par \par \uc2 On June 24, 2013, \uc2 DaVita\uc2 , the dialysis division of \uc2 DaVita HealthCare Partners Inc\uc2 . (\uc2 DaVita HealthCare Partners\uc2 ), announced that it has selected Cureatr, the enterprise messaging and workflow navigation solution for healthcare, to enhance communication and care coordination for care teams at dialysis centers across the country. The Company said that Cureatr's mobile care coordination and reporting system will enable \uc2 DaVita\uc2  foster more robust clinical information sharing, which may help reduce costly hospital admissions. Also, it stated that this partnership allows \uc2 DaVita\uc2  to provide Cureatr's iPhone and web apps to thousands of facility administrators, care managers, nurses, and affiliated nephrologists. The Company also expects this to improve communication between \uc2 DaVita\uc2 's dialysis care teams, resulting in more efficient delivery of patient care.The Full Research Report on \uc2 DaVita Healthcare Partners Inc\uc2 . - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [{\field{\*\fldinst{HYPERLINK "http://www.wsreports.com/r/full_research_report/548a_DVA"}}{\fldrslt{\cf2 \uc2 http://www.wsreports.com/r/full_research_report/548a_DVA}}}\uc2 ]\par \par \uc2 --\par \par \uc2 EDITOR NOTES:\par \par \uc2 \f2 \par    1. This is not company news. We are an independent source and our views do \par       not reflect the companies mentioned. \par  \par    2. Information in this release is fact checked and produced on a best \par       efforts basis and reviewed by a CFA. However, we are only human and are \par       prone to make mistakes. If you notice any errors or omissions, please \par       notify us below. \par  \par    3. This information is submitted as a net-positive to companies mentioned, \par       to increase awareness for mentioned companies to our subscriber base and \par       the investing public. \par  \par    4. If you wish to have your company covered in more detail by our team, or \par       wish to learn more about our services, please contact us at \par       pubco@EquityNewsNetwork.com. \par  \par    5. For any urgent concerns or inquiries, please contact us at \par       compliance@EquityNewsNetwork.com. \par  \par    6. Are you a public company? Would you like to see similar coverage on your \par       company? Send us a full investors' package to \par       research@EquityNewsNetwork.com for consideration. \f28 \par \par \uc2 \f2 COMPLIANCE PROCEDURE\f28 \par \par \uc2 \f2 Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.\f28 \par \par \uc2 \f2 NOT FINANCIAL ADVICE\f28 \par \par \uc2 \f2 Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.\f28 \par \par \uc2 \f2 NO WARRANTY OR LIABILITY ASSUMED\f28 \par \par \uc2 \f2 Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.\f28 \par \par \uc2 \f2 SOURCE Wall Street Reports\f28 \par \par \uc2 \f2 /\f28 \par \par \uc2 Document PRN0000020130627e96r0004p\par }\page {\par\fs20\b \uc2 Kinexus Bioinformatics Corporation\uc2 ; Kinexus  \highlight22\uc2 Launches \highlight\uc2  DrugKiNET KnowledgeBase with 105,000 Experimentally Tested Protein Kinase Drug Interactions\b0\par\par\uc2 744 \uc2 words\par \uc2 27 June 2013\par \uc2 Gene Therapy Weekly\par \uc2 GENT\par 101\par \uc2 English\par \uc2 (c) Copyright 2013 Gene Therapy Week via NewsRx.com   \par \par \uc2 2013 JUN 27 (NewsRx) -- By a News Reporter-Staff News Editor at Gene Therapy Weekly -- \uc2 Kinexus Bioinformatics Corporation\uc2 , a world-leader in the study of molecular intelligence systems, \b \highlight22\uc2 announced the launch\b0 \highlight\uc2  of its DrugKiNET KnowledgeBase ({\field{\*\fldinst{HYPERLINK "http://www.drugkinet.ca"}}{\fldrslt{\cf2 \uc2 www.drugkinet.ca}}}\uc2 ) for the identification and development of drug candidates that potently and selectively inhibit human protein kinases. This open-access website features quantitative data on the effects of over\par \par \uc2 800 chemical compounds on more than 400 protein kinases following careful annotation of hundreds of experiments documented in the scientific literature. This data was then used to train two different proprietary algorithms to predict the inhibitory effects of 550 of these compounds on 500 human protein kinases. This information can guide biomedical researchers in the discovery of new therapeutic targets for existing drugs, and aid in the design of promising \b \highlight22\uc2 new drugs\b0 \highlight\uc2 .\par \par \uc2 At least 538 different protein kinases regulate each other and another approximately 21,500 diverse protein targets to coordinate all of the operations in living cells through complex molecular communications and control networks. Kinases are well recognized by the pharmaceutical and biotech industry as highly productive targets for drug development with applications for cancer, diabetes, Alzheimer's disease and many other diseases. In fact, over 400 human disease have been linked to genetic mutations in the genes that encode protein kinases or the direct actions of environmental toxins that target protein kinases. Over the last decade, more than two dozen kinase inhibitors have already been approved for clinical use, primarily for cancer treatment. By targeting inappropriately active kinases, these small molecule drugs essentially re-program cancer cells for their demise.\par \par \uc2 Over the last year, Kinexus and their collaborators in the Mathematics of Information Technology and Complex Systems (MITACS) groups at the \uc2 University of British Columbia\uc2  and Simon Fraser University have worked to identify the specific parts of different protein kinases that are critical for recognition by each of 550 different compounds that have been experimentally shown to inhibit one or more kinases. These parts, termed Inhibitor Determining Residues (IDR's), may be involved in recognizing and binding drugs, and their identification within DrugKiNET can facilitate further optimization of even more potent and specific protein kinase inhibitory drugs. Previously, Kinexus and its partners identified Substrate Determining Residues (SDR's) in protein kinases that were important for recognition of their protein targets and deposited this information in their open-access PhosphoNET Knowledgebase ({\field{\*\fldinst{HYPERLINK "http://www.phosphonet.ca"}}{\fldrslt{\cf2 \uc2 www.phosphonet.ca}}}\uc2 ).\par \par \uc2 "We believe that DrugKiNET is an extremely unique and powerful resource for the biomedical research community," commented \uc2 Dr. Steven Pelech\uc2 , President and Chief Scientific Officer of Kinexus and a professor in the Department of Medicine at the \uc2 University of British Columbia\uc2 . "Over a third of all pharmaceutical drug development is presently focused on protein kinase inhibitory drugs, but we expect this to increase even more, since the vast majority of protein kinases have yet to be pursued as drug targets, and definition of the precise roles of different kinases in non-cancer-related diseases is still in its infancy."\par \par \uc2 Dr. Pelech added, "We are excited by the prospect that our algorithms can define new protein kinase targets for existing drugs, and that they can identify in the genes that encode protein kinases the specific mutations that may alter their sensitivities to these drugs. As Kinexus has the capability of testing the effects of drug candidates on over\par \par \uc2 350 different purified protein kinases in-house, we also have the ability to experimentally validate many of our drug predictions for our clients."\par \par \uc2 Kinexus is a private, biotechnology company engaged in the research and development of innovative methods to map, track and manipulate cellular communication networks. The application of this knowledge positions Kinexus and its clients in drug development, rational drug design, disease diagnosis and personalized therapies to improve human health.\par \par \uc2 Kinexus currently has agreements with over 1700 research laboratories in companies, universities, government institutions and hospitals in over 35 different countries. To learn more about the diverse proteomics and bioinformatics services offered by Kinexus, please visit {\field{\*\fldinst{HYPERLINK "http://www.kinexus.ca"}}{\fldrslt{\cf2 \uc2 www.kinexus.ca}}}\uc2  or call toll-free at 1-866-KINEXUS.\par \par \uc2 SOURCE \uc2 Kinexus Bioinformatics Corporation\par \par \uc2 Kinexus Bioinformatics Corporation\par \par \uc2 Keywords for this news article include: Genetics, Oncology, Algorithms, Therapeutics, Protein Kinases, Drug Development, Cancer Gene Therapy, Enzymes and Coenzymes, \uc2 Kinexus Bioinformatics Corporation\uc2 , Phosphotransferases (Alcohol Group Acceptor).\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC\par \par \uc2 Document GENT000020130621e96r0001u\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Mylan  \highlight22\uc2 launches \highlight\uc2  generic Micronor tablets, 0.35 mg\b0\par\par\uc2 75 \uc2 words\par \uc2 26 June 2013\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2013. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Mylan's U.S.-based subsidiary \uc2 Mylan Pharmaceuticals\uc2  has \b \highlight22\uc2 launched\b0 \highlight\uc2  Norethindrone Tablets USP, 0.35 mg. Norethindrone Tablets USP, 0.35 mg, are the generic version of Janssen Pharmaceuticals, Inc.'s Micronor\u174\'00\'AE Tablets, 0.35 mg (28-Day Cycle), which are indicated for the prevention of pregnancy. Mylan's partner, \uc2 Famy Care\uc2 ., received final approval from the FDA for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application for this product. \par \par \uc2 Document FLYWAL0020130626e96q001gz\par }\page {\par\fs20\uc2 Generics News\par \b \uc2 Mylan  \highlight22\uc2 Launches \highlight\uc2  Generic Micronor Tablets\b0\par\par\uc2 122 \uc2 words\par \uc2 26 June 2013\par \uc2 MPR, Monthly Prescribing Reference\par \uc2 MPRMPR\par \uc2 English\par \uc2 \u169\'00\'A9 2013 Haymarket Media. All Rights Reserved.   \par \par \uc2 Mylan \b \highlight22\uc2 announced the launch\b0 \highlight\uc2  of Norethindrone Tablets, the generic version of Janssen's Micronor.\par \par {\field{\*\fldinst{HYPERLINK "http://www.empr.com/mylan-pharmaceuticals/manufacturer/19076/"}}{\fldrslt{\cf2 \uc2 Mylan}}}\uc2  announced that the FDA has approved its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for Norethindrone Tablets, the generic version of {\field{\*\fldinst{HYPERLINK "http://www.empr.com/janssen-pharmaceuticals-inc/manufacturer/31382/"}}{\fldrslt{\cf2 \uc2 Janssen's}}}\uc2  Micronor.\par \par {\field{\*\fldinst{HYPERLINK "http://www.empr.com/obgyn/section/1990/"}}{\fldrslt{\cf2 \uc2 RELATED: Ob/Gyn Resource Center}}}\par \par {\field{\*\fldinst{HYPERLINK "http://www.empr.com/micronor/drug/2517/"}}{\fldrslt{\cf2 \uc2 Micronor}}}\uc2  is a progestin-only {\field{\*\fldinst{HYPERLINK "http://www.empr.com/oral-contraceptives/article/123837/"}}{\fldrslt{\cf2 \uc2 oral contraceptive}}}\uc2  indicated for the prevention of pregnancy. Micronor prevents conception by suppressing ovulation, thickening the cervical mucus to inhibit sperm penetration, lowering the midcycle LH and FSH peaks, slowing the movement of ovum through the fallopian tubes, and altering the endometrium.\par \par \uc2 Norethindrone Tablets are available in a 0.35mg dosage strength as 28-Day Cycle packs.\par \par \uc2 For more information call (800) RX-MYLAN or visit {\field{\*\fldinst{HYPERLINK "http://www.mylan.com/"}}{\fldrslt{\cf2 \uc2 Mylan.com}}}\uc2 .\par \par \uc2 Document MPRMPR0020130627e96q0000c\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 ConvaTec \highlight22\uc2 Introduces \highlight\uc2  Silver Version of AQUACEL(R) Foam Dressing\b0\par\par\uc2 761 \uc2 words\par \uc2 24 June 2013\par 12:00\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2013  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 \f2 \par New silver foam dressing builds on success of AQUACEL(R) Foam dressing, fastest-growing \f28 \b \highlight22\uc2 \f2 new product\f28 \b0 \highlight\uc2 \f2  in \f28 \uc2 \f2 ConvaTec\f28 \uc2 \f2  history \par  \f28 \par \par \uc2 \f2 SEATTLE, June 24, 2013 /PRNewswire/ -- \f28 \uc2 \f2 ConvaTec\f28 \uc2 \f2 , a world-leading developer and marketer of innovative medical technologies, today announced it has received 510(k) market clearance from the \f28 \uc2 \f2 U.S. Food and Drug Administration\f28 \uc2 \f2  (FDA) for AQUACEL(R) Ag Foam dressing. Extending the company's leadership position in antimicrobial dressings and building on the successful \f28 \b \highlight22\uc2 \f2 launch\f28 \b0 \highlight\uc2 \f2  of AQUACEL(R) Foam dressing last year, the \f28 \b \highlight22\uc2 \f2 new product\f28 \b0 \highlight\uc2 \f2  is being \f28 \b \highlight22\uc2 \f2 introduced\f28 \b0 \highlight\uc2 \f2  at the WOCN Society's 45(th) Annual Conference from June 23-26 in Seattle, WA.\f28 \par \par \uc2 "Customer reaction to AQUACEL(R) Foam -- the only dressing to combine the comfort of foam with the moist wound healing benefits of an AQUACEL(R) interface -- has been incredible. It is the most successful product launch in our history. Now, we are taking foam dressings to the next level with the introduction of AQUACEL(R) Ag Foam," said Mark Valentine, President, Americas.\par \par \uc2 New AQUACEL(R) Ag Foam dressing is the only silver foam dressing that offers the moist wound healing benefits of an AQUACEL(R) Ag interface, the comfort of foam and the bacteria-killing power of ionic silver. The AQUACEL(R) Ag wound interface features \uc2 ConvaTec\uc2 's proprietary Hydrofiber(R) Technology, which gels on contact with the wound surface. As demonstrated in vitro, the unique gelling action of Hydrofiber(R) Technology locks in wound exudate and harmful bacteria and micro-contours to a simulated wound bed, minimizing "dead space" where bacteria can thrive.\par \par \uc2 "For shallow exuding wounds that require antimicrobial action, the ideal cover dressing should provide comfort for the patient while also effectively managing exudate and fighting infection," stated Kathryn Braun, RN, WRN, IIWCC from Regina, Saskatchewan. "With AQUACEL(R) Ag Foam dressing, clinicians now have an optimal solution for wounds that are prone to infections -- and the peace of mind that comes with the leading brand in advanced antimicrobial dressings."\par \par \uc2 The proprietary Hydrofiber(R) Technology with ionic silver contained in AQUACEL(R) Ag Foam dressing has been proven, in vitro, to kill a variety of pathogens, including certain 'superbugs' such as Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) within 30 minutes, and provide sustained bacteria killing for up to seven days. In an in vitro simulated shallow wound model, AQUACEL(R) Ag Foam dressing killed more P. aeruginosa and S. aureus bacteria in the dressing than other silver foam dressings tested.\par \par \uc2 The gelling action of the AQUACEL(R) Ag interface maintains a moist environment that supports wound healing and prevents the lateral spread of fluid which helps to reduce the risk of maceration to the healthy skin surrounding the wound bed. In in vitro testing, AQUACEL(R) Ag Foam dressing absorbed and retained more fluid under compression, and spread less fluid laterally, than other silver foam dressings tested.[1]\par \par \uc2 "Clinicians around the world rely on AQUACEL(R) Ag dressings," concluded Mark Valentine. "Our goal with AQUACEL(R) Ag Foam dressing is to provide a new standard of care in silver foam dressings, combining comfort with optimal exudate management and antimicrobial power. It is part of our commitment to our customers to help them improve care, prevent infection and reduce total cost of care."\par \par \uc2 The soft, absorbent foam pad is covered by a waterproof protective top layer that provides controlled moisture vapor transmission, whilst providing a barrier against viral and bacterial penetration. The silicone border provides secure skin-friendly adhesion.\par \par \uc2 AQUACEL(R) Ag Foam dressing is available in a wide range of shapes and sizes to conform to a variety of wound types, including sacral and heel wounds.\par \par \uc2 Additional information about AQUACEL(R) Ag Foam and AQUACEL(R) Foam dressings may be found at {\field{\*\fldinst{HYPERLINK "http://www.convatec.com"}}{\fldrslt{\cf2 \uc2 www.convatec.com}}}\uc2  or by calling \uc2 ConvaTec\uc2  customer service at 1-800-422-8811.\par \par \uc2 About \uc2 ConvaTec\par \par \uc2 ConvaTec\uc2  is a leading developer and marketer of innovative medical technologies that have helped improve the lives of millions of people worldwide. With four key focus areas -- Ostomy Care, Wound Therapeutics, Continence and Critical Care, and Infusion Devices -- \uc2 ConvaTec\uc2  products support healthcare professionals from the hospital to the community health setting. For more information, please visit {\field{\*\fldinst{HYPERLINK "http://www.convatec.com"}}{\fldrslt{\cf2 \uc2 www.convatec.com}}}\par \par \uc2 (R)/(TM) indicates trademarks of \uc2 ConvaTec Inc\uc2 .\par \par \uc2 (c) 2013 \uc2 ConvaTec Inc\uc2 .\par \par \uc2 [1] In vitro testing of AQUACEL(TM) Ag Foam dressing and Competitor dressings -- Lateral Spread determination. Market Support WHR13662 MS101. 2013. Data on file, \uc2 ConvaTec\uc2 .\par \par \uc2 SOURCE \uc2 ConvaTec\par \par \uc2 /\par \par \uc2 Document PRN0000020130624e96o000el\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ \uc2 Rockwell Medical\uc2  Files 8K - Entry Into Definitive Agreement >RMTI\b0\par\par\uc2 668 \uc2 words\par \uc2 20 June 2013\par 16:06\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2013, Dow Jones & Company, Inc.   \par \par \uc2 Rockwell Medical Inc\uc2 . (RMTI) filed a Form 8K - Entry Into a Definitive Agreement - with the U.S Securities and Exchange Commission on June 17, 2013.\par \par \uc2 On June 17, 2013, \uc2 Rockwell Medical, Inc\uc2 . (the "Company") and its wholly owned subsidiary, Rockwell Transportation, Inc. (together with the Company, the "Borrower"), entered into a Loan and Security Agreement, dated as of June 14, 2013 (the "Loan Agreement"), with Hercules Technology III, L.P. ("Hercules"). Pursuant to the Loan Agreement, the Company has borrowed $20 million. Proceeds from the loan are intended to be used to fund the Company's clinical trials and for general corporate purposes.\par \par \uc2 The loan will mature and become due on December 1, 2016, subject to adjustment as provided below, and will bear interest at the greater of (i) 12.50% plus the prime rate as reported in The Wall Street Journal minus 3.25%, or (ii) 12.50%. The Borrower will be required to make only monthly interest payments through May 31, 2014 (or August 31, 2014 if Borrower meets primary end points for both Phase 3 trials for its SFP drug prior to December 15, 2013). If the interest only period is extended, the maturity date for the loan will be extended to March 1, 2017. Monthly principal and interest payments will be due on the loan following the interest only period through the maturity date. The loan may be prepaid at any time after June 14, 2014 without penalty. The Company paid a fee of $0.2 million at closing and is required to pay a fee of $1.1 million upon any prepayment or at maturity. The loan will also mature and become due upon a change in control of the Company.\par \par \uc2 In connection with the loan, the Company granted Hercules a security interest in substantially all of the Borrower's assets other than certain intellectual property, motor vehicles, real property and certain other interests. The Loan and Security Agreement also provides for standard indemnification of Hercules and contains representations, warranties and non-financial covenants of the Company. The Loan Agreement also contains covenants that, among other things, limit the Company's ability to incur additional indebtedness, transfer assets acquire assets of or merge with another entity and pay dividends to the Company's shareholders. Hercules is permitted to participate in the next institutional equity offering by the Company, if any, in an amount up to $1 million on the same terms as other investors in such an offering.\par \par \uc2 Events of default under the Loan Agreement include the failure to pay principal or interest payments on time; breach of representations, warranties or covenants; the occurrence of a material adverse effect on the Borrower, the collateral or the perfection of the security interest, or a material impairment of Borrower's ability to perform under the Loan Agreement or Hercules' ability to enforce its rights under the Loan Agreement; certain events involving Borrower's bankruptcy or insolvency; the occurrence of certain judgments; and the occurrence of certain defaults under other agreements to which Borrower is a party.\par \par \uc2 The above description of the Loan Agreement does not purport to be a complete statement of the provisions thereof. Such description is qualified in its entirety by reference to the Loan Agreement, which is attached to this Current Report on Form 8-K and is incorporated herein by reference.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1041024/000110465913050415/a13-15327_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1041024/000110465913050415/a13-15327_18k.htm  }}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1041024/000110465913050415/0001104659-13-050415-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1041024/000110465913050415/0001104659-13-050415-index.htm  }}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 20, 2013 16:06 ET (20:06 GMT)\par \par \uc2 Document DJDN000020130620e96k004t7\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ Pharmacyclics Files 8K - Regulation FD >PCYC\b0\par\par\uc2 195 \uc2 words\par \uc2 20 June 2013\par 12:17\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2013, Dow Jones & Company, Inc.   \par \par \uc2 Pharmacyclics Inc\uc2 . (PCYC) filed a Form 8K - Regulation FD Disclosure - with the U.S Securities and Exchange Commission on June 20, 2013.\par \par \uc2 On June 20, 2013, a presentation entitled "A Prospective, Multicenter, Phase II Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Patients with Relapsed and Refractory Waldenstrom's Macroglobulinemia" related to \uc2 Pharmacyclics, Inc\uc2 .'s product drug candidate Ibrutinib was made at the 12th International Conference on Malignant Lymphoma. A copy of the presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/949699/000092189513001284/form8k07380_06202013.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/949699/000092189513001284/form8k07380_06202013.htm  }}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/949699/000092189513001284/0000921895-13-001284-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/949699/000092189513001284/0000921895-13-001284-index.htm  }}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 20, 2013 12:17 ET (16:17 GMT)\par \par \uc2 Document DJDN000020130620e96k003qf\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 PRESS RELEASE: LeMaitre  \highlight22\uc2 Launches \highlight\uc2  3 Products: 1.5mm Valvulotome, MultiTASC & AlboSure Patch\b0\par\par\uc2 384 \uc2 words\par \uc2 19 June 2013\par 12:00\par \uc2 Dow Jones Newswires\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright (c) 2013, Dow Jones & Company, Inc.   \par \par \uc2 LeMaitre \b \highlight22\uc2 Launches\b0 \highlight\uc2  3 Products: 1.5mm Valvulotome, MultiTASC & AlboSure Patch\par \par \uc2 BURLINGTON, Mass., June 19, 2013 (GLOBE NEWSWIRE) -- \uc2 LeMaitre Vascular, Inc\uc2 . (Nasdaq:LMAT), a provider of peripheral vascular devices and implants, announced today its third product \b \highlight22\uc2 launch\b0 \highlight\uc2  since March. These three \b \highlight22\uc2 new products\b0 \highlight\uc2  strengthen \uc2 LeMaitre Vascular\uc2 's position as a one-stop-shop for peripheral vascular devices: \par \par \uc2 \f2 \par    -- MultiTASCTM Dissection/Transection Device (launched March 27, 2013) \par  \par    -- 1.5mm Expandable LeMaitre(R) Valvulotome (launched April 29, 2013) \par  \par    -- AlboSureTM Vascular Patch (launched June 18, 2013) \f28 \par \par \uc2 \f2 The MultiTASC device is a remote endarterectomy device which dissects and transects arterial plaque in a single pass, reducing procedure times and complications.\f28 \par \par \uc2 \f2 The 1.5mm Expandable LeMaitre Valvulotome is the 7th generation of our flagship valvulotome for in situ bypass. The smaller size allows for more effective valve cutting in smaller vessels, while reducing potential damage to fragile vein walls.\f28 \par \par \uc2 \f2 The AlboSure Patch is a polyester alternative to our XenoSure(R) Biologic Vascular Patch. Both patch platforms are used primarily during carotid endarterectomy surgery.\f28 \par \par \uc2 \f2 "These three product launches underscore LeMaitre's commitment to R&D and our mission to be a one-stop-shop for peripheral vascular devices. Our growing sales force -- now at 83 reps - is eager to bring these updated and expanded product offerings to our vascular surgeon customers, " said George W. LeMaitre, Chairman and CEO.\f28 \par \par \uc2 \f2 About \f28 \uc2 \f2 LeMaitre Vascular\f28 \par \par \uc2 \f2 LeMaitre Vascular\f28 \uc2 \f2  is a provider of devices and implants for the treatment of peripheral vascular disease, a condition that affects more than 20 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. The Company's diversified product portfolio consists of brand name devices used in arteries and veins outside of the heart, including the 1.5mm Expandable LeMaitre Valvulotome, MultiTASC Dissection/Transection Device, and XenoSure Biologic Vascular Patch. Additional information can be found at \f28 {\field{\*\fldinst{HYPERLINK "http://www.lemaitre.com"}}{\fldrslt{\cf2 \uc2 http://www.lemaitre.com}}}\uc2 \f2 .\f28 \par \par \uc2 \f2 LeMaitre, XenoSure and the \f28 \uc2 \f2 LeMaitre Vascular\f28 \uc2 \f2  logo are registered trademarks and MultiTASC and AlboSure are trademarks of \f28 \uc2 \f2 LeMaitre Vascular, Inc\f28 \uc2 \f2 . \f28 \par \par \uc2 \f2 \par CONTACT: \f28 \uc2 \f2 LeMaitre Vascular, Inc\f28 \uc2 \f2 . \par          Mary Nielson \par          +1-781-425-1659 \par          mnielson@lemaitre.com \par          \f28 {\field{\*\fldinst{HYPERLINK "http://www.lemaitre.com"}}{\fldrslt{\cf2 \uc2 http://www.lemaitre.com}}}\par \par \uc2 \f2 (END) Dow Jones Newswires\f28 \par \par \uc2 \f2 June 19, 2013 12:00 ET (16:00 GMT)\f28 \par \par \uc2 Document DJDN000020130619e96j0040f\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw166\pich40\picscaley100\picscalex100\picwgoal2490\pichgoal600
47
4946383961A6002800F700002A4A9CD1D8EA95A4CE4964AAF0F2F85871B18598C6768BBF3957A3E1E5F1677EB8B3BEDCA4B1D5C2CBE3F2F4F9FBFBFDF4F6FAEC
EFF6F8F9FCC6CFE5C5CDE4E0E4F0F1F3F8F5F7FBE1E6F1D5DBEBF7F8FBD9DEEDEEF0F7DFE3F0D4DAEBE3E7F2D7DDECBFC8E1BBC5DFFDFEFEEBEEF6FBFCFDCED5
E8DBE0EEFAFAFC9DABD1AEBAD99EACD2E4E8F2F6F7FBF3F5FAE7EAF4E7EBF4D2D9EAE8EBF4C2CBE2E6E9F3AFBAD9C9D1E6AFBADAA8B5D74F69AE90A0CBCCD4E8
DADFED9FADD3E6EAF3DADFEEAFBBDAD5DBECD9DFEEA1AFD3DDE2EFEEF1F7D2D8E9EFF1F8E9ECF5F5F6FA798DC0798CC0DEE3F0BAC4DFE4E8F3DCE0EEA6B3D5D0
D6E9CBD2E791A1CC7388BFEDEFF7ABB7D73A56A3BEC7E1566EB1C2CAE3F3F5F9B7C1DED3DAEB6C81BBCCD3E7ECEEF6C1CAE2EDEFF6D3DAEA9DABD2D6DCECEFF1
F7C9D1E5C7CFE5C0C9E1FDFDFE94A3CDF5F7FAD0D7E9B7C2DE899AC8E2E6F2D1D7E9FEFFFFA5B2D5D1D7EAB0BBDAFCFDFEA7B4D6E9EDF5FAFAFDD8DEECAEBADA
ADB9D9DCE1EFCBD3E793A2CC8597C6CFD6E9FEFEFEE5E9F37D8FC298A7D0B9C3DFB6C0DDD9DFEDF9FAFCE2E7F2FEFEFFDDE2F06E83BC4E68AD8395C599A8D099
A8CF1B3D95FFFFFF0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000021F90400000000002C00000000A60028000008FF0027091C48B0A0C18308132A5CC8B0A1C38710234A1428491280041019549434
B1A3C78F204336DC38E06102001B45AA5CC9B2E5C18D920C381C00D3A5CD9B3821564429690143033B2BE61C4AB468C502052C624C18A0E2019E071148125010
C080A50207001048C022C105310502855931C04001921010207892ACA40393D0BAED3989A659AE924A0AE409536F5399939A1620D8558140B06ED53A3CDAA0A2
DE8304A4AA4D595000800200D60E4409C067D6AD93BA823E1C761250AA901128282D102DEAD079AB8ECE2AE92EECC756091EA81DB874D3BC4B0B0B5C6D3BAE01
AC0B8F9A768A70355DCA034F1A2000C0F0E60152016BC53B1B2CE0D3089F12FF006ADB3541060601CCAECB1B2FEEC793769BFD2B50B045F4C22711F7A89CFD54
831A9506DD7008B446D75E0A10905401046C075B77A58D55D16BBD5115D963E60D749C6C05D9355057B8B9E5976F530520D501F9ED8758459E31D45F5BED09D4
9662930CB8E246052228D06E0820009A685F45F89F413491855A86B771489087EE5D17180008D8465F85A125459375FB6978A08B920C465A5A9AF967DB80AA05
895A750331C0D966737D372441681587DD5A729105DF24EA159494884E3ED9597D24BE361696736D995C97040D2A5645805124D4A20D740880596846E7607C73
45BA1C859324808097038165188C30A147509EE7CDF55A6EF5A144D5944D51FFB840A50192452397A0D2566245390E34E0446A8C20D01C1A4CE2011245253B54
7FD1F124558C8E72F411059AA6D0C22487F4A1ECB636311B2A4C9CD6F8A847265030C90A124C32C5059370400106DCC61B92B703ED169B41BF3E94C20B45B831
09185D48004915246801850376C8AB7047F472251572BE8E1BD10A11B8A0C2246BB0D0E92417C06B43064414B7F0C80A355C5F8B05E5EBD00E1784F145428A10
E0800B24D75C32A211A9ACD0106F4C42080B1F20B2D00651741081CD481364F2A1D23EF444069380E083430F38F040D258C7DB861891185210014F6D7480591A
5470421E59A73DD42293340275410D58656A00AB51F580CC6AE7ED92145724FF314919570F142B800310C086057A27BE9205224CF2400E4E1054C09D8A577E93
17637C2D89A909BD55D0B3380E4716467B6EA4A9AF705104579DCC597ED31233C00DED4BA9CBF8265A0221903AD86615D0AB407BA2E7B9EA7149B2D401B9BAAE
D2237F4C62441604352632BEB5777ABBB4A5571469E99C2B5DBBE7AC0FAFFC4A85DC31090C67106628ED6C5D1FDA014B25B0F924BE97FCFDEAC68F9F93155418
8414D3CA011DAF724796ED15B04364410F5A20A63F96FC40041598004106571006146E1212085C033778101EEC61127A2083EC06A0A90024852A1DA8000438C8
C2826001102388C14112602FA7DCC5021C58610B7728101438C20C359020437F98D0010E2482873C14C4B542F0818540C0015044221241A0043900210411E8C1
41503089137840088390220F4BB085496C000E1AA043095E80864EADA50E7138820EC528451AF061123A500104FC10810098400651C3C006E828C60FDC601224
F0800402C185493062026920A424078283209CAF0902C1C32437C949960404003B}}
\par\par \b \uc2 Bond Labs Debuts Products at GNC Global Franchise Convention\b0\par\par\uc2 208 \uc2 words\par \uc2 18 June 2013\par \uc2 Manufacturing Close-Up\par \uc2 MFGCLU\par \uc2 English\par \uc2 (c) 2013. Close-Up Media, Inc. All rights reserved.   \par \par \uc2 Bond Laboratories, Inc\uc2 ., an international provider of nutritional supplements for health conscious consumers, marketed primarily through its operating division, NDS Nutrition Products (NDS), has announced that NDS \b \highlight22\uc2 launched\b0 \highlight\uc2  two \b \highlight22\uc2 new products\b0 \highlight\uc2  at the annual GNC Global Franchise Convention held June 10th - 12th in Las Vegas.\par \par \uc2 "We are extremely excited to have again been invited to participate in GNC's Global Franchise Convention where we introduced our newest products into the GNC franchise system," said \uc2 John S. Wilson\uc2 , CEO of Bond Labs. "Convention gives us the perfect opportunity to showcase the newest additions to our already strong line of sports nutrition and weight loss products. ACG3 Charged and LipoRush DS are reformulated, stronger versions of our successful ACG3 and LipoRush products. The initial feedback and reaction at the convention to both products, which feature stronger and more effective ingredients compared to the originals, was extremely exciting. NDS has an established track record of product innovation, which remains a cornerstone of our continued growth and success. Watch for more exciting news to come out of convention in the days ahead," concluded Wilson.\par \par \uc2 More Information:\par \par \uc2 bond-labs.com\par \par \uc2 ndsnutrition.com\par \par \uc2 ((Comments on this story may be sent to newsdesk@closeupmedia.com))\par \par \uc2 Document MFGCLU0020130618e96i0001s\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ \uc2 DARA Biosciences\uc2  Files 8K - Other Events >DARA\b0\par\par\uc2 576 \uc2 words\par \uc2 18 June 2013\par 08:31\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2013, Dow Jones & Company, Inc.  \par \par \uc2 DARA Biosciences Inc\uc2 . (DARA) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on June 17, 2013.\par \par \uc2 On June 18, 2013, \uc2 DARA BioSciences, Inc\uc2 . (the "Company") issued a press release announcing that it had granted T3D Therapeutics, Inc. ("T3D") the exclusive worldwide rights to develop and commercialize DB959, an oral, highly selective, dual nuclear receptor agonist, which it had previously developed through Phase 1 clinical trials for the treatment of diabetes and dyslipidemia.\par \par \uc2 As part of the agreement, executed on June 17, 2013, the Company will receive $250,000 within three business days of execution of the agreement and will receive another $250,000 to be paid no later than December 20, 2013. These initial license fees will be utilized by the Company to eliminate $500,000 in existing liabilities associated with the asset. The Company expects to receive other milestone payments upon achievement of certain development milestones by T3D. A copy of the press release is being furnished as Exhibit 99.1 to this report.\par \par \uc2 Forward-Looking Statements\par \par \uc2 This Form 8-K contains forward-looking statements. Forward-looking statements are projections of events, revenues, income, future economics, research, development, reformulation, product performance or management's plans and objectives for future operations. In some cases you can identify forward-looking statements by the use of terminology such as "may", "should", "anticipates", "believes", "expects", "intends", "forecasts", "plans", "future", "strategy", or words of similar meaning. Forward-looking statements in this Form 8-K include those concerning the Company's receipt of certain milestone payments, the achievement of certain development milestones by T3D and the elimination of $500,000 in existing liabilities. While these forward-looking statements and any assumptions upon which they are based are made in good faith and reflect current judgment regarding the direction of the business operations of the Company, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested in this Form 8-K. These statements are predictions and involve known and unknown risks, uncertainties and other factors, including the risk that the Company cannot execute its business plan for lack of capital or other resources, distribution, partnering or licensing/acquisition opportunities, as well as the risks described in the periodic disclosure documents filed on EDGAR by the Company, copies of which are also available on the company's website. Any of these risks could cause the Company or its industry's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by the forward-looking statements in this Form 8-K. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/919745/000135448813003515/dara_8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/919745/000135448813003515/dara_8k.htm  }}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/919745/000135448813003515/0001354488-13-003515-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/919745/000135448813003515/0001354488-13-003515-index.htm  }}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 18, 2013 08:31 ET (12:31 GMT)\par \par \uc2 Document DJDN000020130618e96i002iz\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ \uc2 Cytokinetics\uc2  Files 8K - Other Events >CYTK\b0\par\par\uc2 329 \uc2 words\par \uc2 18 June 2013\par 07:34\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2013, Dow Jones & Company, Inc.   \par \par \uc2 Cytokinetics Inc\uc2 . (CYTK) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on June 18, 2013.\par \par \uc2 On June 18, 2013, \uc2 Cytokinetics, Inc\uc2 . issued a press release announcing that results from ATOMIC-AHF have been accepted for presentation during a Hot Line Late Breaking Trials Session at the \uc2 European Society of Cardiology\uc2  (ESC) Congress 2013. ATOMIC-AHF is a Phase IIb clinical trial designed to evaluate the safety, tolerability and efficacy of an intravenous formulation of omecamtiv mecarbil compared to placebo in patients with left ventricular systolic dysfunction who are hospitalized with acute heart failure.\par \par \uc2 Amgen\uc2  holds an exclusive, worldwide license to omecamtiv mecarbil and related compounds, subject to \uc2 Cytokinetics\uc2 ' specified development and commercialization participation rights. ATOMIC-AHF was conducted by \uc2 Amgen\uc2  in collaboration with \uc2 Cytokinetics\uc2 . \uc2 Cytokinetics\uc2  is reviewing initial data from ATOMIC-AHF with \uc2 Amgen\uc2 . The ESC policy with regard to clinical trial results accepted for presentation at its Congress is that no results should be disclosed publicly until presented at the Congress or as may otherwise be approved in advance by the ESC. \uc2 Cytokinetics\uc2  does not have current plans to disclose results from ATOMIC-AHF prior to the ESC Congress 2013.\par \par \uc2 A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K, and is incorporated herein by reference.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1061983/000129993313001138/htm_47943.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1061983/000129993313001138/htm_47943.htm  }}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1061983/000129993313001138/0001299933-13-001138-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1061983/000129993313001138/0001299933-13-001138-index.htm  }}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 18, 2013 07:34 ET (11:34 GMT)\par \par \uc2 Document DJDN000020130618e96i0029u\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ Catalyst Pharmaceutical Files 8K - Regulation FD >CPRX\b0\par\par\uc2 298 \uc2 words\par \uc2 17 June 2013\par 17:09\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2013, Dow Jones & Company, Inc.   \par \par \uc2 Catalyst Pharmaceutical Partners Inc\uc2 . (CPRX) filed a Form 8K - Regulation FD Disclosure - with the U.S Securities and Exchange Commission on June 17, 2013.\par \par \uc2 On June 17, 2013, the Company updated its corporate presentation materials on its website. The updated presentation, which is available on the "Events and Presentations" page on the Company's website at {\field{\*\fldinst{HYPERLINK "http://ir.catalystpharma.com/events.cfm"}}{\fldrslt{\cf2 \uc2 http://ir.catalystpharma.com/events.cfm  }}}\uc2 , provides the most updated information about the status of the Company's Phase III clinical trial evaluating Firdapse for the treatment of Lambert-Eaton Myasthenic Syndrome.\par \par \uc2 The information in Item 7.01 of this Current Report on Form 8-K, including the information contained on the Company's website, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that Section. The information in Item 7.01 of this Current Report shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing or document.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1369568/000119312513261439/d555118d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1369568/000119312513261439/d555118d8k.htm  }}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1369568/000119312513261439/0001193125-13-261439-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1369568/000119312513261439/0001193125-13-261439-index.htm  }}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 17, 2013 17:09 ET (21:09 GMT)\par \par \uc2 Document DJDN000020130617e96h005fs\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ Pharmacyclics Files 8K - Other Events >PCYC\b0\par\par\uc2 261 \uc2 words\par \uc2 17 June 2013\par 08:50\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2013, Dow Jones & Company, Inc.   \par \par \uc2 Pharmacyclics Inc\uc2 . (PCYC) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on June 16, 2013.\par \par \uc2 On June 16, 2013, at the \uc2 European Hematology Association\uc2  18th Annual Congress in Stockholm, Sweden, \uc2 Pharmacyclics, Inc\uc2 ., a Delaware corporation (the "Registrant"), issued a press release announcing the results of two separate Phase 2 studies suggesting that ibrutinib, an investigational oral Bruton's tyrosine kinase (BTK) inhibitor, showed efficacy when used as a monotherapy in patients with relapsed/refractory mantle cell lymphoma (MCL) or diffuse large B-cell lymphoma (DLBCL). The Registrant sponsored both studies and is jointly developing ibrutinib with \uc2 Janssen Research & Development, LLC\uc2 . A copy of the press release is attached as Exhibit 99.1.\par \par \uc2 The foregoing description is qualified in its entirety by reference to the Registrant's Press Release dated June 16, 2013, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/949699/000152153613000543/form8k207380_06162013.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/949699/000152153613000543/form8k207380_06162013.htm  }}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/949699/000152153613000543/0001521536-13-000543-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/949699/000152153613000543/0001521536-13-000543-index.htm  }}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 17, 2013 08:50 ET (12:50 GMT)\par \par \uc2 Document DJDN000020130617e96h002sw\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw171\pich40\picscaley100\picscalex100\picwgoal2565\pichgoal600
47
4946383961AB002800F7FF00DACBCB9624288F6B6BBDA3A4C2999AD3C4C4CCBBBBF1F1F1BA151BA78687712023C11E24EEEDEDD1B9BAE5DEDEA71E22A43E42C4
ABABFCFCFCDDDBDBCDC4C4ECE9E9F1EDEDCBB3B4FAFAFAC4A4A5B81E24E9E6E6BD1E24BE9293AB0C12B37A7CAE8081CAAAABE5E1E1A62C30AB1419E1D4D5BCB7
B7B16769E2DDDDC6B3B3B59293B91A20B3898BB28485EAE8E8A30C12BA181EB91C229C0D12E0D9D9F4F2F2A26163BA2026BC9B9BAA696CBE1C22B62025DDD5D5
9D8B8BF6F6F6A13135981E22BD1920B10D14BD2026D2C9C9A35A5DB720269A5254BA8B8DA97375F8F7F7E6E5E5B6161CF4F4F4B5181EA44144D4D1D184191CA1
9FA0C6C3C3AB242ABB1E249C595AB2141AAD9A9BA25255A56C6DA05F61982B2FAA7B7CCCCBCBADACACA3292DAB595CA31419DAD1D19A313596080D885B5CD5CD
CDD7C4C5B21016E2E1E1A34649A21016A27476B5141AF0EAEAB51218DED1D29A14199D4A4DA74D50AB1016AC2126F8F6F69B4143A27C7DAC4A4E96393CDAD6D6
A3050A9B4E51B38E8FB9818296151AB12025C7AFAF8437399B1016A23438F6F4F4B87B7EA45558AD5D6093191EFBFCFC9C3B3FB012188C0204AC181E9C353899
5F61A4393CAC6163EAE3E3B47779B31F24954A4DA4252AE7DDDDB46D70B2161CAA34397D4749AA6E70F4F7F69C191EA34B4EAB292DAB5356A84549F8FAFAAC56
59DCCFCFA84246B05256BA8688ECE6E6B27274955052D5C8C9B01D23A4191EEDECEBA93135B15F62AD6668963134A12125AA3B3FBA1F25B41F24B61C22882528
B61A20FCFAFAF2F4F4B11A20B12E33AB7678B996979B4649B81F25943639F9F9F99C5658F6F8F8BA1017E6E3E3935B5CD9D3D4961217933F42BC2127C2BABAB6
8688ECE3E3E8E3E4B92025A67778BA1D23B81D23A56668B71F25BB2025FEFEFEB61F25FFFFFFFEFFFFFDFEFEB61F24B71E24FCFCFBF8F9F9B71F26B61E24FBFB
FBFDFDFDBFA8A9900D12E3D9D9B99FA0D8CFCFE5DFDFD0BFBFDFCDCDB23C3FC09F9FE3E3E3D2C7C78E474AD8C7C8EFEFEFDFD3D3F5F8F7B87577DDD8D8D9C9C9
D2CDCCE7E7E7D8CCCCFFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A32313636333832333530464231314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3231
363633383234353046423131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3231363633383231353046423131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3231363633383232353046423131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AB00280040
08FF00FF091CF8CF98190A43120E993744998481C64420543884C21E0C04336ADCC8B1A3C78F2039764BC26FA2427E6652326BB7A1021373C642CA14D88DC981
0349CC6DFBB7CD5CC61E82C2F0A296AD68B6222B7E05A3F40F052318C48C0A91D16111C124FAB8DC193125D0AB5796024DF161045D8F810ED86CF1C1966D002E
18FFB5AB62ABAD8F11BB0074FB87CCCF962F76035489F5EF80811A92BED4F90A36509D2F7754F43B37904686472B8A18CDC641571F754C6E84E1B0391B104E82
28FC0D9CE58040667D02D8F5114005E19915882CD150DA282E0ECE3A895A609418902D3BFE9500B4C286D122401EB190D08D800CD29B81485AF92306AEA24510
70FF72652EDE03189A8DC6B0F2A1C73D4039A216CD218A4D825FD6E44387754360BC30C9AC00C3800890E1CE3F15C801036F9B5111C8187214620915C454488C
3540C81001466EB0F04A66D9D8B0C2303C1462CD77D93CD3860F62EC359340EE3493C366391452C625F1F576D47A2D5850C1218D3008DE0A3EF851403DFB00A0
E49200D4730F133D6440470CE9091188020A08A14D3642FC00C503B8E0A28D220A80B200374569B0422D0E0CF44D3F6C00B20407159656042E40D0D1870B025D
4008719B69E3C12C1BFCA38C136838075E0C6B444083403DA880597ABDE510C7052F12C484261E0861D4356DD460C13F1638B36069362C818918DBE8430B1AF2
15FF25C40B7F9CE502048D785A9488A0F8F3D03E889CDA9B354BF461813273B4A123528F7091C43F06E481C066B8BCD00132FFD873C7261CA0998D3656F8A00C
13F9745A1A073284B04D1282D4B104A5DA2C61CB0CFFE8A3461BF269F0C60752A882869045C0F08501996E644E165680980D37DA34B18532026D734633F915C5
0D0C234450F0C61C773C10325A58416569DC94ECADC5452CC0C707B7792C1049C618F384175E48214546EAFCB00215BDE1B2421C25F8A28A072866434D109AB4
F38F39C2AC01C333DEE2A2C117A14858F4B71E7C70402677AC608D51408491814029C88200A51AC0A0871BFF6C7087B09CE910090FB6E46083B736E882892910
04FF5274111A34E209612528B2C2D5365851483BDB1C5089B946D9E0C121E318A24713280A3ACB4BC1909083B7542C714705993241C00BB8C47A940ED45E7D21
210D20580B0C571F458C151EFC4B6951D512F00900841CBE2B1A9A3CD1422E0A17454C0C8F0CE0C714331A9543AF9FFCD18835BB17C1C1123260E38E123B6564
4F0744AB7E271008E4F01D31D4BCA2C8250380EFE60E982CA12837B9500A1D2803849FA9187378437A8841851784001F0D9041C54A133A3D58A01B21B88EEA80
000A4108A400F048C60236C8415094E01F22388415AE41296A50232AC4C88124AEC0057C29AF34D668421F68D08D76C4230438CCA13BD28002157C411744314A
0CFFB160811D90E26CA541800F0AF08F45742E079422D6305C738E7DC027884278C00FB8112B217840137CCAD4396E000B20B02E1B3E0B409BFE41830808457F
3078851F9EF50F1718C1030B700EE872A0BE92154108C95843300A3590120420479B418A1CCFE28E42C0A0373A80C10332E0A21E08830C0B784611D0C40D5CF0
F16EDC28820D16108400B8A31BDEF04318A2571C3A7C8001200C4013147594254C4110F6F840A74A468D1510C21DE670C311E8A0812EBEA01231F1580F52B086
202CC10A56D8C41B3C60844F0CC402C508421BA0690504F0C11371719938C7A91143A0230CCEE4A63AB9D90812B87304443000B6C6D90D1A4881014C8882148C
E1FF85286884125BC0DC66A8D1840718E0592E18663177158459A0802312308405DC40510BF4C07F19D9864637BA0D170D84A31BCD284835EA8D8C60800613AD
A8211EA2916E644296B58B4A201EC18BDA99C61604E309483532D29046CC1CDDE8C639CC618EA166A4023568420C7AD684628CEA021204DB1698281076E0009D
4010820D8AC0D5AE5243080B40800CB8004B386021071CB0C1339EB100121CE11B4BFBC30BF2B856B006401D4DDC471C72F00CB53E0301F04881AB5EF0861C68
B5AB5E7D861010E0814B40EC1F86C0C26E1229C90158C54FAC2C0A0248B10711FC20AB7545C32C46150B53A041AB6BE5000C6A00CB173121036B18999D624082
01FF40C314D3320ABA32E00D090883042B082297AC3006D2D5E3B3A5014221F451812D08EF2830C084C67A80083A08E164D7580211A691840ED06181C6518300
18A10D9E1585037420826B869007012AEF1A7438023EE331A5DDE580044858C439063002F4D0081000F84726B4A08BA572A9A169B880289610440E580112D3C0
A84CDEA1083AE9281BC4E8D20F2C81226268000D7FD8801BA221B2122EE10B2938C01EB090A8CD10E30D89E84726E2F05C6AA0211528A88024ACB0A5E7D03603
13384410FE86864350E00F6D902D1A37510803942216997043055CB00A2AAF02A8FB9091EA94A70D0E68A34E5A84042D042102CAFCA30717780083D1A8034540
21FF1CBA0ACFC04A5A303180E10D9BC922141421842D1B256DB57860024F94489FB5E1D0884E74814EF18D06C43688B8E0C53178F0054213A36468D40626CAE0
0C446643037488866B62710C0F0061ABBDB1410E1AA108166CC0CCFF70C51C729B9D11E0011D59A8430CE4D3492028E21EFE8B0524AC705D1D718010F1B0CAC6
98A08A17E8EAD36DC847173A703D3F8B280EF5F00600C60004D579511367C1C0055AD0817297FB082D6086396271844690B028DAD022982AA48D41282017A923
C657B858945E364AD904C18032E2B1053A2C40B8426C82162CFA07C81965013220C0363050B635F36E058080C34ECC718135049777B59BD511C6B13108EEB538
39FF50C40797E31D3B25850507B0C7213C404BA3DDD80CFFF8860ACA18C525B0F61FF7C0C1647B538418D0E102410E829F43242F769C6303F9088297B5D1E564
CC821DFF48420B7EA13066A9401C0D20446643F445D25560D8CF66963046358F2D745B568118C4203850341BA7C2150593802BDA1B447F0BE22C1508C62694CC
192BC8E1510C68F8B3D1D8045280C01385B88679B9F18C2580C21DE1ABC0538414B926D86207E768C011752484464060033B8916AD31CC0B527021186AD0C5D7
C0038329AC23090540451B76970D188C610FFFE80536AC30FBF35A81083DB0472282F08C34E5600B28F0C50782442364D37926FD200209741088EEBFE211AD89
D8FF3D14F10BEE775F07242804E807328E21D4401681C805A6B3018E72E42210C040440AECA19153284217DD178081C00D24D007AEF10FFBF003BC2080DD5704
6B400B4C4010DE2002D52009756009E5500E9C647F96300592E0093BA06CB180056B607E01080ECDD000DBC004E7F40B02A8039BE00452500D0F0080DDF70BB0
A0026761011DB0066111803AB0066010461D730E33D00792800A4AA8848CE00724271034000292E0044B880A63C0058F424E5A484EE2B00372908455880AA430
86A1300A603009ACC002EBA0042C454FFD000D4FA00452003E287033196107C2F00A40F00C54870B0B203A07286087A425DAE087614000D7B7858AC83134B075
7BFF487590088961D2651C90038CA507EC20611D23017B600E12600226200F5E000DE5340C9B605EBBE2796240194910026BB04045F0067970208B588B1B6301
8CB004A8E81B7C840BE4602708E004B4284EE6200FE68001B1C00F5DD00F139011E7E00FA0304B8994146BF70F3380036D100E52E10195108802710E867000EC
10012C0002E6A80229800234904C02B16E28E000ED108FED8002B1E02212500128208FF188023DB0172B388FFA8802CA904CC64003B1300F03508EE6E807E860
0607006B02810167108D3527355F1009913002BA503B40800917D00322008FF2986366660E2E908F01B90174841B47005CBC1743C7C03670A0089E9603841002
1EFF85027E00018FD0086DB0042B109441B9046FD0085F500DA4A31C4610046FC04DDE9405CA7601E9900CDCD406C9900EFB2010B1904DDB044DC9F04D58810D
B2D0936D000342199430D0068D000B7D3004CA6608205062CFB102CD821105000840501A30700B0630043280065DE94D73C07FE7E007644095D06495E9500010
1912B1A00730B08B17F70394700EA75334E4800073E00F02B101D8B00608A049DCA003BDF4061F071EDA0004E99002E7F00E72E035D2B30604B01769600A41D0
639FB6025BC01407C0028D60604C370A2690058DB08725439A2B8006B4931EDCA06A6490013E5101B5F05CBB72628C790E1DE06C89840689500116105028E245
B3FFF090293002481422BE6400002713E7500084D072A5E16FEE80029A002B462128AA800C13B8056D506C46B3020FA00213A0020F307608A0064AC00090B033
E001040FA031DBD002AB74469F060372B00ADD9065EA233D9C200091400DD8F19FA2200CCCB00E9C00157F66059EE002DB1076F0292B8D100A8FB20760D06252
F10219B00D6E20074D307B9A630FB1400AA78526D40003B0707B05E3022DE06E4B1743D59000B79097CA9303CDC04434300C4B507C9C41024480110D2023C9A5
7E1BE05C0C121E9C7001E6C00C9260A345710D56800334E0027D800042126955800753400545930361E007702508B7800052A301B8600D389A04ABF00123541A
39FFF008D5C000FA800824B078B8F00658D00FFF400948C0759A61036D900814E009E0307BD0410220D09832210DDCC679D4220450000575F06CE1B004888002
E610011EA73F4B200AAC390E1FA09D9BB159138002868322B1880A33600CD8D008DDE2638DD001F61002C05A1430900757D0024A45236170AADD200C50E00390
10AE3EB005838057D210006FD71BBA6005494614B8005662850461440303F00A4DD0A9DAB00B0A10AB51C10D3940079E500A1B730E506561CA933AC5610996C0
6F185640048001ABA01B5ABA3C7580087F3009A2B06B2E5664F6500234862236D05013E00E0B8670CB430282000DD2422D06A404959064FA830B9BB005C2200F
1DFF610E1164B02EB64968820B45000A0A5006CCC08E4B330FB6603F68940B0F0026E1E90193E08D2FA20C42162BB860094B6B53BE610D2AA71C346953D4B056
7D6542626B0353D1008B70068FB62B6D400B26100A31C033C480B0045407095003BC809BC470A065760164706A27D36F0B8006E9800DA7B092023103AC609F9B
61039630029CF008D7804561450620108103B10163C063C5513436800660A0341C730A63F04852610B0AB00B0B80B5D9905D88400396F9020B6514D4900B7520
0A533005A290BBBA2B0A75500C0E700EAE285BB8500E83D00913824681600B7510265DA200017026BC832E0DF010DFA00F97E0341C8070CA430540B00646A00F
66FFE60AE86A27B2380FE6B00788424BD4C028117016FFE00D33B0054B809B8C0A08C35830E7100F32B07830300A57100C43179FB4150176E00F6040A78B8B06
A6800218B00D434554107C8CE7B00D164000F5252B0FB06742F01D0B00050AF00A6162038AA008AF1067EBE109FC47109F90027AF00259D51B9487006B3000C6
6099FB5B1AB352093D700E3B700B6C2A9F71B101C5A08B17C619C886AA3221029CA2281EE6011DD00F21F05D7EA60D2BF0034A530FF0A13A0BB0064740192250
0C8EF0023230C632F0028E2008F7180DEE961E553B80F4560702B00C350572545BC5EAD00D138701C75854DBE00BEE5003C1430DBB630DBC70A11B700241A0BD
14FF644118A00275E05FBC030301300D02C100C790A59A410C45A0037F3B2B87E00B1C73065F00C9C4802E67F00DF5F09E3615034D500307600ED97935E1D164
FF700EE8609E94E233B5403A33E0096D700D2E261FD9C50A52F0078AEB728FA0024980012D10C62FF0CC2FC007BB90028551039B9059D6B00938600EA7600B52
FA1C6F3007F4D203586005219A0D31B00928DC36D3E7B318860B1E6C039C2BB2037B046B0028B9A9074CF152D4D96F05250849A00C9A1004BB232827004BE680
0D7410A2484102C2C07F7030094B00CC3DB3028A8002FD30096FE0670C630577C07FEC90086F906F713B397C920459B009C557044B50074E763AE7CC252F7004
49FF700E70F0056DA0BE05650018D05DCE86423900013C8004015C046D800A399529CA000641A02845D70847403A8650056DA0A55CB209635028F4890608372B
20400376B00E530003C2650D56D0078620105C033773F908376008A7902C3A420DBBCAD3FF207AAB870B1E7004078001EE600BD2B8300E867CFD609B35970D39
00084C640C7E3029F7F960F6E00DF1F027CA63A80DD00FC6CC798B9C7765739ED7560F7055012AE092CF715FE054CB828049A882830F80399A11C361C002962B
60B590AECFC1019B2007AE11011040BAE74202DB5C55CB577336C0DA9B80B00BE345A1C000DB300098F0CD46F1068860B3347007443C24BFD002E36000DE8C26
45FF670548C000B91424B1B2C5D180C41E9104D3B7001CD0DE967807AD650CEEB00640C0DEED1D56BC4A471240017AE0016D6058856821BF61891EF0052DF050
045102A0000468D5DEF79D0C5F60060F5102B680000EEEE00B900C92B003FEA3045520036F00041CB0C102DE6540F0062FC008291013E370027874E139B0001E
4000355D0F618000F6CD01190E0C05600019C4DE7C84007AC0270CD00141C04718EE0127908533910678D00A5A10E55A5005651188151009C720E55A500397C0
06293C1012600F82A00590F005C070E6C0300290500503100B6D481033D00A44A0E5517E0CC730003EF10F3BB00C594EE744D00A112061DE900414C006CEF005
A23E80E6A23002C3C0051490042EB20D1BC0069750037EBE0C6D720011D00AC760E9525E052020057860049E5E03461009334019CB440F74CEE55C4084321110
003B}}
\par\par \b \uc2 GE Healthcare\uc2 ; \uc2 GE Healthcare\uc2  Presents Parkinsonian Syndromes and Alzheimer's Disease Research Data and  \highlight22\uc2 Introduces New Products \highlight\uc2  at Society of Nuclear Medicine and Molecular Imaging Annual Meeting\b0\par\par\uc2 524 \uc2 words\par \uc2 14 June 2013\par \uc2 Health & Medicine Week\par \uc2 HAMW\par 414\par \uc2 English\par \uc2 (c) Copyright 2013 Health & Medicine Week via NewsRx.com   \par \par \uc2 2013 JUN 14 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- \uc2 GE Healthcare\uc2  announced that results from three company studies utilizing DaTscan(TM) (Ioflupane I 123 Injection) in Parkinsonian Syndromes or the investigational imaging agent [18F]flutemetamol will be presented at the 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI 2013) taking place in Vancouver from June 8-11.\par \par \uc2 GE Healthcare\uc2  will also be exhibiting its newest patient-focused solutions including its new hybrid imaging scanner that balances low dose radiation capabilities with high image quality.\par \par \uc2 "We are committed to bringing some of the world's fastest and most effective imaging solutions to market and are proud to exhibit some of these technologies at this year's SNMMI meeting," said Steve Gray, president and CEO, MICT & AW, \uc2 GE Healthcare\uc2 ."\par \par \uc2 GE Healthcare\uc2 -sponsored research study presentations include: DaTscan Presentations Publication 191 - Accuracy of DaTscan(TM) (Ioflupane I 123 Injection) in diagnosis of early parkinsonian syndromes (PS) - presented Monday, June 10, 12:30 - 2:00pm, West Building, Room 215-216 Publication 1781 - Safety profile of DaTscan(TM) (Ioflupane I 123 Injection), a radiopharmaceutical indicated for visualization of the striatal dopamine transporter using SPECT - presented Tuesday, June 11, 2:45 - 4:15pm, West Building, Exhibit Hall A\par \par \uc2 DaTscan is a radiopharmaceutical indicated for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging to assist in the evaluation of adult patients with suspected Parkinsonian syndromes (PS). DaTscan may be used to help differentiate essential tremor from tremor due to PS (idiopathic Parkinson's disease, multiple system atrophy and progressive supranuclear palsy). DaTscan is an adjunct to other diagnostic evaluations. DaTscan/DaTSCAN has not been approved by \uc2 Health Canada\uc2  for use or distribution in Canada.\par \par \uc2 [18F]flutemetamol Presentation Publication 302 - Automated quantification of [18F]flutemetamol data - Comparison with standard of truth based on histopathology - presented Tuesday, June 118:00 AM - 9:30 AM, West Building, Room 215-216\par \par \uc2 [18F]Flutemetamol has not been approved by regulatory authorities, and is not available for sale in any market, including Canada.\par \par \uc2 Visitors to the \uc2 GE Healthcare\uc2  booth (#307) will be able to explore a Technology Pavilion and get a glimpse into the possible future of nuclear medicine and molecular imaging technologies. GE's current transformational technologies will also be on display, including: Optima* NM/CT 640, a new performance SPECT/CT system that helps physicians balance low patient radiation dose and performance efficiency with high image quality Discovery* PET/CT 610, the first double-digit and highest sensitivity found on any PET/CT scanner\u8224\'20\'20 commercially available. Software applications that are helping to provide exam results easier and quicker than prior generation GE solutions.\par \par \uc2 Keywords for this news article include: Dementia, Tauopathies, \uc2 GE Healthcare\uc2 , Brain Diseases, Nanotechnology, Nuclear Medicine, Alzheimer Disease, Molecular Imaging, Emerging Technologies, Parkinsonian Disorders, Neurodegenerative Diseases, Central Nervous System Diseases.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC\par \par \uc2 Document HAMW000020130607e96e00064\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ Salix Pharmaceuticals Files 8K - Other Events >SLXP\b0\par\par\uc2 190 \uc2 words\par \uc2 13 June 2013\par 16:32\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2013, Dow Jones & Company, Inc.   \par \par \uc2 Salix Pharmaceuticals Ltd\uc2 . (SLXP) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on June 11, 2013.\par \par \uc2 On June 11, 2013, \uc2 Salix Pharmaceuticals, Ltd\uc2 . issued a joint press release with \uc2 Progenics Pharmaceuticals, Inc\uc2 . announcing that the FDA is seeking input from an Advisory Committee on Salix's Supplement New Drug Application for Relistor(R) (methylnaltrexone bromide) Subcutaneous Injection, for opioid-induced constipation in patients with chronic pain. A copy of this press release is attached as Exhibit 99.1.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1009356/000119312513257906/d553314d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1009356/000119312513257906/d553314d8k.htm }}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1009356/000119312513257906/0001193125-13-257906-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1009356/000119312513257906/0001193125-13-257906-index.htm }}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 13, 2013 16:32 ET (20:32 GMT)\par \par \uc2 Document DJDN000020130613e96d00566\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw95\pich40\picscaley100\picscalex100\picwgoal1425\pichgoal600
47
49463839615F002800F7FF00ACD19CD5E8F3A5A6A9E0EEF6C8E1EEB2D4A3C4DEB975B25BFDFEFEFAFCF9B3D6E82C8DC03391C289898D66666BD1D0D2E1EEDCB6
B6B8A3CB78A3CC91D2E6C9CEE4F0DDDDDE929296A1A1A462A74484BCDAEDF5FAD0E6F191C3DE757579C9E2F09595999B9B9EF5FAFCC5E0EE858589E6F1E168AD
D2F0F7EE3E96C58DC2DD818185BABABC8D8D914C9ECAB8B8BB6D6D71C6C6C8CDCDCFF9FCFD4299C7B9D9EAD9E9D1529E32C2DEED0E7CB70276B4ACD3E7E6F1F8
A0CCE3F7FAF5CFCFD1D4D4D598C5857CB8D892C27DD8D8DAAAD1E6BCBCBE59A23AEDF5EA95C6E05CA43D9D9DA1FAFAFA69AB4D9AC8E1E8F3F8F7F7F7117FB818
82BA6CAD50469BC81480B965ACD1E1E1E2EAF3E6E3F0F87EB765EAF4F90578B578787CB2B2B5BEDCED72B3D551A1CBC7E0BC88BC71717176D6E8CEBEBEC081B9
69F8F8F92589BEF4F4F4C9C9CAF2F2F2AAAAAC49992661A9D078B35EDEEDD8C0C0C2E6E6E6DDECD6097AB6A5CFE41E85BCB4B4B77BB561D5E7CDECECEDBAD8AD
8DBF77B7D7A9AFAFB1F8FBFDF3F8F0F0F7FB9FCBE2DFEEF7ACACAE60A6420071BD56A03564A846A9CF995AA6CEA0CA8EC4C4C68AC0DCD0E5BFBCDBEBC3DDB871
AF563A94C488BFDC9EC88B96C482A7A7AAE4F0DFE2EFF78ABD745FA540DAEAD386BB6F57A4CD288BBF8EC0795FA8CF7B7B7F67AA4B509D2F0076B10075B3DFEE
F5A0A0A3DEEDF597C7E0E5E5E6EBF4E7DADADB2086BD9CC9E1CACACC76B5D6EFF6ECF5F9F4C3C3C5DBDBDC9DCAE2CDE3C39BC788DBECF4D8EAF3A4A4A7E3E3E4
FBFDFBD3D3D472B057A7CE96AFD29FDCEBD52F8EC11A83BBBDDAB054A2CCE7E7E8E8E8E9F2F8FB98989BCAE1C0E4E4E5B6D7E9CDE3C49EC7EA78B6D77BB5DDDC
DBDCC5DEF0DEDEDFEFEFF0D9EAF4DDECCDF1F7F0F4F3F36CB0D39CC8E6EDF5F0CBE3F0B6B8BBDDEBB79FCBDE0072B8B7D7AAA2CBE7A2CDE3D0E5C7D3E6CB87BC
700C7BB7F8FBF753A2CCB2B2B4EBEBECF9FBF8E1EED5F5F5F5F6F5F5EBF4E890C07A93C37F97C57B9B9B9FDDEDF582B6E5D8D8D9E8F2E3DBEBC571B2D3D7D7D8
5DA6D1AED3E7CFE4C5FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F626520496D61676552656164792220786D704D4D3A496E7374616E636549443D22786D702E6969643A3142304236354442353046303131453639
3838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A314230423635444335304630313145363938384645
4531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E636549443D22786D702E6969643A3142304236
354439353046303131453639383846454531364331343335353638222073745265663A646F63756D656E7449443D22786D702E6469643A314230423635444135
3046303131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D70
6D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDA
D9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A
999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D6C6B6A696867666564636261605F5E5D5C5B5A
595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D2C2B2A292827262524232221201F1E1D1C1B1A
191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C000000005F0028004008FF00FF091C48B0A0C18308132A3468EB9FBF
70F0566D5A48B1A2C58B0365919B902583478F59801430400ECE2500470CC4E2255059128F9A34650056A0D01B60B130EA24C80BC001299420EC1C4AF4DF1B31
0A71942A35C5C4962D60FE4933540AC73F3B4BBD68588A6229121A4B5BE05A4A76E9BF5C4BE92C9DF20FD452494B053979ABB4D48E7F41967650546A060E1CB5
942A0A40F69F27B2A4B40D00476ACBD26245234B9E4CB9724565323300F188E04AA443496C24096399F29CCD19442D9A5894429251870A5CC20707C2112136E6
1C3C2226C3A28AB552094FD544C70682C438CD6B575AE70041E388FCDB30AE7A857F23AADF4858200F42B25BD42EFF9D34B7548E0564EB2CC00106139A520C9A
2C75836A69AB7F3396D69BB474442A4FAD10D00A156EECD00A538D94D20A2AE32C358E406E9015C53F5F48F80F61A550F14F57A5E820105C5B5490C202ADDC95
D0340EDC310606FF2801822E242473813A2C0CC182032E10A2C20B6AC431861F0DFC50840A212CF1CF0B67C4F182121E4460893A4AA8C1C6055CB05086034538
5086002FA8E383034FFC330417EAD0430221BA701141115D14D1801F1160008207C990100706B38C914C737CFEB38A1419BC51093EFF20C08728854871429F8C
52144B3061149048098518914112661820D0047BCC01071C7C18D1E864BC9473CB474CDC12C62A155D234F1827C4FF524209918C62840D9A2092410102959088
AE5278372A41C164E25125BA35D7C31EB77CB2071964B04A1131199046590200BC614643C396360125099D13D6176A81C3CF358E6CD3AD45C32C25422A644962
D852DB21248B370655F1455D41A0925F29D960C8007E4B7103EF526898B081024B9930C0520377B2542DEF3946560AAE90B580099804D06E588208A4C55254A8
C5C114A54491432923C860DF3F2897D2CF854B59BC540AFF38B1C3CE3B388100411F7C50282698FCF14F20043CC28DD1C810BD01025860E2C43F5A101D884001
78318216036931020DDCC8305000343C820A410898A236D77F0C32882957FF61CA2058E43CB708045540C30DC751FF3484032CFE73CA05244440CD1D7A0CC106
178CC0D04B0C023810871C1158A0CE3D2BFC20D018AF5C70012D654CE34117178030CD132B3CEE0E0C6B0C0143113E0CF1040CFF3CE0810F18ACE1070C4BACE0
C22C2E9C110321AAA4E1821C72ECAEC63B1658B06E69AFA871910B0915E1CEF392C5F2061305B4110F3A79BCF1C611D8974FD0011E5D41862CFF8413C6279A14
8287F9E59B93994700F0120E1E35005080F8F4B3CC250CB0888E7CC423063083108CF00B8218C0178790820D3251807204238018810000F0F0114450B01CE43B
481F0AD083125C4116808884A53EA2093E4080131FC91F0609D20C63794408B0DA091FDA208F725C211635C80227FF80F186244821010449401FF057BE6B14C0
171960C2229235993C40B00D3690C726CA418E5B40422100C840031B65803764000F5F1C1602D0C10E8C24220348AC4C027E218503EC61861801440684121900
98A112ACC1E34E00B108961CA42C6481420010900F0948C01A82E44061FA4116B6086329554888233485B69DD56504FF804B29F4F1876F68C319FF1087063430
B5261443186E904E2E56C98C40D012176E50C42304928B20A0A0054818482AD2C10013CCEC1F15800503663089BEC5EC0379411826DA458500346212A9F80711
26910202D88300FFE0003466D0893AFCA3094DA80B7840F18F0F406C430E82422984518D0E0882007568D8C3AAD2FF0F062C85006028051444A0030751A11428
40450A9A908B672C8519DC68842BB8C68CA580E19229B8A422D492823F2CC50E305B0A0E5040047F464106192BC575EAE28A7F486C9E0C830F3C4BA18040A422
08B058D90252EAB0A52CE01F2D588A0E2E4985472820151D18C1063A10047D2C6518C8F0022C1AC1211E08043D69F9075FC82283F2DC2766CCF8C70E96120566
1001091DE0C63FA09083959967182610485011FA2F0E30C3AD29AB8017F4E953A02EE53AFF6AD83F9050962854E00F58B5A8D8FE2108B20C8CB016FD07379E4A
3099096407FE244B3604C9D98A80E00102C19D25A2511001FC4C203DFAC73BBA711036D4EE0E03C1C63F5660248CD9C060468DA2920AAE478853B02102F40885
004870810638A0172CB8000694E0B908808004200805098C44821090C0122E1883254000B90B9C22062A60810AB8440F42B0610C0DD0050B4EF10F0C9040200D
B0C4702FC08206AC37192E084111B830B80684C003BA00012D14120DD01E837672B84304FE91605544C318CB88C60AD410831FA862193EB0C23EF4708608F840
203158821C1E108322AC63082B60C531AC00BA18BC03066778C51A1E50045594C1030361050658F10F36C0001BACD88515761103E1EAC1184518422F54B10F77
7061169DE56C4000003B}}
\par\par \b \uc2 Bond Labs  \highlight22\uc2 Introduces New Products \highlight\uc2  at GNC(R) Global Franchise Convention\b0\par\par\uc2 492 \uc2 words\par \uc2 13 June 2013\par 11:00\par \uc2 Business Wire\par \uc2 BWR\par \uc2 English\par \uc2 (c) 2013  Business Wire. All Rights Reserved.   \par \par \uc2 \f2 \par OMAHA, Neb.--(BUSINESS WIRE)--June 13, 2013-- \f28 \par \par \uc2 \f2 Bond Laboratories, Inc\f28 \uc2 \f2 . (OTCBB:BNLB) ("Bond Labs"), an international provider of innovative and proprietary nutritional supplements for health conscious consumers, marketed primarily through its wholly owned operating division, NDS Nutrition Products ("NDS"), (\f28 {\field{\*\fldinst{HYPERLINK "http://www.ndsnutrition.com"}}{\fldrslt{\cf2 \uc2 www.ndsnutrition.com}}}\uc2 \f2 ) today announced that NDS \f28 \b \highlight22\uc2 \f2 launched\f28 \b0 \highlight\uc2 \f2  two exciting \f28 \b \highlight22\uc2 \f2 new products\f28 \b0 \highlight\uc2 \f2  at the annual GNC(R) Global Franchise Convention held June 10(th) -- 12(th) in Las Vegas.\f28 \par \par \uc2 "We are extremely excited to have again been invited to participate in GNC's Global Franchise Convention where we introduced our newest products into the GNC franchise system," said \uc2 John S. Wilson\uc2 , CEO of Bond Labs. "Convention gives us the perfect opportunity to showcase the newest additions to our already strong line of sports nutrition and weight loss products. ACG3 Charged(R) and LipoRush DS(R) are reformulated, stronger versions of our successful ACG3(R) and LipoRush(R) products. The initial feedback and reaction at the convention to both products, which feature stronger and more effective ingredients compared to the originals, was extremely exciting. NDS has an established track record of product innovation, which remains a cornerstone of our continued growth and success. Watch for more exciting news to come out of convention in the days ahead," concluded Mr. Wilson.\par \par \uc2 About Bond Labs\par \par \uc2 Bond Laboratories\uc2  is a manufacturer of innovative and proprietary nutritional supplements for health conscious consumers marketed primarily through NDS Nutrition Products ("NDS"), a wholly owned operating division. NDS sells over 50 different dietary supplements to promote sports nutrition, improved performance, weight loss and general health exclusively to GNC(R) franchises. Bond Labs is headquartered in Omaha, Nebraska. For more information, please visit {\field{\*\fldinst{HYPERLINK "http://www.bond-labs.com"}}{\fldrslt{\cf2 \uc2 http://www.bond-labs.com}}}\uc2 .\par \par \uc2 Forward-Looking Statement\par \par \uc2 Statements in this release that are forward looking involve known and unknown risks and uncertainties, which may cause the Company's actual results in future periods to be materially different from any future performance that may be suggested in this news release. Such factors may include, but are not limited to: the ability to of the Company to continue to grow revenue; the Company's ability to continue to achieve positive cash flow given the Company's existing and anticipated operating and other costs; and the outcome of the Company's pending litigation with the \uc2 U.S. Department of Labor\uc2  and our former President alleging violations of certain unlawful employment practices in connection with his separation from the Company. Many of these risks and uncertainties are beyond the Company's control. Reference is made to the discussion of risk factors detailed in The Company's filings with the \uc2 Securities and Exchange Commission\uc2 , including its reports on Form 10-K and 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the dates on which they are made.\par \par \uc2 Document BWR0000020130613e96d0009d\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw158\pich40\picscaley100\picscalex100\picwgoal2370\pichgoal600
47
49463839619E002800F70000D1D8EA677EB895A4CE5871B1F0F2F82A4A9C4964AA768BBFB3BEDCC2CBE3E1E5F18598C63957A3A4B1D5F2F4F9FBFBFDF8F9FCEE
F0F7F4F6FAECEFF6DFE3F0E0E4F0F6F7FBDBE0EEE2E6F1DDE2EF9EACD2FEFEFFFEFFFFD9DEEDACB8D8A6B3D5E0E5F1FDFEFEDCE1EFF5F7FAE8EBF4F5F6FAF3F5
F9E4E8F2C6CEE4E5E9F3E1E6F1EAEDF5FCFDFE9FADD3C2CAE3D8DEEDD0D7E9C3CCE3D4DAEBF1F3F8D5DBEB9DABD1B6C1DDAAB6D8C9D1E66F84BDABB7D7FAFAFD
C4CDE4F3F5FAB2BDDA4E68ADB5C0DDFAFAFCFAFBFD92A2CC8E9ECAE4E8F37085BE3855A4E8ECF4FCFDFDEDF0F7ADB9D9BBC4DFB9C3DECAD2E6CCD4E8D2D8EACF
D6E9EBEEF59BAAD0D9DFEECDD5E8D2D8E9B0BBD9E9EDF58697C7EDEFF6D6DCECC6CEE5C6CFE5F2F3F9A3B1D4E9ECF5ECEFF7D1D7E9FDFDFE96A5CEDBE0EDF5F7
FBD0D6E9BCC6E0F9FAFC7E91C35069AEB1BCDA94A4CDF4F5FAC5CDE4B6C0DD7B8DC1E2E7F2536CB0CBD3E7BAC4DFECEEF699A8D0D3D9EABFC8E1FBFCFDB8C2DE
AEB9D9D6DCEB8295C5C0C9E1D0D7E8BEC7E0B2BDDBD2D9EADADFEE8798C7F7F8FBC7CFE4D7DDECD3D9EB6F84BCC1CAE2DFE4F19BA9D1778AC0A6B3D6D3DAEAE7
EAF41B3D95FFFFFF0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000021F90400000000002C000000009E0028000008FF0027091C48B0A0C18308132A5CC8B0A1C38710232E9444B1A2C58B150748DCC8
B1A3C78F10318ABCA811A4C9932853221CC9525249953063CA7C5831C1CC9B387386A4685362800208082E900460528091042619C05840A000910D8C2225C840
928082050C0804E09220014901B6822DD840D2028108445EE5FA72D2D7B05C459E555873E351AB0387161DC8352CC1A57B0B3E0D2A50C158BE870517185020E9
C0AC6225195020F06DE4AB5B0B98459B9860DCC9953B4B0D3C91A7DDC52E93EAF52C1AF0C1C1030DFB153B3B768105040AD4863C89ADA402512DF79654353883
019B27A5AD8D183970B7A28F92A6DBB26BC29F930E1007B01A31F3A515E73AFF85CA9AB95106E3094FE2CD550080AA07847345C0388101035CE7A6B5E878B87B
F8C20D249D43D5598710769394251951E515E49A41B01D7580417D15B49F45E809C41E5E0420B7945FF3115055010AE4C79979FEB9E561740C3654605B0621D8
1B78A455F8578B824942D85130DA381003B5A585D986984D32D461F34DA20050C3E9279A58451EC9DC802E9AE65353042157636B2225059B403C06E6637692F4
349001051445244108E826967A623989D159EDB1E92641543254974E028D1182401F5830090D48F069684A7BF289421E02D560C6247B5C70E8A42025AA130C31
4CD28221930CE1C62411705101A5A44664E94C1A1441001093D8010904774CFF10860B1F38C042A9B85659A64E2DAC3082079390818192935800C22438D090C1
74B9362B50812279F44409313891901C0438D083B3DC0E042D461B3D92C5246A6070C20B0B757006051374EBECB7176D94011E93BC9082430F38F080BBFCDE04
801435D8501001076846D101454150C1053BF4EB304A1B4C6284150625905554BD1D75D503D93EECB147511C61C2245B08C15A91033560000123CCF0F1CB1B79
C1C42449ACA142965AC1AC734A8A0032B024182724C98404195C5186C8594459D2A70EEDED844F5944F4CE1FC511484109E0B8D2D44AE2359E400C104D705103
643850D25139FD2CD49250961D8C544754081193F431074159335B90DA8579FF3DC95302316D1AD34113C4B7D35157C475DC1135F2C5242B1CE2958E13716D58
918013ECB66151954DD7D488B7CDF84957E460D00070EF6D91464653849E8817D924F8AE375A14D5536E8FFE51064D28C0C3C906A99C1404FBEA6EBC084B4C52
C614584BD61300C85D45410512186FBC0B7E843048C40529A09DE27BCD1041F5D61BFFC00F5AF8F04643145010411AE51BCF81A08BE48E90040EE41FBFF58438
C28120685082060E12844988400654B8D7FE74C782915D00041080811E488082496020296C10C3F816B83F1200AB0D3A28011D2600852A446212885041073818
BF13F06112139001040000874930A20B7F60A10E277183444C020C75100816077648C4229A2420003B}}
\par\par \b \uc2 EMD Millipore\uc2  Direct Detect and Muse Products Tapped as Finalists in American Business Awards\b0\par\par\uc2 525 \uc2 words\par \uc2 12 June 2013\par \uc2 Entertainment Close-Up\par \uc2 ENTCUP\par \uc2 English\par \uc2 (c) 2013. Close-Up Media, Inc. All rights reserved.   \par \par \uc2 EMD Millipore\uc2 , the Life Science division of \uc2 Merck KGaA\uc2  of Darmstadt, Germany, was named a finalist in the \b \highlight22\uc2 New Product\b0 \highlight\uc2  of the Year category of the 2013 American Business Awards for two products \b \highlight22\uc2 introduced\b0 \highlight\uc2  this past year: the Muse Cell Analyzer and the Direct Detect Protein Quantitation System.\par \par \uc2 According to a release, the awards are given as a national recognition to \b \highlight22\uc2 new products\b0 \highlight\uc2  that have impacted their industries in significant ways.\par \par \uc2 "Our goal is to always help our customers perform better scientific research and make progress towards the treatment, cure, and prevention of major diseases. Both Muse and Direct Detect products are faster and easier to use than their traditional counterparts in these efforts, reducing workflow and complexity," said \uc2 John Sweeney\uc2 , Head of \uc2 EMD Millipore\uc2 's Bioscience Business Unit. "We are very proud to have these products recognized by the prestigious American Business Awards this year."\par \par \uc2 The company said the Muse Cell Analyzer provides greater accuracy and precision than manual hemocytometry or image-based automated analysis. Through real-time, multi-dimensional information on cell populations, the Muse Cell Analyzer enables faster, more accurate decision-making, more productive workflows and greater insight in to cell health. Muse Cell Analyzer has allowed \uc2 EMD Millipore\uc2 's customers to run more samples in less time with greater accuracy.\par \par \uc2 Additionally, the Direct Detect system for rapid, simplified protein quantitation taps into \uc2 EMD Millipore\uc2 's membrane expertise to enable infrared-based measurement of amide bonds in protein chains, an intrinsic component of every protein, without relying on amino acid composition, dye-binding properties or redox potential. The Direct Detect system enables researchers to improve the speed and accuracy of their quantitation, a necessary component of most downstream applications.\par \par \uc2 More than 3,000 nominations from organizations of all sizes and virtually every industry were submitted to The American Business Awards for consideration in a wide range of categories, including Most Innovative Company of the Year, Management Team of the Year, Best New Product or Service of the Year, and Executive of the Year. Roughly 35 percent of submissions were named finalists by a panel of more than 140 executives over five weeks of judging. \uc2 EMD Millipore\uc2 's Muse and Direct Detect products are both finalists in the New Product of the Year category for Health and Pharmaceutical Products, and will ultimately receive either a Gold, Silver or Bronze "Stevie" Award in a ceremony to be held in San Francisco on September 16.\par \par \uc2 EMD Millipore\uc2  is the Life Science division of \uc2 Merck KGaA\uc2  of Germany and offers a range of performance products, services and business relationships to assist customers' in research, development and production of biotech and pharmaceutical drug therapies.\par \par \uc2 Merck is a pharmaceutical, chemical and life science company.\par \par \uc2 Stevie Awards are conferred in four programs: The American Business Awards, The International Business Awards, the Stevie Awards for Women in Business, and the Stevie Awards for Sales & Customer Service.\par \par \uc2 More information:\par \par {\field{\*\fldinst{HYPERLINK "http://www.stevieawards.com/aba"}}{\fldrslt{\cf2 \uc2 www.stevieawards.com/aba}}}\par \par {\field{\*\fldinst{HYPERLINK "http://www.millipore.com/directdetect"}}{\fldrslt{\cf2 \uc2 www.millipore.com/directdetect}}}\par \par {\field{\*\fldinst{HYPERLINK "http://www.millipore.com/muse"}}{\fldrslt{\cf2 \uc2 www.millipore.com/muse}}}\par \par {\field{\*\fldinst{HYPERLINK "http://www.stevieawards.com"}}{\fldrslt{\cf2 \uc2 www.stevieawards.com}}}\par \par \uc2 ((Comments on this story may be sent to newsdesk@closeupmedia.com))\par \par \uc2 Document ENTCUP0020130612e96c0003j\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 DJ Auxilium Pharmaceuticals Files 8K - Regulation FD >AUXL\b0\par\par\uc2 232 \uc2 words\par \uc2 11 June 2013\par 07:01\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2013, Dow Jones & Company, Inc.   \par \par \uc2 Auxilium Pharmaceuticals Inc\uc2 . (AUXL) filed a Form 8K - Regulation FD Disclosure - with the U.S Securities and Exchange Commission on June 11, 2013.\par \par \uc2 On June 11, 2013, \uc2 Auxilium Pharmaceuticals, Inc\uc2 . ("Auxilium") and Men's Health Network ("MHN") issued a joint press release announcing the launch of a new health awareness program called "Ask About the Curve" to provide information about Peyronie's disease ("PD") and to help empower men to have meaningful discussions about their condition with their partner and their healthcare provider.\par \par \uc2 The foregoing is qualified in its entirety by the text of the press release attached as Exhibit 99.1 hereto and incorporated herein by reference. All readers are encouraged to read the entire text of the joint press release attached hereto.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1182129/000110465913048186/a13-14691_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1182129/000110465913048186/a13-14691_18k.htm }}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1182129/000110465913048186/0001104659-13-048186-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1182129/000110465913048186/0001104659-13-048186-index.htm }}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 11, 2013 07:01 ET (11:01 GMT)\par \par \uc2 Document DJDN000020130611e96b00223\par }\par \b \uc2 Search Summary: gizem2\b0\par \par  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Text\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 ns=C22 and (hlp=((new device or new devices or new drug or new drugs or new product or new products) and (announced the launch or announces the launch or launch or launches or launched or announced new or announces new or announces launch or introduce or introduces or introduced)) or ns=(CDINN or CGVFIL)) and in=(I257 or I372) and fmt=article and date from 01/01/2013 to 12/31/2016 and roo=USA and re=USA and la=en not (ns=(CMARKR or c01 or CIPROF or C41 or C18 or C133 or NRMF or NNAM or NOBT or NLIST or NHOC or C1521 or NAMT) or in=IDDTECH or Drug Administration announced approval)\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Date\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 All Dates\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Source\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 Not US Food and Drug Administration News (Abstracts)\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Author\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 All Authors\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Company\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2  Not U.S. Food and Drug Administration\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Subject\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 All Subjects\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Industry\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 All Industries\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Region\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 United States Not China Not Japan Not Europe\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Language\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 English\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Results Found\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 1,392\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Timestamp\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 30 April 2019 15:13\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row }\par }}